Neuropeptidek és mellékvese szteroid hormonok kölcsönhatásai az adrenokortikotropin elválasztás hipotalamikus szabályozásában by Antoni, Ferenc András
 1 
	  
	  
MTA	  Doktori	  	  Pályázat	  
Tézisei	  
	  
	  
	  
Neuropeptidek	  és	  mellékvese	  szteroid	  hormonok	  
kölcsönhatásai	  az	  adrenokortikotropin	  elválasztás	  
hipotalamikus	  szabályozásában.	  
	  
	  
Antoni	  	  Ferenc	  András	  
	  
	  
	  
Budapest,	  2012
               dc_385_12
 2 
A	  Tézisekben	  használt	  röviditések:	  
	  
AC7	   	   	   adenilil	  cikláz	  7	  
AC9	  	   	   	   adenilil	  cikláz	  9	  
ACTH	   	   	   adrenokortikotróp	  hormon	  
AVP	   	   	   arginin-­‐vazopresszin	  
BK-­‐csatorna	   	   nagy	  vezetőképességű	  Ca2+	  aktiválta	  K+	  csatorna.	  
cAMP	   	   	   adenozin-­‐3‘:5‘-­‐monofoszfát,	  ciklikus	  AMP	  
cGMP	   	   	   guanozin-­‐3‘:5-­‐monofoszfát,	  ciklikus	  GMP	  
CRF	   	   	   bioassay-­‐el	  mért	  corticotropin	  releasing-­‐factor	  
CRF41	   	   	   A	  41	  aminosavból	  álló	  corticotropin	  releasing-­‐factor	  
hERG	   	   	   Humán	  Ether-­‐à-­‐go-­‐go-­‐related	  gene	  K+	  csatorna	  
HPA	   	   	   Hipotalamusz-­‐hipofizis-­‐mellékvese	  rendszer	  
mRNS	   	   	   Hírvivő	  (messenger)	  RNS	  
NO	  	   	   	   nitrogén	  monoxid	  
STREX	   	   	   Stress	  responsive	  exon	  
TREK-­‐1	   	   	   TWIK-­‐related	  K+	  channel	  1	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1.	  BEVEZETÉS	  
	  
Kanditátusi	  értekezésemben,	  amelyet	  1984-­‐ben	  védtem	  meg,	  	  többek	  között	  a	  CRF41-­‐et	  
termelő	  hipofízeotróp	  neuronok	  elhelyezkedésével	  és	  axonjaik	   lefutásával	  foglalkoztam	  
(Antoni	   et	   al.,	   1983).	   	   Röviddel	   ezután	   három	  munkacsoport	   szinte	   egyszerre	   közölte,	  
hogy	  a	  hipofízeotróp	  CRF41-­‐t	   termelő	   	   sejtek	  egy	  másik	  neuropeptidet,	  nevezetesen	  a	  
már	   az	   1960as	   évek	   legelején	   CRF-­‐nek	   tartott	   	   AVP-­‐t	   is	   termelik,	   amelyet	   	   a	   CRF41-­‐el	  
együtt	  szekretálnak	  (Kiss	  et	  al.,	  1984;	  Sawchenko	  et	  al.,	  1984;	  Tramu	  et	  al.,	  1983).	  	  	  
	  
A	   doktori	   értekezésemben	   összefoglalt	   munkák	   a	   fenti	   alapvető	   megfigyelésből	  
kibontakozó	  kérdéseket	  vizsgálták.	  	  Többségükben	  in	  vitro	  rendszerekben	  arra	  kerestünk	  
választ,	  hogy	  levezethető-­‐e	  	  sejtszintű	  jelenségekből	  miért	  szabályozza	  két,	  külön	  génről	  
átíródó	  serkentő	  neuropeptid	  a	  hipofízis	  ACTH	  elválasztását?	  Ahol	  megfelelő	   lehetőség	  
kínálkozott,	  ott	  az	  in	  vitro	  megfigyeléseket	  célzott	  in	  vivo	  vizsgálatokkal	  egészítettük	  ki.	  	  	  
	  
2.	  A	  KISÉRLETEK	  IRODALMI	  HÁTTERE	  ÉS	  FŐBB	  CÉLKITŰZÉSEI	  	  
2.1	   	   Az	   arginin-­‐vazopresszin	   (AVP)	   szerepe	   az	   adrenokortikotróp	   hormon	   (ACTH)	  	  
hipotalamikus	  szabályozásában:	  
	  
A	  neuroendokrin	  szabályozás	  alapeleme	  a	  hipotalamo-­‐hipofízeális	   rendszer.	  Ennek	  egyik	  
fontos	   működési	   módja,	   hogy	   	   hipotalamuszban	   elhelyezkedő	   hipofízeotróp	   idegsejtek	  
axonjai	   az	   eminentia	   mediana	   külső	   rétegében	   végződnek.	   	   Az	   axonvégződésekből	  
felszabaduló	   mediátorok	   a	   hipofízeális	   	   portális	   vérkeringés	   útján	   kerülnek	   az	   elülső	  
hipofízis	   lebenyben	   elhelyezkedő	   célsejtjeikhez.	   	   A	   célsejtekből	   feszabaduló	   hormonok	  	  
pedig	   a	   szisztémás	   vérkeringéssel	   jutnak	   el	   célszerveikhez.	   	   A	   HPA	   tengely	   esetében	   a	  
hipofízisből	   felszabaduló	   ACTH	   	   serkenti	   a	   mellékvesekéregben	   a	   	   szteroid	   hormonok	  
termelését	   aminek	   következtében	   nő	   ezen	   hormonok	   vérszintje.	   	   A	   homeosztatikus	  
egyensúly	   fenntartása	   érdekében	   a	   mellékvese	   szteroidok	   általában	   gátolják	   a	   HPA	  
tengely	   működését,	   mind	   a	   hipofízeotróp	   CRF41	   neuronok,	   mind	   az	   ACTH-­‐t	   termelő	  
adenohipofízeális	  kortikotróp	  sejtek	  szintjén.	  	  
	  
	  A	   hipotalamo-­‐hipofízeális	   rendszer	   további	   működési	   módját	   a	   hipofízis	   hátsó	  
lebenyében,	   másik	   nevén	   neurohipofízisben	   találjuk.	   	   Itt,	   az	   ú.n.	   magnocelluláris	  
neuroszekretoros	   sejtek	   rostjai	   végződnek	   amelyek	   az	   eminentia	   mediana	   belső	  
rétegében	   futnak	   le	   rendeltetési	   helyükre.	   	   Ezek	   a	   rostok	   AVP-­‐t	   	   vagy	   oxytocint	  
tartalmaznak,	   	   többszörös	   varikozitásaikból	   a	   szisztémás	   keringésbe	   jutnak	   a	  
neuropeptidek	   és	   hormonként	   működnek.	   	   	   A	   szisztémás	   vérben	   keringő	   AVP	  
koncentrációja	  mind	  rágcsálokban	  mind	  	  emberben	  1-­‐50	  pmol/L	  között	  mozog,	  ami	  nem	  
elegendő	  az	  ACTH	  elválasztás	  serkentéséhez.	  	  Ezenfelül	  	  a	  neurohipofízeális	  AVP	  szerepe	  
mint	   antidiuretikus	   hormon	   az	   élettani	   szabályozásban	   jól	   ismert.	   	   Végül,	   többen	  
kimutatták	   nem	   AVP	   jellegű	   CRF	   aktivitással	   rendelkező	   anyag	   jelenlétét	   a	  
hipotalamuszban,	   ami	   látszólag	   megerősítette	   azt	   a	   felfogást,	   miszerint	   minden	  
hipofízeális	   sejttípushoz	  egyetlen	  hipotalamikus	   serkentő	  hormon	   rendelhető.	   	   Tehát	  az	  
1970-­‐es	  évek	  végén	  az	  AVP	  CRFszerű	  hatását	  kétkedés	  övezte.	  	  A	  CRF41	  felfedezése	  (Vale	  
et	  al.,	  1981)	  nyomán	  lehetőség	  nyílt	  az	  AVP	  CRF	  szerepének	  újraértékelésére.	   	  Világossá	  
vált,	   hogy	   in	   vitro	   a	   CRF41	   és	   az	   AVP	   szinergisztikusan	   serkentik	   az	   ACTH	   leadást	   és	   a	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CRF41	   sejtek	   AVP-­‐t	   is	   termelnek	   (Antoni,	   1986).	   	   Ugyanakkor	   AVP	   receptor	  
antagonistákkal	   végzett	   in	   vivo	   vizsgálatok	   nem	   támasztották	   alá	   az	   AVP	   ACTH	  
elválasztásban	  játszott	  szerepét.	  	   	  Saját	  munkánkban	  ezért	  arra	  kerestünk	  választ	  az	  AVP	  
milyen	   receptorokon	   keresztül	   fejti	   ki	   hatását	   az	   adenohipofízisre?	   	   Valóban	   csak	   a	  
parvicelluláris	   CRF41	   sejtekből	   származó	   neuropeptidek	   szabályozzák	   az	   ACTH	   leadást?	  	  
Befolyásolja-­‐e	  az	  AVP	  a	  glukokortikoid	  visszacsatolásos	  gátlást	  a	  hipofízis	  szintjén?	  	  
	  
A	   kísérletek	   eredményei	   a	   következők	   (a	   zárójelben	   lévő	   számok	   a	   5.1	   bekezdésnél	  
található	  cikkeket	  jelzik):	  	  
	  	  
2.1.1	  Az	  AVP	  hatása	  az	  elülső	  hipofízis	  szintjén	  újszerű,	  a	  kísérletek	  elvégzésekor	  még	  nem	  
ismert	  membrán	  receptoron	  keresztül	  megy	  végbe.	  
(1-­‐2)	  
	  	  
2.1.2	   Az	   adenohipofízis	   oxytocin	   receptorokat	   tartalmaz,	   azonban	   valószínűtlen,	   hogy	  
ezek	  a	  kortikotróp	  sejtekben	  találhatók.	  
(3-­‐5)	  
	  
2.1.3	   Patkányban	   a	   hipotalamusz	   magnocelluláris	   neuronjaiból	   származó	   AVP	  
depolarizáció	  nyomán	  Ca2+-­‐függő	  módon	  szekretálódik	  az	  izolált	  emimentia	  mediana-­‐ban	  
valamint	  	  kimutatható	  a	  hipofízeális	  portális	  vérben.	  	  
(6-­‐8)	  
	  
	  2.1.4	   A	   vazopresszin	   egyik	   fontos	   szerepe	   a	   glukokortikoid	   visszacsatolás	  
hatékonyságának	   szabályozása	   a	   kortikotróp	   sejtek	   szintjén.	   	   Intenzív	   stresszhelyzetre	  
jellemző	   vazopresszin	   koncentrációk	   mellett	   a	   glukokortikoid	   gátlás	   korai	   késleltetett	  
fázisa	   gyakorlatilag	   nem	   érvényesül.	   	   A	   glukokortikoid	   rezisztencia	   alapja	   a	   jelentősen	  
megnövekedett	  intracellularis	  cAMP	  szint.	  	  
(9)	  
	  
Összefoglalva,	  mind	  a	  parvicelluláris,	  mind	  a	  magnocelluláris	  eredetű	  AVP	  befolyásolhatja	  
az	   ACTH	   elválasztást.	   Magas	   AVP	   szintek	   mellett,	   a	   HPA	   rendszerben	   glukokortikoid	  
rezisztencia	   mutatható	   ki.	   A	   mellékvese-­‐szteroid	   visszacsatolásos	   gátlás	   	   AVP	   által	  
előidézett	   hipofízis	   szintű	   módosulása	   összervezeti	   szinten	   kortikoszteroid	   túltermelést	  
eredményezhet.	  A	  fenti	  eredmények	  részletes	  tárgyalása	  az	  5.3-­‐as	  bekezdés	  alatt	  felsorolt	  	  
34,	  35,	  36,	  38,	  43	  számú	  összefoglaló	  közleményekben	  található.	  	  
	  
2.3	  A	  glukokortikoid	  visszacsatolásos	  gátlás	  mechanizmusa	  az	  adenohipofízis	  szintjén.	  
	  
Az	  ACTH	  elválasztás	  szabályozásának	  tanulmányozása	  világossá	  tette,	  hogy	  az	  AVP	  egyik	  
fontos	   hatása	   kortikotróp	   sejteken	   érvényesülő	   visszacsatolásos	   glukokortikoid	   gátlás	  	  
hatékonyságának	   	   módosítása.	   A	   visszacsatolásos	   gátlás	   időbeli	   lefolyásának	   elemzése	  
során	  általában	  három	  fázist	  különböztetnek	  meg.	  	  Leírtak	  gyors	  gátlást	  amelynek	  hatása	  
az	   alkalmazott	   mérési	   módszerek	   feloldásától	   függően	   akár	   másodpercek	   alatt	  
kimutatható.	   	   In	   vivo	   a	   glukokortikoid	   hatás	   a	   szteroid	   adagolás	   sebességétől	   függőnek	  
mutatkozik,	   ezért	   gyors,	   sebesség-­‐függő	   gátlásnak	   nevezik	   (Dallman	   et	   al.,	   1992)	   (fast,	  
rate-­‐sensitive	   feedback	   inhibition).	   	   Mechanizmusa	   nem	   tisztázott,	   de	   feltehetően	   a	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plazmamembrán	   közvetlen	   közelében	   elhelyezkedő	   glukokortikoid-­‐receptor	   fehérjéken	  
keresztül	   jön	   létre.	   Patkány	   kortikotróp	   sejteken	   végzett	   kísérleteinkben	   ilyen	   jellegű	  
gátlást	   nem	   találtunk	   –	   az	   irodalom	   szerint	   is	   elsősorban	   	   a	   hipotalamusz	   szintjén	  
érvényesül.	   	  A	  glukokortikoid	  gátlás	  második	  fázisa	  a	  hipofízis	  szintjén	   in	  vitro	  a	  szteroid	  
adagolás	  kezdetétől	   számított	  20	  percen	  belül	  kimutatható.	  Korai,	  késleltetett	  gátlásnak	  
nevezik	   (early	  delayed	  feedback	   inhibition)	  és	  alapvető	  fiziológiás	  szerepet	   játszik	  a	  HPA	  
rendszer	   hormon	   szintjeinek	   beállításában.	   Korai,	   késleltetett	   glukokortikoid	   gátlás	   a	  
hippokampusz,	   a	   hipotalamusz	   és	   az	   adenohipofízis	   szintjén	   egyaránt	   kimutatható.	   	   A	  
glukokortikoid	  hatás	  harmadik	  szakasza	  a	  késői	  gátlás	  (delayed	  feedback	  inhibition)	  amely	  
a	  hormon	  elválasztásban	  az	  adagolástól	  számított	  két	  órán	  túl	  érvényesül,	  bár	  a	  génátírás	  
szintjén	   5	   percen	   belül	   észlelhető.	   A	   késői	   gátlás	   elsősorban	   a	   krónikus	   stressz	  
állapotokhoz	  valamint	  a	  mesterséges	  szteroid	  adagolással	  	  előidézett	  tartós	  szteroid	  szint	  
növekedéshez	   kapcsolható.	   	   A	   késői	   gátlás	   egyik	   fontos	   megnyilvánulása	   a	   célsejtek	  
differenciált	   funkcióinak	   glukokortikoid	   hormonok	   által	   történő	   fojtása	   a	   génkifejezés	  
szintjén.	   Ezzel	   szemben	  a	   korai	   késleltetett	   gátlás	   	   gén	   és	   fehérje	   indukción	   alapul	   és	   a	  
differenciált	   funkciókat	   a	   célsejtek	   jelátviteli	   folyamatainak	   szintjén	   módosítja.	  
Kísérleteinkben	  arra	  kerestünk	  választ	  hogyan	  működik	  a	  korai	  késleltetett	  gátlás	  és	  mi	  az	  
AVP	  gátlást	  módosító	  hatásának	  lényege?	  	  	  
	  
A	  főbb	  eredmények	  a	  következők:	  	  
	  
2.3.1	   A	   glukokortikoid	   gátlás	   korai	   késleltetett	   fázisa	   új	   mRNS	   és	   fehérje	   szintézisét	  
igényli.	  
(10,	  11)	  	  
	  
2.3.2	   A	   korai	   késleltetett	   gátlás	   megfelelően	   időzített,	   intracelluláris	   adenozin	   3’:5’	  
monofoszfát	  termelést	  	  indukáló	  ingerrel	  felfüggeszthető.	  
(12)	  
	  
2.3.3	  A	  korai	  késleltetett	  glukokortikoid	  hatás	  membrándepolarizációval	  felfüggeszthető.	  
(13,	  14)	  
	  
2.3.4	   A	   korai	   késleltetett	   gátlás	   egér	   kortikotróp	   tumor	   sejt	   modellben	   a	   nagy	  
vezetőképességű	   Ca2+-­‐aktiválta	   K+-­‐csatornák	   (BK-­‐csatorna)	   	   foszforillációs	   állapotát	  
változtatja	  meg,	  és	  a	  jelenség	  humán	  embrionális	  vesesejtekben	  szintén	  megfigyelhető.	  
(15,	  16,	  17	  ,	  18)	  
	  
2.3.5	  Meglepő	  módon	  normális	  patkány	  kortikotróp	  sejtekben	  a	  BK-­‐csatorna	  nem	  játszik	  
jelentős	   szerepet	   a	   glukokortikoid	   gátlásban:	   a	   szteroid	   hatás	   valószínűleg	   hERG	   	   vagy	  
TREK-­‐1	  típusú	  K+	  csatornákon	  keresztül	  jön	  létre.	  	  
(9,	  14)	  
	  
2.3.6	  A	  glukokortikoid	  visszacsatolási	  gátlás	  fontos	  permisszív	  tényezője	  az	  intracelluláris	  
Ca2+	  ciklikus	  AMP	  bioszintézist	  	  gátló	  hatása,	  amelynek	  célpontja	  az	  adenilil	  cikláz	  9.	  
(19,20)	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2.3.7	  Az	  AVP	  által	  indukált	  glukokortikoid	  rezisztencia	  alapja	  a	  cAMP	  anyagcsere	  utak	  AVP	  
hatására	  bekövetkező	  módosulása.	  Az	   	  adenilil	  cikláz	  9	  helyett	  egy	   	  protein	  kináz	  C	  által	  
serkentett,	   intracelluláris	  Ca2+	  által	  nem	  befolyásolt	  adenilil	   cikláz	  –	  valószínűleg	  adenilil	  
cikláz	  7	  –	  kerül	  előtérbe.	  Ennek	  nyomán	  nagyságrenddel	  magasabb	   intracelluláris	   cAMP	  
szintek	  jönnek	  létre.	  	  	  
(9,	  19,	  20)	  	  	  
	  
	  
A	  fenti	  eredmények	  részletes	  tárgyalása	  az	  5.3-­‐as	  bekezdés	  alatt	  felsorolt	  	  42,	  48,	  58,	  60	  
számú	  összefoglaló	  közleményekben	  található.	  	  
	  
2.	  3	  	  A	  guanozin	  3’:5’	  monofoszfáton	  (cGMP)	  keresztül	  működő	  gátlás	  szerepe	  az	  ACTH	  	  
elválasztás	  szabályozásában.	  
	  
Az	  1970-­‐as	  évek	  közepe	  táján	  	  fedezték	  föl,	  hogy	  a	  NO	  	  serkenti	  a	  szolubilis	  	  guanilil	  cikláz	  
enzimet	  és	  ezáltal	  növeli	  a	  cGMP	  intracelluláris	  koncentrációját.	  Az	  is	  ismert	  volt,	  hogy	  a	  
glukokortikoid	   hormonok	   a	   NO	   szintáz	   enzim	   egyik	   altípusának	   kifejezését	   serkentik.	   A	  
mellékvesekéreg	   hormonok	   hatásmechanizmusának	   vizsgálata	   során	   az	   egyik	  
munkahipotézisünk	   az	   volt,	   hogy	   a	   szteroidok	   a	   NO	   szintáz	   indukciója	   révén	   fejtik	   ki	  
hatásukat	   	   Sikerült	   kimutatnunk,	   	   hogy	   a	   sejtmembránon	   áthatoló	   cGMP	   analógok	  
jelentősen	  gátolják	  a	  CRF41	  és	  AVP	   fiziológiás	  kombinációjával	   serkentett	  ACTH	   leadást.	  	  
Azonban	   nem	   találtunk	   összefüggést	   a	   hipofízeális	   cGMP	   termelés	   és	   a	   glukokortikoid	  
gátlás	   között.	   	   Ezért	   megvizsgáltuk	   milyen	   cGMP	   szintézist	   serkentő	   anyagok	   jöhetnek	  
szóba	  mint	  fiziológiás	  ACTH	  leadást	  gátló	  tényezők?	  	  
	  
A	  kísérletek	  	  főbb	  eredményei	  a	  következők:	  
	  
2.3.1	   A	   cGMP	   analógok	   valamint	   a	   sejten	   belüli	   cGMP	   bioszintézist	   aktiváló	   anyagok	  
gátolják	  a	  neuropeptidek	  által	  serkentett	  ACTH	  leadást	  in	  vitro.	  
(21,	  22	  )	  
	  
2.3.2	   Atriopeptin	   infúziója	   gátolja	   a	   CRF41	   és	   AVP	   kombinációjával	   	   serkentett	   ACTH	  
elválasztást	  éber	  patkányokban.	  	  
(23)	  
	  
2.3.3	   Éber	   patkányokban	   az	   endogén	   atriopeptin	   immun-­‐neutralizációja	   növeli	   az	  
immobilizációs	   stressz	   indukálta	   plazma	   ACTH	   és	   kortikoszteron	   választ	   ,	   tehát	   ezen	  
körülmények	  között	  az	  atriopeptin	  fiziológiás	  ACTH	  leadást	  gátló	  neurohormon.	  
(24)	  
	  
A	   fenti	   eredmények	   összefoglalása	   az	   5.3-­‐as	   bekezdés	   alatt	   felsorolt	   	   43-­‐as	   számú	  
összefoglaló	   közleményekben	   található.	   Mivel	   ez	   az	   összefoglaló	   munka	   meglehetősen	  
régi	  keletű,	  	  az	  alábbiakban	  a	  két	  előző	  témakörhöz	  képest	  részletesebben	  tárgyalom	  	  az	  
atriopeptinnel	  kapcsolatos	  eredményeket.	  	  
	  
Irodalmi	   szinten	   a	   kísérletek	   kivitelezésekor	   az	   atriopeptin	   hipofízeotróp	   hatásairól	  
ellentmondó	  eredmények	  voltak	   forgalomban.	   	  Saját	  munkánk	  kiindulási	  pontja	  a	  cGMP	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hatására	   létrejövő	   gátlás	   amely	   akutan	   izolált	   és	   perifundált	   patkány	   adenohipofízis	  
sejteken	   jól	   reprodukálható	   volt.	   Mások	   több	   napos	   túlélő	   kultúrákban	   próbálkoztak	  
sztatikus	   inkubálásban	  és	  valószínűsíthetően	  ezért	  nem	  észlelték	  a	  cGMP	  illetve	  a	  cGMP	  
szintet	  fokozó	  anyagok	  serkentett	  ACTH	  elválasztást	  gátló	  hatását.	  A	  későbbiek	  során	  akut	  
egér	   hipofízis	   szeletkéken	   (Guild	   et	   al.,	   1999)	   és	   foetalis	   patkány	   hipofízis	   kultúrákban	  
(Chatelain	   et	  al.,	   2003)	  mások	   is	   	  megerősítették	   	   az	   atrialis	  peptidek	  ACTH	  elválasztást	  
gátló	  hatásáról	  tett	  megfigyeléseinket.	  Ezzel	  szemben	  birka	  (Bowman	  et	  al.,	  1997)	  illetve	  
ló	   (Mulligan	   et	   al.,	   1997)	   hipofízis	   sejtekben	   az	   atriopeptin	   ACTH	   elválasztást	   gátló	  	  
hatását	  nem	  sikerült	  kimutatni.	   	  A	  német	   	  klinikai	   irodalomban	  két,	  egymástól	  független	  
munkacsoport	   (Bierwolf	   et	   al.,	   1998;	   Strohle	   et	   al.,	   1998;	   Wiedemann	   et	   al.,	   2000)	   is	  
kimutatta	   az	   atriopeptin	   plazma	   ACTH	   szinteket	   és	   következésképpen	   plazma	   	   kortizol	  
szinteket	   is	   csökkentő	   hatását.	   Tudomásom	   szerint	   a	   NO	   donorokkal	   végzett	   munkánk	  
úttörő	   jellegű	   volt	   az	   adenohipofízis	   működésének	   vizsgálatában.	   Később,	   az	  
adenohipofízeális	   cGMP	   NO–szolubilis	   guanilil	   cikláz	   keletkezési	   útjával	   számos	  
munkacsoport	   foglalkozott	   de	   senki	   nem	   vizsgálta	   az	   ACTH	   elválasztást.	   Mivel	   minden	  
valószínűség	  szerint	  a	  NO	  is	  elsősorban	  cGMP-­‐n	  keresztül	  befolyásolja	  az	  ACTH	  leadást,	  az	  
atriopeptinnel	  kapcsolatban	  említett	  technikai	  problémák	  is	  közrejátszhattak	  abban,	  hogy	  	  
ez	  a	  kérdéskör	  nem	  kapott	  nagyobb	  figyelmet.	  Végül,	  de	  nem	  utolsósorban	  hangsúlyozni	  
szeretném,	   hogy	   akut	   in	   vitro	   modellben	   a	   serkentett	   ACTH	   leadás	   cGMP-­‐n	   keresztül	  
történő	   gátlása	   a	   glukokortikoid	   visszacsatolástól	   függetlennek	   látszik	   (Antoni	   et	   al.,	  
1990b).	   Összefoglalva,	   a	   rendelkezésre	   álló	   frissebb	   irodalom	   megerősítette	   az	  
atriopeptin	   hipofízis	   szintjén	   kifejtett,	   ACTH	   leadást	   csökkentő	   hatásával	   kapcsolatos	  
megfigyeléseinket,	  és	  kiterjesztette	  azokat	  humán	  vizsgálatokra	  is.	  
	  
A	  hipotalamikus	  atriopeptin	  hipofízeotróp	  szerepét	  számos	  neuranatómiai	  megfigyelés	  is	  
valószínűsíti.	   	   Patkány	   agyban	   az	   eminentia	   mediana	   zona	   externában	   atriopeptin	  
immunreaktív	   rostokat	   figyeltek	   meg,	   a	   periventrikuláris	   és	   paraventrikuláris	  
hipotalamikus	  magokban	  pedig	  jelentős	  számú	  atriopeptint	  	  tartalmazó	  idegsejt	  található	  
(Kawata	  et	  al.,	  1985;	  Skofitsch	  et	  al.,	  1986;	  Standaert	  et	  al.,	  1986).	  Ezen	  idegsejtek	  sebészi	  
léziója	   nyomán	   az	   eminentia	   mediana	   atriopeptin	   tartalma	   drasztikusan	   lecsökken	  
(Palkovits	  et	  al.,	  1987).	  Altatott	  patkányok	  hipofízeális	  portális	  vérében	  10x	  magasabb	  a	  
radioimmuoassay-­‐el	  mért	   atriopeptin	   koncentráció	  mint	   a	   perifériás	   vérben	   (Lim	   et	   al.,	  
1990),	  ezenfelül	  a	  hipofízeális	  portális	  vérben	  az	  atriopeptin	  5-­‐28	  a	  domináló	  forma	  míg	  a	  
perifériás	  keringésben	  az	  1-­‐28	  változat	  található	  (Lim	  et	  al.,	  1994).	  	  Saját	  vizsgálatainkban	  
az	  atriopeptin	  5-­‐28	   serkentette	   leghatékonyabban	   	   izolált	  patkány	  adenohipofízis	   sejtek	  
cGMP	  termelését	  [ref(22)].	  Az	  endogén	  atriopeptin	  ACTH	  elválasztást	  gátló	  szerepét	  Fink	  
és	   mtsai	   is	   megfigyelték	   –	   az	   általunk	   alkalmazotthoz	   hasonló,	   	   de	   más	   anti-­‐testtel	  
végrehajtott	  immun-­‐neutralizációs	  módszerrel	  (Fink	  et	  al.,	  1991).	  	  Végezetül,	  ismert,	  hogy	  
a	   mellékvesekéreg	   szteroidok	   serkentik	   az	   atriopeptin	   gén	   kifejezését	   (Gardner	   et	   al.,	  
1986)	   ami	   beleillik	   a	   két	   hormon	   egymást	   ellensúlyozó	   szerepébe.	   Sajnos	   szelektív,	  
kismolekulasúlyú	  atriopeptinerg	  anyagok	  hiányában	  nem	  terjedhettek	  el	  az	  atriopeptin	  és	  
rokon	   peptidjeinek	   (brain	   natriuretic	   factor)	   neuroendokrin	   és	   pszichotróp	   	   hatásait	  
vizsgáló	  kísérletek.	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3.	  	  A	  TUDOMÁNYOS	  EREDMÉNYEK	  JELENTŐSÉGE	  
	  
3.1	  A	  hipofízeális	  AVP	  receptor	  
Az	   általunk	   eredetileg	   az	   adenohipofízisből	   kimutatott	   újszerű	   vazopresszin	   receptor	  
kézikönyvi	  szinten,	  V1b	  vazopresszin	  receptorként	  szerepel	  az	   irodalomban.	   	  A	  receptor	  
gén	   klónozása	   nyomán	   	   kiterjedt	   	   agyi	   lokalizációjáról	   számoltak	   be	   ,	   valamint	  magas	  
mRNS	   szintekről	   az	   immunrendszerben	   (Lolait	   et	   al.,	   1995).	   A	   szervezetben	   játszott	  
funkcionális	  szerepének	  vizsgálata	  mára	  kiterjedt	  irodalommal	  rendelkezik	  (Roper	  et	  al.,	  
2011).	   Két	   nagy	   gyógyszercég,	   a	   Sanofi/Aventis	   (Griebel	   et	   al.,	   2002)	   és	   az	   Organon	  
(Craighead	   et	   al.,	   2008)	   is	   kidolgozott	   kis	   molekulasúlyú,	   szelektív	   V1b	   receptor	  
antagonistát.	  A	  Sanofi	  vegyület	  fejlesztését	  fázis	  II	  klinikai	  vizsgálatok	  nyomán	  2008-­‐ban	  
leállították.	   	   Az	   Organon	   vegyület	   alighanem	   áldozatául	   esett	   az	   Organon-­‐
ScheringPlough-­‐Merck	   láncfúziónak,	   illetve	   felvásárlásnak.	   Legutóbb	   Koob	  
munkacsoportja	   (Edwards	   et	   al.,	   2012)	   számolt	   be	   arról,	   hogy	   patkányban	   	   V1b	  
antagonistával	  megakadályozható	  az	  alkohol-­‐dependencia	  kifejlődése.	   	  Összefoglalva,	  a	  
V1b	  receptor	  mint	  anxiolitikus	  és	  esetleges	  anti-­‐depresszáns	  terápiás	  célpont	  továbbra	  is	  
érdeklődésre	  tarthat	  számot.	  	  	  
	  
3.2	   AVP	   és	   	   glukokortikoid	   hormonok	   kölcsönhatása	   adenohipofízeális	   kortikotróp	  
sejtekben	  
	  
Három	  lényeges	  megfigyelést	  tettünk:	  Először,	  adataink	  alapján	  megalapozottnak	  látszik	  
a	   következtetés,	   hogy	   patkányban	   a	   hipotalamikus	   magnocelluláris	   AVP	   neuronok	  
hipofízeotróp	   funkciót	   töltenek	   be,	   azaz	   a	   magnocelluláris	   sejtekből	   leadott	   AVP	  
befolyásolja	   az	   elülső	   hipofízissejtek	   működését.	   Másodszor,	   adenohipofízeális	  
kortikotróp	   sejtekben	   az	   AVP	   jelentősen	   csökkenti	   a	   glukokortikoid	   visszacsatolásos	  
gátlás	  hatékonyságát.	  Harmadszor,	  a	  glukokortikoid	  rezisztencia	  sejtszintű	  magyarázata	  
a	  kortikotróp	  sejtek	  cAMP	  jelátvitelének	  AVP	  hatására	  bekövetkező	  módosulása.	  	  
	  
3.2.1	   	  Kísérleteinkben	  a	  hipotalamikus	  CRF41	  és	  AVP	  leadás	   in	  vitro	  és	   in	  vivo	  követése	  
alapján	   bizonyítottuk	   a	   magnocelluláris	   AVP	   sejtek	   hipofízeotróp	   szerepének	  
lehetőségét.	   Munkánk	   nyomán	   a	   magnocelluláris	   AVP	   fizikai	   stresszre	   adott	   HPA	  
válaszban	   játszott	   szerepét	   több,	   döntően	   rágcsáló	  modellekben	   végrehajtott	   vizsgálat	  
igazolta,	  	  (összefoglalásukat	  lsd	  (Engelmann	  et	  al.,	  2004;	  Ueta	  et	  al.,	  2011)).	  	  	  Mint	  arra	  
egy	   korábbi	   összefoglaló	   munkámban	   rámutattam	   (Antoni,	   1993),	   a	   kísérletes	  
gyakorlatban	  elterjedt	   nagyobb	   testű	   fajokban,	   pl.	   birka	   és	  macska,	   	   a	   periférián	  mért	  
AVP	   szintek	   nanomoláris	   nagyságendűek,	   ami	   egyértelműen	   amellett	   szól,	   hogy	   a	  
hipofízis	   működését	   is	   befolyásolhatják.	   Emberben	   a	   perifériás	   vérben	   mérhető	   AVP	  
szintje	   a	   rágcsálókhoz	   hasonlóan	   20	   pmol/L	   fölé	   ritkán	   emelkedik,	   viszont	   a	   plazma	  
koncentráció	   változásai	   jelzik	   a	   magnocelluláris	   neuronok	   aktivitását.	   	   A	   klinikai	  
gyakorlatban	  a	  HPA	   rendszer	   glukokortikoid	  gátlásra	  nem	  érzékeny	   (non-­‐szuppresszor)	  
állapotát	  dexamethasone	  adagolással	  diagnosztizálják.	   	  Mai	   ismereteink	  szerint	   (Meijer	  
et	  al.,	  1998)	  a	  dexamethasone	  elsősorban	  a	  hipofízis	  szintjén	  hat	  a	  HPA	  rendszerre,	  tehát	  
az	  AVP	  glukokortikoid	  gátlást	  csökkentő	  hatására	  a	  teszt	  várhatóan	  kiemelten	  érzékeny.	  	  
A	   plazma	  AVP	   szintek	   követése	   és	   a	   dexamethasone	   szuppressziós	   teszt	   kombinációja	  
alapján	   Chrousos	   és	   Gold	  munkacsoportja	   arra	   a	   következtetésre	   jutott,	   hogy	   extrém	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fizikai	   megterhelés	   során	   az	   egyedek	   mintegy	   50%-­‐ban	   neuroendokrin	   glukokortikoid	  
rezisztencia	  alakul	  ki	  és	  ennek	  oka	  a	  magnocelluláris	  neuronok	  magasabb	  AVP	  leadása.	  
(Deuster	  et	  al.,	  2000;	  Deuster	  et	  al.,	  1998).	  	  Egy	  másik	  klinikai	  vizsgálatban	  (Inder	  et	  al.,	  
1997)	   depresszióban	   szenvedő	   betegek	   két	   csoportját	   különböztették	   meg:	   	   magas	  
perifériás	  AVP	  szintek	  esetén	  hiperkortizolémia	  is	  fellépett	  míg	  	  normális	  perifériás	  AVP	  
mellett	   a	   plazma	   kortizol	   szintek	   sem	   mutattak	   eltérést.	   	   Ezek	   a	   megfigyelések	   is	   a	  
magnocelluláris	  AVP	  elválasztás	  hipofízeotróp	  szerepe	  mellett	  szólnak.	  
	  
Nyitott	   kérdés,	   hogy	   a	   magnocelluláris	   	   AVP	   a	   hipotalamusz	   szintjén	   befolyásolja-­‐e	   a	  
hipofízeotróp	   parvicellularis	   CRF41/AVP	   neuronok	   működését?	   	   Számos	   megfigyelés	  
valószínűsíti	   az	   igenlő	   választ.	   	  A	  magnocelluláris	  neuronok	  dendritjeiből	  AVP	   szabadul	  
föl	   (Ludwig	  et	  al.,	  2002)	  a	  CRF41	  sejttestek	  és	  magnocelluláris	  dendritek	  között	  sajátos	  
szinaptikus	  kapcsolatok	  vannak	  (Léránth	  et	  al.,	  1983)	  ,	  a	  hipofízeális	  portális	  vérben	  mért	  
CRF41	  koncentráció	  AVP	  agykamrába	  történő	  adagolása	  nyomán	  csökken	  (Plotsky	  et	  al.,	  
1984).	   Ez	   a	   kérdés	   	   ma	   már	   CRF41-­‐GFP	   egerekből	   nyert	   agyszeletkékben	   valamint	  
csatornarodopszint	   szelektíven	   kifejező	   magnocelluláris	   neuronok	   ingerlésével	  	  
közvetlenül	  vizsgálható.	  	  	  
	  
3.2.2	   	   Az	   AVP	   glukokortikoid	   rezisztenciát	   okozó	   hatásában	   mind	   a	   parvi-­‐	   mind	  
magnocelluláris	   rendszerből	   származó	   AVP	   szerepe	   fölmerül.	   	   Számos	   közleményben	  
számoltak	  be	  olyan	  kísérleti	  beavatkozásról	  amely	  jelentősen,	  akár	  tízszeresen	  is,	  növelte	  
a	  parvicelluláris	  CRF41	  sejtekben	  az	  AVP	  bioszintézist.	  A	  közelmúlt	  epigenetikai	  kutatásai	  
alapján	   úgy	   tűnik,	   hogy	   a	   HPA	   stressz-­‐válasz	   egyik	   fő	   meghatározója	   lehet	   a	   születés	  
utáni	   életesemények	   tartós	   hatása	   a	   hipotalamikus	   AVP	   gén	   kifejezésre	   (Bunck	   et	   al.,	  
2009;	  Murgatroyd	  et	  al.,	  2009).	  	  Humán	  poszt-­‐mortem	  anyagban	  Swaab	  és	  munkatársai,	  
de	  mások	  is	  (Mouri	  et	  al.,	  1993)	  vizsgálták	  a	  hipotalamikus	  AVP	  kifejezést	  (Purba	  et	  al.,	  
1996;	   Raadsheer	   et	   al.,	   1994).	   Eredményeik	   alapján	   fölvetődik,	   hogy	   melankólikus	  
depresszióban	   a	  magnocelluláris	   és	   parvicelluláris	   rendszerben	   egyaránt	   szignifikánsan	  
magasabb	  	  hipotalamikus	  	  AVP	  kifejezés	  okozza	  az	  ehhez	  a	  kórképekhez	  gyakran	  társuló	  
kortizol	   túltengést	   (Holsboer,	   2001).	   Idős	   korban	   szintén	  megnő	   a	   hipotalamuszban	   a	  
CRF41-­‐AVP	  ko-­‐lokalizáció	  ami	  oka	  lehet	  az	  idősekben	  megfigyelhető,	  stressz	  helyzet	  után	  
lassabban	   lecsengő	  plazma	  kortizol	   	   válasznak.	   	  Az	   időskorban	  megnövekedett	   stressz-­‐
indukálta	  plazma	  kortizol	   válasznak	  patogenetikus	   szerepe	   lehet,	  elsősorban	  a	  gyakran	  
fellépő	   szorongásos	   rendellenességekben,	   illetve	   súlyosabb	   esetekben	   progresszív	  
hippocampus	   atrófiában	   (Holsboer,	   2001;	   Sapolsky	   et	   al.,	   2000).	   	   A	   károsnak	   tűnő	  
pszichotróp	   hatásokkal	   ellentétben	   autoimmun	   modellekben	   a	   	   tartós	   kortizol	  
hiperszekréció	   életmentő	   hatású	   (Mason,	   1991).	   	   Beltenyésztett,	   az	   immunreakció	   fő	  
génjeire	   (HLA	   rendszer	   homológok)	   szingenetikus	   patkány	   és	   egértörzsek	   vizsgálatával	  
kimutatható,	   hogy	   mellékvesekéreg	   hormon	   túltengés	   öröklődhet	   és	   javítja	   az	  
autoimmun	  gyulladás	   túlélésének	  esélyeit	   (Mason	   et	  al.,	   1990).	   	  Mai	   tudásunk	  alapján	  
nem	   zárható	   ki	   azonban,	   hogy	   ezeknél	   	   a	   HPA	   „hiperreaktiv“	   állattörzseknél	   is	  
epigenetikus	  tényezők	  dominálnak	  azaz	  további	  vizsgálatokra	  van	  szükség	  az	  állatok	  HPA	  
reaktivitásának	  korai	  életkorban	  történő	  „programozását“	  illetően	  (Holmes	  et	  al.,	  2006).	  	  
További	   fontos	   közlés,	   hogy	   Freund	   adjuvánssal	   indukált	   artritiszben	   szenvedő	  
patkányok	  hipofízeális	   portális	   vérében	  ötször	  magasabb	  AVP	   szinteket	   találtak	  mint	   a	  
kontrollokban	   (Chowdrey	   et	   al.,	   1995).	   Ezzel	   párhuzamosan	   a	   hipofízeotróp	   CRF41	  
sejtekben	   kimutatható	   AVP	   mRNS	  mennyisége	   is	   jelentősen	   emelkedett	   míg	   a	   CRF41	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mRNS	  szintje	  változatlan	  maradt	  (Chowdrey	  et	  al.,	  1995).	   	   	   	  Tehát	  nagy	  valószínűséggel	  
ebben	   az	   állapotban	   a	   parvicelluláris	   AVP	   idézi	   elő	   a	   tartós	   hiperkortizolémiát.	  	  	  
Összefoglalva,	   	   adataink	   rámutattak	   az	   AVP	   glukokortikoid	   visszacsatolást	   módosító	  
hatására,	  amelynek	  jelentős	  szerepe	  lehet	  különböző	  emberi	  kórképek	  patogenezisében	  
és	  lefolyásában.	  	  
	  
	  
3.2.3	   A	   HPA	   rendszerbeli	   glukokortikoid	   korai	   késleltetett	   gátlás	   mechanizmusát	   és	  
hatékonyságának	   meghatározóit	   elemeztük	   a	   hipofízeális	   kortikotróp	   sejtek	   szintjén.	  
Megállapítottuk,	  hogy	  a	  gátlás	  20	  percen	  belül	  kifejlődik,	  új	  mRNS	  és	  fehérje	  szintézisét	  
igényli,	  és	  nagyrészt	  a	  plazma	  membrán	  szintjén	  zajlik.	   	  Egér	  hipofízis	   tumor	  sejtekben	  
kimutattuk,	   hogy	   a	   BK-­‐csatorna	   STREX	   variánsa	   játszik	   szerepet	   	   a	   gukokortikoid	  
hatásban,	   a	   hatás	   lényege	   a	   csatorna	   cAMP-­‐dependens	   foszforillációjának	  
megakadályozása.	   	   A	   glukokortikoidok	   által	   indukált	   gátló	   mechanizmus	   nem	  
sejtspecifikus,	   mivel	   humán	   embrionális	   vesesejtekben	   is	   reprodukálható	   volt	  
amennyiben	  azokban	  kifejeztük	  a	  BK-­‐csatorna	  STREX	  változatát.	  Azaz	  a	  BK-­‐STREX	  variáns	  
alkalmas	   lehet	   a	   glukokortikoid	   hatás	   különféle	   sejtrendszerekben,	   így	   pédául	  
limfocitákban	  történő	  kísérleti	  elemzésére.	  	  
	  
A	   hipotézist,	   miszerint	   	   glukokortikoid	   kezelés	   hatására	   a	   BK-­‐csatornához	   kapcsolódó	  
fehérje	   foszfátáz	   (PPA2)	   mennyisége	   változik	   meg	   nem	   sikerült	   igazolni.	   Ko-­‐
immunprecipitációs	   adataink	   szerint	   a	   csatornafehérjéhez	   konstitutívan	   kapcsolódik	   a	  
PPA2	   és	   ebben	   glukokortikoid	   kezelés	   nyomán	   változást	   nem	   találtunk	   (Yazdi	   et	   al.,	  
2005).	   Elképzelhető,	   hogy	   a	   PPA2	   valamely	   szabályozó	   alegysége	   indukálódik,	   amely	   a	  
csatornán	   horgonyzó	   katalitikus	   alegységet	   aktiválja.	   	   Azonban	   az	   is	   femerül,	   hogy	  
korábbi	  kísérleteinkben,	  amelyekben	  okadáttal	  és	  calyculin	  A-­‐val	  gátolhatónak	  bizonyult	  
a	   BK-­‐csatornákra	   kifejtett	   glukokortikoid	   hatás,	   valójában	   a	   kettős	   specifitású	   fehérje	  
foszfatázok	   (DUSP)	   valamelyikét	   bénítottuk,	   amelyek	   a	   kísérleteink	   végzése	   idejében	  
nem	  voltak	  kellően	   jellemezve.	  A	  BK-­‐csatornához	  konstitutívan	  kapcsolódó	  PPA2	  pedig	  
vagy	  más	  szabályozó	  szerepet	  tölt	  be,	  vagy	  a	  fehérje	  túlkifejezésből	  eredő	  műtermék.	  A	  
frissebb	   irodalomban	   a	   DUSP-­‐k	   szerepe	   a	   glukokortikoid	   hormonok	   hatásában	   széles	  
körben	   elfogadott	   (Beck	   et	   al.,	   2009;	   Clark	   et	   al.,	   2008;	   Tchen	   et	   al.,	   2010),	   de	  	  
neuroendokrin	  kontextusban	  nem	  közöltek	  ilyen	  irányú	  vizsgálatokat.	  	  
	  
További	  meglepetésként	  szolgált,	  hogy	  patkány	  adenohipofízis	  primér	  kultúrákban	  a	  BK-­‐
csatornák	  bénítása	  nem	  módosította	  sem	  a	  kortikoszteron	  sem	  a	  dexamethasone	  ACTH	  
elválasztást	   gátló	   hatását.	   	   Ugyanakkor	   két,	   K+-­‐csatorna	   gátlóként	   is	  működő,	   	   klinikai	  
farmakoterápiában	  is	  megfordult	  anyaggal,	  nevezetesen	  astemizollal	  illetve	  clofiliummal	  	  
a	   kortikoszteron	   gátlás	   megszűnt	   illetve	   jelentősen	   gyengült.	   Mások	   reprodukálták	   az	  
astemizol	   hatását	   (Yamashita	   et	   al.,	   2009)	   ugyanakkor	   velünk	   szemben	   szelektív	   hERG	  
csatorna	   bénítókkal	   is	   fel	   tudták	   függeszteni	   a	   kortikoszteron	   serkentett	   ACTH	   leadást	  
gátló	  hatását.	  	  Mivel	  az	  adenohipofízeális	  kortikotróp	  sejtek	  számos,	  az	  ACTH	  szekréciós	  
választ	   befolyásoló	   K+-­‐csatornát	   tartalmaznak	   (Antoni	   et	   al.,	   1990a;	   Kuryshev	   et	   al.,	  
1997;	   Liang	   et	   al.,	   2011),	   ezeket	   a	   látszólagos	   ellentmodásokat	   akutan	   készült	  
adenohipofízis	   szeletkékből	   azonosított	   kortikotróp	   sejteken	   végzett	   elektrofiziológiai	  
vizsgálatokkal	   kellene	   feloldani.	   	   	   További	   érdekes	   kérdés,	   hogy	   a	   hippocampalis	   CA1	  
régió	   piramis	   sejtjeiben	   is	   kimutatható,	   és	   az	   adenohipofízeális	   szintű	   kortikoszteron	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hatással	  szoros	  párhuzamot	  mutató	  glukokortikoid	  hatás	  (Joëls,	  1997)	  milyen	  típusú	  K+-­‐
csatornán	  jön	  létre?	  	  Mint	  az	  AtT20-­‐as	  sejtek	  példáján	  láttuk,	  szoros	  analógiákat	  mutató	  
„fenotípus“	   dacára	   a	   glukokortikoid	   hatás	   molekuláris	   célpontja	   sejtenként	   változhat	  
annak	  ellenére,	  hogy	  nagy	  valószínűséggel	  a	  szteroid	  adagolás	  nyomán	  ugyanaz	  a	  fehérje	  
készlet	  indukálódik.	  	  
	  
Az	  AVP	  hipofízeális	  glukokortikoid	  gátlást	  felfüggesztő	  hatását	  illetően	  újszerű	  jelenséget	  
figyeltünk	   meg	   –	   „agonist-­‐induced	   plasticity“	   (Antoni,	   2012)	   –	   amely	   kítűnő	   példa	   a	  
jeltátviteli	   rendszerekben	   tapasztalható	   molekuláris	   szintű	   változatosság	   	   élettani	  
szerepének	   szemléltetésére.	   	   Lényege,	   hogy	   agonista	   hatású	   anyagok	   az	   intracelluláris	  
jelátviteli	   rendszerek	   módosítása	   nyomán	   még	   akkor	   is	   alapvetően	   másfajta	  
tulajdonságú	   sejtválaszt	   hozhatnak	   létre,	   amikor	   a	   lényeges	   intracelluláris	   hírvivő	  
molekulák,	   esetünkben	   a	   cAMP	   és	   a	   Ca2+	   változatlanok.	   	   Éppen	   ezért	   ez	  más	   jelenség	  
mint	   a	   „biased	   agonism“,	   amely	   esetben	   egyazon	   receptor	   különböző	   állapotai	   eltérő	  
típusú	  jeltátviteli	  utakat	  aktiválnak.	  	  A	  konkrét	  példa	  a	  kortikotróp	  sejt,	  	  ahol	  a	  fiziológiás	  
koncentrációjú	   CRF41-­‐el	   serkentett	   cAMP	   termelést	   az	   intracelluláris	   Ca2+	   hatékonyan	  
gátolja,	   ezáltal	   visszacsatolási	   kört	   alkotva	  a	   receptor	  aktiválódás	  plazma-­‐membránbeli	  
hatásai	   felé.	   A	   fiziológiás	   szinteket	   jelentősen	   meghaladó	   CRF41	   koncentráció	  
alkalmazása	  esetén	  a	  Ca2+	  visszacsatolás	  cAMP	  bioszintézisre	  gyakorolt	  hatása	  eltűnt	  –	  a	  
cAMP	   	   szintek	   a	   CRF41	   koncentrációval	   egyenesen	   arányosan	   növekedtek.	   A	  
stresszorokra	   jellemző	   2-­‐3	   nmol/L	   AVP-­‐vel	   fiziológiás	   CRF41	   koncentrációk	   mellett	   is	  
előhívható	  volt	  a	  Ca2+	  gátlás	  alól	   felszabadult	  cAMP	  bioszintézis,	  ezenfelül	  a	   jelenséget	  	  
protein	  kináz	  C-­‐t	  aktiváló	  forbol-­‐dibutirát-­‐észterrel	  is	  utánozni	  tudtuk.	  	  Az	  intracelluláris	  
Ca2+	   cAMP	   szintézist	   gátló	   hatásának	   célpontja	   az	   AC9.	   Magas,	   afiziológiás	   CRF41	  
koncentrációk	   esetében,	   illetve	   AVP	   hatására	   bekövetkező	   protein	   kináz	   C-­‐vel	   történt	  
foszforilláció	   nyomán	   valószínűsíthetően	   az	   AC7	   kerül	   előtérbe	   mint	   	   cAMP	  
bioszintetikus	   enzim.	   Az	   AC7	   paralóg	   sajátossága,	   hogy	   Ca2+	  nem	   befolyásolja,	   protein	  
kináz	   C	   hatására	   aktív	   Gsα-­‐val	   jelentősen	   erősebben	   serkentődik	   mint	   defoszforillált	  
állapotban.	   Érdekes	   módon	   	   az	   AC7-­‐t	   a	   frissebb	   irodalom	   depressziós	   kórképek	   és	  
alkohol	   dependencia	   kapcsán	   viszgálja	   (Desrivieres	   et	   al.,	   2011;	   Pronko	   et	   al.,	   2010).	  
További	   farmakológiai	   vizsgálataink	   azt	   mutatták,	   hogy	   AVP	   jelenlétében	   a	   cAMP	  
lebontásban	   Ca2+/calmodulin	   aktivált	   ,	   kis	   affinitású,	   nagy	   kapacitású	   PDE1	   	   dominál,	  
szemben	   	  az	  alacsony	   intenzitású	  CRF41	   ingerrel	   ahol	   a	  PDE4	  nagy	  affinitású,	   azonban	  
korlátozott	  kapacitású	  altípusának	  közreműködése	  valószínű.	  	  
	  
Összegezve,	   adataink	   azt	   mutatják,	   hogy	   az	   AVP	   kortikotróp	   sejtekre	   gyakorolt	  
hatásának	  fő	  eleme	  	  a	  cAMP	  anyagcsere	  utak	  módosulása:	   	  AC9	  mellett	  az	  AC7	  végzi	  a	  
cAMP	   bioszintézis	   nagyobb	   hányadát,	   a	   Ca2+	   visszacsatolásos	   gátlás	   célpontja	   ezért	  
áttevődik	  az	  AC9-­‐ről	  a	  PDE1A-­‐ra.	  Mivel	  a	  PDE1A	  cAMP	  Km-­‐je	  20	  µmol/L	  szemben	  a	  PDE4	  
család	   1µmol/L	   Km-­‐jével,	   a	   sejtek	   AVP	   jelenlétében	   nagyságrenddel	   magasabb	   cAMP	  
mellett	  működnek.	   Ilyen	  magas	  cAMP	  koncentrációk	  mellett	  a	  cAMP	  által	   szabályozott	  
fehérjék	   további	   fajtái	   pl.	   a	   ciklikus	   nukleotidok	   által	   aktiválható	   ioncsatornák	   lépnek	  
működésbe,	  amelyeknek	  kinyílása	   jelentős	  depolarizációt	  erdeményez	  és	  kézenfekvően	  
magyarázhatja	   az	   AVP	   glukokortikoid	   gátlást	   felfüggesztő	   hatását.	   	   Ennek	   a	  
mechanizmusnak	   kísérleti	   bizonyítéka	   egyelőre	   nincs,	   bár	   ismert,	   hogy	   ciklikus	  
nukleotidokkal	  aktiválható	  ioncsatornák	  kifejeződnek	  az	  adenohipofízisben	  (Kaupp	  et	  al.,	  
2002).	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3.3	  Atriopeptin	  mint	  ACTH	  elválasztást	  gátló	  hormon.	  	  
A	  gerinces	  élőlényeknél	  az	  „ős-­‐stressz“	  a	  só-­‐	  és	  	  vízvesztés	  amelynek	  következménye	  az	  ion-­‐	  
és	   folyadékháztartás	  összeomlása	   lehet.	   	  Ennek	  érdekében	  az	  angiotenzin,	  az	  AVP,	  CRF41	  
és	   a	   mellékvesekéreg	   szteroid	   hormonok	   számos	   szervben	   összehangoltan	   a	   víz	   és	  
sóretenciót	   segítik	   elő	   –	   még	   az	   AVP	   izo-­‐ozmozist	   fenntartó	   hatásait	   is	   folyadéktérfogat	  
csökkentéssel	   semlegesíteni	   lehet.	   Ezzel	   szemben,	   az	   atriopeptin	   ACTH	   elválasztást	  
csökkentő	  hatása	  beleillik	  abba	  az	  általános	  képbe,	  hogy	  az	  atriopeptinek	  számos	  szervben	  
összehangoltan	   működve,	   a	   stressz	   által	   kiváltott	   reakciókat	   ellensúlyozzák.	   	   Tehát	   az	  
atriopeptin	  „nyugi“	  hormon	  amely	  ellensúlyozza	  	  a	  fentebb	  felsorolt	  „izgik“	  hatását,	  ez	  által	  
helyreállítva	   a	   homeosztázist.	   	   Mint	   már	   fentebb	   jeleztem,	   számos	   munkacsoport,	   így	  
Telegdy	   és	   mtsai	   is	   (Biró	   et	   al.,	   1996;	   Biró	   et	   al.,	   1995),	   kimutatta	   az	   atriopeptin	  
pszichotróp,	   ezen	   belül	   anxiolitikus	   hatását.	   Mások	   ebből	   kiindulva	   pánik	   betegségben,	  
általános	   szorongási	  betegségben	  és	  alkohol	  megvonási	   tünetek	   	  enyhítésében	   javasolták	  
terápiás	   szerként	   (Kiefer	   et	   al.,	   2002;	   Kiefer	   et	   al.,	   2011)	   (Kellner	   et	   al.,	   2003).	   	   Az	  
atriopeptin	  és	  a	  glukokortikoid	  gátlás	  viszonylagos	  súlyát	  nem	  vizsgálták.	  	  Logikusnak	  tűnik	  
a	   feltételezés,	   hogy	   az	   atriopeptin	   vagy	   egyéb,	   hatását	   cGMP-­‐n	   keresztül	   kifejtő	   gátló	  
tényező	   a	   glukokortikoid	   non-­‐szuppresszor	   állapotban	   kerül	   előtérbe	   az	  ACTH	  elválasztás	  
szabályozásában.	  	  
	  
	  
4.	  	  KÖSZÖNETNYILVÁNíTÁS	  
	  
Köszönetemet	   szeretném	   kifejezni	   mindazoknak	   akik	   tanítottak.	   Kutatói	   tevékenységem	  
szempontjából	   elsősorban	   Makara	   Gábor,	   Palkovits	   Miklós	   és	   Spät	   András	  
akadémikusoknak	  köszönöm,	  hogy	  a	  mesterség	  különféle	  berkeibe	  bevezettek	  és	  tudásukat	  
önzetlenül	   megosztották	   velem.	   Hasonlóképpen	   hálás	   vagyok	   mindenkori	  
munkatársaimnak	  és	  diákjaimnak.	   Közülük	   	   szeretném	  név	   szerint	  megemlíteni	  Megan	  C.	  
Holmes	  professzort,	  akivel	  hosszabb	  ideig	  együtt	  dolgoztam	  és	  még	  hosszabb	  ideje	  együtt	  
élek.	   Szüleim	   támogatása,	   az	   általuk	   teremtett	   otthoni	   környezet	   nélkül	   nem	   valószínű,	  
hogy	   tudományos	   pályára	   lépek.	   Köszönettel	   tartozom	   azoknak	   a	   kollégáknak,	   akik	  
nélkülözhetetlen	  reagensek	  nagylelkű	  adományozásával	  támogatták	  munkámat,	  közülük	  is	  
kiemelném	  Makara	  B.	  Gábor-­‐t	  (MTA	  KOKI),	  	  Philip	  J	  Lowry	  –t	  (University	  of	  Reading),	  	  Kevin	  
J.	  Catt-­‐	  és	  Harold	  Gainer-­‐t	  (mindketten	  NICHD,	  NIH,	  Bethesda)	  valamint	  Geneviéve	  Rougon-­‐
t	  (INSERM,	  Marseille).	  Szeretném	  kifejezni	  hálámat	  a	  kutatásaim	  anyagi	  fedezetét	  biztosító	  
szervezeteknek	   amelyek	   a	   következők	   voltak:	   Magyar	   Tudományos	   Akadémia,	   National	  
Institutes	   of	   Health,	   Bethesda,	  Maryland,	   Egyesült	   Államok,	   University	   of	   Oxford,	   Anglia,	  
The	   Wellcome	   Trust,	   London,	   The	   Medical	   Research	   Council,	   London,	   University	   of	  
Edinburgh,	  Skócia.	  Végül	  pedig	  köszönöm	  jelenlegi	  munkaadómnak,	  az	  Egis	  Gyógyszergyár	  
NyRT-­‐nek,	  a	  pályamű	  elkészítésében	  nyújtott	  támogatását.	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ANTONI. F. A.. M. C. HOLMES. G. B. MAKARA, M. KARTESZI AND F. A. LASZLO. Evidence that the effects of 
arginine-8-va.~opressin tA VP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. PEP- 
TIDES 5(3) 519-522. 1984.--Ovine corticotropin releasing factor (oCRF-41) and AVP act synergistically to stimulate 
pituitary ACTH secretion. In the present study we have investigated whether the effect of AVP, either in the presence or in 
the absence of oCRF-41 (0.5 nmol/1), could be blocked by V, (pressor)-antagonists. Furthermore, oxytocin, and [I- 
deamino.8-D-arginine] vasopressin (dDAVP) were tested for their ability to release ACTH. All experiments were carried 
out in vitro, using segments of rat anterior pituitary glands. The V~-antagonist [I-deamino,penicillamine(o-methyl- 
tyrosine)]AVP inhibited ACTH release induced by AVP or AVP + oCRF-41. However. it also had some agonistic activity 
which was more pronounced in the presence of oCRF-41. An equally potent V~-antagonist, [I-/3-mercapto-/3. 
/3-cyclopentamethyleneproprionic acid (o-methyl-tyrosineJ]AVP, failed to inhibit AVP-stimulated ACTH secretion, and 
also had weak agonist potency. The relatively selective V._, (antidiureticj-agonist dDAVP was 20--30 fold less potent han 
AVP. Oxytocin. a weak V,- and Ve-agonist was only 4-8 fold less potent han AVP. These data are compatible with the 
suggestion that AVP receptors on pituitary corticotrope cells are neither classical V~- nor V._,-receptors. 
Vasopressin-antagonists Oxytocin I-deamino.8-D-arginine-vasopressin Corticotropin-releasing factor 
THE release of ACTH by the anterior pituitary gland is 
stimulated by AVP (cf., I12]). Some earlier studies of this 
effect suggested that it is mediated by V~ (pressor)-receptors 
II. 8.9. 17, 22.25]. Vasopressin also potentiates the ACTH- 
releasing effect of ovine corticotropin-releasing factor 
(oCRF-41) 113]: the receptors involved in this action of AVP 
have not been characterized. More recently, potent, rela- 
tively selective V,-antagonists have been synthesized and 
characterized Icf.. [28]). Two such antagonists, l l-deamino- 
penicillamine(o-methyl-tyrosine)]AVP (dPenTyr[Me]AVP) 
and 11-/3-mercapto-/3,/3-cyclopentamethylenepropionicacid 
to-methyl-tyrosine)]AVP (dlCH~]:,Tyr[Me]AVP) blocked the 
increase of plasma ACTH levels caused by systemic injec- 
tions of AVP II, 17, 22, 25], and it has been generally as- 
sumed that the site of inhibition is at the level of the pituitary 
gland. Based on this assumption V,-antagonists have been 
used in several studies to establish the physiological role of 
AVP in the hypothalamic regulation of ACTH secretion [6, 
10, 17, 22, 25]. The results of these studies have been varia- 
ble, in part perhaps because V,-antagonists may not directly 
inhibit the action of AVP on pituitary ACTH secretion. 
Therefore, we have investigated the effects of 
dlCH._,].-,Tyr[Me]AVP and dPenTyr[Me]AVP on ACTH re- 
lease in vitro. 
METHOD 
Male Wistar rats (220-280 g body weight) from G. Richter 
Ltd., Budapest, Hungary were decapitated, and the anterior 
lobe of the pituitary gland was removed. Segments of the 
anterior pituitary gland were preincubated for 4 hr in 
Krebs-Ringer bicarbonate medium (KRBG), containing 
L-ascorbate (]0 -4 mol/I) and bovine serum albumin (1 g/l), as 
described previously [3]. Subsequently, various peptides 
were added for another hour in fresh medium. The peptides 
used included oCRF-41, dPenTyr[Me]AVP (courtesy of Dr. 
J. Rivier, La Jolla, CA), dlCH~]sTyr[Me]AVP (courtesy of 
'Requests for reprints hould be addressed to F. A. Antoni at his present address: Laboratory of Cell Biology. National Institute of Mental 
Heahh. NIH. Building 36. Rm 3A-17. Bethesda. MD 20205. 
~Presenl address: National Institute of Child Health and Human Development. Endocrine and Reproduction Research Branch. National 
Institutes of Health. Bethesda. MD 20205. 
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FIG. I. Effect of dPenTyr[Me]AVP on the release of ACTH by 
incubated pituitary segments: (X) basal, and in the presence of (©) 
AVP 10 -" tool/I; (Q) oCRF-41 5x 10 -"~ mold; (I--I) AVP 10-" mol/1 and 
oCRF-41 5x 10 -j° mol/I. Values are geometrical means+~R.S.E.M. 
(indicated by bars), n=8 per group. Three-way ANOVA gave signif- 
icant interaction. F(3.112)= 11.9, p<0.01. **p<0.01 when compared 
to the respective value in the absence of antagonist. Dunn's test for 
multiple comparisons. 
Dr. M. Manning, Toledo, OH) and AVP (Peninsula, San 
Carlos, CA). The above were dissolved in acetic acid (0.I 
mol/I), then diluted further in KRBG. Ovine CRF-41 was 
used at a concentration of 5× 10 - '°  mol/I as this is a close 
estimate of the amount of endogenous 41-residue CRF in rat 
pituitary portal p lasma[ I l l .  Oxytocin (G. Richter Ltd.) and 
[I-deamino,8-D-arginine]vasopressin (dDAVP; Ferring A. 
B., Maim6, Sweden or SPOFA, Prague, Czechoslovakia), 
were obtained in solution. The molar concentration of 
oxytocin was calculated assuming that the bioactivity of the 
pure peptide is 486 IU/mg 121,28]. The ACTH content of the 
medium was determined by radioimmunoassay [201, the 
protein content of the pituitary segments was measured ac- 
cording to Peterson [24[. Hormone release is expressed as 
fmol immunoreactive ACTH released per /xg pituitary 
protein. Data were evaluated after log-transformation to
achieve homogeneity of variances 131, by 2- or 3-way 
analysis of variance (ANOVA). Relative potencies for 
agonistic activity were obtained after linearization of the 
dose-response curves by LOGIT-transformation, and 
measuring the distance between the regression-lines along 
the X-axis. Geometrical means~the retransformed standard 
er ror  of the mean (R.S.E.M.) are presented. 
RESULTS 
The effect of AVP in the absence and in the presence of 
oCRF-41 was markedly reduced by dPenTyrlMelAVP in a 
dose dependent manner (Fig. I). However, the antagonist 
itself enhanced basal as well as oCRF-41-stimulated secre- 
ACTH (fmol /ugpr/h) 
8 -  
4 
2 
/ "  ~r,Jt" 
s / 
. . . . . .  - i -  . . . . .  -.x. 
CRF+AVP 
CRF 
AVP 
Control 
0 ~ I-lf ~ I I I 
o lo-  lo-  
d[CH2]5Tyr [Me]AVP (mol/I) 
FIG. 2. Same as Fig. I except hat d[CH._,]sTyr[Me]AVP was used as 
the antagonist. Three-way ANOVA gave significant interaction be- 
tween AVP and the antagonist. F(3,112)=7.0. p<0.01. **p<0.01. 
when compared to the respective value in the absence of 
antagonist. Dunn's test for multiple comparisons. 
tion of ACTH (Fig. I). When increasing concentrations of
AVP t l0 -~° to 2x 10-" mol/I) were combined with oCRF-41, 
or with oCRF-41 and dPenTyrIMelAVP (10 -4 tool/I), it was 
found that the antagonist had agonistic activity approximat- 
ing that of AVP at 2.5× I0 - '° tool/l, and that the effects of 
higher concentrations of AVP tup to 3.2x 10-" mol/I) were 
attenuated tdata not shown). However, the maximal stimu- 
lation of ACTH release achieved was the same in the pres- 
ence of the antagonist as in its absence (oCRF-41 plus A VP 
8xlO -'~ tool~l: 17.4:_Xl.09:oCRF-41 plus AVP 1.28×10 -r
mol/I plus dPenI)'r[Me]A VP: 19.1~ 1.13, ACTH fmol//zg 
protein, geometrical means+XR.S.E.M., n=8 per group). 
The other antagonist, dlCHd.sTyrl MelAVP had no signif- 
icant effect on AVP induced ACTH release. In contrast. 
weak but significant agonist activity could be demonstrated 
(Fig. 2). Preincubation of the tissue t30 rain) with the 
antagonist did not increase its inhibitory potency tdata not 
shown). Arginine-vasopressin oxytocin, dDAVP and dPen- 
Tyr[MelAVP all enhanced oCRF-41 stimulated release of 
ACTH (Fig. 3). The relative potencies were 0.14 and 0.03 for 
oxytocin and dDAVP respectively, while dPenTyrl MelAVP 
did not have full agonist activity. Similar relative potencies 
(oxytocin 0.24, dDAVP 0.05) were obtained for these com- 
pounds when they were applied without oCRF-41 (Fig. 4). 
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FIG. 3. Effect of AVP related peptides on ACTH release in the 
presence of oCRF-41 (5x 10-'" xnol/1). Data were standardized by 
taking basal release as unity, tO) AVP the average R.S.E.M. of the 
curve is: 1.17: (X) oxytocin:l.20: (©) dDAVP:l.26; (El) dPen- 
Tyr(Me)AVP:I.2:n=8 for all data points• 
DISCUSSION 
The data presented above suggest hat receptors for AVP 
on pituitary corticotropes are different from Vr  or V._,- 
receptors. We have shown that dPenTyr[Me]AVP inhibits 
the effect of AVP on pituitary ACTH release in the presence 
or absence of 5 × i 0-'° mol/1 oCRF-41. However, the antagonist 
was found to have significant, albeit partial agonist activity. 
Increasing the concentration of AVP in the presence of an 
inhibitory concentration of dPenTyr[Me]AVP resulted in a 
maximal ACTH release which was identical to that obtained 
without antagonist. Moreover, oCRF-41 enhanced the ef- 
fects of dPenTyr[Me]AVP just as those of other analogs of 
AVP tested. These observations suggest that dPen- 
Tyr[Me]AVP is in fact a partial-agonist, competitive 
antagonist on pituitary AVP receptors. 
In the present study d[CH~].~Tyr[Me]AVP had no statisti- 
cally significant effect on AVP-stimulated ACTH release. 
Nevertheless it is possible that a minor inhibitory action 
demonstrated in cultures of fetal pituitary tissue [4] might 
have been masked by the relatively high variation of the 
present data. Recently. Knepel and coworkers have reported 
[18] that d[CH:].~Tyr[Me]AVP is a weak antagonist of AVP- 
induced /3-endorphin release by corticotrope cells of the 
anterior pituitary gland, however, they could achieve a sub- 
stantial inhibition by high a concentration of antagonist, 
which proved to have agonist activity in our hands. Never- 
theless, it seems clear that dPenTyr[Me]AVP is a more po- 
2- -  
1 
0 
ACTH (x basal ) 
jO  
• • x • o 
• 0.-- -~0  t3 Basa l  
I I I I I I I I I 
0.1 0.5 2.5 12.5 62.5 312.5 1562 7810 39050 
Peptide ( nmoll l  ) 
FIG. 4. Effect of AVP related peptides on ACTH release, oCRF-4I 
was not applied. Pooled data from several experiments standardized 
by taking basal release in respective experiments a unity. (O) AVP 
the average R.S.E.M. of the curve is: I. 19; (X) oxytocin:l. 15; (©) 
dDAVP:I. 16; (Fq) dPenTyr(Me)AVP 1.22. 
tent antagonist of AVP in the pituitary than 
d[CH.,].~Tyr[Me]AVP. The converse is usually found when 
responses mediated by V,-receptors are studied [28]. 
Both dPenTyr[Me]AVP and d[CH2]~Tyr[Me]AVP had 
low, but significant agonist activity and dPenTyr[Me]AVP 
was more potent in this regard. The agonist effect of these 
compounds on pituitary ACTH release could be demon- 
strated in other systems, such as isolated anterior pituitary 
cells and cultures of fetal rat pituitary [4]. In contrast, neither 
of the antagonists used in this study has been shown to have 
Vragonist activity in any system tested [16,28]. Thus it 
seems unlikely that the effect of AVP on pituitary cortico- 
trope cells is mediated by classical V~-receptors. 
Both dPenTyr[Me]AVP and d[CH2]sTyr[Me]AVP pos- 
sess some V._, (antidiuretic) activity [28], hence the ACTH- 
releasing effect could be mediated by V_,-receptors. Accord- 
ingly, we examined the effects of dDAVP, a peptide which is 
as potent as AVP for V._,-type effects, but has very low V~- 
type activity [7, 16, 27, 30]. Both preparations of dDAVP 
used (Ferring and SPOFA) were approximately 25-fold less 
effective than AVP in stimulating the release of ACTH. This 
suggests that the response is not mediated by V.~-receptors 
either. Recent data on the secretion of/3-endorphin by rat 
anterior pituitary tissue in vitro are in agreement with this 
suggestion [18]. Therefore, it could be argued that both V~- 
and V,,-type activities are required for full ACTH releasing 
potency. However, oxytocin a peptide with about 1/100 or 
less of the V1- or the V2-type activities of AVP [2, 7, 16, 21, 
28] was only approximately 5-8-fold less potent than AVP, 
corroborating earlier findings [3,5]. Moreover, it appears 
that similar relative potencies for the ACTH releasing activ- 
ity of AVP analogs are found in the presence or in the ab- 
sence ofoCRF-41 ([3, 5, 18], present study). Hence, it seems 
reasonable to suggest hat the potentiation of oCRF-41 and 
the stimulation of ACTH release by AVP alone are mediated 
by the same type of receptor. This receptor seems to be 
distinct from classical V1- or V2-receptors, and is clearly not 
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identical to the adenylate-cyclase coupled binding sites that 
mediate the action ofo-CRF-41 ([15,29], Holmes,  Antoni and 
Szentendrei,  submitted). 
Our data obtained in vitro are at variance with a number 
of  recent in vivo observations showing that dPen- 
Tyr[Me]AVP as well as d[CH._,].~Tyr[Me]AVP potently an- 
tagonize the stimulation of  ACTH secretion by a systemic 
injection of AVP [i,  17, 22, 25]. Since these observations 
supported earl ier findings [8, 9, 23], it was usually concluded 
that the pituitary actions of  AVP are mediated by V~- 
receptors. However ,  the main site of  action of  AVP in such 
cases is not necessari ly at the pituitary gland. For instance. 
functional as well as morphological evidence suggests that 
AVP may influence the release of 41-residue CRF from the 
hypothalamus [14, 19.26], either by a direct central nervous 
action, or through a secondary mechanism, e.g.. the 
" 'stress" of  a pressor response. 
In summary, we have presented evidence that AVP re- 
ceptors on pituitary cort icotrope cells may represent a novel 
type of receptor. Studies with more specifically designed 
AVP analogs are warranted to investigate further the nature 
of  the effect of  AVP on pituitary ACTH secretion. 
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OXYTOCIN RECEPTORS IN RAT ADENOHYPOPHYSIS: EVIDENCE FROM RADIOLIGAND BINDING STUDIES.
FERENC A. ANTONI
Department of Human Anatomy, South Parks Road, Oxford 0X1 3QX, U.K.
ABSTRACT: The nature of purported receptors for oxytocin (OT) in the rat adenohypohysis was investigated by
means of radioligand binding. Tritium-labeled oxytocin (H-OT) was used as the radioligand. Particulate
fractions prepared from the adenohypophysis of estrogen-treated female rats bound H-OT reversibly and with high
affinity (K^= 1.5 nM). Scatchard plots indicated the presence of a single, low-capacity binding-site (Bmax=33
fmol/mg protein). However, ligand displacement experiments suggested that H-OT labels OT- as well as vasopres-
sin-preferring sites in adenohypophysial membrane-suspensions. When the number of pituitary vasopressin recep-
tors was reduced by adrenalectomy, it was revealed that the ligand-specificity of the high-affinity OT binding
site is similar to that of classical OT receptors. The results show the presence of separate receptors for OT
and vasopressin in the rat adenohypophysis, and hence reinforce the notion that OT may function as a hypophyseo-
trophic hormone.
Oxytocin (OT) is a hypothalamic neurohormone
which, apart from its well-defined actions in peri-
pheral tissues, stimulates the secretion of ACTH and
PRL by a direct action on pituitary cells (1-5). The
mechanism of action of OT in the pituitary gland is
poorly characterized, for instance, it is not known
whether OT activates pituitary-type vasopressin re-
ceptors (6-9), or acts via genuine uterine-type oxy-
tocin receptors. The aim of the present work was to
examine the nature of purported oxytocin receptors in
the anterior pituitary lobe.
MATERIALS AND METHODS
Female Wistar rats (2OO-25Og BW), bred in the
Animal House of the Department of Human Anatomy,
Oxford, were used throughout. It was recognized in
the preliminary stage of the experiments that the
treatment of the animals with estrogen (diethyl-
stilbestrol, SIGMA Co, St Louis, MO) increased the
amount of radiolabeled OT bound by adenohypophysial
membrane-suspensions. Therefore, all animals were
injected with 20 yg of estrogen dissolved in dimeth-
ylsulfoxide 24 and 48 h before decapitation. In some
cases the rats were ovariectomized and/or adrenalec-
tomized 5 days before the day of the experiment.
There were no marked differences in the characteris-
tics of the binding of radiolabeled OT to pituitary
membranes prepared from estrogen-treated or ovariec-
tomized and estrogen-treated rats, hence these re-
sults are reported together.
Anterior pituitary lobes and uteri were collec-
ted in ice-cold saline to be homogenized in 20 mM
NaHC03 and 5mM Na2EDTA (10,11). The homogenates were
spun at 600 x g_ for 5 min at 4 C; the supernatant
was centrifuged 2 x 20 min at 30,000 x g_. The resul-
ting pellets were resuspended in 50 mM TRIS-HC1, pH
7.4, containing 5 mM MgSO4, 100 mg/liter bacitracin
(SIGMA) and 0.5 g/liter BSA (SIGMA No.7906) (7,11).
The concentration of protein was 80-140 ug/tube.
The membrane suspensions were incubated in a
volume of 250 ul at 22 C either in the presence of
increasing concentrations of tritium-labelled 0T ( H-
OT) or 8-arginine-vasopressin (^ H-AVP) both from
Dupont U.K., SA 40 and 67 Ci/mmol, respectively, or
with a constant concentration of radioligand, and
increasing amounts of non-radioactive peptide analo-
gues. These analogues were: OT, AVP (Bachem, Torran-
ce, CA), l-deamino-8-D-Arginine AVP (dDAVP, courtesy
of Ferring AB, Malmd, Sweden), hydroxy-4-threonine-7
glycine 0T (OH-Thr -Gly^-OT, courtesy of M. Manning,
Received: June 13, 1986
Toledo, OH), l-deamino-4-lysine AVP (courtesy of G.
Tcth, Szeged, Hungary).
Bound and free hormone were separated by vacuum
filtration over Whatman GF/C filters. The amount of
radioactivity retained by the filters was measured by
liquid scintillation counting at 45% efficiency.
Non-specific binding, the amount of radioactivity
attached to the filters when the incubation buffer
contained 1 yM OT, was 30-40% of total bound radioac-
tivity when 2.5 nM of 3H-OT was used. Binding
displacement curves were linearized by LOGIT-log
transformation, and inhibitory constants (K-) were
calculated according to Cheng and Prusoff (12).
0 30 6 0 W 0 30 6 0 T O
time (mini
Fig 1. The time-course of association ( lef t panel)
and dissociat ion (right panel) of 3H-OT (2.5 nM) in
adenohypophysial membrane-suspensions. Means of
duplicate measurements.
RESULTS
The association of ^H-OT to pituitary membrane
suspensions reached a steady state by 60 min (Fig 1).
Virtually complete dissociation of the radioligand
was observed upon addition of 5 ml of assay buffer
containing 1 yM 0T (Fig. 1). Estimation of the "on"-
and "off-rates of the reaction (13) yielded a disso-
ciation constant (KJ) of 1.4 nM. In the steady state
(60 min) the specific component of the binding of H-
OT was saturable (Fig. 2) and Scatchard plots sugges-
ted the presence of a single site with K^ = 1.5 +_ 0.1
nM and B = 33+4 fmol/mg protein (n = 3, mean + SEM)
Whenthe specificity of the binding reaction was
examined, 0T and AVP appeared equipotent (Fig 3A),
with a K- of 1.4 and 1.5 nM, respectively, while the
selective antidiuretic agonist dDAVP was 3CHtimes less
2393
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Fig 2. The specific (x) and non-specific (o) compo-
nents of the binding of 3H-OT (2.5 nM) to adenohypo-
physial membrane fraction. Means of duplicates from a
representative experiment. Inset: Scatchard-plot of
the data, Kd 1.7 nM, B m x 39 fmol/mg protein.
potent than the former compounds (data not shown).
The selective oxytocin agonist, OH-Thr4Gly'GT, ap-
peared slightly more potent than OT, but did not
displace 3H-OT completely (Fig. 3A): in 3 experiments
the maximal displacement was 37+3% (mean+SEM). In
the same concentration-range, OH-Thr4Gly^3T failed to
influence the binding of 3H-AVP to pituitary mem-
branes (Fig. 3B), but was, as expected, the most
potent displacer of 3H-GT in rat uterus membranes
(Fig. 3C). The peptide dLys4AVP appeared to provide
the mirror-image of OH-Thr4Gly GT: it displaced only
about 30% of the ^H-OT bound by pituitary membrane
suspensions (Fig. 3A). It was almost as potent as AVP
on the pituitary AVP receptor (Fig. 3B) and proved to
be a low-affinity ligand for uterine OT receptors
(1^=0.5 uM, Fia 3.C). Put together, the data
suggested that ^ H-OT interacts with two types
of receptor in rat adenohypophysis: a uterine-
type OT receptor and the pituitary AVP receptor.
This hypothesis was tested by examining the
ligand profile of 3H-OT binding in pituitary mem-
branes obtained from adrenalectomized, ovariectomized
and estrogen-treated rats. Adrenalectomy reduced the
binding of 3H-AVP by 85% (data not shown, see ref.
10). After adrenalectomy (Fig. 4), the relative
potencies of the analogues tested were the same in
the pituitary membrane-suspension as on the uterine OT
receptor, and, furthermore, OH-Thr4Gly OT completely
displaced 3H-OT.
100 r
50
Hh
0.11 1 5
Cone nM
3t
81 729
Fig 4. Displacement of •'H-OT (2.5 nM) by peptide
analogues in pituitary membrane-suspensions obtained
from ovariectomized, adrenalectomized and estrogen-
treated rats. Symbols as in Fig 3. Means of dupli-
cates .
DISCUSSION
The concentration of OT in hypophysial portal
blood is in the nanomolar range (14,15), which is
sufficient to stimulate the secretion of ACTH and PRL
by pituitary tissue in vitro (1-5). The results pre-
A. 100r
50
B. 100r C. 100r
HI L—
0 0.11 729 81 729
Fig 3. Displacement of 3H-OT (2.5 nM) by 0H-Thr4Gly70T (•), OT (o ), AVP (Q) or dLys4AVP (•) in adenohypo-
physial (A) and uterine (C) membrane fractions obtained from estrogen-treated rats. Panel B shows the displa-
cement of 3H-AVP (1.5 nM) by the same analogues in adenohypophysial membrane fractions from estrogen-treated rats.
Means of duplicates from representatives of at least 3 similar experiments.
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sented here suggest that the hypophysiotrophic ac-
tions of OT may be mediated by typical OT receptors,
which have been previously characterized in the ute-
rus and the mammary gland (11).
In pituitary membrane-suspensions the major
technical difficulty was to characterize the binding
of 3H-OT to the high-affinity site, in the face of
distorting interference from pituitary-type AVP re-
ceptors. These bind OT with a K^ of cca. 100 nM (7)
and are about 5 times more abundant in rat adenohypo-
physis than OT receptors (Antoni, unpublished). Hen-
ce the experimental approach: i) pretreatment of
rats with estrogen, which increased OT receptor
acitivity,(it could not, however, be established with
certainty whether receptor affinity as well as capa-
city were increased , unpublished data); ii) using
relatively low radioligand concentrations; and iii)
adrenalectomy, which selectively down-regulated AVP
receptors, was chosen to minimize the interference
from AVP receptors. Despite these maneuvers, it is
likely that the KJ of the OT receptor is overesti-
mated. Because of the low ratio of specific to non-
specific binding, and limitations on the amount of
tissue that could be used, the "single-site" indi-
cated by the Scatchard-analysis is in all probability
comprised of two components - a high affinity OT
receptor and the pituitary AVP receptor.
Nevertheless, the data clearly show that the
adenohypophysis of the estrogen-treated female rat
contains high-affinity sites which bind ^H-OT. The
ligand-specificity of these sites closely resembles
that of classical OT receptors.
Lactotroph and corticotroph cells are the stron-
gest candidates for cells which may express the OT
receptor. The modulation by estrogen favors the
involvement of lactotrophs which respond to OT, but
not to AVP, by increased PRL release (5). Further-
more, a preliminary study has reported that immuno-
neutralisation of OT attenuated the hypersecretion of
PRL induced by treatment with estrogen or
suckling (16). It should be noted, however, that
gonadal steroids may also modulate the corticotroph
response to the cocktail of hypothalamic ACTH-relea-
sing peptides (CRF-41, OT, AVP etc.) found in median
eminence extracts (17). Immunoneutralization of OT
in vivo reduces the ACTH response to some, but
not all, types of stress (18), suggesting the invol-
vement of OT in the regulation of ACTH release. It
remains to be established whether or not these ef-
fects are mediated through the OT receptor described
in the present study. Finally, OT levels in pituita-
ry portal blood are highest on the afternoon of pro-
estrus (19), a period which is preceded by a prolon-
ged elevation of the concentration of estrogens in
blood. It is therefore attractive to speculate that
pituitary OT receptor activity may be increased just
in time to mediate the effects of the surge of hypo-
thalamic OT release.
In summary, the presence of specific, high-
affinity receptors for OT in the adenohypophysis
further strengthens the notion that OT may function
as a hypophysiotrophic hormone.
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ABSTRACT
Oxytocin may function as a hypothalamic releasing
hormone for prolactin and ACTH secretion in the
rat. In the present study we have investigated the
properties of putative oxytocin receptors in the rat
adenohypophysis by radioligand-binding assay.
A novel oxytocin receptor antagonist [1-(\g=b\\x=req-\
mercapto-\g=b\,\g=b\-cyclopentamethylenepropionicacid),2\x=req-\(ortho-methyl)-Tyr2-Thr4-Orn8-Tyr9-NH2]-vasotocin(OTA) was radioiodinated by the iodogen method to
a specific activity of 0\m=.\6nCi/fmol. The radioiodinated
derivative 125I-labelled OTA (125I-OTA) was reacted
with membrane suspensions prepared from the uterus
or adenohypophysis of female rats which were (a)
ovariectomized for 7 days, (b) ovariectomized and
treated with 5 \g=m\goestradiol-17\g=b\48 h before death or(c) implanted with a piece of silicone elastomer tubing
containing 50 mg diethylstilboestrol (DES) 5 days
before death. In uterine as well as the pituitary
membrane suspensions, the radioligand was bound
reversibly and with high affinity (dissociation con-
stants 0\m=.\2\m=+-\0\m=.\1and 0\m=.\1\m=+-\0\m=.\01nmol/lrespectively;
means + s.e.m., n=3) to a single class of sites with
limited binding capacity, which varied with the type of
pretreatment. Oestradiol-17\g=b\increased the binding
capacity fivefold in the uterus in ovariectomized
rats, but only very low specific radioligand binding
was found in pituitary preparations from the same
animals. Treatment with DES markedly increased
the number of receptors in both the uterus and the
adenohypophysis. Studies with several agonist and
antagonist analogues revealed no difference in the
ligand specificity of the uterine and adenohypophysial
sites binding 125I-OTA, indicating that they are the
same species of receptor. Furthermore, ligand-binding
studies, carried out with tritiated vasopressin as tracer
in pituitary membrane preparations, showed that
OTA is not bound by pituitary vasopressin receptors
at concentrations below 1 \g=m\mol/l.
In summary, 125I-OTA is a highly specific radio-
ligand suitable for the analysis of pituitary oxytocin
receptors. The low number ofoxytocin receptors in the
adenohypophysis of rats treated with oestradiol-17\g=b\
suggests that the prolactin-stimulating action of oxy-
tocin is mediated by highly efficient transmembrane
signalling.
Journal ofEndocrinology (1989) 122, 465\p=n-\470
INTRODUCTION
Substantial evidence indicates that in the rat, oxytocin
may function as a hypothalamic releasing hormone
for prolactin and corticotrophin (ACTH) (Gibbs,
1986; Samson, Lumpkin & McCann, 1986; Antoni,
Kovács, Dohanics et al. 1988; Johnston & Negro-
Vilar, 1988). Stimulation of prolactin release by
oxytocin has also been demonstrated in man (Coirò,
Gnudi, Volpi et al. 1987), suggesting that such a
functional role of oxytocin may not be restricted to
rats.
Similar to other peptide hormones, oxytocin exerts
its actions by binding to cell-surface receptors on tar-
get cells. Specific, high-affinity receptors for oxytocin
have been identified in several tissues including the
anterior pituitary gland (Soloff, 1979; de Kloet,
Voorhuis & Elands, 1985; van Leeuwen, van
Heerikhuize, van der Meulen & Wolters, 1985;
Antoni, 1986 ). The study of pituitary oxytocin recep¬
tors is tedious because of the limitations imposed by
the low number of receptors present and the relatively
low specific activity of the radioligand, tritium-
labelled oxytocin. Furthermore, tritiated oxytocin
binds to vasopressin as well as oxytocin receptors in
the adenohypophysis, making it necessary to deplete
vasopressin receptors before any analysis of genuine
oxytocin receptors can be performed (Antoni, 1986 ).
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These problems may be overcome by the use of radio-
ligands having higher specific activity as well as
greater pharmacological selectivity.
In the present study, we report the pharmacological
characterization of adenohypophysial oxytocin recep¬
tors using a novel, highly selective radioiodinated oxy¬
tocin receptor antagonist peptide (Elands, Barberis,
Jard et al. 1988).
MATERIALS AND METHODS
Animals
Female Wistar rats (200-300 g body weight; Harlan
Olac, Bicester, Oxon, U.K.) were used. Under pento-
barbitone anaesthesia (40mg/kg, i.p.) the animals
received s.c. implants of diethylstilboestrol (50 mg;
Sigma Chemical Co., Poole, Dorset, U.K.) in Silastic
tubing (Dow Corning, Midland, MI, U.S.A.; outer
diameter 5 mm, inner diameter 4 mm) 5-6 days before
decapitation. This treatment markedly increased the
amount of radiolabelled oxytocin bound by adeno¬
hypophysial membrane suspensions (S. E. Chadio &
F. A. Antoni, unpublished data). Other groups of rats
were bilaterally ovariectomized under anaesthesia,
injected s.c. with 5pg oestradiol-17ß (Sigma) 7 days
afterwards and killed 48 h later.
Preparation of membrane suspensions for
receptor-binding assay
Anterior pituitary lobes and uteri were removed and
placed in ice-cold saline. Uteri were cut into small
pieces and homogenized in NaHC03 (20 mmol/1)
containing EDTA (5 mmol/1) for 30 s with an Ultra-
Turrax homogenizer (IKA-Sartorius Ltd, Belmont,
Surrey, U.K.). The homogenate was spun at 600 g for
5 min at 4 °C and the supernatant filtered through a
Whatman no. 1 filter paper (Maidstone, Kent, U.K.)
whilst the pellet was rehomogenized and centrifuged
again at 600 g. This procedure was repeated three
times and the supernatants were pooled. Anterior
pituitary lobes were homogenized in a Teflon-glass
homogenizer and the homogenate was spun at 600 #
for 5 min at 4 °C. The supernatant fractions of uterus
and adenohypophysis were finally centrifuged twice
for 30 min at 30 000 £ at 4°C. The resulting pellets
were resuspended in Tris-HCl buffer (50 mmol/1, pH
7-4) containing MgS04 (3 mmol/1), and protein
content was determined according to the method of
Bradford (1976).
Analogues of oxytocin
The oxytocin agonist peptides used were: oxytocin,
arginine vasopressin (AVP) (Ferring A.B., Malmo,
Sweden), [Thr4-Gly7]-oxytocin (TG-oxytocin) (pro¬
vided by Professor M. Manning, Medical College of
Ohio, Toledo, OH, U.S.A.) and [Ala7]-oxytocin(A-oxytocin) (provided by Professor V. Hruby,
University of Arizona, Tucson, AZ, U.S.A.). The
antagonists used were: [l-(ß-mercapto-ß,ß-cyclopenta-
methylene propionic acid),2-(ortho-methyl)-Tyr2-Thr4-Orn8-Tyr-NH2]-vasotocin (OTA) (provided by
Professor M. Manning) and [l-penicillamine,2-(para-
methy1)
-
Phe2
-
Thr4
-
Orn8]
-
oxytocin (PPT
-
oxytocin)(provided by Professor V. Hruby).
Radioiodination of oxytocin antagonist
Equimolar (0-25 nmol) amounts of OTA and Na125I(IMS-30; Amersham International, Amersham, Bucks,
U.K.) were reacted for 15 min at room temperature in
40pi sodium phosphate buffer (0-5mol/1, pH 60) in
a polypropylene vial previously coated with 10 pg
Iodogen (Pierce Eurochemie, Oud-Beijerland, The
Netherlands) at its bottom (Salacinski, McLean,
Sykes et al. 1981). The reaction was stopped by
the addition of 1 ml 0-1 % (v/v) trifluoroacetic acid(TFA), and the mixture was injected through a Sep-
Pak octadecasilyl silica cartridge (Waters, Harrow,
Middx, U.K.). The cartridge was washed with 8 ml
0-1% TFA and developed with 2 ml each of a 10%
stepwise gradient of acetonitrile (HPLC grade; BDH,
Atherstone, Warwicks, U.K.) in 01% TFA (10-80%,
v/v). Typically 50-60% of the radioactivity appeared
in the void volume (i.e. in the TFA washes), and a
peak containing 30-40% of the activity eluted at 40
and 50% acetonitrile. Both fractions could be used in
the binding assay. The specific activity of the tracer
was estimated by measuring the radioactivity eluting
at 40 and 50% acetonitrile (peptide recovery was
assumed to be 100%) as well as by autodisplacement(Morris, 1976) using the uterine membrane suspen¬
sion. Values ranged between 0-6 and 0-7 nCi/fmol; all
calculations were performed using an initial specific
activity of 0-6 nCi/fmol. In some experiments, tritium-
labelled AVP (New England Nuclear, Boston, MA,
U.S.A.; sp. act. 67 Ci/mmol) was also used.
Receptor-binding assay
Aliquots of membrane suspension (15 pg protein for
uterus, 30 pg protein for pituitary membranes) were
incubated in 250 pi Tris-HCl containing MgS04(3 mmol/1), 0-1 % (w/v) bovine serum albumin (Sigma)
and 0-01% (w/v) bacitracin (Sigma) at 22 °C. For
analysis by the method of Scatchard (1949) 125I-
labelled OTA (125I-OTA; 005 nmol/1) was used, and
increasing concentrations of OTA were added to
achieve saturation of the binding sites. In ligand-
displacement studies, varying concentrations of
unlabelled peptides were added to 0-08 nmol 125I-
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OTA/1. When [3H]AVP was used as radioligand in
displacement studies, 0-8 nmol tracer/1 was used.
After incubation for 60 min, bound and free ligand
were separated by filtration over GF/C filters(Whatman) under reduced pressure (Antoni, 1984).
The amount of radioactivity attached to the filters was
measured in a gamma counter at 70% efficiency. Non¬
specific binding was determined in the presence of
1 pmol oxytocin antagonist/1, and was typically 10(uterus) and 30% (pituitary) of the total amount
of radioactivity bound. Binding-displacement curves
were linearized by log-Logit transformation, and
inhibitory constants were calculated using the concen¬
tration of peptide giving 50% displacement (Cheng &
Prusoff, 1973).
RESULTS
Characterization of the binding reaction in pituitary
and uterine membrane suspensions
The binding of l25I-OTA to the pituitary membrane
suspension was time dependent, reaching apparent
steady-state at 60 min (Fig. 1). Dilution of the tracer
at 60 min by adding 3 ml assay buffer containing
1 pmol OTA antagonist/1 decreased the amount
of radioactivity specifically bound. All subsequent
incubations were terminated at 60 min.
1500
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figure 1. Time-course of the association ( ) and dis¬
sociation ( ) of 125I-labelled [l-(ß-mercapto-ß,ß-cyclopen-
tamethylene propionic acid),2-(ortho-methyl)-Tyr2-Thr4-
Orn8-Tyr'-NH2]-vasotocin (OTA) in adenohypophysial
membrane suspensions prepared from oestrogen-pretreated
rats. Dissociation was induced by adding 3 ml assay buffer
containing 1 pmol OTA/1. The points are means of triplicate
measurements.
Divalent cations of Mg,   , Co or Ca did not
modify the binding of I-OTA to the particulate
fraction; however, Mg2+ was included in the assay
buffer in all experiments since it was required for the
high-affinity binding of agonists.
The specific binding of 125I-OTA to pituitary mem¬
branes was saturable (Fig. 2). Scatchard plots of the
binding isotherms were linear, indicating the presence
of a single class of sites with high affinity (dissociation
constant {  ) 0-1+0-01 nmol/1; mean ± s.e.m.,  = 3)
and low capacity (maximum binding capacity (Bmax)
48 + 2 fmol/mg protein;  = 3) (Fig. 2, insert). The
findings with uterine membrane suspensions were
analogous in all respects, except that the KD was
0-2 + 0-1 nmol/1 (« = 3) and the capacity was much
higher (Bmax 1453 + 22 fmol/mg protein).
6 8 10
Bound (pmol/1)
0-1 0-3
Total OTA (nmol/1)
figure 2. The specific component of the binding of 125I-
labelled [l-(ß,ß-cyclopentamethylene propionic acid),2-(ortho-methyl)-Tyr2-Thr4-Orn8-Tyr-NH2]-vasotocin(OTA)
to the adenohypophysial membrane suspension prepared
from oestrogen-pretreated rats. Increasing amounts ofOTA
were added to tubes containing a constant amount of radio-
label (008 nmol/1). Non-specific binding was 30% oftotal
bound when only tracer was present. Points are means of
duplicate measurements from a representative experiment.
The insert shows the Scatchard plot of the dose-dependent
binding curves.
Comparison of the ligand profiles of uterine and
pituitary sites labelled with ,25I-OTA
A summary of the results of displacement studies
is presented in Table 1. In pituitary membranes,
oxytocin and the selective oxytocin receptor agonist
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TG-oxytocin were equipotent, while AVP and A-
oxytocin were substantially less effective. The antag¬
onist OTA proved to be the most potent ligand of
all the compounds tested, while PPT-oxytocin was
equipotent with oxytocin.
table 1. Potency of oxytocin analogues to compete with
125I-labelled [l-(ß-mercapto-ß,ß-cyclopentamethylene pro-pionicacid),2-(ortho-methyl)-Tyr2-Thr4-Orn8-Tyr9-NHJ-
vasotocin (OTA) binding to receptor sites in membrane
suspensions prepared from adenohypophyses and uteri of
female rats pretreated with oestradiol-17ß. The data are
geometrical means with the retransformed s.e.m. in brackets;
 
= 3-5 rats per group
Ä, (nmol/1)
Adenohypophysis Uterus
Analogue
Antagonists
OTA 0-1(1-09) 0-1(1-1)
PPT-oxytocin 1-5(1-1) 1-4(1-2)
Agonists
Oxytocin 0-8(1-1) 1-2(1-2)
TG-oxytocin 0-6(1-3) 2-3(1-2)
A-oxytocin 3-1(1-6) 10-3(1-3)
AVP 7-4(1-6) 15-5(1-2)
K{, inhibitory constant; PPT-oxytocin, [l-penicillamine,2-(para-methyl)-
Phe4-Thr8-Orn]-oxytocin; TG-oxytocin, [Thr7-Gly4]-oxytocin; A-oxytocin,[Ala7]-oxytocin; AVP, arginine vasopressin.
In uterine membranes, the rank order of relative
potencies was the same as in pituitary membrane sus¬
pension: OTA > oxytocin > TG-oxytocin > PPT-oxy¬
tocin > A-oxytocin > AVP. Moreover, the absolute
values of the respective inhibitory constants were
similar.
Finally, OTA had a very low affinity for pituitary
receptors for vasopressin (Table 2).
Effect of low-dose oestrogen on binding sites for
125I-OTA in the adenohypophysis and uterus
There was no appreciable specific binding of the
radioligand by pituitary membranes prepared from
randomly cyclic female rats or ovariectomized rats. In
contrast, binding sites could be detected still in the
uterus of ovariectomized rats: in two experiments
  
was 0-1 and 0-2 nmol/1 and Bmax 140 and 86 fmol/mg
protein. Injection of 5 pg oestradiol-17ß in ovariecto¬
mized rats increased the concentration of binding sites
in the uterus at 48 h (Bmax 434 + 20 fmol/mg protein,
 
= 3), while the KD was not altered. This type of
table 2. Displacement of [3H]arginine vasopressin (AVP)(0-8 nmol/1) by AVP and [l-(ß-mercapto-ß,ß-cyclopenta-
methylene propionic acid),2-(ortho-methyl)-Tyr2-Thr4-Orn^Tyr'-NHJ-vasotocin (OTA) adenophypophysial
membrane preparations. Data are means ofduplicate
measurements
Concentration % Specific IC,,,(nmol/1) binding (nmol/1)
Analogue
AVP 0-33 97 7-4
1 88
3 62
9 43
27 20
81 11
OTA 11 93 >1000
33 98
100 95
300 99
1000 97
IC50, concentration producing 50% inhibition.
oestrogen treatment had no consistent effect on the
specific binding of l25I-OTA in the adenohypophysis,
which was not sufficiently high to be characterized.
DISCUSSION
The results show that l25I-OTA labels uterine-type
oxytocin receptors in the adenohypophysis of rats
exposed to a pharmacological dose of oestrogen.
The properties of the interaction of 125I-OTA with
uterine and pituitary membrane suspensions fulfil the
classical receptor criteria of high affinity, reversibility
and pharmacological specificity. With the latter, we
found no marked difference between the ligand profile
of the pituitary and uterine receptors labelled by
125I-OTA, suggesting that the radioligand labels
genuine oxytocin receptors in both types of membrane
preparation. The high-affinity binding of the selective
oxytocin agonist TG-oxytocin (Manning & Sawyer,
1985) in both systems is the most important finding in
this regard. Moreover, the rank order of binding
potencies of agonists is largely in agreement with
their reported biological activity in the myometrium(Manning & Sawyer, 1985; Hruby, 1986).
An unusual property of the binding of 125I-OTA is
the lack of a requirement for divalent cations (e.g.Mg2+), which is a prominent feature of the binding of
tritiated oxytocin to its receptors (Pearlmutter &
Soloff, 1979; Antoni, 1986 ). In experiments reported
elsewhere (Antoni & Chadio, 1989), we have studied
this phenomenon in detail and found that similar to
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some other receptor systems (Bird & Maguire, 1978;
Williams, Mullikin & Lefkowitz, 1978), Mg2+ modu¬
lates the affinity of the oxytocin receptor for agonists,
but not antagonists.
We also observed that OTA had a very low affinity
for pituitary vasopressin receptors which is in keeping
with previous observations (Antoni, 1987), showing
that ligands with the bulky hydrocarbon ring attached
to their N-terminal Cys residue have very low affinity
for this type (V3) of vasopressin receptor. Thus 125I-
OTA is a useful tool for the assay of oxytocin
receptors in the anterior pituitary gland.
An interesting characteristic of various biological
responses elicited by oxytocin, including the stimu¬
lation of prolactin secretion, is the modulation of the
response by oestrogens, which is at least partly due to
the regulation of the number of oxytocin receptors in
target tissues (Fuchs, Periyasamy, Alexandrova &
Soloff, 1983; Fahrbach, Morrell & Pfaff, 1985; de
Kloet et al. 1985; Sheldrick & Flint, 1985).
The concentration of oxytocin receptors in the
uterus as well as the adenohypophysis was markedly
increased upon prolonged exposure to a pharmaco¬
logical dose of synthetic oestrogen, confirming pre¬
vious observations (Soloff, 1979; Antoni, 1986 ). A
treatment regimen with oestradiol-17ß, which is a
closer approximation of the physiological situation,
effectively increased oxytocin receptor concentration
in the uterus, but was without detectable effect in the
pituitary gland. It is, however, well documented that
oxytocin stimulates prolactin secretion in rats given
the same treatment with oestradiol (Samson et al.
1986). Thus it is more likely that we failed to detect
oxytocin receptors in the anterior pituitary gland
under these conditions because of the limitations of
the binding assay. In particular, l25I-OTA is a hydro-
phobic peptide, and increasing the concentration of
membrane protein in the assay reduces the ratio of
specific to non-specific binding quite dramatically,
thus limiting the amount of membranes that can be
used.
Furthermore, it is possible that upon exposure to
oestradiol, oxytocin secretion from the hypothalamus
increases and oxytocin receptors are down-regulated,
whilst transmembrane signalling becomes amplified,
and thus a substantial hormonal response is found
despite the scarcity of cell-surface receptors for
oxytocin. A similar situation exists in adrenalecto¬
mized rats where pituitary receptors for vasopressin
and corticotrophin-releasing factor are virtually
undetectable (Wynn, Hauger, Holmes et al. 1984;
Antoni, 1987), the post-receptor inositol lipid and
adenylate cyclase responses are reduced (Wynn et al.
1984; Todd & Lightman, 1987), yet the amount of
ACTH secreted upon stimulation with vasopressin is
actually enhanced (Antoni, 19860). Further studies
are needed to clarify these issues for the case of
oxytocin-stimulated prolactin release.
In summary, we show that 125I-OTA is a highly
specific radioligand for the detection of oxytocin
receptors in the anterior pituitary gland.
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ABSTRACT
We have previously characterized specific oxytocin
receptors in the rat anterior pituitary gland, using a
highly selective oxytocin receptor antagonist as radio\x=req-\
ligand. The aim of the present study was to examine
whether occupation of these receptors by oxytocin
produces a stimulation of prolactin release and a rise
in the accumulation of total inositol phosphates in
the rat adenohypophysis. Anterior pituitary cells
harvested from randomly cycling and diethylstil-
boestrol (100 \g=m\gs.c.)-treated rats were perifused
with Dulbecco's minimal essential medium at a rate
of 0\m=.\3ml/min. Oxytocin and the specific oxytocin
agonist [Thr 4-Gly 7]-oxytocin (TG-OT) both stimu-
lated a significant prolactin release at concentrations
of 10-6 and 10-7 M. Oestrogen treatment did not
affect the response to oxytocin, indicating that there
is no straightforward correlation between receptor
number and prolactin secretory response in the rat
pituitary gland.
The involvement of phosphoinositide hydrolysis
was investigated in dispersed anterior pituitary cells
and uterine tissue from randomly cycling rats. Oxy-
tocin and arginine-vasopressin stimulated a signifi-
cant (P<0\m=.\05)and dose-related increase in total
inositol phosphates, vasopressin being more potent.
The specific oxytocin agonist TG-OT had no effect
on total inositol phosphate production in pituitary
cells, but when tested in uterine tissue it significantly(P< 0.05) stimulated the accumulation of total inosi-
tol phosphate at all concentrations tested (10-5 to
10-9 m). In conclusion, the data show that oxytocin
has prolactin-releasing activity, acting on specific
receptors in the anterior pituitary gland. Further-
more, although oxytocin receptors in the rat uterus
are coupled to the inositol phospholipid cycle, it
would appear that this is not a prerequisite for the
stimulation of prolactin secretion when specific oxy-
tocin receptors in the rat adenohypophysis are
activated.
Journal of Molecular Endocrinology (1993) 10, 107-114
INTRODUCTION
Oxytocin is one of several neuropeptides which
stimulate the secretion of prolactin by a direct action
on anterior pituitary cells (Lumpkin et al. 1983; Abe
et al. 1985; Horn et al. 1985; Samson et al. 1986;
Schramme & Morrison, 1986). Oxytocin has been
detected in rat hypophysial portal blood at levels
which exceed those in peripheral blood by a factor
of 50-100 (Gibbs, 1984), suggesting that it may con¬
tribute to the regulation of the release of anterior
pituitary hormones. Oxytocin receptors in the rat
adenohyphophysis resemble uterine receptors with
respect to ligand pharmacology (Chadio & Antoni,
1989). However, the conditions for the oxytocinergic
stimulation of adenohypophysial hormone secretion
have not been fully defined. The formation of inosi¬
tol phosphates (IPs) has been implicated in various
target tissues as a mediator of the action of oxytocin(Marc et al. 1986; Schrey et al. 1986), but the mecha¬
nism of action of oxytocin in the anterior pituitary
gland has not been investigated.
The objectives of this study were to investigate
the prolactin-releasing activity of oxytocin in vitro
and to examine whether oxytocin receptors in the rat
anterior pituitary gland increase the production of
IPs when activated by the hormone.
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MATERIALS AND METHODS
Animals
Female Wistar rats (200-300 g body weight) were
purchased from Harlan Olac, Bicester, Oxon, U.K.
For perifusion studies, two groups of rats were used:
a) randomly cycling and b) injected s.c. with 100 pg
diethylstilboestrol (Sigma Chemical Co., Poole,
Dorset, U.K.) and killed 48 h later. For the measure¬
ments of formation of IPs randomly cycling rats
were used.
Chemicals
Oxytocin and arginine-vasopressin were provided
by Ferring A. B. (Malmö, Sweden). [Thr4-Gly7]-
Oxytocin (TG-OT) and [l-(ß-mercapto-ß,ß-cyclo-
pentamethylene propionic acid),2-(ortho-methyl)-
Tyr -Thr -Orn -Tyr -NH2]-vasotocin (OTA) were
kindly provided by Prof. M. Manning (Medical Col¬
lege of Ohio, Toledo, OH, U.S.A.). Hepes, DNAse
I, lima bean trypsin inhibitor and other reagents
were purchased from Sigma Chemical Co. and tryp¬
sin TRK from Lome Laboratories (Reading, Berks,
U.K.). Myo-[2-3H]inositol was from Amersham
International pic (Amersham, Bucks, U.K.) and AG
1 X8 was obtained from Bio-Rad (Watford, Herts,
U.K.).
Perifusion of isolated rat anterior
pituitary cells
Isolated cells were prepared from adenohypophyses
by modifying previously published procedures(Gillies & Lowry, 1978; Dobson & Brown, 1985).
The anterior pituitary lobe was separated from the
posterior lobe and minced with a razor blade to
segments of approximately 05 mm diameter or
15
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Basal 10" 10"'
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10"
FIGURE 1. The release of prolactin by perifused anterior pitu¬
itary cells from randomly cycling rats in response to oxy¬
tocin. Four columns of cells were exposed to various
concentrations of oxytocin for 2-5 min in a randomized
complete block design. Data are means ± s.E.M. .(n = 4/group).
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figure 2. Effects of oxytocin on prolactin release by perifused
anterior pituitary cells from animals treated with diethylstil-
boestrol. Values are means ± S.e.m. (rc = 4/group).
smaller. The tissue fragments were placed in
Dulbecco's minimal essential medium (DMEM;
Gibco, Paisley, Strathclyde, U.K.), buffered with
22 mM Hepes at pH 7-4 containing 2-5 g trypsin/1,
2-5 g bovine serum albumin (BSA)/1 (ICN Bio-
medicals Ltd, High Wycombe, Bucks, U.K.), 1 mg
DNAse 1/1 (0-5 ml solution per gland) and incubated
at 37 °C for 20 min. To facilitate dispersion, the tis¬
sue segments were aspirated into a 5 ml Pipetman
tip (Gilson, Worthington, OH, U.S.A.) every 5 min,
and after 20 min they were triturated with a plastic
pipette (Sterilin, Hounslow, Middlesex, U.K.)
equipped with a 1 ml Pipetman tip. The suspension
was filtered over 100 pm nylon mesh and centrifuged
at 100 £ for 10 min at room temperature. The pellet
was resuspended in 1 ml DMEM containing 2-5 g
BSA/1, 1 mg DNAse/1, 105 kallikrein units of aproti-
nin/1, and centrifuged again. The final pellet was
resuspended in 1 ml DMEM containing 2-5 g
BSA/1, mixed with preswollen Sephadex G-10(Pharmacia, Milton Keynes, Bucks, U.K.) and
loaded onto columns. Two pituitaries per column
were used in experiments with randomly cycling rats
and one pituitary per column for experiments with
diethylstilboestrol-treated rats. The columns were
perfused overnight at 37 °C, because a variable pro¬
lactin release in response to oxytocin in acutely dis¬
persed cells had been observed. Similar findings
have been reported by others (Luque et al. 1986).
The volume of the columns was adjusted to 0-5 ml
and perifusion was started by a multichannel peri¬
staltic pump at a rate of 0-3 ml/min. Test materials,
dissolved in the perifusion medium, were applied to
the system as 2-5-min pulses.
Fractions of the column effluent were collected at
2-5-min intervals and 50 pi aliquots of the effluent
were assayed for prolactin, using the kit provided
by the National Hormone and Pituitary Program of
NIADDK (Bethesda, MD, U.S.A.). Results were
expressed relative to rat PRL RP-3 reference prepa¬
ration. Iodination of the rat prolactin was performed
using the oxidant l,3,4,6-tetrachloro-3a,6a-
diphenylglycouril (Iodogen; Pierce Eurochemie,
Oud-Beijerland, The Netherlands) according to the
method described by Salacinski et al. (1981). Equi-
molar (0-25 nmol) amounts of rat prolactin and
Na1 5I (IMS-30; Amersham International pic) were
reacted for 15 min at room temperature in 40 pi
sodium phosphate buffer (0-5 M, pH 7-5) in a poly¬
propylene vial previously coated at its bottom with
10 pg Iodogen. The reaction was stopped by the
addition of 0-5 ml phosphate buffer (0-5 m) and the
reaction mixture was separated on a Sephadex
G-25 M column (Pharmacia, Uppsala, Sweden) in
005 m sodium phosphate. Fractions (1 ml) were col¬
lected and counted on a gamma counter. The sensi¬
tivity of the assay was 005 ng/tube. The inter- and
intra-assay coefficients of variation were 12-5 and
6-5% respectively.
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figure 3. A representative experiment illustrating the stimulation of
prolactin release by perifused anterior pituitary cells from diethyl-
stilboestrol-treated rats in response to oxytocin. The solid boxes show
the application of various concentrations of oxytocin.
Measurement of the accumulation of IPs
To study the effect of oxytocin on the hydrolysis of
phosphoinositides, 5x10 dispersed anterior pitu¬
itary cells or myometrial strips, free of endometrium,(200 mg wet weight/ml) were incubated overnight in
Krebs-Ringer medium supplemented with 2-5 mM
Ca2+, 0-2% (w/v) BSA, 11 mM glucose and 20 mM
Hepes, pH 7-4 at 37 °C, with 25 pCi myo-[ Hjinositol. After being washed in radioisotope-free
medium, samples of the cell or tissue slice suspen¬
sion were incubated for 10 min in the presence of
10 mM LiCl, which has been reported to promote
IP accumulation (Berridge et al. 1982). Peptides to
be tested were subsequently added for up to 30 min
at 37 °C. The reaction was terminated by adding
200 pi ice-cold 15% (w/v) trichloroacetic acid. After
rapid centrifugation of the acid extracts, the total IP
content of the supernatant was determined as
described by Berridge et al. (1983), using anion-
exchange chromatography on Dowex AG 1 X8
columns. Results are expressed as percentages of
stimulation compared with control.
Data analysis
The data are expressed as the means ±s.e.m. and
analysed statistically by analysis of variance followed
by Duncan's multiple range test, using the SPSS
computer package (Version M, 1979). Differences
where P<005 were considered to be significant. Net
release was defined as (X + Y) —2B, where X is the
2-5-min fraction collected during the presence of
stimulus (a 70-s transit-time sample was discarded),
Y is the next 2-5-min fraction and B the basal value
immediately before application of the stimulus.
RESULTS
Effects of oxytocin on prolactin release
The effects of increasing concentrations of oxytocin
on prolactin release by perifused anterior pitu¬
itary cells obtained from randomly cycling rats are
shown in Fig. 1. Oxytocin caused a concentration-
dependent stimulation of prolactin secretion. In two
independent experiments, oxytocin at 10~6 and
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figure 4. Effects of various concentrations of [Thr -Gly ]-oxytocin (TG-OT) on
prolactin release by perifused anterior pituitary cells. The solid line illustrates a
representative experiment. The hatched bars show the mean net prolactin release in four
separate columns. Values are means ± S.e.m. (w = 4).
10 M significantly (P<005) stimulated prolactin
release. Significant (P<005) stimulation of pro¬
lactin release by oxytocin was also observed in
experiments with cells from animals treated with
diethylstilboestrol (Fig. 2). When the data from the
two experiments were analysed, a greater (P<005)
response was observed at 10 M oxytocin in cells
from untreated rats, while the mean response to oxy¬
tocin did not differ (P<0T7) between experiments
with cells from untreated and diethylstilboestrol-
treated rats, despite the well documented increase in
pituitary oxytocin receptor number in the latter
group (Chadio & Antoni, 1989). Figure 3 illustrates
a representative example of the effects of oxytocin
on prolactin release by perifused anterior pituitary
cells from diethylstilboestrol-treated rats.
Effects of oxytocin analogues on
prolactin release
In order to obtain further information about the
specificity of the response and the nature of the
receptor which mediates the action of oxytocin, the
highly specific oxytocin agonist TG-OT (Lowbridge
et al. 1977) and the selective oxytocin antagonist
OTA (Elands et al. 1987) were used in experiments
with cells from diethylstilboestrol-treated rats. The
secretion of prolactin was stimulated by TG-OT in a
concentration-dependent manner. Significant effects
were observed at 10~6 and 10~7M TG-OT (Fig.
4). A 5-min pulse of oxytocin at 10 M released
3T4±0-35ng prolactin (meanis.E.M., w = 8) and
this was reduced to 0-26 ± 007 ng prolactin (mean
is.E.M., n = 8) in the presence of 10~6 M OTA.
Accumulation of IPs
Figure 5 illustrates the effects of oxytocin, vasopres¬
sin and TG-OT on the total accumulation of IP in
dispersed anterior pituitary cells from randomly
cycling female rats. Stimulation of anterior pituitary
cells by increasing concentrations of vasopressin and
oxytocin produced a dose-dependent increase in
total IP production, vasopressin appearing to be con¬
siderably more potent. In contrast, TG-OT had no
effect on IP accumulation in pituitary cells, but when
tested in uterine slice suspensions it significantly
(P<0-05) stimulated the production of total IP at all
concentrations tested (Fig. 6).
DISCUSSION
This study demonstrates that oxytocin stimulates
the release of prolactin from anterior pituitary cells
by acting on oxytocin receptors. Furthermore, the
activation of the inositol phospholipid cycle did not
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FIGURE 5. Dose—response curves for the accumulation of total inositol
phosphate (IP) in anterior pituitary cells from randomly cycling
rats after treatment with oxytocin (O), arginine-vasopressin (•) and[Thr4-Gly7]-oxytocin (*). Results are expressed as percentages of
corresponding controls. Values are means ± s.E.M. (*i= 4—6).
appear to be essential for the stimulation of prolactin
release, since the specific agonist TG-OT increased
prolactin secretion but had no effect on the accumu¬
lation of IPs.
It is well established that oestrogens increase the
number of oxytocin receptors in the rat adenohypo-
physis (Chadio & Antoni, 1989). Prolactin secretion
in response to oxytocin was not affected in cells har¬
vested from diethylstilboestrol-treated animals in
the present study, suggesting that processes down¬
stream from receptor activation are also influenced
by treatment with oestrogen. A dissociation between
receptor regulation and cell responsiveness has been
reported previously in lactotrophs (Platia et al.
1986). Treatment with oestrogen in vitro decreases
the number of angiotensin II receptors without
affecting the response of prolactin to angiotensin II.
Morever, in pituitary corticotrophs corticotrophin-
releasing factor (CRF)-stimulated adrenocorticotro-
phin (ACTH) release is increased after adrenalec-
tomy, despite a marked decrease in pituitary CRF
receptors (Wynn et al. 1985).
The mode of action of oxytocin in the pituitary
gland has not been previously investigated. In the
main target tissues, the uterine smooth cells and the
mammalian myoepithelial cells, it has been shown
that oxytocin enhances the breakdown of membrane
polyphosphoinositides, leading to the production of
IPs, which cause Ca mobilization from intracellu¬
lar stores (Marc et al. 1986; Schrey et al. 1986; Soloff
et al. 1988). In the present study, oxytocin and vaso¬
pressin both enhanced the accumulation of IPs in
dispersed anterior pituitary cells, vasopressin being
more potent than oxytocin, in agreement with pre¬
vious studies on pituitary vasopressin receptors(Antoni, 1984; Raymond et al. 1985; Todd &
Lightman, 1987).
The anterior pituitary gland contains receptors for
vasopressin which are coupled to the inositol phos-
pholipid cycle and bind oxytocin. Vasopressin
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figure 6. Dose-response plots for the accumulation of total inositol
phosphate (IP) in rat (a) anterior pituitary cells and (b) uterine tissue
preparations after treatment with the specific oxytocin agonist [Thr
-Gly ]-oxytocin (TG-OT). Values are means ± s.E.M. (« = 4—6). In the
rat uterus all concentrations tested (10~6 to 10"8 m) resulted in peak IP
values significantly (P<005) different from the control, while in anter¬
ior pituitary cells no significant accumulation of the IPs was detected.
receptors are confined to corticotrophs (about 4—8%
of the total number of hormone-producing pituitary
cells) (Baker et al. 1970; Childs et al. 1982) and possi¬
bly thyrotrophs (2-6% of hormone-producing cells)
(Childs, 1983; Dada et al. 1984). The higher potency
of vasopressin with respect to the stimulation of IP
accumulation suggests that oxytocin in fact acts
through the pituitary vasopressin receptor to activate
inositol lipid breakdown. This suggestion is further
supported by the finding that the highly specific oxy¬
tocin agonist TG-OT did not affect the production
of IPs at any of the concentations used (10 to
10~ m). As lactotrophs constitute about 50% of
hormone-producing cells (Dada et al. 1984), and in
view of the marked effect of vasopressin on the accu¬
mulation of IPs derived from a maximum of 14% of
the cells, it seems unlikely that a change in pituitary
accumulation of IPs evoked by TG-OT eluded
detection because of the low proportion of cells
responding. The same agonist peptide, when tested
in uterine tissue preparations, produced a dose-
dependent increase in total IPs and was also active
in stimulating pituitary prolactin release.
Taken together, the present data confirm previous
findings that oxytocin has prolactin-releasing acti¬
vity, although at relatively high concentrations.
Whether or not oxytocin is physiologically important
in regulating prolactin secretion at the pituitary level
remains to be established. It is of note, however, that
prolactin is regulated by multiple factors of hypo-
thalamic origin which may interact synergistically to
stimulate hormone release (Delaescalera & Weiner,
1992). A well-known example is the synergistic
interaction of vasopressin and CRF (Antoni, 1986),
in which case vasopressin alone produces little or no
ACTH release at physiological concentrations, but
is strongly stimulatory in the presence of CRF.
Finally, it appears that while oxytocin receptors are
coupled to the inositol phospholipid cycle in the rat
uterus, this is not a prerequisite for the stimulation
of prolactin secretion upon the activation of specific
oxytocin receptors in the adenohypophysis.
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Corticotrophin-releasing peptides in rat hypophysial portal
blood after paraventricular lesions: a marked reduction in the
concentration of corticotrophin-releasing factor-41, but no
change in vasopressin
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ABSTRACT
Previous data show that corticotrophin-releasing
factor-41 (CRF-41), arginine vasopressin (AVP) and
oxytocin are released into hypophysial portal blood.
It has been presumed that the CRF-41 originates
mainly from parvicellular neurones of the para-
ventricular nuclei (PVN); however, AVP and oxytocin
could also be derived as a consequence of preterminal
release from magnocellular projections to the neuro-
hypophysis. The latter has been suggested to be the
case for AVP as assessed by studies of the median emi-
nence in vitro. Here we have investigated the source of
CRF-41, AVP and oxytocin in hypophysial portal
blood of adult male Wistar rats 8\p=n-\10days after surgi-
cal lesioning of the PVN. In PVN-lesioned animals the
output of CRF-41 into hypophysial portal blood was
reduced by about 90%, and that of oxytocin by about
40%: however, the output of AVP into portal blood
was reduced only by about 10%. The release of AVP
into portal blood increased after adrenalectomy; this
increased release could be returned to normal by
treatment with dexamethasone. No change of AVP
release occurred after adrenalectomy in animals in
which the PVN had been lesioned. These results show
(i) that most of the CRF-41 released into hypophysial
portal blood is derived from the PVN, (ii) that in
PVN-lesioned animals AVP and oxytocin release
remains at near normal or 60% of normal respect-
ively, suggesting that a substantial amount of both
neuropeptides in portal blood is derived as a conse-
quence of preterminal release from supraoptic nuclei
projections in the median eminence, and (iii) that
glucocorticoid feedback inhibition of AVP release is
exerted at the level of the PVN.
Journal of Endocrinology (1990) 125, 175\p=n-\183
INTRODUCTION
The secretion of hormones by the anterior pituitary
gland is controlled by neurohormones released into
hypophysial portal blood from nerve terminals in the
median eminence. Corticotrophin-releasing factor-41(CRF-41) and arginine vasopressin (AVP) appear to be
the principal hypothalamic neurohormones that regu¬
late the secretion ofadrenocorticotrophin (ACTH) (for
reviews see Antoni, 1986; Rivier &Plotsky, 1986; Jones
& Gillham, 1988). Current evidence indicates that these
neuropeptides are transported to the median eminence
in four different hypothalamic neural pathways(Antoni, 1986; Whitnall, 1988).
First, some nerve cells in the parvicellular sub¬
divisions of the hypothalamic paraventricular nuclei
(PVN) (Armstrong, Warach, Hatton & McNeill,
1980) synthesize both CRF-41 and AVP, and give rise
to an axonal projection that terminates in the external
layer of the median eminence (Tramu, Croix & Pillez,
1983; Kiss, Mezey & Skirboll, 1984; Sawchenko,
Swanson & Vale, 1984a). Secondly, it has been
suggested that there is an anatomically similar CRF-
41-containing pathway that does not normally con¬
tain AVP (Whitnall, 1988). Thirdly, it is well known
that preterminal axons of vasopressinergic magno-
cellular neurones traverse the median eminence in its
internal layer and terminate in the neural lobe of the
pituitary gland. The cell bodies of these axons are
found in the magnocellular part of the PVN, the
supraoptic nucleus and some accessory cell groups
scattered in the anterior lateral hypothalamus.
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Fourthly, oxytocinergic magnocellular neurones also
contain CRF-41 (Burlet, Tonon, Tankosic et al. 1983;
Sawchenko, Swanson & Vale, 19846); their axonal
projection to the median eminence is similar to that of
magnocellular vasopressinergic cells.
Functional studies have suggested the involvement
of all four of these pathways in the regulation of the
hormonal response to stressful stimuli (for reviews see
Antoni, 1986; Gibbs, 1986; Antoni, Kovács, Dohanits
et al. 1988). However, with the exception of the parvi-
cellular CRF-41/AVP system the evidence is indirect
and inconclusive (Antoni, 1986).
The origin of AVP in hypophysial portal blood
remains controversial because it has not been estab¬
lished with certainty whether or not magnocellular
axons release AVP into hypophysial blood. The
majority of previous studies suggest that the concen¬
tration of AVP in hypophysial portal blood is not
altered after removal of the neurohypophysis (Recht,
Hoffman, Haldar et al. 1981; Gibbs, 1985; Horn,
Robinson & Fink, 1985; Plotsky, 1985). Hence, it was
inferred that AVP released by magnocellular neurones,
which have axon terminals in the neurohypophysis,
does not reach the adenohypophysis in significant
amounts. However, in-vitro studies (Holmes, Antoni,
Aguilera & Catt, 1986a) indicate that preterminal
magnocellular axons in passage through the median
eminence may secrete AVP. In addition, exocytosis of
neurosecretory granules along vasopressinergic axons
in the internal layer of the median eminence has been
reported also using the tannic acid fixation method(Buma & Nieuwenhuys, 1988).
In the present study we have examined whether
AVP released by preterminal magnocellular axons is
found in hypophysial portal blood. The hypothesis
was tested by examining neuropeptide release into
pituitary stalk blood in animals in which the PVN (the
parvicellular source of AVP and the major source of
CRF-41) were lesioned.
MATERIALS AND METHODS
Animals
Male albino Wistar rats (200-280 g body weight;
Harlan-Olac, Bicester, Oxon, U.K.) were used
throughout. The animals were kept under controlled
conditions of lighting (on between 08.00 and 20.00 h in
Oxford, and between 05.00 and 19.00 h in Edinburgh)
and temperature (22 °C), and had free access to pelleted
food and tap water.
Paraventricular lesions and collection of hypophysial
portal blood
Under sodium pentobarbitone anaesthesia (Sagattal;
May & Baker, Dagenham, Essex, U.K.; 40 mg/kg i.p.),
the PVN were bilaterally destroyed with a specially
designed microknife as described by Makara, Stark,
Kapócs & Antoni (1986). Sham lesions were per¬
formed by lowering the tip of the microknife in the
midline to 3 mm below the surface of the skull. Some
animals were bilaterally adrenalectomized or sham-
adrenalectomized 24 h after the hypothalamic surgery
under ether anaesthesia.
Between 8 and 10 days after the hypothalamic
surgery, the animals were anaesthetized with sodium
pentobarbitone and surgically prepared for the collec¬
tion of hypophysial portal blood as well as peripheral
venous blood from the jugular vein according to
previously published procedures (Horn et al. 1985).
Briefly, collection of hypophysial portal blood was
started shortly (3-5 min) after the exposure and tran-
section of the stalk, 30-45 min after the induction of
anaesthesia. Portal blood was collected during two
consecutive 30-min periods. Peripheral blood was
sampled immediately before the pituitary stalk was cut
for portal blood collection and again at the end of the
second 30-min period of portal blood collection. Blood
samples were collected in chilled plastic tubes contain¬
ing aprotinin (Fink, Robinson & Tannahill, 1988).
Adrenalectomy and dexamethasone treatment
In a separate experiment, rats were bilaterally adrenal¬
ectomized under ether anaesthesia. Dexamethasone
(250 pg/kg; Sigma, Poole, Dorset, U.K.) or its vehicle,
dimethylsulphoxide, were injected s.c. once daily for 7
days at 17.30 h. Animals were caged singly 24 h before
being killed by decapitation between 09.00 and
10.00 h. Trunk blood was collected in chilled poly¬
propylene tubes containing Na2 EDTA.
Hormone assays
Plasma was separated from blood cells by centrifu-
gation, and analysed for CRF-41, AVP, oxytocin,
ACTH and corticosterone content by specific
radioimmunoassays (Fink et al. 1988).
Corticotrophin-releasingfactor-41
The antiserum used in the radioimmunoassay was an
anti-rat(r)CRF-41 purchased from IgG Corporation(Nashville, TN, U.S.A.) used at a dilution of 1/11 000,
and l25I-labelled[Tyr°]-rCRF-41 was used as tracer.
Bound was separated from free antigen by precipitation
with anti-rabbit
 -globulin (Scottish Antibody Produc¬
tion Unit, Carluke, Lanarkshire, U.K.). Specificity of
the assay was tested by determining cross-reaction with
several hypothalamic and related peptides; dynorphin,
ß-endorphin, luteinizing hormone-releasing hormone(LHRH), somatostatin-14, thyrotrophin-releasing
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hormone, sauvagine, ovine CRF-41 and ACTH.
Cross-reaction was less than 0T% for all these pep¬
tides at concentrations of up to 1 pg/ml. The sensi¬
tivity of the assay was 0-5-1-0 fmol/tube at 90% tracer
bound, the interassay coefficients of variation (C.V.)
were 13-5 and 9-4% for the low- (16 fmol/tube) and
high- (64 fmol/tube) quality control samples respect¬
ively, and the intra-assay coefficients of variation were
10-9 and 3-4% for the low- and high-quality control
samples respectively.
Arginine vasopressin
Antiserum RAS-8103 from Peninsula Laboratories (St
Helens, Merseyside, U.K.) was used. Cross-reactions
were: [Lys8]-vasopressin, 3%; pressinole acid, <0T%;
 -humanatriopeptin, < 0-1%; oxytocin, <01%;vaso-
pressin metabolite neuropeptide, < 0-1 % and CRF-41,
< 0-1 %. Intra- and inter-assay coefficients of variation
were 6-5 and 9-8% respectively. Bound was separated
from free hormone as for CRF-41. Sensitivity was
1 fmol/tube of standard obtained from Cambridge
Research Biologicals, Harston, Cambridge, U.K.
Oxytocin
Antiserum AF106 from Cambridge Research Biologi¬
cals gave the following cross-reactions: mesotocin,
0-36%; isotocin, <001 %; lysine vasopressin,
<0·01%; AVP, <0-01%; Pro-Leu-Gly NH2,
<0·01%, LHRH, <0-01%; ACTH, <0·01%; CRF-
41, <0-01%. Bound was separated from free hor¬
mone as for CRF-41. Sensitivity was 1-2 fmol/tube of
standard obtained from Cambridge Research Biologi¬
cals. Intra- and inter-assay coefficients of variation
were 9-4 and 10-2% respectively.
Adrenocorticotrophin
The rabbit anti-ACTH serum was purchased from IgG
Corporation and used at a final dilution of 1/30000.
This antiserum cross-reacted at less than 0-5% with a-
melanocyte-stimulating hormone (a-MSH), ß-MSH,
corticotrophin-like intermediate lobe peptide, ß-
lipotrophic hormone (ß-LPH),
 -LPH and the endor-
phins. The antigen-primary antibody complex was
precipitated with anti-rabbit  -globulin (Scottish
Antibody Production Unit). The lower limit of sensi¬
tivity of the assay was 013-0-25 fmol/tube and the
inter- and intra-assay coefficients of variation were
13-4 and 5-4% respectively.
Corticosterone
The primary corticosterone antiserum was raised in
rabbits and generously provided by Dr D. Kime(Sheffield). The cross-reaction of the corticosterone
antiserum was: corticosterone, 100%; cortisol, 10%;
aldosterone, 0-4%; deoxycorticosterone, 18-2%; pro¬
gesterone, 4-8%; compound S, 6-1% and dexametha¬
sone, < 0-01%. The sensitivity was 3 pmol/tube at 90%
tracer bound and the inter- and intra-assay coefficients
of variation were 10-8 and 6-7% respectively.
Histology
The brain of each PVN-lesioned animal was fixed in
10% (v/v) formalin, embedded in Paraplast, and serial
coronal sections of the hypothalamus (15 pm) were
cut on a microtome. Every fifth section was mounted
and stained with cresyl-violet. The configuration of
the lesion was inspected at 40  magnification. Only
animals with a complete lesion of the PVN are
included in the results. Typically, the anterior com-
missural nucleus was partly or completely destroyed;
caudally the rostral portions of the dorsomedial
nucleus were affected in some cases. Laterally, the
lesion does not extend beyond the fornix (Makara,
Stark, Kárteszi et al. 1981; Makara et al. 1986).
RESULTS
Methodological considerations
The contents of CRF-41, AVP and oxytocin in portal
plasma and the concentration of ACTH and corticos¬
terone in peripheral plasma as well as the volumes of
blood collected in animals subjected to sham PVN
lesion, or sham lesion plus sham adrenalectomy were
similar to each other and to the values in intact ani¬
mals. Therefore the values were analysed together as
the same 'control' group. The haematocrit values for
hypophysial portal blood increased in rats given dexa¬
methasone. There was considerable variation in the
volume of blood collected from the transected stalk
within the groups of animals (typical range 200-
1000 pi). In the case of PVN-lesioned and adrenalec-
tomized rats the average blood volume collected was
significantly different from the control value (Table 1).
Examination of the concentrations of AVP and CRF-
41 in the hypophysial stalk plasma of all control ani¬
mals revealed significant (P<0-01) inverse linear
correlation with the volume of portal blood collected(for AVP, r= -0-66; for CRF-41, r= -0-64; « = 33).
Furthermore, a similar relationship was apparent
between portal plasma AVP levels and blood volume
in PVN-lesioned rats (r= -0-63; « = 20;  < 0-01). In
contrast, the total amount of peptide released during
the sampling period did not show such correlations,
presumably because the secretory rate of peptides into
hypophysial portal blood is not dependent on blood
flow in the portal system. Hence, in the following
sections the values of neuropeptide contents in
hypophysial portal blood are considered throughout.
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table 1. Content and concentration of corticotrophin-releasing factor-41 (CRF-41), arginine vasopressin (AVP) and
oxytocin in rat hypophysial stalk blood after various treatments: PVN-L, paraventricular hypothalamic lesions; DEX,
dexamethasone treatment; ADX, adrenalectomy. Data shown are geometrical means with the retransformed s.e.m. in
parentheses, except for haematocrit values which are means ± s.e.m.
Blood vol.
(µ1/30 min)
Treatment
Control
Periodi 510(114)
Period 2 447(1 14)
PVN-L
Periodi 536(1-23)
Period 2 428(1-24)
PVN-L + DEX
Periodi 696(111)
Period 2 515(1-12)
ADX
Periodi 400(117)
Period 2 302(1-20)
ADX + DEX
Periodi 619(117)
Period 2 529(1-23)
ADX+ PVN-1
Periodi 301(117)
Period 2 277(1-27)
Haematocrit
(%)
33-7+1-8
36-9 + 31
40-5* ±1-4
32+1-7
Peptide content (fmol/30 min) Peptide concn (nmol/1)
44**:
30-2
:2-2
:2-7
CRF-41
43(1
35(1
4**(1
4(1
6**(1
5(1
16**(1
9(1
29*(1
20(1
3**(1
2(1
11)
10)
11)
id
12)
17)
20)
23)
13)
12)
 )
24)
AVP
614(110)
354(116)
493(1-22)
277(1-15)
735(1-22)
373(117)
960(1 10)
508(1 13)
686(1 14)
438(119)
708(1-12)
385(1-19)
Oxytocin
235(114)
112(118)
103*(110)
73(1-15)
97*(109)
65(114)
CRF-41
012(115)
010(110)
001(110)
001(111)
001(112)
001(115)
0-06(1-20)
005(1-20)
0-08(1 17)
008(1 15)
001(112)
001(118)
AVP
1-7(1-19)
1-1(1-18)
1-5(1-34)
0-8(1-25)
1-8(1-23)
11(114)
3-6(116)
2-5(1-20)
1-9(1-17)
1-4(1-33)
3-4(1-19)
20(1-26)
Oxytocin  
0-7 (1-28)
0-4 (116)
0-31(1-23)
0-3 (1-21)
0-2 (112)
0-2 (117)
13
12
Hypophysial stalk blood was collected from surgically prepared rats under anaesthesia with pentobarbitone for two consecutive 30-min periods designated
1 and 2.
*P < 005, **P < 001 compared with respective control values (Kruskall-Wallis test, followed by Mann-Whitney U test), (only data for content in period 1
were analysed).
The trends of the changes in the content of peptides
in stalk plasma brought about by the various treat¬
ments were the same during both periods of portal
blood sampling, except for the case of oxytocin in the
control group.
Effects of PVN lesions on CRF-41, AVP and oxytocin
in hypophysial portal blood
The amount of CRF-41 in hypophysial portal blood
was markedly reduced by the PVN lesions (Table 1),
while AVP levels were not affected. Treatment of
PVN-lesioned rats with 250 pg dexamethasone/kg per
day had no significant effect on the content of CRF-41
or AVP in hypophysial portal blood. The data on
CRF-41 and AVP for the first collection period are
also presented in Fig. la as percentiles of the
respective controls.
In control rats the amount of oxytocin in portal
blood during the first 30 min of sampling was signifi¬
cantly higher than in PVN-lesioned rats (Table 1), but
this difference was not apparent during the second
30 min of collection. Treatment with dexamethasone
had no significant effect on the oxytocin content of
hypophysial portal blood in PVN-lesioned rats.
CRF-41 and AVP in hypophysial portal blood from
adrenalectomized rats
In order to validate the effectiveness of the PVN lesion
and dexamethasone treatment in suppressing parvi-
cellular AVP and CRF-41 secretion, experiments were
also performed in adrenalectomized rats.
Between 7 and 9 days after bilateral adrenalectomy,
the content of AVP in portal blood rose significantly,
whilst the levels of CRF-41 were reduced to less than
half the control value (Table 1 and Fig. la). Lesioning
of the PVN blocked the increase of portal blood AVP
concentration that was observed in adrenalectomized
animals (Table 1 and Fig. la). Treatment with dexa¬
methasone (250pg/kg) also suppressed the effect of
adrenalectomy on portal blood AVP content, but
failed to return the content of CRF-41 in hypophysial
portal blood to the control value.
Plasma ACTH and corticosterone concentrations in
rats prepared for collection of hypophysial portal blood
The plasma ACTH levels in PVN-lesioned animals
with an intact pituitary stalk were 40% lower than in
sham-operated 'control' rats (Table 2 and Fig. lb).
After the sectioning of the stalk, the levels of ACTH
fell to a similar level in both groups (compare values 1
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figure 1. Effect of paraventricular hypothalamic lesions(PVN-L), adrenalectomy (ADX) and dexamethasone treat¬
ment (DEX) on (a) the content of41-residue corticotrophin-
releasing factor (hatched bars) and arginine vasopressin(open bars) in hypophysial portai plasma, and (b) the con¬
centration of ACTH (open bars) and corticosterone(hatched bars) in peripheral plasma of rats under anaesthe¬
sia with pentobarbitone. Data (period 1 values) are
expressed as percentage of the respective control groups
from Tables 1 and 2. The bars represent the retransformed
S.e.m., the numbers in parentheses show the numbers of ob¬
servations.
and 2 in Table 2). The plasma concentration of corti¬
costerone was the same in both groups of animals and
also decreased to a similar level upon transection of
the pituitary stalk (compare values 1 and 2 in Table 2).
Treatment with dexamethasone reduced plasma
ACTH as well as corticosterone concentrations in
PVN-lesioned rats (Table 2).
Adrenalectomy increased plasma ACTH, and this
was largely prevented by lesioning of the PVN, whilst
treatment with dexamethasone was less effective
(Table 2).
table 2. Concentration ofACTH and corticosterone in
peripheral plasma in rats prepared for collection of hypo¬
physial stalk blood, after various treatments: PVN-L, para-
ventricular hypothalamic lesions; DEX, dexamethasone
treatment; ADX, adrenalectomy. The first sample (1) was
taken immediately before the transection of the stalk, the
second (2) was collected after 65 min at the end of the stalk
blood collection. Data are geometrical means with the
retransformed s.e.m. in parentheses.
ACTH (pmol/1) Corticosterone (nmol/1)
Treatment
Control
Periodi 93(106) 1055(107)
Period2 28(108) 341(111)
PVN-L
Periodi 52(lll)tt 1083(106)
Period2 18(116) 286(117)
PVN-L + DEX
Periodi 17(l-49)*tt 88(l-23)*tt
Period 2 <4-5 20(117)
ADX
Periodi 244(1 -10)tt <40
Period 2 106(113) <40
ADX + DEX
Periodi 167(l-37)f <40
Period 2 22(1-37) <40
ADX + PVN-L
Periodi 127(112)t <40
Period 2 33(119) <40
*/><0-QI compared with PVN-L values; t/><0O5, ttOOI compared with
control (Kruskal-Wallis test followed by Mann-Whitney U-test).
Basal levels of plasma ACTH in adrenalectomized and
dexamethasone-treated rats
In the sham-adrenalectomized control group plasma
ACTH was 7-1 +2-2 pmol/1, (mean + s.E.M. « = 6) and
increased to 114 + 33 pmol/1 (« = 6) 7 days after
adrenalectomy. Dexamethasone (250 pg/kg per day)
decreased plasma ACTH to below control levels(1-8 ±0-7 pmol/1).
DISCUSSION
The most striking findings of this study are that the
integrity of the PVN is not necessary to maintain nor¬
mal levels of AVP in hypophysial portal blood, but
that lesioning of the PVN resulted in a marked reduc¬
tion in the amount of CRF-41 released into hypo¬
physial portal blood. Thus, after PVN lesion, the bulk
of AVP found in the hypophysial portal blood from
pentobarbitone-anaesthetized rats probably orig¬
inates from the preterminal axons of supraoptic
magnocellular neurones.
Validity of the experimental model
Various techniques have been developed for the
assessment of the activity of hypothalamic CRF-41 or
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AVP neurones (see Antoni, 1990 for review). All the
methods are invasive, in that the normal functioning
of the hypothalamo-hypophysial pathways has to be
perturbed. The degree of the disruption of normal
function is the major factor determining the utility
of a particular technique as applied to a particular
problem.
Comparison of the anaesthetized rat models(Gibbs, 1985; Plotsky, 1985; Eckland, Todd, Jessop
et al. 1988; Fink et al. 1988) in which animals are
exposed to acute surgical trauma, with the recently
published observations in conscious sheep prepared
with chronic cannulas (Caraty, Grino, Locatelli &
Oliver, 1988; Engler, Pham, Fullerton et al. 1989) con¬
firm that the initial levels of CRF-41 and AVP in the
anaesthetized rat model are relatively high. However,
mild stress in the sheep increases the concentrations of
these peptides to the levels found in anaesthetized rats.
Thus the concentrations ofCRF-41 and AVP measured
in anaesthetized rats are not unrealistically high.
In the present study, rats were used since hypo¬
thalamic neuroanatomy is known in considerable
detail in this species. Pentobarbitone anaesthesia was
chosen because it causes a less severe activation of
the hypothalamo-pituitary-adrenocortical axis than
urethane (Fink et al. 1988). Interestingly, the concen¬
trations of CRF-41, AVP and oxytocin in the pitu¬
itary portal blood of pentobarbitone-anaesthetized
rats are not markedly different from the levels found
in urethane-anaesthetized rats. Some of the responses,
e.g. the increase of AVP after adrenalectomy, do
appear blunted; the possible reasons for this are
discussed in a subsequent section of the paper.
Origin of AVP in hypophysial portal blood of PVN-
lesioned rats
Disparate changes of the concentrations of CRF-41
and AVP in the hypophysial portal blood of rats and
sheep have been reported previously (Gibbs, 1985;
Caraty, Grino, Locatelli & Oliver, 1988; Plotsky, 1985;
Eckland, Todd, Jessop et al. 1988; Engler, Pham,
Fullerton et al. 1989; Fink et al. 1988), but analysis of
the functional anatomy underlying such phenomena
has not been attempted in vivo. Given the current level
of understanding of the hypothalamic topography out¬
lined in the Introduction, the dissociation of AVP and
CRF release may have two alternative explanations:
either parvicellular neurones spared by the lesion
increase the production of AVP and effectively com¬
pensate the loss of over 90% of the cell population, or
the AVP found in hypophysial portal blood after PVN
lesions is released by preterminal magnocellular axons
of supraoptic origin.
With respect to the first alternative, it is well estab¬
lished that the region ofthe PVN contains practically all
the neurones that synthesize CRF-41 as well as AVP and
send axons to the external lamina of the median emi¬
nence (Antoni, 1986; Swanson, Sawchenko, Lind &
Rho, 1987). Consonant with this, the lesion performed
here depleted at least 90% of the CRF-41 content of
the median eminence (Antoni, Palkovits, Makara et al.
1984; Bruhn, Plotsky & Vale, 1984; Holmes et al. 1986 ;
Makara et al. 1986) and abolished depolarization-
induced release of CRF-41 from the median eminence
in vitro (Holmes et al. 1986 ).
Despite the precipitous fall in portal blood CRF-41,
it is clear that some parvicellular CRF-41 neurones,
particularly those in a perifornical location, are
spared by the PVN lesion (Makara, Antoni, Stark &
Kárteszi, 1984). These cells can respond to gluco¬
corticoid deficiency by enhancing AVP synthesis
several-fold, while the production and release of
CRF-41 is not markedly altered (Holmes, Antoni,
Catt & Aguilera, 19866, Plotsky & Sawchenko, 1987).
Since PVN lesions do reduce the amplitude ofcircadian
peaks of corticosterone in the circulation (Ixart,
Alonso, Szafarczyk et al. 1982), i.e. the overall gluco¬
corticoid feedback signal is diminished, it is possible
that the surviving parvicellular neurones may switch to
high AVP production, and thus produce the pattern of
hypophysial portal CRF-41 and AVP levels observed
in the present study. However, treatment of PVN-
lesioned rats with the synthetic glucocorticoid dexa¬
methasone failed to influence the amount of AVP in
portal blood, while the same treatment prevented the
increase of portal blood AVP content brought about
by bilateral adrenalectomy. It is therefore highly
unlikely that the AVP in the portal blood of PVN-
lesioned rats is released by parvicellular neurones that
are inhibited by glucocorticoid hormones.
More plausibly, AVP may be derived from the pre¬
terminal axons of supraoptic magnocellular neurones
in the median eminence, as suggested on the basis of
studies in vitro (Holmes et al. 1986 ; Antoni, 1986).
Further support for this is provided by recent studies
showing, directly at the ultrastructural level, that both
AVP and oxytocin are released by exocytosis from
preterminal magnocellular axons in the internal layer
of the median eminence (Buma & Nieuwenhuys,
1988). Finally, the data on oxytocin levels in portal
blood indicate that a proportion of oxytocin may be
also released from preterminal axons in the median
eminence in PVN-lesioned rats.
Portal blood AVP and CRF-41 in adrenalectomized
rats
These experiments were performed to verify the
effectiveness of PVN lesions combined with dexa¬
methasone treatment in suppressing parvicellular
CRF-41/AVP neurones.
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A course of dexamethasone injections that effect¬
ively prevented the increase of portal blood AVP in
adrenalectomized rats had only a variable, statistically
insignificant effect on ACTH. These findings are com¬
plementary to those ofPlotsky, Otto & Sapolsky ( 1986)
who reported that the acute removal of gluco¬
corticoid feedback had no effect on CRF-41 or AVP in
rat pituitary portal blood, whilst ACTH in peripheral
plasma was increased. Thus, under the conditions of
portal blood collection, glucocorticoid action at the
pituitary level appears to be a major determinant of
plasma ACTH levels. Alternatively, changes in the rate
of release of other CRFs (see Antoni, 1986, for review)
or the putative corticotrophin release-inhibiting factor(see Engler et al. 1988) may occur.
A somewhat surprising finding is the decrease of
CRF-41 in portal blood 7 days after adrenalectomy,
in contrast to the increase in AVP. Such a pattern
of changes is not without precedent; previous studies
on in-vivo (Plotsky & Sawchenko, 1987) or in-vitro
experimental models (Holmes et al. 19866) gave
similar results, although the time-intervals after
adrenalectomy, and the method of achieving reduced
adrenocortical function were somewhat different. All
studies concur, however, that adrenalectomy pro¬
duces a preponderance of AVP over CRF-41 in the
hypophysiotrophic CRF-41/AVP system.
It seems possible that anaesthesia with pentobarbi-
tone suppresses stimulatory inputs to CRF-41/AVP
neurones. This would explain why the increase in the
AVP content of hypophysial portal blood after
adrenalectomy was relatively small, about 1-6-fold,
compared with the five-fold increase reported by
Koenig, Meltzer, Devane & Gudelsky (1986) who
used a similar 5-day time-interval after adrenalectomy
but anaesthesia with urethane, and also why CRF-41
levels were actually reduced after adrenalectomy. This
possibility is all the more plausible because enhance¬
ment of the synthesis as well as the release of CRF-
41 appears to occur after adrenalectomy (Alonso,
Szafarczyk & Assenmacher, 1986; Young, Mezey &
Siegel, 1986; Berkenbosch & Tilders, 1988), and there
is evidence that this requires neural inputs which may
be suppressed by pentobarbitone (Sawchenko, 1988;
Murakami, Akana, Dallman & Ganong, 1989).
The PVN lesions blocked the rise of AVP content in
portal blood after adrenalectomy, and this correlated
well with the markedly reduced rise of plasma ACTH
in these animals. However, AVP content in hypo¬
physial portal blood was not reduced by the lesion
when compared with controls. These findings confirm
previous reports measuring AVP release in vitro(Knepel, Nutto, Meyer & Vlaskovska, 1984; Antoni,
1986) or AVP mRNA and immunoreactivity in situ(see Antoni, 1986, for review) in suggesting that the
AVP secretory response to adrenalectomy takes place
in the parvicellular CRF-41/AVP neurones of the
PVN.
Treatment with dexamethasone prevented the rise
ofAVP in portal blood caused by adrenalectomy, but
failed fully to return the concentration of CRF-41 to
the control value. This conforms with an earlier report(Fink et al. 1988), and indicates that the long-term
control of CRF-41 and AVP secretory capacity by
parvicellular neurones may be differently sensitive to
glucocorticoids.
Taken together, the evidence obtained here shows
that the combination of PVN lesions and dexametha¬
sone treatment should be sufficient to suppress any
compensatory responses in parvicellular CRF-41/
AVP neurones that are spared by the PVN lesion.
Plasma ACTH and corticosterone levels during the
collection of hypophysial portal blood
Plasma ACTH and corticosterone levels in peripheral
blood were measured to assess the possible impact of
the PVN lesion on pituitary-adrenocortical function,
and to establish whether there are any differences in
the glucocorticoid feedback signal during the periods
of portal blood collection. Plasma ACTH was
reduced by 40% after PVN lesions, a change that is
not proportional to the 90% reduction of the CRF-41
content of hypophysial portal blood. It is likely that
under the conditions of the experiment, pituitary
corticotroph cells are driven to near the maximum of
their secretory capacity (plateau of dose-response to
CRF-41 and AVP). Thus the large drop in CRF-41
levels may not translate into a similar reduction in
ACTH levels. A reduced clearance of ACTH from the
circulation seems unlikely as an alternative expla¬
nation, because ACTH levels declined at a similar rate
in PVN-lesioned and sham-lesioned animals after the
transection of the pituitary stalk.
Lesioning of the PVN had no appreciable effect on
plasma corticosterone levels during portal blood
collection. Thus changes of glucocorticoid feedback
during the sampling are not responsible for the marked
dissociation of AVP and CRF-41 release into hypo¬
physial portal blood. Substantial reductions (50-60%)
of stimulated ACTH levels may occur without any
change in plasma corticosterone (e.g. see Szafarczyk,
Malaval, Laurent et al. 1987), which readily explains
why, despite the decrease of plasma ACTH concen¬
tration, the PVN lesion had no effect on plasma
corticosterone levels.
In summafy, the data on ACTH and corticosterone
suggest that under the conditions of portal blood
sampling, hypothalamic ACTH-releasing factors as
well as pituitary ACTH are secreted in excess over
what is required for maximal stimulation of their
respective target cells.
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Implications of the present observations for
hypothalamic function in intact animals
An important issue for consideration is whether the re¬
lease of magnocellular AVP into hypophysial portal
blood is unique to the PVN-lesioned rat, or does it also
occur in intact animals, and if so, is it of functional
significance? The results ofa number ofprevious studies
where hypophysial stalk blood was collected from
otherwise intact rats can only be satisfactorily explained
by assuming that the AVP measured is derived from
magnocellular AVP-ergic neurones (Antoni, 1990). The
possibility that AVP of magnocellular origin actually
enters hypophysial portal capillaries has been ad¬
dressed in the past under the assumption that the AVP is
of neurohypophysial origin (Oliver, Mical & Porter,
1977; Recht et al. 1981). These studies gave diametric¬
ally opposite results. As far as preterminal magnocellu¬
lar hormone secretion is concerned, it is possible that the
AVP released enters the lumen of fenestrated subepen-
dymal capillary loops (Page & Dovey-Hartman, 1984)
and may contribute to the regulation of adenohypo¬
physial corticotrophs. As noted earlier, direct morpho¬
logical demonstration of AVP release by preterminal
magnocellular axons in the median eminence has been
presented (Buma & Nieuwenhuys, 1988). If magnocel¬
lular neurones do indeed participate in the regulation of
ACTH secretion, then it should be expected that
osmotic stimulation increases plasma ACTH concen¬
tration. Unfortunately, this issue is highly controversial(for review see Irving, Alexander & Donald, 1989),
primarily because of the variety of experimental
approaches used. Importantly, however, in a carefully
controlled study, Irving et al. (1989) show that in con¬
scious horses acute infusion of hypertonic saline in¬
creases plasma ACTH levels, and this increase is highly
correlated with the rise of AVP in pituitary venous
blood. These data therefore favour the hypothesis ofthe
magnocellular regulation ofpituitary ACTH release.
In summary, the destruction of the parvicellular
CRF-41/AVP neurosecretory system in the PVN fails
to reduce the concentration of AVP in rat hypophysial
stalk blood, while 90% of CRF-41 is eliminated. We
conclude that the bulk of AVP in rat hypophysial
stalk blood originates from preterminal axons of
supraoptic magnocellular neurones.
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Posttranslational Modulation of Glucocorticoid
Feedback Inhibition at the Pituitary Level
MIN CHIN LIM, MICHAEL J. SHIPSTON, AND FERENC A. ANTONI
Medical Research Council Brain Metabolism Unit, Department of Neuroscience (M.C.L., F.A.A.), and Membrane Biology
Group, Section of Biomedical Sciences (M.J.S.), University of Edinburgh, Edinburgh, Scotland, United Kingdom EH8 9JZ
Diagnostic tests of hypothalamic-pituitary-adrenocortical
function in psychiatric illness largely report the interaction of
hypothalamic secretagogues with glucocorticoids at the pi-
tuitary level. This study investigated whether the efficiency of
glucocorticoid inhibition is subject to modulation by intra-
cellular processes that enhance cAMP accumulation and/or
facilitate membrane depolarization. The secretion of ACTH
induced by corticotropin-releasing factor (CRF; 0.1 nM) in pri-
mary cultures of rat anterior pituitary cells was markedly
inhibited upon a 2-h exposure to 100 nM corticosterone. Argi-
nine vasopressin (2 nM) enhanced the cAMP as well as the
ACTH responses to CRF and reduced the efficiency of glu-
cocorticoid inhibition of ACTH release. The action of arginine
vasopressin was mimicked by rolipram, an inhibitor of cyclic
nucleotide phosphodiesterase type 4. Application of the broad
specificity K channel blockers clofilium and astemizole pro-
duced minor or no significant enhancement of CRF-induced
ACTH release, respectively, but opposed the inhibitory effect
of corticosterone. Specific blockers of HERG, KCNQ, and Isk
channels had no effect on ACTH release under any condition
examined. In summary, these data reveal multiple sites of
posttranslational modulation of adrenal corticosteroid action
at the level of the pituitary gland, which appear important for
the outcome of diagnostic tests of hypothalamic-pituitary-
adrenocortical function. (Endocrinology 143: 3796–3801, 2002)
CORTICOSTEROID feedback inhibition of the hypotha-lamic-pituitary-adrenocortical (HPA) axis is a key pro-
cess in the maintenance of body homeostasis (1, 2). It is well
established that the anterior pituitary corticotrope cell is a
pivotal target of corticosteroid feedback (3, 4). Diagnostic
tests of HPA axis function in major psychiatric disorders
essentially report secretagogue-glucocorticoid interaction at
the anterior pituitary corticotrope cell (5, 6). The cellular
mechanisms underlying corticosteroid feedback action re-
main to be clarified (3, 4, 7). Previous studies of rat anterior
pituitary tissue and the mouse corticotrope tumor cell line
AtT20 in vitro have helped to delineate a model of glucocor-
ticoid inhibition of corticotropin releasing-factor (CRF)-
induced ACTH release (3, 4). In AtT20 cells, CRF inhibits
large conductance Ca2-activated K channels (BK channels)
through protein kinase A, resulting in sustained depolariza-
tion and enhanced exocytosis (8). Protein(s) rapidly (30 min)
induced by glucocorticoids enhances protein phosphatase
activity in the vicinity of BK channels and thus blocks the
action of protein kinase A (9). As a result, intracellular free
Ca2 transients are clamped at levels that activate the stress
hormone regulated BK channel variant expressed in AtT20
cells (10), but are insufficient for substantially enhanced se-
cretory activity (11). The nature of the rapidly induced pro-
tein(s) remains unclear; current candidates include annexin
I (7) and dex-ras 1 (12).
Several physiological studies indicate that the efficiency
of glucocorticoid feedback inhibition undergoes plastic
changes depending on the stressor stimulus. For example,
glucocorticoid feedback inhibition of plasma ACTH levels
was not apparent in rats subjected to hemorrhage (13). In rats
with chronic autoimmune inflammation, exaggerated and
prolonged increases in plasma corticosteroids are vital for
survival and involve a resetting of the negative feedback
effect on the HPA axis (14, 15). In humans, strenuous exercise
gives rise to a dexamethasone nonsuppressor phenotype (16,
17). A common feature of all of the aforementioned para-
digms is activation of the hypothalamic vasopressinergic
neurosecretory system (18). Indeed, several groups have re-
ported that rat pituitary cells exposed to high, nonphysi-
ological levels of arginine vasopressin (AVP) showed signs
of markedly reduced glucocorticoid feedback (19–21). Es-
cape from dexamethasone inhibition upon injection of lysine
vasopressin has also been reported in humans (22). The
present study investigated the hypothesis that physiological
levels of AVP are sufficient to bring about glucocorticoid
resistance at the pituitary level in vitro. Furthermore, phar-
macological tests were carried out to delineate the possible
mechanism(s) of action of AVP and corticosterone. The data
demonstrate that physiological levels of AVP in combination
with CRF induce glucocorticoid resistance of stimulated
ACTH release. The reduction of glucocorticoid inhibition
correlated with the magnitude of the cAMP response in-
duced by the secretagogues. Finally, clofilium and astem-
izole, which are blockers of several recently characterized K
channels, also reversed the inhibitory action of corticos-
terone, but had no apparent effect on cAMP accumulation.
Taken together, the data reveal multiple sites of posttrans-
lational modulation of corticosteroid action at the level of the
pituitary gland, which appear important for the outcome of
diagnostic tests of HPA function.
Abbreviations: AVP, Arginine vasopressin; CRF, corticotropin-
releasing factor; HPA, hypothalamic-pituitary-adrenocortical; SOC,
store-operated Ca2 channel.
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Materials and Methods
Reagents
Reagents for tissue culture and RIAs were previously described (23).
Synthetic human 41-amino acid residue CRF and AVP were obtained
from Bachem (St. Helens, UK). Astemizole was purchased from Sigma-
Aldrich (Gillingham, UK). Clofilium tosylate was obtained from RBI
(Sigma, Poole, UK). The following compounds were generously pro-
vided by the manufacturers: Rolipram—Schering AG (Berlin, Germany);
E4031—Eisai Chemical Co. Ltd. (Kashima-gun, Ibaraki-ken, Japan);
dofetilide (UK-68,798)—Pfizer Central Research (Sandwich, UK); WAY-
123,398—Wyeth-Ayerst Research (Princeton, NJ); and chromanol
293B—Hoechst-Marion (Frankfurt/Main, Germany).
Cell cultures
Dispersed rat anterior pituitary cells were prepared from the pituitary
glands of male Wistar rats (30–40 d postnatally; Charles River Ltd.,
Margate, UK) as previously described (23). Approximately 5  104
cells/well were plated in 24-well tissue culture plates (Falcon, B&D, Le
Point de Claix, France) and cultured in DMEM containing 2.5% fetal
bovine serum (Harlan-Sera-lab, Belton, Loughborough, UK) and 7.5%
horse serum (Sigma, H-1138). Monitoring of the ACTH response to
various stimuli was as detailed previously (23). Briefly, corticosterone or
vehicle was applied in fresh, serum-free medium 2 h before stimulation
with CRF. Blockers of K channels were applied 30 min before and
during the 60-min incubation with CRF. In some experiments cellular
cAMP content was also measured. The cells were pretreated as described
for ACTH release, and the incubation was terminated by aspiration of
the medium, immediately followed by the addition of 0.1 m HCl. Cel-
lular cAMP was extracted into 0.1 m HCl by repeated freeze-thawing,
acetylated, and quantified by RIA (24).
Data analysis
Data were evaluated by one- or two-way ANOVA, followed by mul-
tiple comparisons as appropriate. Results presented as a percentage of
control ACTH release were derived from the raw data according to the
formula: (X  B)/(C  B)  100%, where X is the value analyzed, B is
the basal ACTH secretion, and C is the amount of ACTH observed in the
presence of a control stimulus.
Results
Vasopressin (2 nm) enhanced the response to CRF (0.1 nm),
but failed to stimulate ACTH when given alone (Fig. 1A).
Pretreatment with corticosterone produced a dose-depen-
dent inhibition of CRF-induced ACTH release (Fig. 1B). The
efficiency of this inhibition was markedly reduced by AVP.
The cAMP phosphodiesterase inhibitor rolipram mimicked
the effects of AVP on the ACTH response as well as its
inhibition by corticosterone (Fig. 2). AVP enhanced the
cAMP response to CRF at both 10 and 60 min (Fig. 3A). A
series of similar studies with various CRF and AVP concen-
trations revealed that the ability of 100 nm corticosterone to
suppress ACTH secretion markedly diminished as the ago-
nist-evoked cAMP response increased (Fig. 3B).
Plasma membrane K channels are prominent targets of
cAMP-dependent phosphorylation (25) and have been pre-
viously implicated in the action of glucocorticoids in corti-
cotrope cells (8) as well as in hippocampal pyramidal neu-
rons (26, 27). As previous results with the blocker
tetraethylammonium (23) excluded the involvement of a
number of well characterized K channels in glucocorticoid
action in our experimental system, the class III antiarrhyth-
mic agent clofilium and the antihistamine drug astemizole
were tested. These drugs are blockers of HERG, KCNQ, and
IsK type channels, all of which are expressed in pituitary cells
(28). Both agents significantly reduced the efficiency of glu-
cocorticoid inhibition, (Fig. 4), but when applied above 10m
inhibited CRF-induced ACTH release (not shown) and thus
were not tested further at concentrations higher than 10 m.
Most notably, 10 m astemizole was without effect on basal
and CRF-induced ACTH release (Fig. 5A), but markedly
reduced the inhibitory effect of up to 1 m corticosterone
(Fig. 5B). Clofilium modestly enhanced the ACTH response
to CRF and also reduced the ability of corticosterone to
inhibit CRF-stimulated ACTH release (Fig. 5, C and D) Im-
portantly, neither drug altered the cAMP response to 0.1 nm
CRF at 10 or 60 min (not shown), suggesting that the site of
action is downstream of cAMP. The involvement of potential
targets of clofilium and astemizole, namely, HERG-, KCNQ-,
and Isk-type channels, was addressed by applying the se-
lective blockers E4031, dofetilide, WAY-123,398 (all at 1–10
m), and chromanol 293B (5–50 m), respectively. None of
these drugs had a statistically significant effect on basal or
CRF-induced ACTH release, and there was also no alteration
of the inhibition of 0.1 nm CRF-induced ACTH release by 100
nm corticosterone (data not shown).
FIG. 1. AVP reduces the efficiency of glucocorticoid feedback inhibi-
tion. A, ACTH response elicited by 0.1 nM CRF and 2 nM AVP. Col-
umns represent means; bars indicate the SEM (n 4/group). The effect
of CRF was significant (P  0.01), and there was a significant (P 
0.05) interaction between CRF and AVP (by two-way ANOVA). B,
Concentration-dependent inhibition of 0.1 nM CRF-evoked ACTH re-
lease by corticosterone in the absence and presence of 2 nM AVP. Data
are expressed as a percentage of the net ACTH release evoked by the
respective control stimulus. Values are the mean SEM (n 4/group).
*, P  0.05 compared with corresponding vehicle-treated group by
one-way ANOVA, followed by Dunnett’s test. Results shown are rep-
resentative of eight experiments.
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Discussion
These data demonstrate that the agonist-induced cAMP
response is a major determinant of the outcome of early gene
induction by glucocorticoids. Furthermore, they raise the
possibility that novel plasma membrane K channels medi-
ate corticosteroid negative feedback in anterior pituitary cor-
ticotrope cells. Collectively, the results highlight the potential
for posttranslational modulation of the negative feedback
action of adrenal corticosteroids at the pituitary level.
The idea that AVP reduces glucocorticoid feedback was
previously proposed (see Ref. 18 for review). However, the
issue has not been addressed directly using physiological
levels of secretagogue and by examining the effect of a range
of corticosteroid concentrations. In a similar in vitro model
Vale and co-workers (29) showed that the efficiency of in-
hibition of ACTH release by a 16-h exposure to dexameth-
asone was dependent on the size of the stimulus: ACTH
release induced by 0.01–0.1 nm CRF was significantly more
suppressed than that evoked by 1–100 nm CRF. Further in
vitro studies reported reduced inhibition of ACTH release
upon the introduction of AVP with CRF compared with CRF
alone, but the concentrations of the neuropeptides were
grossly pharmacological (20, 21). The present study shows
for the first time, using physiologically relevant concentra-
tions of CRF as well as AVP, that AVP induces resistance to
corticosterone feedback inhibition.
The level of CRF in pituitary portal plasma is maximally
0.3 nm; at this concentration corticotropes are far from max-
imally stimulated. In vivo, further enhancement of the hy-
pothalamic drive is achieved by AVP, which is copackaged
and cosecreted with CRF in parvicellular hypophysiotropic
neurons of the hypothalamic paraventricular nuclei (18, 30–
32). In addition, there is evidence that AVP is released into
hypophysial portal blood by the anatomically distinct vaso-
FIG. 2. The cyclic nucleotide phosphodiesterase inhibitor rolipram
mimics the effects of AVP. A, ACTH response to 0.1 nM CRF and 0.1
mM rolipram (Roli). Solid columns indicate means; bars indicate the
SEM (n  4/group). The effect of CRF was significant (P  0.01), and
there was a significant (P  0.05) interaction between CRF and
rolipram by two-way ANOVA. B, Concentration-dependent inhibition
of 0.1 nM CRF-evoked ACTH release by corticosterone in the absence
and presence of 0.1 mM rolipram. Data are expressed as a percentage
of the net ACTH release evoked by the respective control stimulus.
Values are the mean  SEM (n  4/group). *, P  0.05 compared with
corresponding CRF group by one-way ANOVA, followed by orthogonal
contrasts. Results shown are representative of four experiments.
FIG. 3. Intracellular cAMP levels are a principal determinant of the
efficiency of glucocorticoid feedback inhibition. A, Potentiation of the
cAMP response to CRF by AVP. Columns are the means; bars indicate
the SEM (n  4/group). The basal cAMP level measured at time zero
was 153.11  7.44 fmol/well. The effect of CRF was significant (P 
0.01) at both time points, and there was a significant (P  0.05)
interaction with AVP at both time points by two-way ANOVA. B, The
degree of inhibition of stimulated ACTH secretion by 100 nM corti-
costerone plotted against the intracellular cAMP levels measured at
60 min. CRF or CRF and AVP in combination were used. The numbers
indicate the nanomolar concentrations of the respective secreta-
gogues. Data points are the average of four determinations.
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pressinergic magnocellular neurons of the supraoptic and
hypothalamic paraventricular nuclei, which do not synthe-
size CRF (see Ref. 18 for review). The synthesis of AVP by
parvicellular cells has been shown to change dramatically in
animal models; for example, chronic stress produces marked
increases in AVP synthesis with little or no change in CRF
(18, 33). The level of AVP in the hypophysial portal blood of
various species ranges between 0.3 and 2 nm (18). Somewhat
lower, up to 0.4 nm levels have been reported for human
inferior petrosal sinus blood (34). Thus, the concentration of
AVP used in the present study represents the upper extreme
of the physiological range, characteristic of magnocellular
activation (e.g. hemorrhage) or a state of enhanced parvicel-
lular AVP synthesis.
Postmortem analysis of the hypothalamus of patients with
depression indicated an increased degree of coexpression of
CRF and AVP in the PVN (35). Similar findings were re-
ported with aging (36), which is also characterized by a
reduced sensitivity toward glucocorticoid feedback inhibi-
tion (37, 38). Acute paradigms, which have indicated an
association of dexamethasone nonsuppression in humans
with elevated plasma AVP, were listed in the introduction.
Taken together, these studies have provided evidence that
AVP counteracts glucocorticoid feedback in humans.
The principal mode of action of AVP in corticotroph cells
is amplification of the cAMP response to CRF through pro-
tein kinase C (18, 39). The enhancement of the cAMP re-
sponse to low physiological concentrations of CRF by AVP
is dramatic, up to 10- to 15-fold in the physiological range,
and is characterized by acute plastic changes in the cAMP
signaling cascade (40, 41). The augmentation of CRF-induced
ACTH release by AVP is modest by comparison with the
enhancement of the cAMP response. Thus, it is reasonable to
suggest that amplification of the CRF-evoked cAMP has
downstream targets other than CRF-evoked exocytosis. In-
deed, the present study shows directly that the efficiency of
glucocorticoid feedback on stimulated ACTH release is in-
versely related to the secretagogue-induced cAMP response.
The finding that exaggerated cAMP accumulation and
consequently augmented activation of protein kinase A can
override glucocorticoid inhibition is in agreement with the
hypothesis that glucocorticoid feedback action is mediated
by a protein phosphatase that opposes the action of protein
kinase A (42). Plasma membrane K channels are common
targets of protein kinase A and glucocorticoid inhibition (8,
23). In AtT20 and transfected HEK293 cells, glucocorticoids
modulate the activity of a protein phosphatase in the vicinity
of the STREX variant BK channel to counteract protein kinase
A stimulated by CRF-induced cAMP (42, 43). In rat anterior
pituitary cells, depolarization of the membrane potential ab-
rogated glucocorticoid feedback inhibition of stimulated
ACTH release (3, 23, 44), which is consonant with the hy-
pothesis that feedback is mediated by plasma membrane K
channels. However, no evidence for the involvement of BK
or other tetraethylammonium-sensitive K channels could
be demonstrated in cultured rat anterior pituitary cells (23).
The findings with clofilium and astemizole presented here
suggest that atypical, as yet uncharacterized plasma mem-
brane K channels may mediate glucocorticoid feedback in-
hibition in cultured rat anterior pituitary corticotropes. Spe-
cific blockers of HERG-, KCNQ-, and Isk-type K channels,
all of which are reportedly expressed in the adenohypoph-
ysis (28), failed to alter the effect of corticosterone. It is of note
that the concentration of astemizole required to oppose glu-
cocorticoid inhibition was similar to that required for the
blockage of store-operated Ca2 channels (SOCs) in GH3
pituitary tumor cells (45). Intriguingly, dofetilide was inac-
tive in this respect, similar to the present findings (45). It is
not immediately obvious how SOCs would be important for
early inhibition by glucocorticoids. However, Ca2 entry via
SOC could be intricately linked to subplasmalemmal
changes in intracellular Ca2 and could be important for the
activity of Ca2-activated K channels that mediate glu-
cocorticoid feedback inhibition (26, 27, 46). Clofilium as well
as astemizole inhibit more than one type of K channel
(47–50). Thus, it cannot be excluded that their action to op-
pose glucocorticoid feedback is due to generalized depolar-
ization, which is known to reduce the efficiency of glucocor-
ticoid inhibition (3, 23).
In summary, these data show that the efficiency of corti-
FIG. 4. Clofilium and astemizole attenuate the inhibition of CRF-
stimulated ACTH release by 100 nM corticosterone. The effects of
clofilium (A) and astemizole (B) on basal (E) or 0.1 nM CRF-evoked
ACTH release in the absence (F) and presence (Œ) of 100 nM corti-
costerone (CORT) pretreatment are shown. Data are expressed as a
percentage of the net ACTH release evoked by the respective control
stimulus. Values are the mean  SEM (n  3–7/group). *, P  0.05
compared with corresponding stimuli in the absence of clofilium or
astemizole. Where error bars are not visible, the SEM is less than the
space required for the symbol. Results shown are representative of
three and two experiments for A and B, respectively.
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costeroid feedback inhibition may be markedly modified by
agents acting on the cellular targets of glucocorticoid-
induced proteins. A fundamental determinant of the effi-
ciency of feedback inhibition is the magnitude of the cAMP
response evoked by hypothalamic secretagogues. Finally,
whether the observed effects of clofilium and astemizole on
glucocorticoid feedback are clinically relevant requires fur-
ther investigation.
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Rapid as well as Delayed Inhibitory Effects of
Glucocorticoid Hormones on Pituitary
Adrenocorticotropic Hormone Release Are Mediated by
Type II Glucocorticoid Receptors and Require Newly
Synthesized Messenger Ribonucleic Acid as well as
Protein*
GOVINDAN DAYANITHI AND FERENC A. ANTONI
Department of Human Anatomy, University of Oxford, Oxford, 0X1 3QX, England
ABSTRACT. Glucocorticoid hormones suppress the release of
ACTH by the anterior pituitary gland: rapid feedback inhibits
hormone secretion within 30 min of steroid application, delayed
feedback is most effective at 1-2 h, and slow feedback becomes
manifest in several hours. The aim of the present study was to
determine the type of glucocorticoid receptor that mediates the
rapid and delayed feedback actions of glucocorticoids and
whether genomic activation occurs during the rapid and delayed
time domains.
Rat anterior pituitary cell columns were perfused with Dul-
becco's minimum essential medium, 41-residue CRF (10~9 M)
was used as the secretagogue, which stimulated ACTH secretion
to a peak of about 8- to 10-fold of basal release. The amount of
ACTH released upon repeated 5 or 10 min stimulation with CRF
was constant. Treatment with 10~7 M corticosterone for 20 min
immediately before and for 10 min during stimulation with CRF
reduced ACTH release by about 50% (rapid feedback), while at
1 h and 2 h after the initial exposure to corticosterone the
secretory response was 33% and 15% of control, respectively.
The effect of corticosterone was prevented by the type II gluco-
corticoid/progesterone antagonist RU 38486 (10 6 M). The se-
lective type II receptor agonist RU 28362 (10~7 M) was even
more potent than corticosterone in inhibiting ACTH release;
the time course of action was similar. When actinomycin D (10~4
M) was applied in conjunction with RU28362 or corticosterone,
no inhibitory effects appeared up to 2 h after the exposure to
steroid. Puromycin (10~4 M), given during and for 1 h after the
administration of the steroid prevented the rapid as well as the
delayed (1 h) inhibitory action of RU28362. When puromycin
was removed from the system, a 75% inhibition of stimulated
ACTH release developed at 2 h after the application of the
steroid, indicating that translatable messenger RNA (mRNA)
was still present in the cells. Cycloheximide (10~4 M) was only
partially effective at inhibiting rapid or delayed feedback, and
increasing its concentration impaired the ACTH response to
CRF-41.
In summary, at the pituitary level the rapid as well as the
delayed feedback inhibition of ACTH secretion by adrenal cor-
ticoids is exerted via type II glucocorticoid receptors. Further-
more, both rapid and delayed feedback require the synthesis of
new mRNA and protein. (Endocrinology 125: 308-313, 1989)
THE NEUROENDOCRINE control loop that regu-lates the activity of the hypothalamo-pituitary -
adrenocortical axis is closed by the negative feedback
actions of adrenocortical glucocorticoid hormones (1-3).
The inhibitory action of glucocorticoids is exerted at
multiple target sites, of which only two have been une-
quivocally identified to date: neurons in the hypotha-
lamic paraventricular nucleus that produce CRFs and
the corticotrope cells in the adenohypophysis (cf. Ref.
2).
The suppression of ACTH secretion by glucocorticoid
Received January 3, 1989.
Address requests for reprints to: F. A. Antoni, MRC Brain Metab-
olism Unit, University Department of Pharmacology, Edinburgh, EH8
9J2, Scotland.
* This work was supported by the Wellcome Trust U.K.
hormones has been divided into three time domains:
rapid, evident within 30 min, delayed, manifest later
than 30 min but within 2 h, and slow, apparent after
several hours of exposure to glucocorticoids (cf. Refs. 1-
3). The rationale of discerning these time domains is the
assumption that the effects of steroids during these in-
tervals are exerted through different intracellular proc-
esses. For instance, the generally held view is that rapid
feedback is mediated by a nongenomic action of gluco-
corticoids, whereas delayed effects are brought about via
the well defined cytoplasmic receptors that bind to chro-
matin and regulate messenger RNA (mRNA) transcrip-
tion (cf. Refs. 1-4).
A further basis for the discrimination of the actions of
steroids in target cells is the identification of various
types of receptors for these hormones. For instance, the
308
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actions of glucocorticoids are exerted through at least
two types of structurally different receptor molecules
designated type I (mineralocorticoid) and type II (glu-
cocorticoid) (5-7). Recently, it has been suggested that
rapid and delayed feedback are mediated by different
types of receptors (8).
At the pituitary level, slow feedback is known to sup-
press the expression of the gene that encodes the POMC
precursor molecule (4), and to affect aspects of trans-
membrane signaling by some but not all ACTH secreta-
gogues (9). The exact nature of the cellular actions of
rapid and delayed feedback is not known.
In the present study we have examined the type of
glucocorticoid receptor involved in rapid and delayed
feedback and studied the effects of the inhibition of
mRNA and protein synthesis on the action of the ste-
roids.
Materials and Methods
Chemicals
Rat CRF-41 was supplied by Peninsula (St. Helen, U.K.);
actinomycin D, aprotinin, corticosterone, cycloheximide,
DNAse I, HEPES, lima bean trypsin inhibitor, puromycin were
from Sigma (St. Louis, MO); trypsin TRK came from Wor-
thington Biochemical Corp (Freehold, NJ); and BSA (Miles
Tissue culture grade) from Miles Laboratories (Elkhart, IN).
The synthetic steroids RU38486, a type II glucocorticoid/pro-
gestin antagonist, and RU28362, a selective type II agonist,
were generously supplied by Roussel Uclaf, Romainville,
France.
Perfusion of anterior pituitary cell columns
For each experiment 8-10 randomly cycling female Wistar
rats 250-350 g body wt (Harlan-Olac, Bicester, U.K.) were
killed by decapitation.
Anterior pituitary cells were isolated by modifying previously
published procedures (10-12). The anterior pituitary lobe was
separated from the posterior lobe and minced with a razor blade
to approximately 0.5 mm diameter or smaller segments. The
tissue fragments were placed in Dulbecco's minimum essential
medium (MEM) (GIBCO, Grand Island, NY) buffered with 22
mM HEPES at pH 7.4 containing 2.5 g/liter trypsin, 2.5 g/liter
BSA, 1 mg/liter DNAse I (0.5 ml solution per gland) and
incubated at 37 C for 20 min. To facilitate dispersion the tissue
segments were aspirated into a 5 ml Pipetman (Gilson, Wor-
thington, OH) tip every 5 min, and after 20 min they were
triturated with a 5 ml plastic pipette (Sterilin, Hounslow, U.K.)
equipped with a 1 ml Pipetman tip. The suspension was filtered
over 100 /im nylon mesh and centrifuged at 100 X g for 10 min
at room temperature. The pellet was resuspended in 5 ml
Dulbecco's MEM-HEPES containing 2.5 g/liter BSA, 1 mg/
liter DNAse I, 0.5 g/liter lima bean trypsin inhibitor, 105
kallikrein units/liter aprotinin, and centrifuged again. The final
pellet was resuspended in 1 ml Dulbecco's MEM-HEPES and
2.5 g/liter BSA and mixed with 1 ml peswollen Sephadex G-10
cell columns (11) which were kept in a thermostated incubator
at 37 C. The volume of the column was adjusted to 0.6 ml, and
perifusion was started with a multichannel peristaltic pump at
a rate of 1 ml/5 min. Fractions of the effluent were collected
every 5 min on ice. The transit time from the medium reservoir
to the fraction collector was 1.5 min. After an equilibration
period of 2 h, various treatments were applied.
Fifty microliter aliquots of the effluent were assayed for
immunoreactive ACTH content using antiserum no. 6 (courtesy
of G. B. Makara, Budapest, Hungary) by RIA (13) with double
antibody precipitation. The assay standard human ACTH139
was kindly provided by CIBA-Geigy A.G. (Basel, Switzerland).
Data analysis
After a 5 min exposure to secretagogues the concentration
of ACTH in the column effluent increased in three consecutive
5 min fractions. Net ACTH release is therefore defined as (X
+ Y + Z)/3(B), where X is the fraction collected during the
presence of stimulus (1.5 min transit time effluent discarded),
Y and Z are the next consecutive 5 min fractions, and B is the
basal value immediately before the application of a stimulus.
In the case of 10 min stimulation with CRF, net ACTH release
was calculated similarly from four consecutive 5 min fractions.
There was substantial variation in the net release of ACTH
induced by CRF-41 between cloumns in different experiments
which made it necessary to standardize the data.
In cases where data analysis was between columns, net
ACTH release is expressed as percentage of the net ACTH
release elicited by 1 nM CRF-41, which was applied to all
columns. Statistical evaluation was by one-way analysis of
variance and Dunnett's test for multiple comparisons.
Comparisons within columns were made in experiments de-
picted in Figs. 2 and 3. Here, data are expressed as percentage
of the total amount of ACTH released by the respective column
during the entire period of sampling. Statistical evaluation was
by one-way analysis of variance with correction for repeated
measures followed by Dunnett's test.
Results
Response to CRF-41
Figure 1 shows the dose-response relationship of net
ACTH release and 5 min pulses of CRF-41 (KT10 to 10"8
M). In all subsequent experiments CRF-41 was used at
the intermediate concentration of 10~9 M. Repeated ap-
plications of 10~9 CRF-41 released similar amounts of
ACTH up to 6 h (Fig. 2).
Characterization of the receptor mediating glucocorticoid
action
Application of corticosterone for 25 min suppressed
stimulated but not basal ACTH release in a time-de-
pendent manner; the effect at 25 min was not statistically
significant but was marked at 1 and 2 h after the with-
drawal of the steroid (Fig. 3). If CRF-41 was applied for
10 min instead of 5, the rapid inhibitory action was more
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FIG. 1. The release of ACTH by perifused anterior pituitary cells in
response to CRF-41. Four columns of cells were exposed to various
concentrations of CRF-41 for 5 min in a randomized complete block
design. Data are means of the net release of hormone; bars indicate the
SE. The basal rate of secretion in this experiment was 130 ± 10 fmol/
15 min (n = 12).
TT
FIG. 2. The release of ACTH by perifused anterior pituitary cells in
response to repeated stimulation with 10~9 M CRF-41. Data are ex-
pressed as the percentage of the total amount of ACTH detected in the
fractions assayed from the respective columns. This procedure was
necessary to compensate for the interexperimental variability of ACTH
release. Data are means ± SEM; • , application of CRF-41.
prominent, reducing net ACTH release by 50% (Fig. 4).
The type II glucocorticoid/progesterone antagonist
RU38486 blocked the action of corticosterone (Fig. 4).
The highly selective type II glucocorticoid agonist
RU28362 potently suppressed CRF-41-induced ACTH
release by 60% within 25 min of application, the degree
of inhibition increasing to 90% by 2 h (Fig. 5).
FlG. 3. Effect of 10"7 M corticosterone on CRF-41-stimulated ACTH
release by perifused anterior pituitary cells. Corticosterone was applied
for 25 min as indicated by ffl; • show application of 10~9 M CRF-41 for
5 min. Data are expressed as percentage of the total amount of ACTH
detected in the fractions assayed from the respective columns. The
points represent means; the bars show the SE. The effect of corticoster-
one was significant (P < 0.01) at 5 and 6 h.
100
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FlG. 4. Antagonism of the feedback action of corticosterone by
RU38486 in perifused anterior pituitary cells. Data are expressed as
percentage of the net amount of ACTH released during the first 10
min exposure to 10~9 M CRF-41. The points are means; the bars show
the SE. M, RU38486 (10~6 M), • , corticosterone (10~7 M); • , CRF-41; ",
P < 0.01 when compared with the control group.
Effects of inhibitors of mRNA and protein synthesis on
rapid and delayed feedback.
As shown in Fig. 6. the lag time between the applica-
tion of RU28362 and the appearance of the inhibition of
ACTH release is greater than 15 min even if the dose of
steroid is increased.
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FIG. 5. Effect of RU28362 on ACTH release induced by CRF-41 in
perifused anterior pituitary cells. Data are expressed as percentage of
the net amount of ACTH released after the first 5 min exposure to
10~9 M CRF-41. m, Actinomycin D 10~4 M, 35 min; D, RU28362 (10~7
M) 25 min; • , CRF-41 (10~9 M) 5 min. The glucocorticoid effect was
significant (P < 0.01) at all time points. At 4 h the RU28362 +
actinomycin D values are significantly different (P < 0.05) from con-
trol.
100
SO
Hh
Tlme (h)
FIG. 6. Evidence for a lag time in the action of RU28362 on stimulated
ACTH release in perifused anterior pituitary cells. The points are
means; the bars show the SE. W, RU28362 for 15 min; • , CRF-41 10"9
M for 5 min.
The rapid as well as the delayed inhibitory action of
RU28362 could be almost completely abolished by treat-
ment with an inhibitor of mRNA synthesis, actinomycin
D (Fig. 5). Similar data were obtained using corticoster-
one (not shown).
100 -
n-5
Time [h]
FIG. 7. Effect of puromycin on rapid and delayed feedback inhibition
of stimulated ACTH release in perifused anterior pituitary cells. Data
are expressed as percentage of the amount of ACTH released in
response to the first CRF-41 stimulus. The points are means; the bars
show the SE; in the case of the group receiving puromycin only,
individual values from two columns are shown. M, Puromycin (10~4 M)
for 95 min; D, RU28362 (10~7 M) for 25 min; • , CRF-41 (10"9 M) for 5
min. The RU28362 group contains data presented in Fig. 5.
No rapid or delayed (1 h after steroid) inhibitory effect
of RU28362 appeared in the presence of puromycin, an
inhibitor of protein synthesis (Fig. 7). However, a marked
suppression of ACTH release developed within 1 h after
the removal of the drug (Fig. 7) indicating the presence
of translatable mRNA. The hormonal response to CRF-
41 returned toward normal by 3 h after steroid exposure
in both RU28362- as well as RU28362- and puromycin-
treated cell columns.
In experiments with cycloheximide (10~4 M), another
blocker of protein synthesis, a partial blockade of rapid
as well as delayed inhibition by RU28362 (10~7 M) was
observed: At 20-25 min net ACTH release in cyclohex-
imide-treated columns was 72 and 76% of control us. 12-
68% of which is the 99% confidence interval of the group
treated with RU28362 only (presented in Fig. 7); at 80-
85 min 53 and 65% vs. -11 to -16%, (after this stimulus
cyloheximide was discontinued); at 140-145 min 20 and
22% vs. - 5 to -23%; at 200-205 min 58 and 65% vs. 54-
86%.
When the concentration of cycloheximide was in-
creased to 5 X 10~4 M, the CRF-41-induced release of
ACTH became highly variable, suggesting toxic side-
effects (not shown).
Discussion
The present study shows that the glucocorticoid inhi-
bition of CRF-41-stimulated ACTH secretion by adeno-
hypophysial corticotropes is mediated via type II recep-
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tors and requires newly synthesized mRNA and protein.
The complexities of the study of glucocorticoid feed-
back in vivo make it necessary to devise simpler in vitro
models to analyze the cellular mechanism of action of
glucocorticoid hormones in corticotrope cells. Previous
work in this area has produced widely discrepant find-
ings, e.g. the lag time of the onset of the steroid effect
has been reported to be anywhere from virtually imme-
diate (14) to nonapparent until 24 h (15). It is likely that
the diversities of these reports are due to the use of
different experimental models, ranging from AtT-20 tu-
mor cells to hemipituitaries and a similarly wide variety
of stimuli of ACTH secretion. Furthermore, as pointed
out by Johnson et al. (16) "The magnitude and, in some
cases, the direction of the glucocorticoid response are
sensitive to the conditions to which the cells are ex-
posed." It seems important to note in this context that
under in vivo conditions glucocorticoid administration
reduces the plasma ACTH response to CRF-41 within
10-15 min (17, 18).
Regarding the time course of the inhibitory effects of
steroids on CRF-41-induced ACTH release, our data are
in agreement with the majority of previous studies re-
porting lag times between 10-30 min for rapid feedback
in vitro (8, 11, 19-22). In our hands corticosterone was
effective within 30 min, RU28362 within 25 min. The
somewhat longer lag time of corticosterone is possibly
due to the fact that it is a substantially less potent
activator of type II receptors than RU28362 (23, 24). If
a smaller stimulus of ACTH release is used, e.g. CRF-41
at 0.1 nM, corticosterone is also effective within 25 min
(Dayanithi, G., and F. A. Antoni, unpublished data).
It is of interest that RU28362, a steroid not bound by
transcortin (23), also exhibited a significant lag time of
action. Previously, it could be argued that the relatively
slow nature of the onset of the corticosterone effect is
due to intracellular buffering by transcortin-like binders
(cf. Refs. 1-3).
The results with the antagonist RU38486 [type II/type
I selectivity -1000-fold (24)] and the agonist RU28362
[type II/type I selectivity > 3000-fold (23)] strongly
suggest the exclusive involvement of type II glucocorti-
coid receptors in the rapid as well as delayed pituitary
feedback actions of adrenal steroids. Regarding delayed
feedback these findings are in agreement with previous
preliminary reports (25, 26). In contrast, Abou-Samra et
al. (8) concluded, on the basis of the differences in the
EC50 values for corticosterone at 40 min and 3 h after
application in the incubation medium, that rapid and
delayed effects are mediated by different receptor types.
However, no selective receptor ligands were used in their
studies.
On the whole, our findings strengthen the notion that
the suppressive actions of glucocorticoids in stress are
mediated by the type II receptor or a receptor species
closely related to it ( 7, 27).
While it is generally agreed that delayed glucocorticoid
feedback requires mRNA synthesis, the issue whether it
is important for rapid effects is controversial. Portanova
and Sayers (28) reported that rapid steroid feedback (30
min) in normal pituitary cells is not blocked by actino-
mycin D, whereas that in cells from adrenalectomized
rats is abolished by the drug. We find a clear inhibition
of rapid as well as delayed feedback effects with actino-
mycin D in cells obtained from intact rats. Apart from
the differences in experimental methods, e.g. a 20-fold
higher concentration of actinomycin D was used by us,
andperifused cells in Dulbecco's MEM-HEPES vs. static
incubations in Krebs-Ringer solution etc., we have no
explanation for this difference.
Controversies in the literature are also evident regard-
ing the need for ongoing protein synthesis in rapid feed-
back. In general, cycloheximide is not an effective inhib-
itor of the rapid effects of glucocorticoids despite an
almost complete suppression of total pituitary protein
synthesis (8, 19, 29). We found cycloheximide at 10~4 M
to be only partially effective even in the case of delayed
feedback, whereas a higher concentration impaired the
secretory response to CRF-41. Brattin and Portanova
(19) showed puromycin to be an effective inhibitor of
rapid feedback in pituitary cells of adrenalectomized rats.
We demonstrate here that puromycin abolishes both
rapid and delayed feedback in cells of intact animals
without any deleterious effects on stimulated ACTH
release. Furthermore, delayed feedback can be demon-
strated after the withdrawal of puromycin, indicating
that steroid-induced mRNA is present and cellular func-
tions are restored toward normal after the prolonged
exposure to puromycin.
In summary, under the conditions used in the present
study, the mechanism of rapid and delayed feedback
appeared identical in terms of receptor pharmacology
and sensitivity to inhibitors of protein and mRNA syn-
thesis. It is only the degree of inhibition of ACTH release,
increasing progressively with time, that sets apart rapid
and delayed feedback in this system. The rapidity of the
onset of the negative feedback mechanism is indicative
of a primary induction of mRNA transcription that does
not require the synthesis of additional transcription fac-
tor proteins (30).
We conclude that the early (0.5-3 h) feedback inhibi-
tion of pituitary ACTH release by glucocorticoids is
mediated by a newly synthesized protein that suppresses
hormone release induced by CRF-41.
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Pituitary Corticotrope Tumor (AtT20) Cells as a Model 
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Glucocorticoids* 
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ABSTRACT 
The utility of the established ACTH secreting mouse pituitary tumor 
cell line AtTZO for investigating early glucocorticoid inhibition was 
examined. Three different strains of the cell line Dl, D16v, and Dl6:16, 
respectively, were analyzed. In initial studies CRF and phorbol esters 
were used as secretagogues to examine the properties of hormone 
secretion. In a perifusion system (cells in suspension) Dl cells failed to 
respond to the secretagogues, whereas both D16v and Dl6:16 cells were 
responsive. However, hormone release declined upon repeated exposure 
to secretagogue in both D16v and D16:16 cells and similar data were 
obtained when cells adhering to cover slips were perifused. In static 
incubation D16:16 cells gave more consistent results especially with 
respect to inhibition by glucocorticoids and were used in all subsequent 
studies. Synthetic glucocorticoids acting through the type II receptor 
inhibited CRF-induced ACTH release within 45 min; at 120 min, 
stimulated release was strongly (80-90%) suppressed. In contrast, no 
consistent inhibition by corticosterone could be found. In the presence 
of glycyrrhetinic acid, an inhibitor of Ilo-hydroxysteroid dehydroge- 
nase, a high concentration of corticosterone (10 pM) did produce a 
slight inhibition of ACTH release. Dexamethasone also inhibited 
ACTH release induced by the calcium channel activator compound 
(+)202-791. The accumulation of CAMP in response to CRF was not 
altered by dexamethasone. The inhibitory effect of synthetic glucocor- 
ticoids on ACTH release was prevented by blockers of messenger RNA 
(actinomycin D, dichlorobenzimidazole ribofuranoside) or protein (pu- 
romycin) biosynthesis, indicating the induction of new proteins. Im- 
munoblotting for lipocortin I (annexin I) and chromogranin A revealed 
no induction by dexamethasone of any of these proteins in Dl6:16 
cells. Messenger RNA encoding lipocortin I was not detectable and was 
not induced by treatment with dexamethasone in D16:16 cells. These 
data show that the AtT20 D16:16 strain is a useful model for early 
glucocorticoid action, which is mediated by type II receptors and 
involves the induction of new protein(s). Notably, induction of lipocor- 
tin I messenger RNA or protein could not be detected at a time when 
the inhibitory effect of glucocorticoids on stimulated hormone secretion 
was maximal. (Endocrinology 131: 2873-2880, 1992) 
G LUCOCORTICOID hormones suppress the secretion of ACTH by anterior pituitary corticotropes i?z uivo and 
in vitro (see Ref. 1 for review). The action of glucocorticoids 
in the pituitary gland occurs in two main phases, which will 
be referred to as early (0.5-2 h) and slow (>6-8 h) feedback 
inhibition. Early glucocorticoid inhibition is mediated by type 
11 glucocorticoid receptors and requires the induction of new 
protein(s) (2-4). The nature and function of the new pro- 
tein(s) is not precisely known, although recent data suggest 
that early glucocorticoid inhibition is caused by the suppres- 
sion of stimulus-evoked intracellular calcium signals (5, 6). 
Slow inhibition involves the repression of the biosynthesis 
of proopiomelanocortin (see Ref. 7 for review) and possibly 
the inhibition of CAMP generation by corticotropin-releasing 
factor (CRF) (8). 
The low proportion of corticotropes in the adenohypo- 
physis and the fact that virtually all cells of the gland are 
responsive to glucocorticoids make the biochemical charac- 
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terization of newly induced proteins and messenger RNAs 
(mRNA) in corticotropes extremely difficult. A more viable 
alternative would be the use of a nominally homogeneous 
population of cells such as the AtT20 cell line derived from 
a radiation-induced anterior pituitary tumor (9). This cell line 
currently has three strains: 1) Dl is the cell line first derived 
from the tumor and maintained as a suspension culture (10); 
2) the D16v strain is a line derived from the Dl cells and 
grows as a monolayer (10, 1 l), and 3) the D16:16 strain 
subcloned from D16v cells on the basis of high intracellular 
@-endorphin content (12). The signalling pathways activated 
by secretagogues such as CRF and the mechanism of slow 
glucocorticoid inhibition (>24 h) have been extensively char- 
acterized (for reviews see Refs. 7, 13, 14). In contrast, only a 
few studies have addressed the mechanism of early gluco- 
corticoid inhibition (12, 15, 16), and the findings reported 
are controversial on several counts. In particular, the time 
course of the inhibition, the requirement for protein induc- 
tion, and the secretagogues used for eliciting ACTH release 
were all different in these experiments. The aim of the 
present study was to analyze early glucocorticoid inhibition 
of stimulated ACTH release in AtT20 cells in order to deter- 
mine whether these cells could be a useful model for the 
characterization of proteins induced by glucocorticoids in 
anterior pituitary corticotropes. 
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Materials and Methods 
Reagents 
All culture media were obtained from GIBCO BRL (Paisley, Scotland); 
sera were from GIBCO and Seralab (Crawley Down, Sussex). BSA 
(fraction V, pH 7) was from ICN (High Wycombe, Bucks, U.K.). Anti- 
biotics and phorbol-dibutyrate ester (PdBu) were obtained from Sigma 
(Poole, Dorset, U.K.); ACTH and rat 41.residue corticotropin-releasing 
factor (CRF) from Bachem UK, (Saffron Walden, Essex, U.K.). The 
synthetic glucocorticoid type II receptor agonist RU28362 (17) was 
donated by Roussel Uclaf, Romainville, France; the L-type calcium 
channel activator (+)202-791 (18) was a gift from Sandoz (Basel, Swit- 
zerland), nimodipine, a dihydropyridine blocker of calcium-channels 
was from Semat (St Albans, Hertfordshire, U.K.). Mouse monoclonal 
antibody (MAb 105) against human recombinant lipocortin (annexin)I 
and recombinant protein were kindly provided by Biogen Inc. (Boston, 
Ma) (19). A polyclonal rabbit antiserum against bovine chromogranin A 
was kindly supplied by Dr. D. K. Apps, Department of Biochemistry, 
University of Edinburgh, Edinburgh, U.K. All other substances were of 
the highest analytical grade available. 
Cell Culture 
AtT20 Dl (passage unknown) cells were obtained from the ATCC 
cell line, through PHLS (Porton Down, Salisbury, U.K.), and maintained 
in suspension culture in Ham’s FlO media supplemented with 10% fetal 
bovine serum (FBS) and grown in an atmosphere of 5% CO2/95% air. 
Cells were passaged at a ratio of 1:4 every 7 days. AtT20 D16:16 (passage 
13) cells were provided by Dr. S. L. Sabol, N.I.H., Bethesda, Md. (12); 
AtT20 D16v (passage 21) were from the laboratory of K. Docherty, 
University of Birmingham, Birmingham, U.K. These cultures were rou- 
tinely maintained in monolayer in Dulbecco’s modification of Eagle’s 
medium with 25 mM glucose, supplemented with 10% FBS and grown 
in an atmosphere of 5% C02/95% air. Media changes were carried out 
every 4-5 days. D16 cells were passaged at a ratio of I:4 every 7 days, 
using PBS (pH 7.4), containing EDTA (0.025%) and glucose (10 mM). 
All experiments were performed with cells of passage 35 or less. In order 
to optimize the performance of D16 cells in hormone secretion studies, 
various batches of serum were tested for rate of cell growth, ACTH 
secretory response to CRF, and its inhibition by dexamethasone. The 
batch of FBS used in this study contained 30 nM cortisol as measured by 
RIA. 
Hormone secretion 
Static incubation. For static ACTH release experiments, the cells were 
seeded onto polystyrene 24-well tissue culture plates at a density of 5 X 
lo4 cells per well and grown for 6-7 days, with a medium change on 
day 3 or 5. Experiments were performed in Dulbecco’s modification of 
Eagle’s medium, buffered with HEI’ES (25 mM), pH 7.4, containing 
0.25% BSA, and penicillin (100 U/ml)/streptomycin (100 U/ml) (medium 
A). Before experimental incubations, the cultures were washed free of 
serum-containing medium and equilibrated with medium A for 2 h at 
37 C. Experimental incubations were carried out in a water-bath at 37 
C, for the times and with concentrations of drugs indicated in the figure 
legends. Incubation was stopped by placing the culture plates on ice for 
lo-15 min. An aliquot of medium was taken from each well, centrifuged 
at 800 rpm for 10 min at 4 C, and the supernatants obtained stored at 
-40 C. Immunoreactive ACTH was measured by double antibody 
precipitation RIA (4) using a primary antiserum (AS846 courtesy of Dr. 
G. B. Makara, MTA KOKI, Budapest, Hungary) that weakly cross-reacts 
with cu-MSH (13%) (20). Under the conditions employed, the assay 
detects 1 fmol/tube of human ACTH,-A~ (courtesy of CIBA-Geigy Ltd, 
Basel, Switzerland), intraassay coefficient of variation is ll%, interassay 
coefficient of variation is 12%. For the measurement of monophosphate 
(CAMP), cells were incubated in the presence of 0.5 mM isobutylme- 
thylxanthine (IBMX). The reaction was stopped by adding ice-cold 0.1 
M HCI, and the cells were homogenized by ultrasound disruption. The 
levels of CAMP in the acidic extracts were measured by RIA using 
antiserum cAB4 (courtesy of K. J. Catt, NICHD, NIH, Bethesda, MD) 
(21). 
Perifusion. Perifusion of AtT20 cells was performed as described for 
dispersed rat anterior pituitary cells (4). Briefly, 5 x lo6 cells were mixed 
with Sephadex G-10 and perifused in 0.5 ml chambers with medium A 
at a flow rate of 200 wl/min; fractions of the perifusate were collected 
on ice every 2.5 min. After a 2-h stabilization period, secretagogue pulses 
were applied as described under Results. Alternatively, D16:16 cells were 
grown on glass coverslips (19 mm diameter), treated with poly-L-lysine 
at 5 pg/cm* (Sigma), and perifused at 200 pl/min in a 0.5-ml perifusion 
chamber. The release of ACTH per secretagogue pulse was determined 
as previously described (4). 
Preparation of crude pellet and supernatant total protein 
homogenates 
Cells (l-2 X 107) were homogenized by sonication (3 x 20 set) on 
ice in 250 ~1 10 mM Tris/HCl, pH 8.0, 1 mM EDTA, and 0.25 mM 
phenylmethylsulphonylnuoride and spun at 100 X g. The supernatant 
was centrifuged at 12,000 X g for 30 min at 4 C and the pellet 
resuspended in 50 ~1 of homogenization buffer; both supematant and 
pellet fractions were stored at -40 C before use. 
Isolation of Ca”+-binding proteins from AtT20 D16:16 cells 
Calcium binding proteins were isolated using a modification of the 
calcium precipitation-elution method described by Woolgar et al. (22) 
for the isolation of annexins from mammalian brain, All subsequent 
steps were performed at 4 C. Cells (approximately 5 x 108) were 
homogenized by sonication (3 X 20 s) in 0.5 ml of 10 mM HEPES, pH 
7.4, containing 150 rnM NaCl, 5 rnM EGTA, and 0.25 rnM phenylmeth- 
ylsulfonylfluoride and centrifuged for 30 min at 40,000 X g. The super- 
natant was removed and CaCIZ added to 1 rnM excess (final concentration 
6 mM); after 15 min, the sample was centrifuged at 40,000 x g for 30 
min. The pellet was washed sequentially with 2 vol of 10 rnM HEPES, 
pH 7.4, 150 mM NaCI, and 1 mM CaCI, followed by 10 mM HEPES, pH 
7.4, and 1 rnM Ca&. The pellet was resuspended in 0.1 vol 10 rnM 
HEPES, pH 7.4, 10 mM EGTA, and centrifuged for 30 min at 100,000 X 
8. The supernatant was collected and stored at -40 C before use. Protein 
concentration was determined using the method of Bradford (23). 
Gel-electrophoresis and Western-blotting 
Samples were boiled for 5 min in the presence of 2.5% sodium 
dodecyl sulphate and 5% P-mercaptoethanol and electrophoresed on 
lo-15% continuous gradient Phastgel sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis gels as described by the supplier (Pharmacia, 
Milton Keynes, U.K.). Proteins were transferred to Immobilon PVDF 
membranes (Millipore, Watford, Herts, U.K.) by electroblotting on the 
Phastsystem using the protocol supplied. 
Membranes were blocked in 50 rnM Tris-HCI, pH 7.6, containing 3% 
low fat milk powder (Marvel) for 1 h. After 5 X 5 min washes in Tris 
containing 0.1% Tween-20, blots were incubated overnight at 4 C with 
primary antibody. Blots were washed for 5 x 5 min at room temperature 
in Tris/Tween, incubated with a 1:200 dilution of the appropriate 
biotinylated antimouse or antirabbit immunoglobulin G antibodies to 
the primary antibody (Dakopatts, Denmark) in Tris for 1 h, washed 5 X 
5 min Tris/Tween, and incubated with a 1:300 dilution of streptavidin 
biotinylperoxidase complex (Amersham, Aylesbury, Bucks) for 45 min. 
Blots were developed after a 3 X 5 min wash in Tris/Tween using 
diaminobenzidine tetrahydrochloride hydrate (Aldrich, Poole, Dorset) at 
a concentration of 0.75 mg/ml in Tris-HC1 containing 0.02% H202. After 
5-10 min at room temperature, the reaction was terminated by washing 
extensively in dH20. 
RNA isolation and Northern blotting 
Total cellular RNA was isolated using the acid guanidinium thiocya- 
nate-phenol-chloroform method (24), mRNA was isolated by two 
rounds of poly-dT-cellulose chromatography (25). RNA samples and 
markers were separated by electrophoresis on a denaturing 1% agarose 
gel containing 6% formaldehyde using 1 X MOPS [(0.04 M morpholi- 
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nopropane sulphonic acid), 10 rn~ sodium acetate, 1 mM EDTA, pH 8.01 
as buffer. The RNA was transferred onto a Hybond N nylon membrane 
(Amersham, Bucks, UK) by capillary blottingbvernight in 20X SSC (1X 
SSC is 0.15 M sodium chloride. 0.015 M sodium citrate, uH 7.0). RNA 
was bound to Hybond N by exposing to UV light for 5 min. Blots were 
prehybridized at 65 C for i5 min inhybridization buffer [lo% dextran 
sulohate (mol wt. 500000, Siema). 1 M NaCI. 1% SDSl. Hvbridization 
wab performed overnight at 6x C using fresh buffer containing 100 rg/ 
ml denatured salmon sperm DNA and 1 x 10h dpm/ml of radiolabeled 
complimentary DNA (cDNA). Blots were subsequently washed in 1X 
SSC at 65 C for 30 min. Blots were autoradiographed for 5 days for 
blots probed with the lipocortin I cDNA probe. Blots were stripped and 
reprobed for a-tubulin and autoradiographed for 5 h for RNA standard- 
ization. 
cDNA probes 
A 1376-base pair human lipocortin I cDNA (Biogen Inc, Boston, Ma) 
was cut from plasmid pUC 13 with EcoRl. The a-tubulin probe was a 
1400-base pair human cDNA which was cut from the Pstl site of 
plasmid pSP64. The cDNA was separated from plasmid DNA by elec- 
trophoresis on a 1% low melting point agarose gel. Eluted cDNA was 
denatured by heating at 95 C for 5 min and labeled with 50 mCi of (o- 
“I’-dcytidine 5’.triphosphate (CTP) (Amersham, Bucks, UK) by random 
primer elongation (Amersham) to a specific activity of l-4 x 10R dpm/ 
peg DNA. 
Results 
Perifusion 
Initial studies were performed to verify the utility of the 
AtT20 cell strains in a perifusion model because this system 
is best suited for examining hormone secretion by normal rat 
corticotropes (for reviews see Refs. 26 and 27). Both D16v 
and D16:16 cells responded to 10 nM CRF and PdBu in 
perifusion using cells suspended in a matrix of Sephadex G- 
10 or cells maintained as a monolayer on glass coverslips. 
However, the secretory response declined on repeated appli- 
cation of secretagogue irrespective of the duration of stimu- 
lation (2.5-5 min) or interstimulus period (30-60 min) (data 
not shown). In contrast, Dl cells failed to respond to secre- 
tagogues altogether in the perifusion system (data not 
shown). 
Static incubation 
Secretagogue action. AtT20 D16:16 cells grown as monolayer 
on plastic 24-well tissue-culture trays consistently responded 
to CRF and PdBu (Fig. la). The time-course of CRF- and 
PdBu-stimulated ACTH release was linear over 5-30 min of 
incubation (data not shown). Stimulus to basal ratios of 
ACTH release at various time-points became constant after 
20 min of continuous exposure to 10 nM CRF or 10 nM 
PdBu, typically giving a 2-fold increase of ACTH release 
above basal. The CRF response could be enhanced further 
by combining CRF with 0.25 mM BaCl, (CRF/Ba) (Fig. la), 
which causes depolarization by blocking Ca*+-activated K+ 
channels (28,29). The release of ACTH induced by CRF, 
CRF/Ba, or PdBu could be blocked by the dihydropyridine 
calcium channel antagonist nimodipine (Fig. lb). The ACTH 
response of D16v cells to the secretagogue agents was con- 
siderably more variable than that of D16:16 cells; in some 
experiments, no significant increase of ACTH release could 
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FIG. 1. a, Effects of CRF, CRF combined with 0.25 mM BaCl,, and 
PdBu on ACTH release from AtT20 D16:16 cells in static incubation: 
b, blockage of CRF CRF/Ba- and PdBu-stimulated ACTH release by 
the dihydropyridine calcium channel blocker nimodopine. Nimodopine 
(0.1 HIM) was given for 30 min before the application of secretagogue, 
and was also present during the 20-min stimulus period. All data are 
expressed as the percentage of basal ACTH release which ranged 
between 0.7 and 1.4 pmol/well in these experiments. Data are mean f 
SEM (n = 4-8 per datum point). 
be demonstrated upon exposure to CRF. Attempts to improve 
reproducibility by serum-starving D16v cells for various pe- 
riods (16) were not successful, and therefore all subsequent 
studies were performed in D 16: 16 cells. 
Early glucocorticoid inhibition. Pretreatment with 10 nM dex- 
amethasone significantly inhibited CRF (10 nM)-stimulated 
ACTH release within 45 min and increased further after 90 
min of pretreatment: basal, 0.44 + 0.02; CRF, 0.97 + 0.03; 
45 min dexamethasone+CRF, 0.76 + 0.04; 90 min dexa- 
methasone+CRF, 0.62 + 0.04; data are ACTH pmol/well 
released in 20 min, means f SEM, n = 6 per group. RU28362, 
a specific type II receptor agonist (17), inhibited CRF-stimu- 
lated ACTH release in a dose-dependent manner (Fig. 2). 
Dexamethasone also inhibited ACTH release evoked by the 
dihydropyridine L-channel activator (+)202-791: dexameth- 
asone pretreatment (10 nM for 2 h) reduced (+)202-791 (1 
PM for 20 min) stimulated ACTH release to 56.0 + 10.3% of 
the control (+)202-791 stimulus. Dexamethasone had no 
detectable effect on CRF-induced CAMP accumulation (Table 
1). 
Overall, in 52 experiments, RU28362 or dexamethasone 
pretreatment (up to 2 h) had no significant inhibitory effect 
on basal ACTH release, although in some individual experi- 
ments a statistically significant inhibition (typically 20%) was 
found. Hormone release stimulated by CRF or CRF/Ba was 
invariably inhibited by these synthetic steroids in all experi- 
ments. In contrast, corticosterone only inhibited CRF-stimu- 
lated ACTH secretion when used at the high concentration 
of 10 PM and in conjunction with glycyrrhetinic acid, an 
inhibitor of 1 l&hydroxysteroid dehydrogenase (Fig. 3). 
Blockers of mRNA (actinomycin D, dichlorobenzimidazole 
ribofuranoside) or protein synthesis (puromycin) dose de- 
pendently prevented the action of RU28362 on CRF/Ba 
stimulated ACTH release suggesting that the induction of 
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of glucocorticoids. The hallmarks of early glucocorticoid in- 
hibition: onset within 2 h, mediation by type II receptors, 
requirement for mRNA and protein synthesis, could be all 
demonstrated in AtT20 D16:16 cells, which is in agreement 
with the properties of early glucocorticoid action in a variety 
of systems, including normal anterior pituitary cells (l-4, 
30). 
Secretory response 
RU28362 log (M) 
FIG. 2. Inhibition of stimulated ACTH release from AtT20 D16:16 
cells by the specific type II glucocorticoid receptor agonist, RU28362. 
The control stimulus was 10 nM CRF and 0.25 mM Bach in combina- 
tion; RU28362 was applied for 2 h before the stimulus at various 
concentrations. Data are expressed as the percentage of the increment 
in ACTH release (0.9 pmol/well) evoked by the control stimulus, basal 
release was 0.3 + 0.03 pmol/well. Data are means + SEM (n = 4 per 
group). 
new mRNA and protein(s) is required for the inhibitory effect 
(Fig. 4). Similar data were obtained using dexamethasone to 
inhibit CRF-induced ACTH release (5). 
Protein(s) involved in early glucocorticoid inhibition 
Lipocortin I mRNA was constitutively expressed in AtT20 
Dl cells; however, no induction of lipocortin I mRNA was 
observed after 24 h of dexamethasone treatment (Fig. 5a). In 
contrast, lipocortin I mRNA or protein were undetectable in 
AtT20 D16:16 cells, and no induction of mRNA or protein 
was evident after a 1.5 h exposure to 10 nM dexamethasone 
(Fig. 5c and 6), when inhibition of stimulated ACTH release 
was clearly evident. Chromogranin A (bands at about 74 and 
33 kilodaltons) immunoreactive proteins were present in 
D16:16 cells; however, no increase of the intensity of im- 
munostaining of these protein bands could be observed upon 
a 1.5-h treatment with dexamethasone (data not shown). 
Discussion 
These data suggest that the D16:16 subclone of AtT20 
cells is a suitable model to study the early inhibitory effects 
An important feature of early glucocorticoid inhibition in 
normal corticotropes is that it is restricted to stimulated 
ACTH secretion (2-4, 31). Thus, an adequate secretory re- 
sponse is important for the study of this effect of glucocor- 
ticoids. AtT-20 cells have relatively high rates of basal secre- 
tion which is probably due to the frequent spontaneous 
membrane depolarizations and neuron-like action potentials 
observed in electrophysiological studies (28, 32, 33), which 
are correlated, at least qualitatively, with large spontaneous 
excursions in the concentrations of intracellular free calcium 
(5, 33). Furthermore, blockage of dihydropyridine-sensitive 
calcium channels reduces basal ACTH secretion in these cells 
(34), suggesting that a proportion of basal hormone output 
occurs via the regulated secretory pathway and thus may be 
susceptible to inhibition by glucocorticoids. Recent studies in 
D16v cells using biochemical markers of the regulated and 
constitutive secretory pathways also show that approxi- 
mately 60% of unstimulated (“basal”) hormone release is 
derived from the regulated pathway (35). The portion of 
basal release derived from the regulated pathway may vary 
from experiment to experiment, which would explain the 
variability of the effect of glucocorticoids on basal secretion. 
Whether spontaneous electrical activity is also intrinsic to 
normal corticotropes remains controversial because the stud- 
ies reported in the literature so far are discrepant on this 
point, two suggesting virtually no spontaneous fluctuations 
of intracellular free calcium (36, 37) and a third reporting 
rhythmic oscillations of the membrane-potential and tem- 
porally correlated large excursions of intracellular free cal- 
cium concentrations (38). Possibly because of the relatively 
high spontaneous activity, in AtT20 cells the size of the 
secretory response to CRF is rather small, maximally 3-fold 
in our hands, which is similar or smaller than that reported 
by others in D16:16 cells (39). One important difference is 
that in our studies the cells were incubated for only 20-30 
min with secretagogue in order to stay within the time 
TABLE 1. Effect of dexamethasone on CRF-stimulated accumulation of CAMP 
pmol CAMP per well 
Time (mm) 
0' 2' 5' 10’ 20’ 30’ 
Treatment 
Basal (4) 3.16 f 0.35 3.43 + 0.08 3.43 + 0.39 3.55 + 0.47 3.78 + 0.27 3.40 + 0.39 
10 nM CRF-41 (3) 3.47 f 0.23 21.33 f 1.05 16.34 + 1.99 9.98 f 0.74 8.46 1- 0.23 6.47 + 0.23 
10 nM CRF-41 + dexamethasone (3) 3.16 f 0.35 19.50 f 1.56 15.10 + 0.78 9.67 k 0.59 7.45 + 0.66 7.41 + 1.05 
Data are expressed as pmol of CAMP generated per well for the respective time period. IBMX (0.5 mM) was applied for 15-min before time 
zero, fresh IBMX was applied with the stimulus at time zero. No accumulation of CAMP in response to CRF was observed in the absence of 
IBMX. Dexamethasone (10 nM) was applied for 1.5 h before the respective CRF stimulus and had no effect on basal CAMP levels at any time 
point. Data are means f SEM (n = 3-4 per group). 
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FIG. 3. Effect of corticosterone on CRF/Ba-stimulated ACTH release 
from AtTLO D16:16 cells. The control stimulus was a 20-min combi- 
nation of 10 nM CRF and 0.25 mM BaCl*; corticosterone was applied 
for 2 h before the stimulus at various concentrations with (shaded box) 
and without (open bon) 10 pM glycyrrhetinic acid, an inhibitor of ll@- 
hydroxysteroid dehydrogenase. Data are means f  SEM from a repre- 
sentative experiment performed in sextuplicate; corticosterone had no 
effect on basal ACTH release. (*) P < 0.05 compared to 10 pM 
corticosterone alone and control CRF/Ba stimulus (one-way analysis 
of variance, followed by Newman-Keuls test). 
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FIG. 5. Northern blotting for lipocortin I mRNA in AtTPO Dl and 
D1616 cells. a, Autoradiograph of 20 pg total RNA from AtT20 Dl 
cells hybridized with ((Y-~*P) dCTP labeled lipocortin I cDNA and 
exposed for 5 days. Cells were incubated for 24 h in the presence (+) 
or absence (-) of 1 pM dexamethasone. b, Blot a) rehybridized with ((Y- 
3ZP) dCTP labeled cY-tubulin cDNA and exposed for 5 h. c, autoradi- 
ograph of 2 pg poly(A+) mRNA from AtT20 D16:16 cells hybridized 
with (WEEP) dCTP labeled lipocortin I cDNA and exposed for 5 days. 
Cells were incubated for 1.5 h in the presence (+) or absence (-) of 10 
nM dexamethasone. d, Blot c) rehybridized with (cY-~*P) dCTP labeled 
cY-tubulin cDNA and exposed for 5 h. 
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FIG. 4. Blockade of early glucocorticoid inhibition of stimulus-evoked 
ACTH secretion in AtT20 D16:16 cells by blockers of mRNA transcrip- 
tion, actinomycin D, and dichlorobenzimidazole ribofuranoside (DRB), 
or the protein synthesis blocker puromycin. The control stimulus was 
a combination of 10 nM CRF and 0.25 mM BaCl,; the specific type II 
receptor agonist RU28362 (100 nM for 2 h) was used as the glucocor- 
ticoid. Data are means f  SEM (n = 4-8 per group), expressed as 
percentage of the amount of ACTH released by cells exposed to the 
secretagogue stimulus (2.7 pmol/well); the dashed line shows the inhi- 
bition achieved by 100 nmol/l RU28362; basal release was 33 + 2% of 
the control stimulus. Blockers were applied at various concentrations 
for 20 min before RU28362 addition; DRB and puromycin were contin- 
ued during the exposure to RU28362, whereas actinomycin D was 
removed after the first 20 min. 
FIG. 6. Immunoblotting for lipocortin I protein in AtT20 D16:16 cells. 
Cells were incubated in the presence (+) or absence (-) of 10 nM 
dexamethasone for 1.5 h. Crude supernatant (S) and calcium precipi- 
tated (Ca”) samples contained 2 pg/lane, crude pellet samples (P) 
contained 1 pg/lane, and cloned lipocortin I standard (LC 1) contained 
25 rig/lane. Samples were electrophoresed on a lo-15% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis Phastgel, electroblotted to 
Immobilon PVDF, and reacted for lipocortin I using monoclonal MAb 
105 at 1:lOOO dilution. 
domain of early inhibition. Other workers usually incubate 
for longer, l-3 h, periods in order to attain higher basal to 
stimulus ratios. 
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Although some reports have suggested that AtT20 cells 
respond to the other physiologically important ACTH secre- 
tagogue vasopressin (15, 40), most workers, including our- 
selves, have found no effect of vasopressin in this cell line 
(13, 26). However, the pathway of secretion operated by 
activation of protein kinase-C is present in these cells (see 
Ref. 14 for review) and is susceptible to early glucocorticoid 
inhibition as reported by Phillips and Tashjian for D16v cells 
(16). 
Both CRF- and phorbol-ester stimulated ACTH release 
require the entry of calcium into the cells via dihydropyridine 
sensitive (L-type) calcium channels (34, 41). The combined 
stimulus CRF/Ba is similarly inhibited by nimodipine (pres- 
ent study); thus, AtT20 cells appear simpler than normal 
corticotropes (42, 43) with respect to calcium channel phar- 
macology. 
Characteristics of glucocorticoid effect 
Overall, the time-course and pharmacology of early inhi- 
bition in AtT20 cells are similar to those reported for normal 
anterior pituitary cells. The onset of inhibition is within 60 
min, it is mediated by type II receptors, it requires the 
synthesis of new mRNA as well as protein (2-4), and finally, 
the site of inhibition is beyond CAMP generation (44, 45). 
The most striking discrepancy is the lack of a substantial 
inhibition by the physiological glucocorticoid, corticosterone. 
Previous studies have also reported this phenomenon with 
respect to slow inhibition of basal secretion in Dl cells and 
have shown that the hormone receptor complex is translo- 
cated less efficiently into the nucleus by corticosterone when 
compared with dexamethasone (46), although the correlation 
between nuclear translocation and biological action is by no 
means straightforward in this system (47). In our hands, a 
small, but significant inhibition by corticosterone could be 
demonstrated in the presence of glycyrrhetinic acid which is 
a blocker of 1 lb-hydroxysteroid dehydrogenase (for review 
see Ref. 48) a major metabolizing enzyme of corticosterone. 
The possibility that this effect is due to activation of type I 
receptors by corticosterone or glycyrrhetinic acid itself is 
highly unlikely, because AtT20 D16 (not specified whether 
16:16 or 16~) as well as Dl cells only contain the type II 
receptor (49, 50). Furthermore, RU28362, a very highly se- 
lective type II receptor agonist is a powerful inhibitor of 
stimulus-evoked ACTH release in AtT20 cells showing that 
early inhibition does not require activation of type I receptors. 
Hence, it is reasonable to suggest that the low potency of 
corticosterone is at least partly due to metabolism by 11/3- 
hydroxysteroid dehydrogenase. 
A requirement for protein induction, but no change in 
lipocortin I protein mRNA 
Inhibition of DNA transcription with two structurally and 
mechanistically distinct blockers prevented the early inhibi- 
tory effect of glucocorticoids in D16:16 cells. Furthermore, 
blockage of mRNA translation with puromycin was also 
effective in this regard, which is in agreement with the study 
of Phillips and Tashjian in D16v cells (16) as well as previous 
work with normal pituitary cells (3, 4). With respect to the 
nature of the induced protein(s) it was of primary interest to 
examine the possible role of lipocortin I a purported mediator 
of early glucocorticoid action in macrophages and other 
systems (see Ref. 51 for review). Lipocortin I mRNA or 
protein could not be detected in the D16:16 subclone even 
after dexamethasone pretreatment. Furthermore, although 
lipocortin I is present in the anterior pituitary gland, D16v 
and Dl cells, no evidence for its induction by glucocorticoids 
has been found (52). Work on the induction of lipocortin I 
in other systems has also cast doubt on its suggested primary 
and generic function as a mediator of glucocorticoid action 
(for example, see Refs. 53 and 54). Among other candidate 
proteins, chromogranin A, a secretory vesicle associated pro- 
tein (55, 56), has been implicated in slow (>24 h) glucocor- 
ticoid inhibition of ACTH release in AtT20 D16v cells (57), 
although no evidence for its regulation by glucocorticoids in 
normal corticotropes has been documented (58). We found 
no induction of chromogranin A protein in AtT20 D16:16 
cells in the time-interval for early inhibition in this system. 
In summary, these data show that most of the important 
properties of early glucocorticoid inhibition observed in nor- 
mal corticotropes have been retained in AtT20 D16:16 cells. 
The single significant discrepancy is the low potency of the 
natural glucocorticoid corticosterone, which is possibly due 
to the inactivation of this steroid by llfl-hydroxysteroid 
dehydrogenase in AtT20 cells. Thus, AtT20 D16:16 cells 
appear to be a suitable model for the characterization of 
proteins involved in early glucocorticoid inhibition. Impor- 
tantly, this study also shows that the purported glucocorti- 
coid second messenger protein lipocortin I is not induced by 
glucocorticoids in AtT20 D16:16 cells at a time when a 
biologically relevant action of the steroids, the inhibition of 
stimulated ACTH release, is clearly manifested. 
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Inactivation of Early Glucocorticoid Feedback by 
Corticotropin-Releasing Factor in Vitro 
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ABSTRACT. We have investigated the interaction between 
hypothalamic ACTH secretagogues and adrenocortical glucocor- 
ticoids in rat anterior pituitary tissue using an in vitro perifusion 
system. 
Repeated 5 min pulses of 41-residue CRF (CRF-41) or argi- 
nine vasopreesin (AVP) were applied at 1 h intervals for up to 7 
h. Administration of 0.1 PM cbrticosterone 30 min before and 
durine the 5 min 0.1 nM CRF-41 stimulus at 5 h resulted in a 
signifilcant inhibition of CRF-41 stimulated ACTH release 
within 30 min. Inhibition of ACTH release also developed if no 
CRF-41 stimulus was applied in conjunction with steroid at 5 h. 
In contrast, if the exposure to corticosterone (0.1 PM, 35 min 
total duration) was started simultaneously with the application 
of CRF-41 at 5 h, no inhibition of ACTH release ensued. Simi- 
larly, no inhibition of CRF-41-stimulated ACTH release was 
observed when corticosterone was started simultaneously with a 
5 min pulse of cyclic 8-(4Chlorophenylthio) AMP (8CPT- 
CAMP), a cell membrane permeant analog of CAMP. 
In contrast to CRF-41 and 8CPT-CAMP, AVP failed to 
modify glucocorticoid-induced inhibition of AVP- or CEF-41- 
stimulated ACTH release. Moreover, CRF-41 did not prevent 
the glucocorticoid-induced inhibition of AVP-stimulated ACTH 
release. 
In summary: 1) CRF-41 inactivates early glucocorticoid in- 
hibition of CRF-41-stimulated ACTH secretion, and this is 
mimicked by a cell membrane permeant analog of CAMP; 2) 
AVP does not inactivate alucocorticoid-induced inhibition of 
stimulated ACTH release; 3) the data point to an acute inter- 
action between the CAMP/protein kinase A and glucocorticoid- 
responsive intracellular pathways. Such differential modulation 
of feedback inhibition by CRFs may be of functional importance 
in Go. (Endocrinology 130: 2213-2218,1992) 
C ORTICOTROPIN releasing factor-41 (CRF-41) and arginine vasopressin (AVP) are the major physio- 
logical hypothalamic regulators of ACTH secretion from 
anterior pituitary corticotrophs while the adrenocortical 
glucocorticoids, released in response to elevated ACTH 
levels, inhibit ACTH release over several time domains 
(for reviews see Refs. l-4). At the pituitary level early- 
onset glucocorticoid inhibition decreases stimulated 
ACTH release within 30 min; the maximal effect is 
apparent within l-2 h of glucocorticoid application. This 
action is mediated through type II glucocorticoid recep- 
tors and requires the synthesis of new messenger RNA 
as well as protein (5-8). 
Using an in vitro perifusion model we have reported 
that the characteristics of early-onset glucocorticoid in- 
hibition of stimulated ACTH release are dependent on 
both the nature of the secretagogue as well as the tem- 
poral relationship between secretagogue and glucocorti- 
coid application. Notably, early-onset glucocorticoid in- 
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hibition of CRF-41 stimulated ACTH release did not 
develop if CRF-41 was applied at the start of corticoster- 
one exposure. In contrast, AVP had no such action on 
early-onset inhibition of AVP-stimulated ACTH release 
(7). 
In this study we have investigated whether CRF-41 
blocks early-onset glucocorticoid inhibition and whether 
the action of CRF-41 is reproduced by its intracellular 
second messenger CAMP. Furthermore, we have inves- 
tigated whether there is any interaction between CRF- 
41 and AVP with respect to the blockage of glucocorti- 
coid-induced inhibition. 
Materials and Methods 
Animals 
Female exbreeder Wistar rats (259-399 g body wt) were 
obtained from Charles River Ltd (Margate, Kent, UK) or 
Harlan-Olac (Bicester, Oxon, UK) and maintained four to a 
cage under controlled conditions of lighting (lights on 0500 h, 
off 1900 h) and temperature for at least 2 weeks before use with 
free access to standard lab chow and water. 
Reagents 
Rat CRF-41, AVP, and human ACTHcl-Bg, were supplied by 
Bachem Inc. (Saffron Walden, Essex, UK); corticosterone was 
2213 
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from Sigma Chemical Company Ltd (Poole, Dorset, UK). 
Cyclic 8-(4-Chlorophenylthio) AMP (8-CPT-CAMP) was from 
Boehringer Mannheim UK &ewes, Sussex, UK). General 
chemicals were from BDH (Poole, Dorset, UK). 
Perifusion 
Perifusion of isolated rat pituitary segments was performed 
as previously described (7). Briefly, anterior pituitary glands 
were cut into eight segments and perifused at 200 pl/min with 
Dulbecco’s modified Eagle’s medium buffered with 25 mM 
HEPES (Gibco-BRL, Paisley, Strathclyde, UK), pH 7.4, con- 
taining 0.25% BSA, 100 U/liter penicillin, and 100 U/liter 
streptomycin (Gibco-RBL, Paisley, Strathclyde, UK) at 37 C. 
Typically four perifusion columns were run in parallel with one 
pituitary equivalent of randomly distributed pituitary segments 
used per perifusion column. Column effluent was collected 
every 5 min on ice and stored at -40 C before assaying for 
ACTH immunoreactivity. After an initial preperifusion period 
of 3 h to allow basal ACTH release to stabilize, 5 min pulses of 
secretagogue were applied every 1 h for up to 7 h after the start 
of the experiment. Various treatments were applied as described 
in the figure subscripts. 
RIA and data analysis 
The RIA for immunoreactive ACTH in the column effluent 
was performed as previously described (9) using antiserum no.6 
(courtesy G. B. Makara, MTA-KOKI, Budapest, Hungary). 
Net ACTH release per 5 min exposure to secretagogue was 
determined for each stimulus as previously described (6). Net 
ACTH release is defined as ((V, + VP+. . . . , . +V,)/nJ - (B] 
where V1 is the fist 5 min fraction collected during the stimulus 
(199 set transit time discarded) and Vz to V, are the next n 
consecutive fractions that are elevated with respect to basal 
ACTH release (B) immediately before the application of the 
stimulus. For 1OnM CRF-41 or AVP, n = 5. For 0.1 nM CRF- 
41, n = 3. Because of the variability in absolute ACTH release 
between experiments data were standardized by expressing the 
net ACTH release elicited by a treatment as a percentage of 
that elicited by CRF-41 (or AVP) alone. The net ACTH release 
at 4 h was defined as the 100% release value in all columns. 
Statistical evaluation between different treatments at each 
time point was performed using the Kruskal-Wallis test with 
multiple comparisons for several independent samples, or the 
Mann-Whitney U-test for two independent samples (10). 
Results 
CRF-41 and 8-CPT-CAMP inactivate glucocorticoid 
inhibition of CRF-41-stimulated ACTH release 
Corticosterone pretreatment (0.1 PM for 35 min) sig- 
nificantly (P < 0.05) inhibited CRF-41-stimulated 
ACTH secretion within 30 min of corticosterone appli- 
cation (Fig. 1) before ACTH release returned toward 
control 2.5 h after steroid application. Corticosterone 
induced inhibition of CRF- and AVP-stimulated ACTH 
release developed with a similar time profile (data not 
shown). 
4 5 6 7 
Time (h) 
FIG. 1. Early-onset co&co&crone-induced inhibition of CRF-ll-stim- 
ulated ACTH secretion in perifused rat anterior pituitary gland aeg- 
menta. The control group (0) received repeated 5 min pulses of 0.1 nM 
CRF-41 (solid uertical bars); the other group (0) received corticosterone 
(0.1 PM, 35 min total exposure; horizontal hatckd bar) 30 min before 
the start of the CRF-41 pulse at 5 h. Data are expressed aa a percentage 
of the net ACTH released by a 5-min pulse of CRF-41 applied at 4 h. 
Data are means f  SEM (n = 4-?‘/group). *, P C 0.05 (nonparametric 
Mann Whitney U-test) compared with the control group. 
CRF-41 stimulated ACTH release was also signifi- 
cantly inhibited when no CRF-41 stimulus was applied 
during the exposure to corticosterone (Table 1). Omis- 
sion of the CRF-41 stimulus at 5 h had no effect on the 
responses to subsequent pulses of CRF-41; thus these 
controls were pooled with controls receiving CRF-41 at 
5 h. Early-onset glucocorticoid inhibition did not develop 
when CRF-41 was applied at the start of corticosterone 
exposure, suggesting that CRF-41 inactivates glucocor- 
ticoid-induced inhibition (Table 1). Furthermore, the cell 
membrane permeant CAMP analog, 8-CPT-CAMP [O.l 
mM for 5 min (ll)] also prevented the subsequent inhi- 
bition of CRF-41 induced ACTH release when applied 
at the start of corticosterone exposure (0.1 pM, 35 min 
duration) at 5 h (Table 1). At this concentration a 5 min 
pulse of 8-CPT-CAMP elicited 26.0 + 5.1% of the ACTH 
released by 0.1 nM CRF-41 and did not modify the ACTH 
release to subsequent CRF-41 pulses (Table 1). 
To investigate whether the inactivation of glucocorti- 
coid-induced inhibition was specific to the CAMP path- 
way, 10 nM AVP (that acts via the inositol phosphate/ 
protein kinase C pathway) was applied for 5 min at 5 h. 
The release of ACTH in response to a 5 min pulse of 10 
nM AVP at 5 h was 186.2 + 24.0% (n = 14) of the 0.1 
IIM CRF-41 stimulus applied at 4 h. The CRF-41 stimulus 
at 6 h released similar amounts of ACTH compared to 
CRF-41 controls; however, down-regulation of the CRF- 
41 response at 7 h occurred in columns treated with AVP 
at 5 h (Table 1). Importantly, when AVP was applied at 
the start of corticosterone exposure, significant (P c 
0.01) inhibition of CRF-41-stimulated ACTH release 
occurred at 6 h (Table 1). These data suggest that inac- 
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TABLE 1. Inactivation of corticosterone-induced inhibition of CRF- 
4l-stimulated ACTH secretion by CRF-41 and the CAMP analog, 8 
CPT-CAMP, in perifused rat anterior pituitary segments 
Net ACTH released ( W) 
6h 
CRF-41 
n 
lh 
CRF-41 
n 
100% CRF-41 (7) 98.0 f  8.4 99.0 f  9.9 
n 
Corticoeterone (4) 61.5 f  9.9” 54.3 f  9.3 
eL1 
Corticosterone + 108.4 f  4.3b 111.2 f  12.4’ 
CRF-41 (5) 
ea 
n 
8-CPT-CAMP (8) 103.5 f  15.1 76.3 f  12.2 
cl 
Corticoeterone + 8- 101.2 f  13.2” 106.0 f  13.6b 
CPT-CAMP (6) 
eo 
0 
AVP (4) 82.5 f  4.3 48.0 f  15.6 
Corticosterone + 
AVP (4) 
32.3 f  18.7’ 50.0 f  12.4 
All groupe received 5 min pulses of 0.1 nM CRF-41 at 4, 6, and 7 h. 
The various treatments applied, along with their temporal relationship 
of application, are shown in the 5 h treatment column. 8-CPT-CAMP 
was applied for 5 min at 0.1 mM. AVP for 5 min at 10 nM. Corticosterone 
(0.1 PM, 35 min total exposure) was etarted simultaneously with the 5 
h stimulus. Data are expressed aa a percentage of the net ACTH 
released by a 5-min pulse of 0.1 nM CRF-41 applied at 4 h in all groups. 
Because omission of the 5 h CRF-41 stimulus did not affect subsequent 
stimulated ACTH releaee data from control columns receiving no CRF- 
41 at 5 h were pooled with the CRF-41 control group. Values are means 
f  SEM; the number of experiments in each treatment group are shown 
in parentheses. 
OP < 0.05 compared to CRF-41 control. 
b P < 0.05 compared to corticoeterone alone. 
‘P < 0.05 compared to AVP control using nonparametric Kruskal- 
Wallis test. 
tivation is specific to the CRF-4l/cAMP pathway. 
The duration of corticosterone exposure is also impor- 
tant in determining the characteristics of early-onset 
inhibition. When CRF-41 was applied at the start of a 
continuous corticosterone infusion inhibition of CRF- 
41stimulated ACTH release developed 2 h after the start 
of corticosterone treatment (Fig. 2). 
Glucocorticoid inhibition of A VP-stimulated ACTH 
release is not modulated by CRF-41 
CRF-41(0.1 nM) applied simultaneously with the start 
of corticosterone exposure (35 min duration) at 5 h could 
not prevent the corticosterone-induced inhibition of 
AVP-stimulated ACTH release at 6 h (Table 2). Al- 
2 or t 
4 5 6 7 
Time (h) 
FIG. 2. Inhibition of CRF-41-stimulated ACTH secretion by continu- 
ous exposure to corticosterone started simultaneously with a 5 min 
CRF-41 stimulus in perifused rat anterior pituitary segments. The 
control groupe (0) received repeated 5 min pulses of 10 nM CRF-41 
(solid vertical bars) every 1 h. The other group (0) received 0.1 PM 
corticosterone (horizontal hatched bar) started simultaneously with the 
5 h stimulus and maintained to the end of the experiment. Data are 
expressed as a percentage of the net ACTH released by a 5-min pulse 
of CRF-41 applied at 4 h. Data are means f  SEM (n = 4-g/group. *, P 
< 0.05 (nonparametric Mann-Whitney U test) compared with the 
control group. 
TABLE 2. CRF-41 does not inactivate corticosterone-induced inhibi- 
tion of AVP-stimulated ACTH secretion in perifused rat anterior 
pituitary segments 
Net ACTH released (%) 
4h 
AVP 
5h 
Treatment 
6h 
AVP 
7h 
AVP 
100% AVP (9) 100.2 f  9.7 87.1 f  5.7 
la 
Corticosterone + 60.4 f  4.5” 101.0 f  18.6 
AVP (5) 
m 
CRF-41 (5) 94.8 f  9.5 65.6 f  16.1 
n 
Corticosterone + 41.4 f  12.ob 63.8 f  17.2 
CRF-41 (5) 
r 
All groups received 5 min pulses of 10 nM AVP at 4,6, and 7 h. The 
various treatments applied, along with their temporal relationship of 
application, are shown in the 5 h treatment column. Corticosterone 
(0.1 PM, 35 min total exposure) was started simultaneously with the 5 
h stimulus; CRF-41 was applied for 5 min at 0.1 nM. Data are expressed 
as a percentage of the net ACTH released by a 5-min pulse of 10 nM 
AVP applied at 4 h in all groups. Values are means f  SEM; the numbers 
of experimenta in each treatment group am shown in parentheses. 
a P c 0.05 compared to AVP control. 
b P < 0.01 compared to CRF-41 treated control using nonparametric 
Kruskal-Wallis test. 
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though CRF-41 appears to decrease the subsequent re- 
sponse to AVP at 7 h (Table 2) this effect is not statis- 
tically significant and is a consequence of one column 
out of the five in the group releasing a very low amount 
of ACTH at 7 h. Increasing the concentration of CRF- 
41 to 10 nM also failed to modify the inhibition by 
corticosterone (data not shown). Because these columns 
received AVP before the application of CRF-41 and 
corticosterone at 5 h, we examined whether this AVP 
pretreatment could prevent the CRF-inactivation of glu- 
cocorticoid inhibition. In order to test this, CRF-41 (0.1 
nM) stimuli were applied at 3 h, 4 h, and 5 h, and 10 nM 
AVP applied at 6 and 7 h. Corticosterone (0.1 pM, 35 
min duration) started simultaneously with CRF-41 at 5 
h resulted in significant (P < 0.05, using nonparametric 
Kruskal Wallis test) inhibition of AVP-stimulated 
ACTH release compared to control even under these 
conditions. The net ACTH release expressed as a per- 
centage of the 4 h CRF-41 stimulus for control and 
corticosterone-treated groups, respectively, was: at 6 h 
186.7 + 45.4% vs. 67.8 + 16.6% and at 7 h 214.7 + 48.0% 
vs. 97.8 + 31.2% (n = 3-4/group). Furthermore, CRF-41 
prevented the corticosterone-induced inhibition of CRF- 
&-stimulated ACTH release after pretreatment of the 
segments with 10 nM AVP (data not shown) further 
suggesting that CRF-41 can only inactivate glucocorti- 
coid-induced inhibition of CRF-41-stimulated ACTH re- 
lease. 
Discussion 
The present study demonstrates that CRF-41 inacti- 
vates early glucocorticoid inhibition of CRF-41-stimu- 
lated ACTH secretion from perifused rat anterior pitui- 
tary corticotrophs in vitro, and that this action is me- 
diated by CAMP. Furthermore, the data suggest that 
glucocorticoids act via distinct mechanisms to inhibit 
CRF-41- and AVP-stimulated ACTH secretion. 
CRF-41 inactivates early glucocorticoid inhibition of 
CRF-41 -stimulated ACTH release 
The data confirm our previous observations showing 
that the development of early glucocorticoid inhibition 
of CRF-41-stimulated ACTH secretion is dependent 
upon the relative timing of application of CRF-41 with 
steroid (7). However, our previous data did not resolve 
whether the timing phenomenon was a result of CRF-41 
activating some step in the glucocorticoid-induced inhi- 
bition (for example posttranslational modification of the 
induced protein) when CRF-41 was applied after the 
start of corticosterone exposure, or alternatively, that 
CRF-41 inactivates glucocorticoid-induced inhibition, 
perhaps by preventing the protein induction, when ap- 
plied simultaneously with the start of corticosterone 
exposure. 
CRF-41-stimulated ACTH release was significantly 
inhibited by corticosterone when no CRF-41 stimulus 
was applied during the exposure to corticosterone; simi- 
lar results were also observed with the type II glucocor- 
ticoid receptor agonist RU28386 (M. J. Shipston and F. 
A. Antoni, unpublished data). Furthermore, application 
of CRF-41 or an analog of its intracellular messenger 
CAMP, simultaneously with the onset of corticosterone 
exposure, prevented the subsequent inhibition of CRF- 
41-stimulated ACTH release. Thus, it appears that CRF- 
41 actually prevents the action/induction of the gluco- 
corticoid-induced protein(s) when applied at the start of 
glucocorticoid exposure. Interestingly, the duration of 
corticosterone exposure also plays a role in the charac- 
teristics of early glucocorticoid inhibition of CRF-41- 
stimulated ACTH release because if CRF-41 is applied 
simultaneously with the start of corticosterone then in- 
hibition of CRF-41-stimulated ACTH release develops 
after 2 h of continuous steroid exposure. 
The precise mechanism by which CRF-41 prevents 
glucocorticoid inhibition of ACTH release is not clear. 
However, because it can be reproduced with a CAMP 
analog but not with AVP (an activator of the inositol 
phosphate/protein kinase C pathway), it seems reason- 
able to suggest that the inactivation of glucocorticoid 
action is, in fact, mediated by CAMP and/or CAMP 
dependent phosphorylation. In turn, this may interfere 
with glucocorticoid action through modulation of the 
state of glucocorticoid receptor phosphorylation (12), and 
possibly preventing translocation of the hormone-recep- 
tor complex into the nucleus (13-15). Furthermore, tran- 
scription factors such as c-fos or CAMP response element 
binding protein (CREB) which are induced or activated 
by CAMP (16), have been shown to interfere with glu- 
cocorticoid-induced gene transcription (17-21). Alter- 
natively, CRF-41 may induce some posttranslational 
modification in, or alter events downstream of, the 
glucocorticoid-induced protein to prevent the inhibition 
of CRF-41 stimulated ACTH secretion. 
It is of interest that a reduction in glucocorticoid 
receptor number and glucocorticoid receptor mRNA lev- 
els develops 6 h after exposure to activators of CAMP 
synthesis in AtT-20 corticotroph tumor cells (22). Thus, 
CRF-41 acting via CAMP exerts both short- (present 
findings) and long-term (22) control over glucocorticoid 
action at the pituitary level. In turn, reciprocally oppos- 
ing actions are provided by early- and late-onset gluco- 
corticoid inhibition of CRF-41 action on ACTH release 
and biosynthesis (cf Refs. 3 and 23 for reviews). 
CRF-41 does not inactivate glucocorticoid-induced 
inhibition of A VP-stimulated ACTH release. 
Intriguingly, CRF-41 failed to prevent glucocorticoid 
induced-inhibition of AVP-stimulated ACTH secretion. 
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From among the several possible explanations to this 
phenomenon, on the basis of the present data we can 
exclude that the priming of the tissue segments with 
AVP inhibits the action of a subsequent CRF-41 pulse 
to prevent glucocorticoid inhibition, or that priming with 
CRF-41 is required for this effect of CRF-41. Thus, it 
appears that glucocorticoids suppress CRF-41- and AVP- 
induced ACTH secretion through different mechanisms. 
Indeed, previous evidence indicates that distinct pools of 
ACTH are mobilized by these neurohormones: CRF-41 
releases a stored, slow-turnover pool of ACTH, whereas 
AVP-induced secretion is derived from a rapid-turnover 
pool of hormone (7, 24). A further possibility, (this in 
fact does not exclude the previous one) is that distinct 
populations of corticotrophs are involved (cf Refs. 24 and 
25) in which CAMP phosphorylation targets are ex- 
pressed in a cell-specific manner. 
4. 
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Depolarization counteracts glucocorticoid inhibition of
adenohypophysical corticotroph cells*
1,2,3M.C. Lim, 2M.J. Shipston & 1F.A. Antoni
1MRC Brain Metabolism Unit, Department of Pharmacology, 2Department of Physiology, University of Edinburgh,
Edinburgh EH8 9JZ
1 In AtT20 mouse corticotroph tumour cells large conductance Ca2+-activated K+-channels (BK-
channels) have an essential role in the early glucocorticoid inhibition of adrenocorticotrophin (ACTH)
secretion evoked by corticotrophin-releasing factor. The present study examined whether or not BK-
channels are also pivotal to glucocorticoid inhibition of normal rat anterior pituitary cells.
2 A membrane-permeant, non-metabolizable cyclic AMP analogue, 8-(4-Chlorophenylthio)adenosine-
3',5'-cyclic-monophosphate (CPT-cAMP) was used as the primary secretagogue stimulus, as this mimics
the increase of intracellular cyclic AMP caused by corticotrophin-releasing factor, but is not subject to
the complex Ca2+-dependent regulation of cyclic AMP metabolism that is evident in corticotroph cells.
3 Experiments in AtT20 cells showed that ACTH secretion stimulated by 1 mM CPT-cAMP was
suppressed to 34+1.5% (n=12) of the control stimulus by a maximal dose of 100 nM dexamethasone.
The ACTH secretion evoked by the combination of 1 mM CPT-cAMP with either 5 mM (7)BayK8644
(L-type Ca2+-channel activator) or 5 mM TEA (K+-channel blocker) was respectively 69.1+7.6% and
69.3+11.8% of control after 2 h preincubation with 100 nM dexamethasone (P50.05 vs CPT-cAMP).
The ACTH response elicited by 5 mM (7)BayK8644 and 5 mM TEA given together was completely
resistant to inhibition by 100 nM dexamethasone. Furthermore, TEA and (7)BayK8644 given together
synergistically stimulated ACTH release in combination with 0.1 mM or 1 mM CPT-cAMP, and these
ACTH responses were not inhibited by 100 nM dexamethasone.
4 In primary cultures of rat anterior pituitary cells, TEA (up to 20 mM), charybdotoxin (30 nM) or
apamin (100 nM) failed to modify the glucocorticoid inhibition of 0.1 mM CPT-cAMP-induced ACTH
release. The combination of 5 mM TEA and 5 mM (7)BayK8644 elicited a small but significant increase
in ACTH secretion but did not modify the inhibition of 0.3 mM CPT-cAMP-induced ACTH secretion by
100 nM dexamethasone.
5 In primary cultures of rat anterior pituitary cells, depolarization of the membrane potential with
40 mM KCl enhanced the ACTH response to CPT-cAMP and markedly reduced the maximal inhibitory
eect of dexamethasone to 55+1.2% as well as that of corticosterone to 33+2.1% vs 100+2.5% and
100+1.9% inhibition respectively, when 0.1 mM CPT-cAMP was used alone. Introduction of 5 mM
(7)BayK8644 with 40 mM KCl in this system had no additional eect on glucocorticoid inhibition.
6 No glucocorticoid inhibition of ACTH release to any of the stimuli applied was observed in cells
pretreated with the mRNA synthesis inhibitor, 5,6-dichloro-furanosyl-benzimidazole riboside (DRB)
(0.1 mM) or the protein synthesis blocker, puromycin (0.1 mM).
7 In summary, early glucocorticoid inhibition of stimulated ACTH release by cultured rat anterior
pituitary cells was dependent on the synthesis of new mRNA and protein. Depolarization of the
membrane potential potentiated CPT-cAMP-induced ACTH secretion in AtT20 cells as well as cultured
rat corticotrophs and this was associated with a resistance to the early inhibitory eect of
glucocorticoids. Glucocorticoid inhibition in rat anterior pituitary corticotrophs was unaltered by
TEA, charybdotoxin as well as apamin, and hence it is unlikely to involve predominantly BK-or SK-type
Ca2+-activated K+-channels.
8 These results support the thesis that a prime target of glucocorticoid feedback inhibition in anterior
pituitary corticotrophs is the membrane potential and indicate that glucocorticoid-induced proteins
regulate the activities of several distinct plasma membrane ion channels.
Keywords: Pituitary gland; potassium channels; dexamethasone; corticosterone; AtT20 cells; stress
Introduction
Adrenal corticosteroids are powerful regulators of gene
expression in several organ systems of the body. The plasma
levels of these steroids are controlled through a neuroendo-
crine feedback loop which ensures that corticosteroid levels are
optimal for homeostatic adaptation (Dallman et al., 1992).
Major sites of corticosteroid feedback action include the
anterior pituitary gland, the hypothalamus and further sites in
the central nervous system (Sapolsky et al., 1990).
The cellular mechanisms underlying corticosteroid feedback
of the hypothalamic-pituitary-adrenocortical system are not
well understood. The anterior pituitary corticotroph has
served as a useful model to examine this problem (Antoni,
1996; Buckingham, 1996). In corticotroph cells corticosteroid
inhibition typically occurs in two main phases, designated
early (within 2 h) and late (2 – 24 h) (Antoni, 1996; Bucking-
ham, 1996). Late inhibition appears to be mediated by negative
regulatory elements in DNA and leads to the suppression of
3Author for correspondence.
* A preliminary report of this work has been published in Journal of
Endocrinology 152 S P156, 1997.
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the proopiomelanocortin (ACTH precursor) (Lundblad &
Roberts, 1988), the type 1 corticotrophin releasing-factor
(CRF) receptor (Pozzoli et al., 1996) and possibly other genes.
In contrast, the early component of inhibition is brought about
by glucocorticoid-induced protein(s), the identity of which is
unclear at present (Shipston, 1995; Antoni, 1996; Buckingham,
1996).
Recent studies in the mouse corticotroph tumour cell line
AtT20 (Shipston et al., 1996) have shown that high
conductance Ca2+-activated K+-channels (BK-channels) play
an essential role in the inhibitory eect of dexamethasone on
CRF-induced ACTH secretion. Briefly, activation of adenylyl
cyclase by CRF produces an increase of cyclic AMP-
dependent phosphorylation and triggers Ca2+-dependent
action potentials which lead to the exocytotic release of ACTH
(see Antoni, 1993). An important element of this stimulatory
eect is the inhibition of BK-channels by cyclic AMP-
dependent protein kinase (Shipston et al., 1996). Treatment
with dexamethasone for 90 min prevented the action of CRF
and cyclic AMP analogues on BK-channels through a process
requiring the synthesis of mRNA and protein (Shipston et al.,
1996). Accordingly, the blockade of BK-channels by char-
ybdotoxin (Antoni, 1996) or iberiotoxin (Shipston et al., 1996)
obliterated the inhibitory eect of dexamethasone on
stimulated ACTH release.
The aim of the present study was to examine whether BK-
channels are also essential for corticosteroid feedback
inhibition in non-tumoural corticotroph cells. Experiments
were carried out in vitro, using AtT20 cells and primary
cultures of rat anterior pituitary cells. A cell-permeant cyclic
AMP analogue resistant to hydrolysis by cyclic nucleotide
phosphodiesterases (PDEs) was used as the stimulus in
combination with various compounds that cause membrane
depolarization. The rationale for this design was that increases
of intracellular cyclic AMP induced by agonists are strongly
suppressed by intracellular Ca2+ in both AtT20 and normal rat
corticotrophs (Antoni et al., 1995; Antoni, 1997), hence
changes of cyclic AMP metabolism induced by corticosteroids
could mask eects downstream of cyclic AMP formation.
The results clearly show that in contrast to AtT20 cells,
blockage of BK-channels fails to counteract early glucocorti-
coid inhibition in cultures of rat anterior pituitary cells.
Importantly, however, corticosteroid inhibition in the rat
pituitary culture system was markedly reduced upon depolar-
ization with high extracellular KCl, in which respect its
behaviour is analogous to AtT20 cells. Thus, the findings
support the notion that early inhibition by glucocorticoids
involves control of the membrane potential by rapidly induced
proteins.
Methods
Reagents
Unless otherwise indicated all reagents were from Sigma U.K.
(Poole, Dorset), and of the highest grade available. The
sources of other materials were as follows: CRF (human),
ACTH (human) synthetic charybdotoxin (Bachem U.K. Ltd.,
Saron Walden); corticosterone (Roussell-UCLAF, Romain-
ville, France); 8-(4-chlorophenylthio)adenosine-3',5'-cyclic-
monophosphate (CPT-cAMP, BIOLOG, Bremen, Germany);
tetraethyl ammonium hydrochloride (TEA, Aldrich, Gilling-
ham, Dorset); (7)BayK8644, (RBI, Sigma, U.K.); (+)202-791
(Novartis, U.K.); TRL-3 trypsin (Worthington, Lorne
Laboratories, Reading, U.K.); Sheep anti-ACTH serum was
generously provided by Prof P.J. Lowry, University of
Reading; anti-sheep/goat IgG donkey serum was generously
provided by the Scottish Antibody Production Unit, Carluke,
Scotland.
Cell culture
Male Wistar rats (120 – 200 g) were caged singly with free
access to pelleted food and tap water in a light- and
temperature-controlled environment for 24 h, and sacrificed
by decapitation before 10.30 a.m. Precautions were taken to
avoid any stressful stimulation of the animals. The anterior
pituitary glands were collected and placed in a plastic Petri
dish so that the ventral surfaces of the glands contacted the
bottom of the dish. The glands were chopped twice (the second
time after 908 rotation of the specimen platform) on a hand-
operated McIlwain tissue-chopper setting 0.5 mm and lowest
blade force. The tissue segments were incubated in Hank’s
balanced salt solution without Ca2+ and Mg2+ (HBSS,
GIBCO, Life Technologies, Paisley) supplemented with 25 mM
HEPES pH 7.4, 0.15 mM CaCl2, 0.15 mM MgSO4,
0.5 mg ml71 trypsin, 0.01 mg ml71 DNAse I (Sigma D-4527)
and 0.25% bovine serum albumin (BSA, Sigma A-7906) for
30 min at 378C under constant shaking at 250 cycles/min, on a
IKA Vibrax orbital shaker. Following trypsinization, 200 ml of
104 kallikrein unit/ml Trasylol1 (Bayer U.K.) was added and
the tissue segments were triturated with a 1 ml Gilson pipette
tip attached to the end of a 5 ml polystyrene pipette for
10 min. The suspension was then filtered through 70 mM nylon
mesh and centrifuged at 200 g for 10 min. The pelleted cells
were resuspended in 5 ml HBSS supplemented with 25 mM
HEPES pH 7.4, 0.15 mM CaCl2, 0.15 mM MgSO4,
0.01 mg ml71 DNAse I, 0.25 mg ml71 soybean trypsin in-
hibitor (Sigma T-6522), recentrifuged and suspended in
Dulbecco’s Modified Eagle’s Medium (DMEM, containing
4.5 g glucose/L) supplemented with 2.5% foetal calf serum
(Harlan Seralab, Sussex) and 7.5% horse serum (Sigma H-
1138). Cell viability as assessed by Trypan Blue exclusion was
over 95%. Approximately 56104 cells/well were plated in 24-
well plates and cultured in a humidified incubator with 5%
CO2/95% air at 378C for 4 days.
AtT20 cells were maintained in DMEM (containing 4.5 g/L
glucose) supplemented with 10% foetal calf serum as
previously described (Woods et al., 1992). All cells used were
of passage 30 or less.
Assay of ACTH secretion
The experimental procedures for ACTH secretion were
identical for AtT20 cells and primary cultures. The cells
were first washed free of serum with 260.5 ml of
incubation medium (DMEM, GIBCO 31600-026, without
Na2HCO3, supplemented with 25 mM HEPES pH 7.4 and
0.25% BSA (Sigma, A-4378) and incubated in this medium
at 378C for 1 h, after which steroids and inhibitors of
mRNA or protein synthesis were introduced, and incuba-
tion was continued for a further 2 h. Steroids were
dissolved at 1072 M in dimethylsulphoxide and diluted with
incubation medium. Corresponding vehicle controls con-
tained the requisite amounts of dimethylsulphoxide
throughout.
In the case of primary cultures, K+ channel blockers and
Ca2+-channel activators were added during the last 30 min of
the 2 h preincubation period because normal corticotrophs
appear to be relatively resistant to depolarization. After 2 h of
preincubation, the wells were washed once more with
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incubation medium and the secretagogues and requisite
inhibitors were added in 0.5 ml of fresh incubation medium.
In some experiments, high KCl medium which was composed
of two parts incubation medium and one part 120 mM KCl,
1 mM MgSO4, 1.8 mM CaCl2, 25 mM HEPES 0.25% BSA,
Ca2+-free medium (120 mM NaCl, 2.4 mM KCl, 1.2 mM
K2HPO4, 1.2 mM MgSO4, 4.5 g/L D-glucose, 0.2 mM EGTA,
25 mM HEPES, 0.25% BSA, Minimum Essential Medium
vitamins and amino acids) or Ca2+-free high KCl medium (two
parts of the Ca2+-free medium mixed with one part of 120 mM
KCl, 1.2 mM MgSO4, 0.2 mM EGTA, 25 mM HEPES, 0.25%
BSA, vitamins and amino acids) were used. The test incubation
period was 60 min for primary cultures and 30 min for AtT20
cells after which the tissue culture trays were placed on ice.
Any cells detached from the bottom of the wells were pelleted
by centrifugation at 200 g for 10 min at 48C after which
aliquots of the supernatant were collected and assayed for
ACTH content by radioimmunoassay. Sheep anti ACTH
serum used in the assay was generously provided by Prof P.J.
Lowry, University of Reading and the donkey antisheep IgG
serum was obtained from the Scottish Antibody Production
Unit, Carluke, Scotland.
Analysis of results
Each experiment was carried out at least twice with n replicates
for each treatment within each experiment. All data are
presented as mean+s.e.mean and were analysed by 2- or 1-
way analysis of variance followed by Dunnett’s test, Newman
Keuls’ test or contrast of means where appropriate. Results
presented as percentage of control ACTH release were derived
from the raw data as follows: (X –B)/(C –B)6100%, where B
refers to the basal ACTH secretion, C refers to ACTH
secretion elicited by the control stimulus and X refers to
ACTH secretion elicited by the control stimulus in the presence
of dexamethasone or corticosterone.
Results
Experiments with AtT20 cells
Response to CPT-cAMP and dexamethasone Concentration-
dependent stimulation of ACTH release was evoked by CPT-
cAMP (Figure 1) and the response plateaued at 1 mM CPT-
cAMP. Pretreatment with 100 nM dexamethasone significantly
reduced the increase in CPT-cAMP-stimulated ACTH secre-
tion, basal hormone output remained unaltered (Figure 1).
Eects of depolarizing agents The ACTH response to 1 mM
CPT-cAMP could be enhanced further by the application of
Figure 1 The eect of CPT-cAMP on ACTH secretion by AtT20
cells pretreated for 2 h with vehicle (*) or 100 nM dexamethasone
(*). Means, the bars indicate s.e.mean, n=5/group. Where error
bars are not visible, the s.e.mean bar is less than the space required
for the symbol. Results shown are representative of four identical
experiments.
Figure 2 Eect of membrane depolarizing agents, 5 mM
(7)BayK8644 (BayK) and 5 mM tetraethylammonium (TEA) on
ACTH secretion elicited by 1 mM CPT-cAMP (CPT) after 2 h
preincubation with vehicle or 100 nM dexamethasone in AtT20 cells.
Data are means, bars indicate s.e.mean, n=4/group. (A) The empty
columns show ACTH release by vehicle treated cells and the hatched
columns show release after treatment with dexamethasone. {P50.02
for the interaction between CPT alone and the respective depolarizing
agents alone, 2-way ANOVA. *P50.05 when compared to
corresponding vehicle-treated release, 1-way ANOVA followed by
contrast of means. (B) data are expressed as % change in the amount
of ACTH secretion caused by dexamethasone when compared with
the respective control groups shown in A. **P50.05 when compared
with CPT alone. 1-way-ANOVA followed by Dunnett’s test. Results
shown are representative of two identical experiments.
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5 mM tetraethylammonium (TEA) or the Ca2+-channel
activator (7)BayK8644 at 5 mM (Figure 2A). Both of these
compounds stimulated ACTH release when given alone and
exhibited synergistic interaction with CPT-cAMP. Similar data
were obtained with another L-channel activator (+)202 – 791
at 5 mM (not shown).
The release of ACTH evoked by 1 mM CPT-cAMP was
inhibited by 65.8+8.9% (n=5) by 100 nM dexamethasone,
while basal secretion was not significantly altered (Figure 2A
and B). The inhibition of ACTH secretion stimulated by a
combination of 1 mM CPT-cAMP and 5 mM TEA or 1 mM
CPT-cAMP and 5 mM (7)BayK8644 was significantly
attenuated to 30.7+11.8% and 31.9+7.6% (P50.05, n=5),
respectively (Figure 2A and B). The combination of 1 mM
CPT-cAMP with 5 mM (+)202 – 791 also significantly reduced
the inhibition of the stimulated ACTH secretion by 100 nM
dexamethasone to 27+1.3% (P50.05, n=4/group, 1-way-
ANOVA, Dunnett’s test).
As both (7)BayK8644 and TEA partially reversed
dexamethasone inhibition of CPT-cAMP stimulated ACTH
secretion, the combination of these compounds with CPT-
cAMP was tested subsequently, using a submaximal concen-
tration (0.1 mM) of CPT-cAMP as well as 1 mM CPT-cAMP.
The ACTH secretion elicited by 0.1 mM CPT-cAMP was
significantly potentiated by 5 mM (7)BayK8644 and 5 mM
TEA given together (Table 1). CPT-cAMP-induced ACTH
secretion was inhibited by dexamethasone (1 nM to 1 mM) in a
concentration dependent manner by up to 84% (Table 1). The
combination of 5 mM (7)BayK8644 and 5 mM TEA elicited a
3-fold increase in ACTH secretion over basal levels and this
response was not inhibited by dexamethasone (Table 1). The
ACTH response elicited by the combination of 0.1 mM CPT-
cAMP, 5 mM (7)BayK8644 and 5 mM TEA was also fully
resistant to inhibition by 1 – 1000 nM dexamethasone (Table
1).
Similar results were obtained by combining 1 mM CPT-
cAMP with 5 mM TEA and 5 mM (7)BayK8644. A summary
of these data (Figure 3) shows that the extent of resistance to
glucocorticoid inhibition was independent of the amplitude of
stimulus-evoked ACTH secretion. For instance, although the
ACTH response elicited by 5 mM TEA or 1 mM CPT-cAMP
alone were similar, the ACTH response to 5 mM TEA was
much more resistant to dexamethasone inhibition than the
ACTH response to 1 mM CPT-cAMP.
Taken together, these results are in agreement with previous
studies of CRF-induced ACTH release in AtT20 cells, which
have shown that early glucocorticoid inhibition is eectively
antagonized by depolarization of the membrane potential
(Woods et al., 1994) and that TEA sensitive K+-channels,
particularly BK-type channels underlie the inhibitory action of
corticosteroids (Shipston et al., 1996).
Experiments with primary cultures of rat anterior
pituitary cells
Response to CPT-cAMP The time-course of the ACTH
response to CPT-cAMP was close to linear over 4 h (Figure
4A). The concentration-response relationship between CPT-
cAMP and ACTH release was similar at 60, 120 and 240 min,
in that 0.1 mM CPT-cAMP elicited close to maximal
Table 1 Characterization of the ACTH secretory response to CPT-cAMP, TEA and (7)BayK8644 in the presence of increasing
dexamethasone concentrations in AtT20 cells
Dexamethasone (nM)
0 3 10 100 1000
Vehicle 608+63
0.1mM CPT
5mM TEA+
5mM BayK
0.1mM CPT+
5mM TEA+
5mM BayK
1122+136
(100+26%)
1883+65
(100+5%)
2919+93*
(100+4%)
860+94
(49+18%)
1973+125
(107+10%){
2912+126
(100+5%){
795+57
(36+11%)
1767+57
(91+4%){
2593+170
(86+7%){
734+19
(25+4%)
1783+84
(92+7%){
2626+62
(87+3%){
690+22
(16+4%)
1743+167
(89+13%){
3016+161
(104+7%){
Data show ACTH release expressed in fmol per well and represent means+s.e.mean. of four replicates per treatment group. Values in
parentheses represent percentages of control ACTH release (mean+s.e.mean), as defined in Methods. *P50.02 for the interaction
between CPT and TEA/BayK in the absence of dexamethasone pretreatment, 2-way ANOVA. Statistical analysis of the eect of
dexamethasone was carried out on the data expressed as percentages (values shown in parentheses) of the respective stimulus-evoked
release, {P50.05 when compared to the corresponding CPT group, 1-way ANOVA followed by Dunnett’s test. Results shown are
representative of two identical experiments.
Figure 3 Size of the ACTH secretory response fails to predict the
degree of dexamethasone inhibition in AtT20 cells. Data were plotted
as stimulus strength vs ACTH response, where stimulus strength is
the size of the evoked release of ACTH expressed as % of the
response to 1 mM CPT-cAMP run in the same experiment, and
ACTH response is the size of the ACTH response to the respective
stimulus in cells preincubated with 100 nM dexamethasone, expressed
as percentage of the control (i.e. no dexamethasone) response. Data
are means n=4/group. Symbols: CPT, 1 mM CPT-cAMP; BayK,
5 mM (7)BayK8644; TEA, 5 mM tetraethylammonium; BayK/TEA,
combination of 5 mM (7)BayK8644 and 5 mM tetraethylammo-
nium;+sign indicates that two stimuli were applied together. Results
shown are representative of two identical experiments.
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stimulation of ACTH release (Figure 4B). This was not the
case at 30 min, where 1 mM CPT-cAMP was significantly
more eective than 0.1 mM CPT-cAMP. All subsequent
experiments were terminated at the 60 min time-point.
Lack of an eect of K+-channel blockers and BayK8644 on
corticosteroid inhibition of ACTH release Corticosterone
(100 nM) reduced the ACTH response to 0.1 mM CPT-cAMP
by 74.8+10.8% (n=5) and this was not modified in the
presence of TEA (5 – 20 mM) or (7)BayK8644 (5 mM). Similar
findings were obtained with 30 nM dexamethasone. Combina-
tion of 5 mM TEA and (7)BayK8644 (5 mM) produced a
significant enhancement of the ACTH releasing eect of CPT-
cAMP (0.3 mM) (Basal: 34+6 fmol/well; CPT-cAMP: 125+5
fmol/well, P50.0001, n=6; TEA+BayK: 60+6 fmol/well,
P50.0002, n=5; CPT-cAMP+TEA+BayK: 204+14 fmol/
well, P50.03, interaction, n=7, 2-way-ANOVA) but failed to
modify the inhibition by 100 nM dexamethasone (% inhibition
of CPT-cAMP vs CPT-cAMP+TEA+BayK: 63+7% vs
66+6%, n=4). Finally, preincubation with charybdotoxin
(30 nM) or apamin (100 nM) and the combination of these
agents with 0.1 mM CPT-cAMP also failed to modify
corticosterone inhibition of stimulated ACTH secretion (not
shown).
These data indicate that in contrast to AtT20 cells, TEA-
sensitive ion-channels are not fundamentally important for
corticosteroid inhibition of ACTH secretion in primary
cultures of rat anterior pituitary cells.
Depolarization with 40 mM KCl counteracts glucocorticoid
eect on ACTH The ACTH responses to 0.1 mM CPT-
cAMP and 40 mM KCl are shown in (Table 2). KCl (40 mM)
synergized with 0.1 mM CPT-cAMP to stimulate ACTH
release, furthermore, it produced a marked reduction in the
inhibitory eect of dexamethasone (Table 2). Omission of
Ca2+ from the incubation medium completely blocked ACTH
release induced by CPT-cAMP alone or CPT-cAMP and KCl
(not shown). Dexamethasone (10 nM) inhibited the ACTH
response to 0.1 mM CPT-cAMP and 40 mM KCl by only
44+12% (n=4), while that evoked by 0.1 mM CPT-cAMP
was completely blocked. Similar results were also obtained
using the naturally occurring corticosteroid corticosterone
(Table 2).
The data above demonstrate that depolarization of the
membrane potential markedly reduces the early inhibitory
eect of glucocorticoids. However, the lack of a complete
block of steroid action by 40 mM KCl raises the question of
whether or not the inhibitory eect may be completely
accounted for by the rapid induction of mRNA and protein
by glucocorticoids.
Blockers of mRNA and protein synthesis abolish glucocorticoid
inhibition The inhibition of 0.1 mM CPT-cAMP stimulated
ACTH secretion by 10 nM dexamethasone was eliminated in
the presence of 5,6-dichloro-furanosyl-benzimidazole riboside
(DRB), an adenosine analogue and inhibitor of heteronuclear
RNA synthesis (Egyha´zi et al., 1982) (Figure 5A). In the
presence 40 mM KCl, DRB suppressed ACTH secretion
elicited by 0.1 mM CPT-cAMP but no further change was
observed after treatment with dexamethasone (Figure 5B).
Therefore, the residual inhibition by corticosteroids observed
in the presence of 40 mM KCl and 0.1 mM CPT-cAMP is likely
to be due to glucocorticoid blockade of this DRB sensitive
mechanism. Similar results were obtained using 0.1 mM
puromycin, an inhibitor of protein synthesis (not shown).
Discussion
The data presented here show that control of the membrane
potential is essential for glucocorticoid inhibition of stimulated
ACTH release in both AtT20 cells and primary cultures of rat
anterior pituitary cells. However, in contrast to tumoural
AtT20 cells where BK-channels are pivotal targets of
glucocorticoid action (Shipston et al., 1996), blockage of BK-
and other TEA-sensitive K+-channels failed to modify the
inhibitory action of glucocorticoids in normal rat pituitary
cells. Thus the data conform with the general hypothesis that
glucocorticoids modulate the function of plasma membrane
ion channels to reduce cellular responses of excitable cells
(Joe¨ls & de Kloet, 1994), and indicate that glucocorticoid-
Figure 4 Eect of CPT-cAMP on ACTH secretion by primary
cultures of rat anterior pituitary cells. (A) Time-course of hormone
release in cells treated with vehicle (*), 30 mM CPT-cAMP (*),
0.1 mM CPT-cAMP (^) or 1 mM CPT-cAMP (~). (B) Concentra-
tion-dependent stimulation of ACTH secretion by CPT-cAMP at
30 min (~), 1 h (~), 2 h (*) and 4 h (*) of incubation. Means,
bars indicate s.e.mean, n=4/group. Where error bars are not visible,
the s.e.mean bar is less than the space required for the symbol.
Results shown are representative of two identical experiments.
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induced proteins may regulate the function of multiple plasma
membrane ion channels.
Characteristics of the primary culture system as a model
for secretagogue-glucocorticoid interaction and the use of
CPT-cAMP
Previous studies have established that the main hallmarks of
early glucocorticoid inhibition are: (i) selectivity for stimulated
ACTH release, (ii) mediation through Type II glucocorticoid
receptors, (iii) manifestation within 2 h, and (iv) a requirement
for new mRNA and protein synthesis reviewed in (Shipston,
1995). These features have been largely retained in the AtT20
D16:16 cell line (Antoni, 1996), and also characterize the rat
anterior pituitary primary culture system (Abou-Samra et al.,
1986, and present study).
A further important property of the primary culture
system is its responsiveness to physiological concentrations of
CRF and AVP (Vale et al., 1983; Oki et al., (1990)). A
somewhat surprising feature is the low response to
depolarizing stimuli such as 40 mM KCl and BayK8644
given alone. These stimuli have been reported as inducers of
robust ACTH release by acutely prepared pituitary cells
(Gillies & Lowry, 1978; Antoni & Dayanithi, 1990b), tissue
segments (Taylor et al., 1993) as well as AtT20 cells (Guild &
Reisine, 1987). A plausible explanation of this finding is that
the aforementioned preparations possess spontaneous elec-
trical activity, which may be due to endogenous pacemaker
potentials (e.g. AtT20 cells), or is derived from factors
released upon tissue injury due to dissection in pituitary
segments (Taylor et al., 1993), or is a remnant of the trophic
actions of CRF in vivo (Ixart et al., 1991). Spontaneous
electrical activity will facilitate the eects of the usage-
dependent L-channel activator (7)BayK8644 (Sanguinetti &
Kass, 1984). Furthermore, the secretagogue potencies of
(7)BayK8644 as well as high KCl are likely to depend on
tonic cyclic AMP-dependent phosphorylation which is
required for the optimal functioning of L-type Ca2+ channels
(Armstrong & Eckert, 1987) and exocytotic processes
(Morgan et al., 1993).
With respect to the requirement for cyclic AMP, it is known
that acutely dispersed cells produce much more reliable
responses to short pulses CRF if ‘primed’ with several pulses
of the peptide (Antoni et al., 1990b). Moreover, it has been
reported that cyclic AMP and Ca2+ synergize to trigger ACTH
release from permeabilized AtT20 cells (Guild, 1991), further
indicating that cyclic AMP-dependent processes acting in
parallel to the mobilization of Ca2+ are important for the
secretory response of corticotroph cells. It is of note that while
depolarization with 40 mM KCl was not a reliable stimulus of
ACTH release on its own, it consistently produced a
synergistic enhancement of the CPT-cAMP induced ACTH
response. As the main result of KCl depolarization is Ca2+
influx through voltage-operated channels (Meier et al., 1988),
the synergy of CPT-cAMP and KCl depolarization appears
analogous to the Ca2+ potentiation of cAMP-induced ACTH
release in AtT20 cells. Similar results have been obtained using
physiological concentrations of CRF (Lim et al., unpublished).
A cell- membrane permeant, non-metabolizable analogue of
cyclic AMP, CPT-cAMP, was used as the secretagogue
stimulus in this study in order to produce a sustained increase
in cyclic AMP-dependent phosphorylation. As the physiologi-
cal ACTH secretagogues, CRF or CRF and AVP in
combination, activate cyclic AMP-dependent phosphorylation
in corticotrophs (see Antoni, 1993), CPT-cAMP will mimic
this aspect of agonist action. It is also clear that CRF-induced
cyclic AMP responses are subject to negative feedback
regulation by intracellular free Ca2+ at the level of adenylyl
cyclase and cyclic AMP hydrolysis in AtT20 cells (Antoni,
1996) as well as rat anterior pituitary cells (Antoni, 1997).
CPT-cAMP is largely resistant to Ca2+-feedback and this
property makes it a potentially useful tool for studying
processes of ACTH release downstream of cyclic AMP
formation. It is of note, however, that CRF elicits oscillations
of intracellular free Ca2+ in AtT20 cells as well as normal rat
corticotrophs, (see Antoni, 1993 for review), which may be
accompanied by oscillations of intracellular cyclic AMP levels
(Cooper et al., 1998). Thus, clamping the intracellular cyclic
AMP through CPT-cAMP, which leads to sustained increases
of intracellular free Ca2+ as opposed to oscillations (Mollard
Table 2 Counteraction of glucocorticoid inhibition of the ACTH secretory response by 40mM KCl in primary cultures of rat anterior
pituitary cells
Corticosterone (nM)
0 3 10 100 1000
Vehicle 100.4+11.0
0.1mM CPT
40mM KCl
0.1mM
CPT+40mM KCl
163.8+6.9
(100+11%)
125.5+2.9
284.8+4.1*
(100+2%)
150.8+8.1
(80+13%)
269.8+16.3
(92+9%)
132.6+15.2
(51+24%)
260.8+7.6
(87+4%){
86.4+2.1
(722+3%)
221.9+23.1
(66+13%){
80.3+3.0
(731+5%)
216.3+22.7
(63+12%)
Dexamethasne (nM)
0 3 10 100
Vehicle 66.1+7.0
0.1mM CPT
40mM KCl
0.1mM
CPT+40mM KCl
112.8+5.3
(100+11%)
127.6+14.4
280.6+27.2**
(100+13%)
62.8+2.5
(77+5%)
192+31.8
(59+15%){
54.5+3.3
(725+7%)
187.2+26.1
(56+12%){
52.0+3.1
(730+7%)
165.2+11.8
(46+6%){
Data show ACTH release expressed in fmol per well and represent means+s.e.mean. of four replicates per treatment group. Values in
parentheses represent percentages of control ACTH release (mean+s.e.mean), as defined in Methods. *P50.0001 and **P50.004 for
the interaction between CPT-cAMP and KCl in the absence of glucocorticoid pretreatment, 2-way ANOVA. Statistical analysis of the
eect of glucocorticoids was carried out on the data expressed as percentages (values shown in the parentheses) of the respective
stimulus-evoked release, {P50.05 when compared to the corresponding CPT group, 1-way ANOVA followed by contrast of means.
Results shown are representative of two and three identical experiments for the corticosterone and dexamethasone dose responses
respectively.
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et al., 1992), may potentially alter some properties of the
ACTH response when compared with physiological agonists.
Indeed, inhibition of mRNA or protein synthesis significantly
attenuated the release of ACTH by rat pituitary corticotrophs
to CPT-cAMP-based stimuli, whereas such manipulations
were without eect on CRF-induced ACTH secretion (Day-
anithi & Antoni, 1989; Taylor et al., 1993 and Lim et al.,
unpublished). In other respects, however, CPT-cAMP-stimu-
lated ACTH release was largely dependent on extracellular
Ca2+ and blocked by glucocorticoids similarly to ACTH
secretion evoked by CRF.
Properties of early glucocorticoid inhibition in AtT20
cells
The results with AtT20 cells extend previous work from this
laboratory examining CRF-induced ACTH release in these
cells. Overall, ACTH release induced by CPT-cAMP alone
was potently inhibited by dexamethasone. By contrast,
responses to stimuli that cause depolarization such as TEA,
(7)BayK8644 or (+)202 – 791 were resistant to glucocorti-
coid inhibition. It was also clear that the nature of the
stimulus rather than the size of the evoked response predicted
the degree of glucocorticoid inhibition in AtT20 cells. Thus,
these data are in full agreement with earlier findings from this
laboratory indicating that the principal target of corticoster-
oid inhibition is the membrane potential (Pennington et al.,
1994; Shipston et al., 1996) rather than the secretory
apparatus as proposed by others (Castellino et al., 1992).
Further, the data are in agreement with the findings that BK-
channels (Shipston et al., 1996) are pivotal for glucocorticoid
inhibition in AtT20 cells.
Corticosterone action in primary cultures: deviation from
and convergence to AtT20 model
Importantly, the involvement of plasma membrane ion-
channels in glucocorticoid action has not been previously
addressed in normal rat corticotrophs. A report from another
laboratory has shown (Halili-Manabat et al., 1995) that
ACTH secretion stimulated by the depolarizing agent
veratridine, an opener of tetrodotoxin sensitive Na+-channels
is resistant to inhibition by dexamethasone, and our group has
reported similar findings in preliminary form using combina-
tions of CRF and veratridine (Antoni & Woods, 1992).
However, no stimuli physiological to corticotrophs have been
identified so far that operate through Na+-channels and thus
counteract glucocorticoid feedback inhibition (Antoni, 1993;
Halili-Manabat et al., 1995).
In sharp contrast to AtT20 cells, concentrations of TEA as
high as 20 mM failed to dent significantly the early inhibitory
action of corticosterone or dexamethasone in primary cultures
of rat anterior pituitary cells. Also of note is that apamin and
charybdotoxin, blockers of SK- and BK-type Ca2+-activated
K+-channels were also without eect. In contrast to the
channel blockers tested so far, 40 mM KCl synergized with
CPT-cAMP to stimulate the release of ACTH, while having
relatively little eect on its own. Furthermore, the early
inhibitory eects of dexamethasone as well as corticosterone
were drastically reduced with CPT-cAMP and KCl as the
stimulus. The release of ACTH under these conditions was
fully dependent on extracellular Ca2+, hence indicating that
the mechanism of hormone release is not fundamentally
altered by the addition of 40 mM KCl.
Overall, these findings are surprising, as channels sensitive
to the K+-channel blockers applied in the present study, and
functionally relevant for the regulation of ACTH release have
been previously reported in various preparations of cortico-
troph cells (Marchetti et al., 1987; Antoni & Dayanithi, 1990a).
The possibility that the K+-channel profile of corticotrophs is
altered by culture conditions cannot be discounted at present.
A recent report (Lee & Tse, 1997) suggests that CRF-induced
activation of cultured rat pituitary corticotrophs is the result of
the inhibition of a K+-current that is insensitive to TEA as well
as 4-aminopyridine. However, as noted above, the role of K+
Figure 5 Eect of the RNA synthesis inhibitor 5,6-dichloro-
furanosyl-benzimidazole riboside (DRB) on ACTH secretion in
primary cultures of rat anterior pituitary cells. 100 mM DRB and
100 nM dexamethasone (DEX) were applied 2 h before challenging
the cells with (A) 0.1 mM CPT-cAMP or (B) 0.1 mM CPT-cAMP and
40 mM KCl for 60 min. Basal ACTH release was 44+3 fmol/well
and was not altered by DRB or dexamethasone. Data are means,
bars indicate s.e.mean, n=5/group. *P50.05 when compared with
control group receiving vehicle only. 1-way-ANOVA followed by
Newman-Keuls test. Results shown are representative of four
identical experiments.
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channels in glucocorticoid feedback has not been previously
examined in non-tumoural corticotrophs.
The nature of the residual inhibitory eect of glucocorti-
coids on KCl/CPT-cAMP stimulated ACTH release was
revealed in experiments with inhibitors of protein and mRNA
synthesis. As some reports suggested that early corticosteroid
inhibition does not require gene induction (Taylor et al., 1993)
we have re-examined this issue in the primary culture system.
Similarly to actinomycin D (Arimura et al., 1969; Portanova &
Sayers, 1974; Dayanithi et al., 1989) DRB blocked the early
corticosteroid inhibition of ACTH release, indicating a
requirement for mRNA synthesis. Moreover, DRB as well as
puromycin caused similar reductions in ACTH release induced
by 40 mM KCl/0.1 mM CPT-cAMP in the presence of 100 nM
dexamethasone, which had no additional eect in the presence
of these agents. The findings indicate that in case of relatively
high (44 fold basal) ACTH responses elicited by CPT-cAMP-
based stimuli the ACTH secreted is derived through the
synthesis of new mRNA and protein, plausibly POMC, which
is blocked by glucocorticoids. In contrast to CPT-cAMP-based
stimuli, there was no apparent requirement for mRNA or
protein synthesis when CRF was used to stimulate ACTH
release (Abou-Samra et al., 1986; Dayanithi et al., 1989; Taylor
et al., 1993). Thus oscillating Ca2+/cAMP signals may be more
ecient in mobilizing/processing ACTH without a require-
ment for de novo protein synthesis than CPT-cAMP which
elicits prolonged elevations of intracellular Ca2+ lacking an
oscillatory pattern (Mollard et al., 1992).
In summary (Table 3), it is intriguing that the same
physiologically relevant phenotype of early corticosteroid
inhibition is found in AtT20 cells and rat corticotrophs,
including counteraction by membrane depolarization, but the
underlying membrane-control mechanisms have strikingly
distinct pharmacology. Further studies should clarify whether
glucocorticoids are capable of inducing dierent families of
ion-channel subunits depending on the cell system under study
(Attardi et al., 1993; Levitan et al., 1996) or evoke the synthesis
of proteins that regulate the activity of several distinct ion
channels through generic mechanisms such as protein
phosphorylation (Wang et al., 1997). Data from our
laboratories (Shipston et al., 1996) favour the latter possibility
in the case of adenohypophysial corticotrophs.
We thank Prof P.J. Lowry (University of Reading) for the generous
provision of sheep anti-ACTH serum, the Scottish Antibody
Production Unit for anti-sheep and anti-rabbit IgG serum,
Novartis, U.K. for (+)202 – 791.
Table 3 Comparison of early corticosteroid inhibition of
stimulated ACTH release in AtT20 cells and primary
cultures of rat anterior pituitary cells
Common features:
Onset within 2 h
Mediated by Type II glucocorticoid receptor
Requirement of new mRNA and protein
synthesis
Specific for agonist-induced release
Opposed by depolarization of the membrane
potential
Specific features:
AtT20 cells
Mediated by BK-type potassium channels
Primary cultures
Mediated by unidentified ion channel
May involve transcriptional block of protein
expression required for sustained release of
ACTH
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Adrenal corticosteroids have well known and pro-
found effects on neurons and neuroendocrine cells, but
the underlying cellular mechanisms are poorly under-
stood. The present study analyzed membrane currents
and ACTH release in AtT20mouse pituitary corticotrope
tumor cells. Patch-clamp analysis revealed a significant
and selective inhibition of calcium-activated (BK-type)
potassium channels upon activation of protein kinase A
by corticotropin-releasing factor or 8-chlorophenylthio-
cAMP. The synthetic glucocorticoid dexamethasone had
no effect on potassium currents evoked by depolariza-
tion but prevented the inhibitory effect of protein ki-
nase A activators. The action of dexamethasone had the
hallmarks of protein induction, i.e. a lag time and sensi-
tivity to inhibitors of DNA transcription and mRNA
translation. In parallel, the specific BK channel blocker
iberiotoxin abolished early glucocorticoid inhibition of
corticotropin-releasing factor-stimulated ACTH secre-
tion. In summary, the present data show that glucocor-
ticoid-induced proteins render BK-type channels resist-
ant to inhibition by protein kinase A and that this action
of the steroid is pivotal for its early inhibitory effect on
the secretion of ACTH.
Stressors provoke a cohort of homeostatic defense mecha-
nisms by the central nervous, the immune, and the metabolic
control systems of the body (1). Adrenal corticosteroids released
during the stress response terminate many of these adaptive
responses through the rapid induction of proteins, the nature
and mechanism of which are not understood (1–4).
A common motif of corticosteroid action in hippocampal neu-
rons (5, 6) and pituitary somatolactotrope cells (7) is the regu-
lation of potassium channels that are important determinants
of cellular excitability. In hippocampal neurons, the target of
glucocorticoid action has not been defined. In somatolactotrope
cells, glucocorticoid induction of Kv1.5 voltage-regulated potas-
sium channel subunits has been demonstrated (7).
A physiologically important early action of glucocorticoids is
the suppression of CRF1-induced ACTH secretion from anterior
pituitary corticotropes (for reviews see Refs. 8 and 9). CRF
stimulates ACTH release through activation of protein kinase
A and the enhancement of calcium influx through voltage-
operated calcium channels (10–12). In turn, glucocorticoids
rapidly (within 2 h) inhibit CRF-stimulated ACTH secretion
through the induction of new protein(s) (2, 8, 10, 13, 14), while
basal secretion remains unchanged. The early inhibition of
stimulated ACTH release in AtT20 corticotropes is antagonized
by membrane depolarization (13, 15), calcium channel activa-
tor drugs (11, 16), and potassium channel blockers (15, 16),
collectively suggesting that the actions of glucocorticoids may
involve potassium channels. However, the well established glu-
cocorticoid induction of the Kv1.5 channel protein does not
occur in AtT20 corticotropes (17).
In endocrine cells and neurons large conductance calcium-
and voltage-activated potassium (BK) channels have been pro-
posed as important negative feedback regulators of voltage-de-
pendent calcium influx (18). Such channels have been previ-
ously identified in AtT20 corticotrope tumor cells (19, 20).
This report describes a correlated study of the regulation of
BK channels and ACTH release by CRF and glucocorticoids in
the mouse anterior pituitary corticotrope cell line AtT20. The
data demonstrate that glucocorticoid-induced proteins prevent
protein kinase A-dependent inhibition of BK channels and that
this is pivotal to early glucocorticoid inhibition of CRF-induced
ACTH secretion.
MATERIALS AND METHODS
AtT20 D16:16 Cell Culture—Clonal mouse anterior pituitary (AtT20
D16:16, passage 19–30) cells were maintained as described previously
(14) except that cells were passaged by brief trypsinization 1 week
before replating on glass coverslips. Cells (3–7 days postplating) were
treated with dexamethasone or vehicle (0.01% Me2SO) for 2 h at 37 °C
in serum-free HEPES-buffered Dulbecco’s modified Eagle’s medium.
Cells were then transferred to physiological saline containing (in mM):
140 NaCl, 5 KCl, 25 HEPES, 0.8 MgCl2, 2 CaCl2, 30 glucose, and 0.001
tetrodotoxin (TTX), pH 7.4, at room temperature (19–24 °C) for electro-
physiological recording. Regulation of currents in control and dexa-
methasone-treated cells was performed in parallel on the same passage
of cells to avoid intrapassage variations.
Electrophysiology—Whole cell currents were recorded under voltage
clamp using the amphotericin B (200 mg/ml) perforated patch configu-
ration of the whole cell patch clamp recording technique (21). Data
acquisition and voltage protocols were controlled by an Axopatch 200
amplifier and pCLAMP software (Axon Instruments Inc., Foster City,
CA). All traces are leak-subtracted records from cells with compensated
series resistance of ,15 megaohms. Pipettes were manufactured from
Garner 7052 glass with resistances of 1.5–3 megaohms in physiological
saline after fire polishing.
For determination of outward potassium currents cells were voltage-
clamped at 260 mV in physiological saline containing (in mM): 140
NaCl, 5 KCl, 25 HEPES, 0.8 MgCl2, 2 CaCl2, 30 glucose, and 0.001 TTX,
pH 7.4. The patch pipette contained (in mM): 95 KCH3SO3, 55 KCl, 10
HEPES, 2 MgCl2, 0.1 CaCl2, and 200 mg/ml amphotericin B, pH 7.35.
Outward potassium currents were evoked by 100-ms step depolariza-
tion (230 to 150 mV), and the average steady-state current amplitude
between 90 and 100 ms was determined at each potential. Outward
currents were stable for .1 h in this configuration. Single BK channel* This work was supported by Wellcome Trust Advanced Training
Fellowship Grant 038763/Z/93/Z (to M. J. S.). The costs of publication of
this article were defrayed in part by the payment of page charges. This
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with 18 U.S.C. Section 1734 solely to indicate this fact.
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1 The abbreviations used are: CRF, corticotropin-releasing factor;
ACTH, adrenocorticotropin; Me2SO, dimethyl sulfoxide; TTX, tetrodo-
toxin; IbTx, iberiotoxin; BK, large conductance calcium- and voltage-
activated potassium channel; TEA, tetraethylammonium; 8-CPT-
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events were recorded using the cell-attached patch configuration. Cells
were voltage-clamped at 0 mV in high potassium saline to eliminate the
membrane potential, and the magnesium to calcium ratio adjusted to
limit calcium entry (in mM: 140 KCl, 5 NaCl, 5 MgCl2, 10 HEPES, 1
CaCl2, 30 glucose, pH 7.4. The patch pipette contained physiological
saline supplemented with 0.001 mM TTX and 100 nM apamin, and
single channel events were recorded during repeated (0.1 Hz) 100-ms
depolarizations to 130 mV. Under these conditions control Po values at
130 mV were similar (,0.5) to that recorded in isolated patches depolar-
ized to 130 mV and exposed to ,200 nM intracellular free calcium (20).2
For isolation of high threshold voltage-activated calcium currents,
cells were voltage-clamped at 240 mV in (mM): 120 N-methyl-D-gluca-
mine, 30 TEA-Cl, 2 MgCl2, 20 HEPES, 10 CaCl2, and 20 glucose, pH
7.35, with CH3SO3H. The patch pipette contained (in mM): 95
CsCH3SO3, 35 CsCl, 5 MgCl2, 40 HEPES, and 200 mg/ml amphotericin
B, pH 7.35, with CsOH. Calcium currents were evoked by 100-ms
depolarization, and peak calcium current was determined. Under the
recording conditions used currents were stable for .30 min, and inward
calcium current was completely blocked by 200 mM Cd21 and 70–80% by
1 mM nifedipine.
ACTH Secretion and Intracellular cAMP Determination—For intra-
cellular cAMP determination and ACTH secretion studies, cells were
plated (5 3 105cells/well) in 24-well plates and used 4–5 days postplat-
ing. Cells were incubated in HEPES-buffered Dulbecco’s modified
Eagle’s medium at 37 °C for 2 h with 1 mM dexamethasone or vehicle
(0.01% Me2SO). Cells were washed twice and equilibrated for 15 min at
room temperature in physiological saline used for outward potassium
current determination except that TTX was excluded and 0.1% w/v
bovine serum albumin was included to aid ACTH recovery. CRF (100
nM) was then applied for various times as indicated in the legends. IbTx
was applied to the cells 15 min before CRF application. For intracellular
cAMP determination, medium was aspirated and cells lysed in ice-cold
0.1 N HCl by freeze thawing and cAMP content in the acid extracts
determined. ACTH and cAMP were assayed using specific double pre-
cipitation radioimmunoassays as described previously (14).
Reagents—CRF and ACTH were from Bachem (UK) Ltd., Saffron
Walden, UK; 8-CPT-cAMP and Rp-cAMPS were from Boehringer
Mannheim UK, Lewes, East Sussex, UK; iberiotoxin was from the
Peptide Institute, Japan. All other reagents were from Sigma or
Aldrich. Dexamethasone was stored at 220 °C at 10 mM in Me2SO.
Final vehicle concentrations were ,0.01% and had no effect on
calcium or potassium currents.
RESULTS AND DISCUSSION
In control cells voltage clamped through amphotericin-per-
forated patches in physiological saline at 260 mV, a 100-ms
depolarization evoked large outward currents that reached a
steady-state level before the end of the pulse. Variations in the
rate of inactivation of the outward currents were observed
between cells (compare Figs. 1A and 2B) that were independent
of passage number or incubation temperature (19–24 °C). This
slow inactivation was observed in ;20% of both control and
glucocorticoid-treated cells. No qualitative differences in regu-
lation of steady-state current, measured between 90 and 100
ms, reported here were observed between inactivating and
non-inactivating currents.
CRF Inhibition of Potassium Currents Is Mediated by Protein
Kinase A—Bath application of a CRF concentration (100 nM)
maximally effective with respect to ACTH release in this sys-
tem (14) inhibited the steady-state outward potassium current
(mean 6 S.E., 29.6 6 8.6%, n 5 7, p , 0.01, Kruskal-Wallis
test, at 130 mV) at all potentials examined (Fig. 1, A and B).
The time course of CRF inhibition of potassium currents fol-
lowed the time course of CRF-stimulated intracellular cAMP
accumulation (Fig. 1C). The effect of CRF was significantly
reduced by pretreatment of cells with the protein kinase A
inhibitor Rp-cAMPS (Fig. 1D) (22). Steady-state outward po-
tassium current was also significantly inhibited (30.3 6 2.3%,
n 5 10, at 130 mV, p , 0.01) after bath application of
the cell-permeant protein kinase A activator, 8-CPT-cAMP
(0.1 mM).
These data show that the reduction of outward potassium
current by CRF is through activation of protein kinase A. This
finding corroborates previous evidence that protein kinase A
activation in corticotropes results in membrane depolarization2 M. J. Shipston, unpublished data.
FIG. 1. CRF inhibits the BK component of the outward steady-
state current via activation of protein kinase A in intact AtT20
D16:16 cells. A, representative (1 of 7 cells) leak-subtracted traces of
voltage-activated outward current (at 130 mV) in control cells before
and after exposure to 100 nM CRF. AtT20 cells were voltage-clamped
through amphotericin B-perforated patches at 260 mV in physiological
saline containing 1 mM TTX. B, the current/voltage relationship deter-
mined from the same cell in A. Average steady-state outward current
was determined between 90 and 100 ms at each potential as described
under “Materials and Methods.” C, time course of 100 nM CRF inhibi-
tion of outward steady-state potassium current (filled circle, measured
at 130 mV) and CRF-stimulated intracellular cAMP accumulation
(open circle, n 5 3). Inhibition of outward current is expressed as the
percentage inhibition of the outward steady-state current at each time
point with respect to the pre-CRF-treated current amplitude (Io). In-
tracellular cAMP accumulation was determined under identical condi-
tions, in the absence of phosphodiesterase inhibitors, as described
under “Materials and Methods.” D, pretreatment of cells with the pro-
tein kinase A inhibitor, Rp-cAMPS (100 mM), or the selective BK inhib-
itor, IbTx (100 nM), blocks CRF inhibition of outward steady-state
current. Data are expressed as the percent change in the control out-
ward steady-state current, Io (at 130 mV) by CRF (100 nM) alone,
Rp-cAMPS (100 mM) 1 CRF, IbTx (100 nM) alone, and IbTx 1 CRF.
Number in parentheses represents number of cells in each group. Means
6 S.E. are shown; *, p , 0.05 (non-parametric Kruskal-Wallis test). E,
representative records (1 of 4) from a cell-attached patch in 140 mM KCl
during consecutive (0.1 Hz) 100-ms depolarizations to 130 mV before
(control) and 5 min after CRF application. Open (o) and closed (c) states
of channel are shown. F, representative plot of BK channel mean open
probability versus time from a cell-attached patch recording as in E.
Bath application of 100 nM CRF reduces average open probability (Po)
of the ;120-picosiemens BK channel in cell-attached patches. Po was
determined during consecutive (0.1 Hz) 100-ms patch depolarization to
130 mV and plotted as a function of time.
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and sustained calcium influx through voltage-sensitive L-type
calcium channels (19, 23, 24); in parallel, inhibition of protein
kinase A by various methods also blocks the hormone secretory
response to CRF in AtT20 cells (25, 26).
The Target of Protein Kinase A Action Is the BK Potassium
Channel—Both iberiotoxin (100 nM), a highly specific blocker of
BK type channels (27) and TEA (1 mM), a broader spectrum
blocker, inhibited the steady-state outward current by 34.0 6
6.5% (n 5 4, Fig. 1D) and 52.9 6 6.3% (n 5 9), respectively. No
significant inhibition of the residual outward current by CRF
(or 8-CPT-cAMP) occurred in cells pretreated with 100 nM
iberiotoxin (mean inhibition, 6.2 6 5.6%, n 5 4, Fig. 1D) or 1
mM TEA (mean inhibition, 5.1 6 7.2%, n 5 4). Similar results
were obtained with 100 nM charybdotoxin (n 5 2).
Bath application of 100 nM CRF significantly (p , 0.05)
reduced the average open probability of single large conduct-
ance (;120 picosiemens) BK channels in 4/6 patches in cell-
attached patch recordings (Fig. 1, E and F). The time of onset
(;2 min) of the effect of CRF was identical to that seen for the
macroscopic current (compare Fig. 1, C and F).
These results clearly show that CRF and cAMP suppress the
activity of BK channels in AtT20 cells under conditions when
these channels are exposed to elevated intracellular free cal-
cium levels that enhance their open probability (20). As BK
channels are thought to act as immediate negative feedback
inhibitors of voltage-dependent calcium influx, inhibition of
these channels is a key element for optimal activation of cal-
cium channels involved in hormone secretion (18).
Previous evidence shows that BK channels may be up- or
down-regulated by reversible cAMP-dependent phosphoryla-
tion (28). However, in pituitary cells only protein kinase A-de-
pendent inhibition has been found so far (29, 30), and the
present study is the first example of inhibition of BK channels
by a physiologically relevant cAMP-mobilizing hypothalamic
peptide, CRF.
Dexamethasone Prevents Inhibition of Potassium Current by
Protein Kinase A—Pretreatment with 1 mM dexamethasone for
2 h, which produces maximal inhibition of CRF-stimulated
ACTH release (14), blocked the inhibition of outward steady-
state potassium current by 8-CPT-cAMP (Fig. 2, A and D) or
CRF (Fig. 2D). This effect of dexamethasone was prevented
with actinomycin D (0.1 mM, Fig. 2B) or puromycin (2 mM, n 5
2), indicating a requirement for de novo RNA and protein
synthesis, a defining feature of early inhibition (8, 14). In
addition an acute (10 min) exposure to dexamethasone did not
block CRF inhibition of the steady-state current (not shown).
In the absence of protein kinase A activation, dexametha-
sone had no significant effect on mean current density, thresh-
old of activation, or sensitivity to 100 nM IbTx or 1 mM TEA of
the steady-state outward current (Fig. 2, C and D), in agree-
ment with a previous study (16).
Similar to the findings with the macroscopic current, no
significant inhibition of single BK channels was observed by
CRF in cell-attached patch recordings (0/5 patches) from dex-
amethasone-treated cells.
These observations show that dexamethasone action is me-
diated by newly induced proteins and is selective for BK chan-
nels inhibited by protein kinase A. Glucocorticoids have also
been reported to enhance a 4-aminopyridine (4-AP)-sensitive
potassium current in AtT20 cells (16). In functional secretion
assays 4-AP affects ACTH release; however, 4-AP alone does
not reverse glucocorticoid inhibition of CRF-stimulated ACTH
release (16). In contrast, blockade of BK channels alone with
IbTx (Fig. 3) completely reverses the inhibitory effect of dexa-
methasone suggesting BK channels are a primary target for
glucocorticoid action in AtT20 cells.
The early inhibitory effect of glucocorticoids on CRF-stimu-
lated ACTH release also requires mRNA and protein synthesis
(2, 8, 10, 14), and in this respect the characteristics of the action
of dexamethasone on BK channels and ACTH release are iden-
tical. The selectivity of the effect of dexamethasone on protein
kinase A-inhibited BK channels also helps to explain why early
glucocorticoid inhibition suppresses CRF-stimulated ACTH re-
lease but does not affect basal output of hormone (2, 8, 13, 14).
Effects of Dexamethasone Are Not Secondary to Changes in
Calcium Currents—As intracellular calcium ions are potent
activators of BK channels and glucocorticoids reportedly (31)
enhance calcium entry to stimulate potassium currents in hip-
pocampal neurons, the actions of CRF and dexamethasone on
calcium currents were also analyzed.
As shown by others previously (12) CRF enhanced peak
pharmacologically isolated high voltage-activated calcium cur-
FIG. 2. Dexamethasone prevents protein kinase A-mediated
inhibition of BK currents in intact AtT20 D16:16 cells. A, repre-
sentative (1 of 8 cells) leak-subtracted traces of voltage-activated out-
ward current (at 130 mV) before and after exposure to 8-CPT-cAMP
(0.1 mM, 10 min) in AtT20 cells pretreated for 2 h with the glucocorticoid
agonist, dexamethasone (1 mM). B, 8-CPT-cAMP inhibits outward
steady-state current in dexamethasone-treated cells pretreated with
the mRNA transcription inhibitor, actinomycin D (0.1 mM applied 15
min before and during dexamethasone treatment). A representative
trace at 130 mV from 1 of 3 cells is shown. C, current/voltage relation-
ship of steady-state outward current density from control (open squares,
n 5 43) and dexamethasone-treated (filled squares, n 5 29) cells.
Outward steady-state current at each potential was normalized to
membrane capacitance to compensate for variations in cell size and
expressed as mean current density, pA/pF. D, summary of effect of bath
application of CRF (100 nM, 5 min), 8-CPT-cAMP (5 min, 0.1 mM), IbTx
(20 min, 100 nM), or TEA (2 min, 1 mM) on outward steady-state
potassium current determined at 130 mV. Data are expressed as the
percentage change (% change Io) in outward steady-state current com-
pared with pretreated control current amplitude (Io) as described in Fig.
1C. Cells were voltage-clamped at 260 mV as described in Fig. 1 and
under “Materials and Methods.” The number in parentheses indicates
number of cells per group. Means 6 S.E. are shown.
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rents in control (mean increase at 120 mV was 44 6 15%, n 5
4) and dexamethasone-treated (33 6 5%, n 5 5) cells. Similar
enhancement was also seen with 8-CPT-cAMP (n 5 2). Dexa-
methasone pretreatment (2 h, 1 mM) had no significant effect
on peak calcium current density (measured at 120 mV: con-
trol, 8.9 6 1.5 pA/pF (n 5 8); dexamethasone, 9.2 6 1.4 pA/pF
(n 5 7).
On the basis of these data it seems reasonable to suggest that
direct modulation of calcium influx through high voltage-acti-
vated calcium channels is not responsible for the effects of
dexamethasone on BK currents. Moreover, previous work indi-
cates a reduction (11, 32) or no significant change (10) in the
average levels of intracellular free calcium after dexametha-
sone treatment in AtT20 cells, thus excluding increases in
intracellular free calcium levels derived from intracellular
sources as mediators of the effect of the steroid.
Iberiotoxin-sensitive Channels Are Pivotal for Early Glu-
cocorticoid Inhibition of CRF-stimulated ACTH Release—
Under the same conditions that were used to monitor outward
potassium currents, CRF (100 nM) stimulated ACTH release to
157 6 6% (n 5 6) of basal levels. IbTx (100 nM) or TEA (1 mM)
alone elicited a small but statistically significant (p , 0.05
non-parametric Kruskal-Wallis test) ACTH response (114 6
2%, n 5 3 and 127 6 7%, n 5 5 of basal, respectively). IbTx had
no significant effect on CRF-stimulated ACTH secretion (155 6
7.9%, n 5 6 of basal release). TEA (1 mM) significantly (p ,
0.05, Kruskal-Wallis test) enhanced CRF-stimulated ACTH
release to 185 6 10.5% (n 5 5) of basal. AtT20 cells contain
multiple voltage-activated potassium conductances (16), and in
this system 1 mM TEA blocks a greater proportion of outward,
steady-state, voltage-activated current than 100 nM IbTx (Fig.
2D). The effects of these inhibitors are not additive (not shown),
indicating that TEA blocks iberiotoxin-sensitive BK channels
as well as other potassium conductances in this system.
The IC50 of dexamethasone to block CRF-induced ACTH
release was 7.7 6 1.9 nM (n 5 6). Importantly, IbTx (100 nM) as
well as TEA (1 mM) completely blocked the inhibitory effect of
1 mM dexamethasone on CRF-stimulated ACTH secretion (Fig.
3). Furthermore, dexamethasone (1 mM) had no significant in-
hibitory effect on ACTH secretion stimulated by IbTx or TEA
alone.
Final Comment—Taken together with previous results (8,
12) the present data suggest that concerted cAMP-dependent
phosphorylations of L-type calcium channels as well as BK-
type potassium channels are required for triggering the ACTH
secretory response to CRF. Inhibition of BK channels by cAMP-
dependent phosphorylation prevents the calcium-induced feed-
back hyperpolarization mediated by these channels and thus
enhances voltage-activated calcium entry (18). The critical role
of this process in CRF-stimulated ACTH secretion is shown by
the observation that dexamethasone prevents protein kinase A
inhibition of BK channels and in turn that selective blockage of
BK channels abolished the early inhibition of ACTH release.
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FIG. 3. IbTx prevents early glucocorticoid inhibition of CRF-
stimulated ACTH secretion. A, static incubation assays of CRF-
stimulated ACTH secretion were performed at room temperature
(24 °C) under the conditions used to monitor outward currents as de-
scribed under “Materials and Methods.” CRF (100 nM) was applied for
30 min. TEA (1 mM) was applied during the CRF exposure, and IbTx
(100 nM) was applied .15 min before and during CRF exposure. Cells
were treated for 2 h with 1 mM dexamethasone or vehicle (0.01%Me2SO)
as appropriate. ACTH release for each treatment in dexamethasone-
treated cells (open box) is expressed as the percent of the respective
control (absence of dexamethasone, filled box) stimulus (100%). In these
studies CRF (100 nM) stimulated ACTH release to 157 6 6% (n 5 6) of
basal levels. IbTx (100 nM) or TEA (1 mM) alone elicited a small but
significant (p , 0.05) ACTH response (114 6 2%, n 5 3 and 127 6 7%,
n 5 5 of basal, respectively). IbTx had no significant effect on CRF-
stimulated ACTH secretion (155 6 7.9%, n 5 6 of basal release). TEA
(1 mM) significantly (p , 0.05, non-parametric Kruskal-Wallis test)
enhanced CRF-stimulated ACTH release to 185 6 10.5%, (n 5 5) of
basal. Means 6 S.E. are shown; *, p , 0.01 compared with control
ACTH release (non-parametric Kruskal-Wallis test).
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Large-conductance calcium- and voltage- acti-
vated potassium (BK) channels play a fundamental
role in the signaling pathways regulating mouse
anterior pituitary corticotrope function. Here we
describe the cloning and functional characteriza-
tion of the components of mouse corticotrope BK
channels. RT-PCR cloning and splice variant anal-
ysis of mouse AtT20 D16:16 corticotropes revealed
robust expression of mslo transcripts encoding
pore-forming a-subunits containing the mouse ho-
molog of the 59-amino acid STREX-1 exon at splice
site 2. RT-PCR and functional analysis, using the
triterpenoid glycoside, DHS-1, revealed that native
corticotrope BK channels are not functionally cou-
pled to b-subunits in vivo. Functional expression of
the STREX-1 containing a-subunit in HEK 293 cells
resulted in BK channels with calcium sensitivity,
single-channel conductance, and inhibition by pro-
tein kinase A identical to that of native mouse cor-
ticotrope BK channels. This report represents the
first corticotrope ion channel to be characterized
at the molecular level and demonstrates that
mouse corticotrope BK channels are composed of
a-subunits expressing the mouse STREX-1 exon.
(Molecular Endocrinology 13: 1728–1737, 1999)
INTRODUCTION
The excitability of anterior pituitary cells is tightly con-
trolled by G-protein-linked receptor-mediated regula-
tion of multiple ion channels in the plasma membrane
of target cells (1–3). Although pharmacological and
electrophysiological analysis has revealed the nature
of some of these ion channels, molecular components
of anterior pituitary ion channels are poorly
characterized.
In mouse AtT20 corticotropes large conductance
calcium- and voltage- activated potassium (BK) chan-
nels play a pivotal role in the regulation of ACTH se-
cretion (4, 5). In this system the stimulatory neuropep-
tide, CRH, potently inhibits BK channels through
protein kinase A (PKA)-mediated phosphorylation of
the BK channel complex (5, 6). Importantly, glucocor-
ticoids prevent PKA inhibition of BK channels, and this
action of the steroid is pivotal to early glucocorticoid
inhibition of ACTH secretion in this system (4–6).
In contrast to the multiple gene families of other
voltage-dependent cation channels, the pore-forming
a-subunits of BK channels are encoded by a single
gene, Slo (7, 8), that undergoes extensive, hormonally
regulated, alternative RNA splicing (9, 10). These
splice variants give rise to channels with different func-
tional properties, including calcium sensitivity, single-
channel conductance, and regulation by intracellular
signaling pathways (11–14). In addition, association of
a-subunits with accessory subunits may result in dif-
ferential channel properties or modify their cellular dis-
tribution (15–18).
Mouse corticotrope BK channels display consider-
ably higher calcium sensitivity (6) than previously iden-
tified a-subunits cloned from mouse brain. Further-
more, in common with native BK channels from
several cell types of the anterior pituitary (5, 19, 20),
mouse corticotrope BK channels are inhibited by PKA-
mediated phosphorylation, whereas the majority of
brain BK channels are activated by PKA (21, 22).
Elucidation of the molecular components of BK
channels in specific cell types is beginning to reveal
the molecular basis for their functional role in funda-
mental physiological processes (23, 24). To further
address the functional role, and molecular regulation,
of BK channels in mouse corticotrope cell function, we
0888-8809/99/$3.00/0
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have 1) characterized and cloned the BK channel
a-subunit splice variants expressed in mouse AtT20
D16:16 corticotropes, and 2) directly compared the
functional characteristics (calcium sensitivity and reg-
ulation by PKA) of these identified subunits expressed
in HEK 293 cells with native AtT20 D16:16 BK
channels.
This report represents the first corticotrope ion
channel to be functionally characterized at the molec-
ular level. We demonstrate that mouse corticotrope
BK channels are composed of a-subunits expressing
the mouse homolog of the previously described cys-
teine-rich STREX-1 exon (10, 25). Furthermore, the
STREX-1 a-subunit variants expressed in HEK 293
cells are inhibited by PKA-mediated phosphorylation.
RESULTS AND DISCUSSION
Cloning and Splice Variant Analysis of Mouse
Corticotrope BK Channel a-Subunits
Cloned RT-PCR products of the entire open reading
frame (ORF) of BK channel a-subunits from AtT20
D16:16 corticotropes had sequence identical to pre-
viously published mouse brain mslo BK channels (8,
26) with variations at known mammalian splice sites
(25) (Fig. 1A). The majority of full-length cDNA clones,
as well as RT-PCR products spanning a-subunit splice
sites expressed in mouse AtT20 D16:16 corticotropes,
contained the mouse variant of the previously de-
scribed cysteine-rich, 59-amino acid insert at splice
Fig. 1. BK Channel a-Subunit Splice Variants Expressed in Mouse AtT20 Corticotropes
A, Schematic of mammalian splice site inserts characterized in mouse AtT20 D16:16 corticotropes by RT-PCR analysis (see
Materials and Methods) with predicted inserts represented by single amino acid codes. B, Amino acid sequence alignment of
mammalian STREX-1 inserts characterized to date: mouse (AtT20 D16:16 cell and normal mouse pituitary, this study); rat
chromaffin cells (25) and rat anterior pituitary (this study); rabbit kidney tubules (29); and human pancreatic islets (27). Boxed
amino acids indicate differences from the mouse STREX-1 insert. Note: the STREX-2 insert (10) that contains additional amino
acids at the N terminus of the STREX-1 exon have not been included in the alignment. Alignment positions are relevant to the start
proline (P) amino acid of the respective splice insert. C, Western blot analysis of BK channel a-subunit expression in partially
purified membrane fractions using the C-terminally directed aslo(9132926) antibody as described in Materials and Methods. This
antibody recognizes the VNDTNVQFLDQDDD motif in the C-terminal tail (indicated by * in panel A) conserved in all mslo variants
(28). Membranes were isolated from: HEK 293 cells stably expressing the mouse AtT20 corticotrope STREX-1 variant (10 mg/lane,
STREX-1); native AtT20 cells (40 mg/lane, AtT20); and mock transfected HEK 293 cells (40 mg/lane, HEK).
Molecular Components of Mouse Corticotrope BK Channels 1729
               dc_385_12
site 2, termed STREX-1 (10, 25). In approximately 25%
of clones, either the IYF motif or null (ZERO) insert was
expressed at splice site 2 (Fig. 1A). No evidence for
inserts at splice sites 1, 3, or 4 was found (Fig. 1A). A
STREX-1 splice site 2 insert identical to that charac-
terized in AtT20 D16:16 corticotropes was also ex-
pressed in adult mouse anterior pituitary.
The mouse corticotrope splice site 2 insert
(STREX-1) was similar, at the amino acid level, to
recently identified STREX-1 exons in other mammalian
endocrine cells including rat chromaffin cells (25) and
human pancreatic islets (27) (Fig. 1B). Western blot
analysis was performed using the C-terminally di-
rected a-subunit antibody aslo(9132926) (28) that rec-
ognizes all mslo variants. Immunoblotting of partially
purified plasma membranes from native mouse AtT20
corticotropes and HEK 293 cells stably expressing the
entire coding region of the cloned STREX-1 a-subunit
revealed expression of an approximately 125-kDa im-
munoreactive protein band that was not detectable in
mock transfected HEK 293 cells: the predicted molec-
ular mass of the STREX-1 variant from translation of
the ORF is 131 kDa.
Functional Characterization of Mouse
Corticotrope a-Subunits Expressed in
HEK 293 Cells
Expression of the STREX-1 and ZERO variants of
mouse AtT20 corticotrope BK channel a-subunits in
HEK 293 cells resulted in large outward macropatch
voltage- and calcium-activated potassium currents
(Fig. 2). In mock transfected HEK 293, under identical
recording conditions, outward macropatch calcium-
or voltage-activated potassium currents were not ob-
served (Fig. 2A). Furthermore, RT-PCR (not shown)
and Western blot (Fig. 1D) analysis did not reveal
endogenous BK channel expression in this cell line.
Transfection of cloned mouse AtT20 corticotrope BK
channel a-subunits lacking the proposed initiator me-
Fig. 2. Functional Characterization of STREX-1 and ZERO a-Subunits Expressed in HEK 293 Cells
A, Representative isolated inside-out macropatch recordings from mock transfected HEK 293 cells and cells expressing the
mouse AtT20 D16:16 corticotrope STREX-1 a-subunit. The intracellular face of patches was exposed to 0.1 mM [Ca21]i as
described in Materials and Methods in the absence of ATP under physiological potassium gradients. Patches were held at 250
mV and depolarized for 500 msec to the respective potential (240 to 180 mV). B, Relative conductance-voltage plots for the
STREX-1 (open square, n 5 9) and ZERO (closed square, n 5 4) variants determined from macropatch recordings under the
conditions in panel A. The lines show the best fit of a single Boltzmann function (see Materials and Methods). C, Representative
current recordings at 1 40 mV demonstrating the effect of [Ca21]i (,10 nM (0), 0.1 mM, and 0.5 mM) on outward STREX-1
macropatch currents under the conditions in panel A with 1 mM ATP in the intracellular solution. D, Plot of unitary current
amplitude as a function of activation voltage determined at 0.1 mM [Ca21]i as in panel A for the STREX-1 (open square, n 5 8)
variant expressed in HEK 293 cells and native AtT20 BK channels (open circle, n 5 8). The inset shows representative unitary
current records from patches expressing the STREX-1 variant in HEK 293 cells at 1 40 mV (top trace) and 0 mV (bottom trace),
respectively. All data are means 6 SEM with error bars within the symbol size unless otherwise indicated.
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thionine (8, 26) in HEK 293 cells did not result in
functional BK channel expression (M. J. Shipston, R.
Duncan, and L. Tian, unpublished data).
The half-maximal activation voltage (V50) for the
STREX-1 variant exposed to 0.1 mM [Ca21]i in physi-
ological potassium gradients was 30.7 6 1.6 mV (n 5
9) compared with 96.1 6 3.8 mV (n 5 4) for the ZERO
variant (Fig. 2B). Exposure of the intracellular face of
ZERO channels to 10 mM [Ca21]i resulted in a V50 of
15.3 6 2.4 mV (n 5 3). The V50 for the STREX-1 variant
is similar to that observed for the majority (. 90%) of
native mouse AtT20 BK channels (26.3 6 5.8 mV, n 5
11, not shown) under identical recording conditions.
Furthermore, the negative shift in V50 is similar in mag-
nitude to that observed between other mammalian
STREX-1 and corresponding ZERO BK a-subunit vari-
ants expressed in mammalian cell lines (25, 29). In-
creasing [Ca21]i at the intracellular face of patches
expressing the STREX-1 variant resulted in outward
macropatch currents with faster activation kinetics
and larger steady-state current amplitude, demon-
strating the calcium sensitivity of the channel (Fig. 2C).
It is likely that native AtT20 BK channels (, 10%) with
low calcium sensitivity are composed of ZERO a-sub-
unit variants.
The slope conductance of homomeric unitary
STREX-1 channels [127.2 6 4.2 picosiemens (pS), n 5
8] in physiological potassium gradients was not sig-
nificantly different from the slope conductance of na-
tive mouse AtT20 corticotrope channels recorded un-
der identical conditions (125.2 6 3.6 pS, n 5 8, Fig.
2D). In contrast, the slope conductance of the homo-
meric ZERO channel variant was significantly greater
(145.3 6 3.1 pS, n 5 7) than either STREX-1 or native
mouse AtT20 corticotrope channels (not shown).
b-Subunits Are Not Integral Components of BK
Channels in Mouse AtT20 Corticotropes
Taken together, these data suggest that native mouse
AtT20 corticotrope BK channels are largely composed
of the a-subunit STREX-1 variant. However, in some
systems, including vascular smooth muscle cells (24),
BK channel a-subunits functionally associate with reg-
ulatory b-subunits that confer enhanced calcium sen-
sitivity compared with the a-subunit expressed alone
(16, 30). To establish whether the enhanced calcium
sensitivity of native mouse AtT20 corticotrope is a
result of expression of the STREX-1 exon rather than
association of ZERO variants with b1- or b2-subunits,
we assayed the sensitivity of native mouse AtT20 BK
channels for the triterpenoid glycoside, DHS-1 (16,
30). Previous studies have shown that submicromolar
concentrations of DHS-1 activates BK channels only
when the b1 (or b2)-subunit is functionally coupled to
a-subunits (16, 25, 30). Coexpression of the ZERO
a-subunit variant with b1-subunit in HEK 293 cells
resulted in a leftward shift of the half-maximal activa-
tion potential by approximately 60 mV to 35.3 6 7.4
mV, (n 5 3) at 0.1 mM [Ca21]i compared with the ZERO
variant alone (see Fig. 2B). Application of 100 nM
DHS-1 to the intracellular face of patches containing
ZERO 1 b1-subunit resulted in robust activation
(259.0 6 86.7%, n 5 4) of channel activity in all
patches tested (Fig. 3, A and B) that reversed to con-
trol upon washout. In contrast, under identical record-
ing conditions, application of 100–500 nM DHS-1 to
the intracellular face of patches from native mouse
AtT20 BK channels or HEK 293 cells expressing the
STREX-1 a-subunit variant or ZERO subunits alone
(Fig. 3B) had no significant effect on BK channel ac-
tivity. Previous studies (25) have reported that b1-
subunits increase the sensitivity of the STREX-1 vari-
ant to [Ca21]i and DHS-1. Furthermore, RT-PCR
analysis using degenerate primers based on the pub-
lished mouse, human, and bovine b1-subunit se-
quences (16, 31) support our functional data that na-
tive mouse AtT20 corticotropes do not express
endogenous b1-subunits (Fig. 3C). As a positive con-
trol for the RT-PCR screen, RNA from HEK 293 cells
cotransfected with the ZERO a-subunit and b1-sub-
unit showed robust expression (Fig. 3C). Thus, as
DHS-1 has no effect on endogenous BK channel ac-
tivity, b1-subunit transcripts are not expressed, and
native AtT20 BK channels do not inactivate (5, 6, 32),
our data suggests that the previously described b1- or
b2-subunits are not integral components of native
AtT20 corticotrope BK channels (16, 30).
STREX-1 a-Subunits Are Inhibited by
cAMP-Mediated Protein Phosphorylation
BK channels from mouse AtT20 corticotropes are po-
tently inhibited by cAMP-dependent PKA activity inti-
mately associated with the channel protein (5, 6). BK
channels in other anterior pituitary cell types are also
inhibited by PKA-dependent phosphorylation (19, 20).
Previous studies have shown that expression of the
human BK channel a-subunit homolog of the ZERO
variant in Xenopus oocytes results in channel activa-
tion by PKA (33). Thus, to investigate whether the
mouse STREX-1 variant could be the functional target
for PKA-mediated inhibition in mouse AtT20 cortico-
tropes, we examined the effect of activating endoge-
nous PKA activity in excised inside-out patches from
HEK 293 cells expressing the STREX-1 variant.
Application of 1 mM cAMP to the intracellular face of
patches, in the presence of Mg-ATP, resulted in a
robust inhibition of channel activity at both the mac-
ropatch and unitary current level (Figs. 4 and 5) in all
patches tested. In macropatch recordings maximal
inhibition (mean percentage change in pretreatment
steady-state outward current, Io, was 247.5 6 3.6%,
n 5 4, P , 0.01 determined at 1 40 mV) was observed
10 min after application of cAMP to the intracellular
face of the patch at all potentials examined (Fig. 4,
A–C). The inhibitory effect of cAMP was completely
blocked by the specific PKA inhibitor peptide,
PKI(5224) (mean percentage change in Io was 5.5 6
13.2%, n 5 3). Furthermore, in the absence of ATP,
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cAMP alone had no significant inhibitory effect. In-
deed, removal of ATP resulted in a small, but signifi-
cant, increase in steady-state outward current by
24.6 6 11.9%, n 5 4, P , 0.05 after 10 min (not
shown). In an inside-out patch containing a single
STREX-1 BK channel, application of cAMP to the in-
tracellular face of the patch resulted in a robust inhi-
bition of single-channel mean open probability (Po)
with a time course similar to that observed for macro-
patch records (Fig. 5, A–C). Furthermore, in three other
patches in which unitary currents could be resolved,
cAMP significantly inhibited NPo (P , 0.01), an effect
that was blocked by PKI(5224) (n 5 2 patches; not
shown).
Taken together, these results demonstrate that
cAMP-dependent activation of PKA closely associ-
ated with the STREX-1 BK channel complex inhibits
STREX-1 channel activity expressed in HEK 293 cells.
As native BK channels in AtT20 mouse corticotrope
cells are potently inhibited by PKA closely associated
with the channel complex (6), our data suggest that the
STREX-1 a-subunit, or a protein that functionally as-
sociates with the STREX-1 a-subunit in corticotropes
and HEK 293 cells, is the functional target for PKA-
mediated inhibition.
Mouse Corticotrope BK Channels Are
Predominantly Composed of the STREX-1
a-Subunit Variant
The data presented in this report provide the first
molecular and functional characterization of an ion
channel expressed in anterior pituitary corticotropes.
Several lines of evidence suggest that mouse AtT20
corticotrope BK channels are composed of a-subunits
containing the mouse homolog of the previously de-
scribed 59-amino acid, cysteine-rich, STREX-1 exon
at splice site 2 (10, 25).
First, cDNA cloning and RT-PCR splice site anal-
ysis revealed robust expression of STREX-1 con-
taining a-subunits in mouse AtT20 corticotropes.
Importantly, an identical STREX-1 exon is expressed
Fig. 3. Mouse Corticotrope BK Channel a-Subunits Are Not Functionally Coupled to b-Subunits
A, Representative traces of the effect of 100 nM DHS-1 applied to the intracellular face of a patch excised from HEK 293 cells
coexpressing the ZERO mouse AtT20 corticotrope BK channel a-subunit and bovine b1-subunit (b1) in HEK 293 cells. Traces from
the same patch are for control (Control), 5 min after DHS-1 application (1 DHS-1), and 5 min after DHS-1 washout (wash). B,
Summary of effect of DHS-1 on coexpressed channels as in A (ZERO 1 b1, n 5 4, 100 nM DHS-1); native mouse AtT20
corticotrope BK channels (AtT20, n 5 5, 100–500 nM DHS-1); and mouse AtT20 corticotrope STREX-1 subunits expressed alone
in HEK 293 cells (STREX-1, n 5 3, 100–500 nM DHS-1). Data are expressed as the mean % activation (percentage increase in
channel NPo 5 min after DHS-1 application relative to pretreatment control) 6 SEM. **, P , 0.01 (ANOVA) compared with STREX-1
or AtT20 group. C, Representative 1% agarose gel of ethidium bromide-stained PCR products generated as described in
Materials and Methods from: pcDNA3 plasmid containing bovine b1 subunit construct (pBKb); reverse transcription (RT) product
from HEK 293 cells transiently coexpressing the mouse AtT20 ZERO corticotrope BK a-subunit variant and bovine b1 subunit
(ZERO 1 b1); RT product from mock transfected HEK 293 cells (HEK); and RT product from native mouse AtT20 corticotropes
(AtT20). Molecular weight markers (mw: 100-bp ladder) are shown; arrow indicates position of full-length b1-subunit transcript.
MOL ENDO · 1999 Vol 13 No. 10
1732
               dc_385_12
in normal adult mouse anterior pituitary gland and a
highly homologous exon (2 amino acid differences
out of 59) is expressed in rat anterior pituitary cells.
Second, functional expression of the STREX-1
a-subunit in HEK 293 cells revealed channels with
almost identical calcium sensitivity, unitary conduc-
tance, and inhibition by PKA as for the majority (.
90%) of native AtT20 D16:16 BK channels under
identical recording conditions. In contrast, expres-
sion of the ZERO a-subunit variant resulted in chan-
nels with higher single-channel slope conductance
and significantly lower calcium sensitivity compared
with the STREX-1 a-subunit or native AtT20 BK
channels. Finally, RT-PCR analysis and functional
assays using the triterpenoid glycoside, DHS-1, re-
vealed that the high calcium sensitivity of native
mouse AtT20 corticotrope BK channels is not a re-
sult of association of a-subunits with previously de-
scribed b-subunits (16, 30).
Importantly, the STREX-1 a-subunit variant, as for
endogenous BK channels in mouse AtT20 cortico-
tropes (6), is inhibited by PKA-dependent protein
phosphorylation. Indeed, several putative PKA con-
sensus phosphorylation sites can be assigned from
primary sequence data that are distributed across the
C-terminal intracellular domain. However, we cannot
exclude that the STREX-1 a-subunit associates with
unidentified regulatory subunits, in native AtT20
Fig. 4. Activation of PKA Inhibits Macropatch STREX-1 BK Currents
A, Representative outward macropatch currents from HEK 293 cells stably transfected with the STREX-1 variant before
(control) and 10 min after application of 1 mM cAMP to the intracellular face of the patch. Macropatch currents were determined
as in Fig. 2 by depolarization from 250 mV to the respective potential (240 to 1 80 mV) with 0.1 mM [Ca21]i and 1 mM ATP. B,
Current-voltage relationship for the traces shown in panel A above. Peak steady-state current (Io) was determined 450 msec into
the pulse and plotted as a function of membrane potential. C, Effect of cAMP on Io 10 min after application of 1 mM cAMP to the
intracellular face of macropatches (cAMP, n 5 4) or after preincubation with the specific PKA inhibitor, PKI(5224), and subsequent
10 min application of cAMP (cAMP 1 PKI, n 5 3). Data were determined as in panel A with percentage change in Io determined
at 1 40 mV and expressed as mean 6 SEM; P , 0.01 (t test) compared with cAMP 1 PKI group
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D16:16 corticotropes or HEK 293 cells, that confer
sensitivity to PKA inhibition.
Increasing evidence suggests that the STREX-1 or
STREX-2 (STREX) exon (10, 25) is widely expressed in
neuroendocrine cells including pancreatic b-cells and
adrenal chromaffin cells (25, 27) as well as anterior
pituitary corticotropes (this study). Thus, the STREX
exon may be a common feature of neuroendocrine
cells in which BK channel a-subunits retain a high
sensitivity to calcium in the absence of functional in-
teraction with b-subunits, as described for vascular
smooth muscle cells (24). Intriguingly, the rat STREX
exons expressed in adrenal chromaffin cells is hor-
monally regulated by the stress axis and has been
proposed to be expressed in excitable cells associ-
ated with enhanced repetitive action potential firing
(10, 23). Thus, the STREX variants in other compo-
nents of the stress axis, including anterior pituitary
cells, may also be under dynamic long-term regulation
as well as involved in the short-term regulation of
corticotrope function by CRH and other signaling
pathways (5, 6, 32). Elucidation of the molecular com-
ponents of mouse corticotrope BK channels reported
in this study should allow us to define further the
functional role, and molecular regulation, of these im-
portant multiple coincidence detectors in anterior pi-
tuitary corticotropes.
MATERIALS AND METHODS
Cell Culture
AtT20 D16:16 cells were maintained as previously described
(5). Briefly, cells were maintained in DMEM containing 10%
FCS (Harlan Seralab, Crawley Down, UK) in a humidified
atmosphere of 95% air-5% CO2 at 37 C. Cells were routinely
passaged every 7 days using 0.25% trypsin in HBSS con-
taining 0.1% EDTA after reaching 80% confluency. HEK 293
cells, a generous gift from David N. Sheppard, University of
Edinburgh, were maintained as for AtT20 D16:16 cells except
cells were passaged every 3–4 days.
Isolation of cDNAs Encoding Mouse Corticotrope BK
Channels
An RT-PCR strategy was used to amplify cDNAs encoding
the entire ORF of mouse anterior pituitary AtT20 D16:16
corticotrope BK channel a-subunits. Briefly, total cellular
RNA from approximately 107 mouse AtT20 D16:16 cortico-
tropes was isolated using standard techniques (34) and
mRNA purified using poly (A) quik columns (Stratagene, La
Jolla, CA) according to the manufacturer’s instructions. One
microgram of this RNA was used as template in a first strand
cDNA synthesis directed from an anchored deoxyoligo d(T)
primer (59-TTCTAGAATTCAGCGGCCGC(T)30N1N2), using
Superscript II reverse transcriptase (Life Technologies, Inc.,
Paisley, UK). The resultant cDNA was diluted and used in a
PCR to amplify the entire ORF using forward (spanning initi-
ator methionine: 59-GAT GGA TGC GCT CAT CAT MCC G)
and reverse (spanning stop codon: 59-CTG GGA TAG GCA
TTA TCC GGC TCA) deoxynucleotides, with Expand poly-
merase (Roche Diagnostics Ltd, Lewes, UK). PCR product(s)
were ligated to a T/A vector (pCR2.1, Invitrogen, San Diego,
CA) and completely sequenced on both strands (OSWEL
DNA Services, Southampton, UK). The STREX-1 variant se-
quence has been deposited in Genbank, accession number:
AF156674.
Splice Variant Analysis
First-strand cDNA from mRNA isolated from AtT20 D16:16
cells and adult mouse anterior pituitary glands was generated
as described above. Analysis of splice sites was performed
using primers encompassing splice sites 1–3: forward (59-
CAG AGT CAA GAT AGA GTC AGC); reverse (59-AAG TGG
CAT CAC CAG GTT CCG) and for splice site 4: forward
(59-GAT ACT TCG CTT CAG GAC AAG G); reverse (59-AAT
GTC TGC GGA GTG CTG TAG C). In some experiments a
nested PCR approach, with external primers that spanned
the pore region and splice sites 1–4 in the first round ampli-
fication, followed by a second round amplification with the
above internal primer sets, was used to confirm splice vari-
Fig. 5. Closely Associated PKA Inhibits Single STREX-1 BK
Channels
A, Representative unitary current records from an isolated
inside-out patch containing a single BK channel from HEK
293 cells stably expressing the STREX-1 variant before (Con-
trol) and 10 min after (1 cAMP) application of 1 mM cAMP to
the intracellular face of the patch. Patches were exposed to
0.5 mM [Ca21]i and 1 mM ATP and depolarized to 0 mV for 60
sec at the respective time point. B, Diary plots of mean
single-channel open probability (Po) determined every sec-
ond (vertical solid bars) 3 min before and 10 min after the
application of cAMP. C, Mean Po determined from 60 sec of
continuous recording and plotted as a function of time for the
above. cAMP (1 mM) was applied at 0 min for the duration of
the experiment (horizontal open bar).
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ants (not shown). PCR products were characterized by gel
electrophoresis and restriction digestion, and products of
interest were ligated into the T/A vector pCR2.1 (Invitrogen)
and sequenced on both strands.
For RT-PCR analysis of b1-subunit expression, degenerate
primers were designed against the published bovine, human,
and mouse b1-subunits (16, 31). Forward primer: 59-ATG
GKR AAG AAG CTG GTG ATG GCC; reverse primer: 59-TCT
GRG CCG CCA GGA TGG; and PCR products analyzed as
above.
Construction of Expression Plasmids and Expression in
HEK 293 Cells
Subcloning of the entire ORF of AtT20 BK channel subunits
into pcDNA3.1 resulted in low expression of channels in HEK
293 cells compared with channel constructs containing ad-
ditional 59- and 39-untranslated region (UTR) (14). To improve
channel expression HindIII-NheI restriction fragment(s) from
AtT20 BK channel clones, spanning splice sites 1–3, were
ligated into the HindIII-NheI site of the mbr5 mslo (8) variant
(Genbank accession number: L16912). The HindIII-NheI sites
are conserved in all mslo variants, and constructs were gen-
erated from the mbr5-BSmxt plasmid construct, a generous
gift from Dr Lawrence Salkoff (Washington University, St.
Louis, MO) (8). The mbr5 clone is identical in sequence to
characterized mouse corticotrope clones except that splice
sites 1–4 do not contain inserts and mbr5 contains additional
59- and 39-UTR. Thus mbr5 is identical to the ZERO variant
(see Results) isolated from AtT20 D16:16 corticotropes. The
KpnI-XbaI fragment of mbr5 encompassing the entire ORF
and additional 59- and 39-UTR and containing either the
AtT20 null splice site 2 (ZERO, see Results) or containing the
AtT20 STREX-1 splice site 2 insert (STREX-1) were sub-
cloned into the mammalian expression vector pcDNA3.11 or
pcDNA3.11 zeo respectively (Invitrogen BV, Leek, The Neth-
erlands) for expression in HEK 293 cells.
The bovine tracheal smooth muscle cell BK channel b1-
subunit (b1) cDNA was kindly provided by Dr. Reid J. Leonard
(Merck Research Laboratories, Rahway, NJ) (16). The EcoRI-
NotI fragment encoding the entire ORF was subcloned into
the mammalian expression vector pcDNA3.11 zeo (Invitro-
gen BV).
For transient transfections, HEK 293 cells were seeded
onto glass coverslips 24 h before transfection at 40% con-
fluency and transfected with 1 mg of the respective expres-
sion plasmid using lipofectamine (Life Technologies, Inc.)
essentially as described by the manufacturer. For cotrans-
fections, b1-subunit DNA was transfected at a 5-fold excess
over the a-subunit. Cells were used 24–72 h after the start of
transfection at between 40–80% confluency. Stable cell lines
were created as above by seeding in 24-well cluster dishes
(Costar, Cambridge, MA), and stable transformants were se-
lected for zeocin resistance using 0.2 mg/ml zeocin
(Invitrogen).
Electrophysiology
BK channels in AtT20 D16:16 corticotropes or cloned chan-
nels expressed in HEK 293 cells were analyzed under volt-
age-clamp in the excised inside-out configuration of the
patch clamp technique at room temperature (20–24 C) using
physiological potassium gradients essentially as previously
described (6, 14). The pipette solution (extracellular) con-
tained (in millimolar concentration): 140 NaCl, 5 KCl, 0.1
CaCl2, 5 MgCl2, 20 glucose, 10 HEPES, pH 7.4. The bath
solution (intracellular) contained (in millimolar concentration):
140 KCl, 5 NaCl, 2 MgCl2, 1 or 5 (1,2-bis-O-aminophe-
noxy)ethane-N,N,N9,N9-tetraacetic acid (BAPTA), 30 glucose,
10 HEPES, pH 7.35, with free calcium [Ca21]i buffered to the
concentration indicated in the respective figure legend and
calculated as previously described (35). For [Ca21]i greater
than, or equal to, 1 mM, dibromo-BAPTA was used as the
calcium buffer.
Data acquisition and voltage protocols were controlled by
an Axopatch 200 A or B amplifier and pCLAMP6 software
(Axon Instruments Inc., Foster City, CA). All recordings were
sampled at 10 kHz and filtered at 2 kHz. For patches in which
unitary currents could be resolved, channels were voltage
clamped at the potential indicated in the respective figure
legend. Mean steady-state single-channel open probability
(Po) was determined from at least 30 sec of continuous
recording under each experimental condition. For macro-
patch recordings, outward BK currents were evoked by 500-
msec step depolarizations (250 to 1 80 mV), and the steady-
state current amplitude, averaged from five consecutive
depolarizations 450 msec into the pulse, was determined at
each potential. For macropatch recordings with seal resis-
tances . 10 GV leak subtraction was not routinely applied.
Pipettes were manufactured from Garner no. 7052 glass,
coated with sylgard, and had typical resistances of between
2–10 MV in bath solution after fire polishing. Patches con-
taining a single BK channel (verified at 1 80 mV and 10 mM
[Ca21]i) were extremely rare (,0.5% of total patches) even
with pipette resistance values . 10 MV.
Additional analysis and curve fitting was performed using
Igor Pro3.1 (Wavemetrics Inc., Lake Oswego, OR). Conduc-
tance values (G) were calculated from peak current (I) mea-
sured at 450 msec into the voltage pulse using the relation-
ship G 5 I/(V-Ek) where V is the activation potential and Ek is
the calculated potassium reversal potential. Conductance-
voltage curves were fit with a single Boltzmann function,
G(V) 5 Gmax/(11 exp(V50 2 V)/k), where Gmax corresponds to
the maximal conductance, V50 is the voltage for half-maximal
activation, V is the activation potential, and k is the slope
factor reflecting the voltage dependence of conductance.
Western Blotting
Partially purified membrane homogenates from AtT20 D16:16
cells were prepared by homogenizing approximately 107 cells
on ice in the following (in millimolar concentration): 150 KCl,
5 EGTA, 2 MgCl2, pH 10.6, containing 12 U/ml aprotinin, 5
mg/ml leupeptin, 6 mM 4-(2-aminoethyl)benzenesulfonyl
fluoride, and 4 mM Pepstatin A followed by two freeze thaw
cycles. After centrifugation for 5 min 1,000 3 g at 4 C, the
resultant supernatant was pelleted at 40,000 3 g to give the
crude membrane fraction. Protein samples (10–40 mg) were
separated on a 10% SDS gel and electroblotted to Immobilon
polyvinylidene fluoride membranes. Membranes were
blocked for 2 h at room temperature with PBS containing 0.1
mM EDTA, 0.1% Triton X-100, pH 7.4 (PBS-TE), and 5%
(wt/vol) low-fat milk (Marvel). Blots were incubated overnight
at 4 C with a 1:2000 dilution of the affinity-purified antibody
aslo(9132926) [directed toward residues 913–926 of the pore-
forming a-subunit of mouse brain BK channels (28)] in
PBS-TE containing 1% wt/vol Marvel. Blots were washed five
times with PBS-TE and incubated for 45 min at room tem-
perature with horseradish peroxidase-conjugated antirabbit
IgG (Amersham Pharmacia Biotech, Piscataway, NJ; 1:5000
final dilution) in PBS-TE containing 5% (wt/vol) Marvel. After
five washes in PBS-TE, blots were incubated with enhanced
chemiluminescence (ECL) reagents (Amersham Pharmacia
Biotech) according to the manufacturer’s protocol and blots
were exposed to ECL film in the linear response range (Am-
ersham Pharmacia Biotech).
Reagents
ATP magnesium or potassium salt, was from Sigma-Aldrich
Co. (St. Louis, MO) and stored as buffered 1 M stock solutions
at 220 C before use. ATP and cAMP were buffered in bath
solution to pH 7.35 and applied to the intracellular patch by
gravity perfusion with 10 volumes of bath solution at a flow
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rate of 1–2 ml/min. PKI5224, BAPTA, dibromo-BAPTA, and
Fura-2 were obtained from Calbiochem (Nottingham, UK).
DHS-1 was a generous gift of Dr. Owen McManus (Merck
Research Laboratories, Rahway, NJ). The C-terminal
aslo(9132926) antibody was a generous gift of Dr. Hans-Guen-
ther Knaus (University of Innsbruck, Innsbruck, Austria). All
other reagents, unless otherwise stated, were of the highest
analytical grade available from Sigma-Aldrich Co. Ltd., Poole,
UK, or Merck Ltd., Poole, UK.
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Adrenal glucocorticoids are pivotal for adaptation to
environmental challenge in a wide range of tissues
including the central nervous and endocrine systems
(Sapolsky et al. 2000). These hormones can potently
modify the electrical excitability of target cells through
regulation of ion channel activity that requires the rapid
induction of new proteins. Increasing evidence suggests
that in neurones and endocrine cells, potassium channels
are important targets for glucocorticoid action. For
example glucocorticoids rapidly induce the expression of
potassium channel subunits in some systems (Levitan et
al. 1991; Attali et al. 1995), but in both hippocampal CA1
neurones and neuroendocrine anterior pituitary
corticotroph (AtT20) cells (Joels & de Kloet, 1989;
Shipston et al. 1996; Tian et al. 1998), the activity of
Ca2+-activated potassium channels is modulated by
glucocorticoid-induced signalling pathways. In both of
these systems glucocorticoid action is mediated by type II
glucocorticoid receptors, occurs within 2 h, and requires de
novo synthesis of mRNA as well as protein. However, the
underlying mechanism(s) are poorly understood.
Large-conductance Ca2+-activated potassium channels
(BK channels) are pivotal targets of glucocorticoids in
AtT20 cells (Shipston et al. 1996; Tian et al. 1998). In
these neuroendocrine cells, cAMP-generating agonists
inhibit BK channels through cAMP-dependent protein
kinase (PKA). Proteins rapidly induced by the synthetic
glucocorticoid dexamethasone block the inhibition of BK
channels by PKA, and this is crucial for the suppression
of stimulated ACTH release by glucocorticoids (Shipston
et al. 1996). The effect of glucocorticoids on BK channels
is blocked by low nanomolar concentrations of okadaic
acid (Tian et al. 1998), suggesting an involvement of
serine/threonine protein phosphatases, for example
protein phosphatase (PP) 1 or 2A in glucocorticoid action.
AtT20 cells express two major BK channel splice variants,
ZERO and STREX (Shipston et al. 1999). Unlike many
Alternative splicing determines sensitivity of murine
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1. Large-conductance Ca2+- and voltage-activated potassium (BK) channels are important
regulators of cellular excitability. Here, we present a patch-clamp electrophysiological analysis
of splice-variant-specific regulation by the synthetic glucocorticoid dexamethasone (DEX) of
BK channels consisting of cloned STREX or ZERO a-subunit variants expressed in human
embryonic kidney (HEK 293) cells. 
2. STREX channels in isolated membrane patches were inhibited by protein kinase A (PKA) and
this was blocked on pre-treatment of intact cells with DEX (100 nM) for 2 h.
3. The effect of DEX required the synthesis of new mRNA and protein. Furthermore, it required
protein phosphatase 2A (PP2A)-like activity intimately associated with the channels, as it was
blocked by 10 nM okadaic acid but not by the specific protein phosphatase-1 inhibitor peptide
PPI-2.
4. ZERO variant channels that lack the STREX insert were activated by PKA but were not
influenced by DEX. ZERO channels containing a mutant STREX domain (S4STREXA) were also
activated by PKA. Importantly, DEX blocked PKA activation of S4STREXA channels in a
PP2A-dependent manner. 
5. Taken together, the STREX domain is crucial for glucocorticoid regulation of BK channels
through a PP2A-type enzyme. Moreover, glucocorticoids appear to induce a generic set of
proteins in different types of cells, the actions of which depend on the expression of cell-specific
targets.
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other voltage-gated potassium channels, the pore-
forming BK channel subunits are derived from a single
gene that undergoes extensive hormonally regulated
alternative splicing (Adelman et al. 1992; Butler et al.
1993; Pallanck & Ganetzky, 1994; Tseng-Crank et al.
1994; Xie & McCobb, 1998; Xie & Black, 2001). The
STREX variant is identical to ZERO except for a 59
amino acid insert at site 2, which is one of at least five
different splice sites in the C terminal portion of the BK
channel a-subunit protein encoded by the mammalian Slo
gene (Saito et al. 1997; Shipston et al. 1999). The STREX
insert confers enhanced calcium sensitivity to BK
channels (Saito et al. 1997; Shipston et al. 1999).
Furthermore, STREX channels are inhibited, whereas
ZERO channels are activated, by PKA closely associated
with the channel complex (Tian et al. 2001). 
In this report we have examined whether the pore-
forming subunits of BK channels are targets for
glucocorticoid regulation and whether such modulation is
dependent upon the BK channel splice variant expressed.
To address these issues we have investigated the
regulation of the cloned BK channel splice variants,
STREX and ZERO, heterologously expressed in human
embryonic kidney 293 (HEK 293) cells. We demonstrate
that the STREX insert confers glucocorticoid sensitivity
on BK channels by targeting a glucocorticoid-induced
signalling pathway, involving serine/threonine protein
phosphatases, to potassium channels. Differential
modulation of BK channel splice variants by gluco-
corticoids would provide a powerful mechanism to tune
the excitability of glucocorticoid-sensitive target cells. 
METHODS
Construction of BK channel splice variant and mutant
cDNA constructs
The cloning and sub-cloning of the mouse BK channel splice variants
and respective site directed mutants into the mammalian expression
vector pcDNA3 or pcDNA3.1+ (Invitrogen, Leek, The Netherlands)
have been described previously (Clark et al. 1999; Shipston et al.
1999; Tian et al. 2001). Briefly, the ZERO variant lacks inserts at
mammalian splice sites 1–5 and STREX channels are identical except
for a 59 amino acid cysteine-rich insert at mammalian splice site 2
that increase the apparent calcium sensitivity of the channel (Saito et
al. 1997; Shipston et al. 1999). The ZERO variant is activated by
PKA, requiring a functional serine residue at position 869 within a
putative PKA consensus motif present in the C-termini of all
mammalian BK channel variants. The STREX variant is inhibited
by PKA, dependent upon a conserved serine residue (S4) within the
STREX insert itself. The S4STREXA mutant has this serine residue
mutated to alanine. The STREX-S869A mutant has a single point
mutation of the conserved serine residue at position 869 to alanine.
Site-directed mutagenesis was performed using Quik-change
(Stratagene) and verified by DNA sequencing. The constructs used in
these studies are shown schematically in Fig. 6B.
HEK 293 and AtT20 D16:16 cell culture and transfection
HEK 293 and AtT20 D16:16 cells were subcultured as previously
described (Shipston et al. 1996, 1999). Briefly, cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % fetal
calf serum (FCS) in a humidified atmosphere of 95 % air–5 % CO2 at
37 °C. Cells were routinely passaged every 3–7 days using 0.25 %
trypsin in Hanks’ buffered salt solution (HBSS) containing 0.1 %
EDTA. For immunoblotting studies, cells were grown to 70–80 %
confluence in 75 cm2 flasks. For electrophysiological assays, cells
were plated on glass coverslips in six-well cluster dishes. 
For transient transfections of BK channels, HEK 293 cells were
seeded onto glass coverslips in six-well cluster dishes at a density to
allow cells to reach 40–60 % confluence after 24 h. Cells were then
transfected with 1 µg of the respective cDNA using lipofectamine
(Life Technologies) in DMEM, essentially as described by the
manufacturer. After 5 h, medium was supplemented with 10 % FCS,
replaced after 24 h and electrophysiological recordings made 24–72 h
post-transfection. Stable cell lines containing different BK variants
were also created from these transfections and the transformants
were then selected and maintained for neomycin or zeocin resistance
using 0.2 mg ml_1 zeocin (Invitrogen) or 0.8 mg ml_1 geneticin (Life
Technologies) as appropriate. The HEK 293 cells do not express
endogenous BK channels at the mRNA (by RT-PCR), protein
(Western blotting) or functional electrophysiology level.
For luciferase assays, HEK 293 cells were plated directly into the six-
well cluster dishes and transfected as above except that transfections
and subsequent maintenance of cells was carried out in steroid-free
medium (DMEM supplemented with insulin–transferrin–selenium
(ITS, Sigma-Aldrich) supplement. The mammary tumour virus long
terminal repeat (MMTV-LTR)–luciferase reporter construct (Leckie
et al. 1995) was a generous gift from Dr K. Chapman (University of
Edinburgh). Similar results were obtained with other artificial serum
replacements and supra-maximal stimulation was identical in 10 %
FCS. However, the majority of FCS batches contain low to sub-
nanomolar concentrations of cortisol that preclude accurate
determination of the full dose–response range of MMTV-
LTR–luciferase reporter activity to the synthetic glucocorticoid
agonist dexamethasone.
Western blot analysis of glucocorticoid receptors
AtT20 and HEK 293 whole cell extracts (from ~107 cells) were
prepared by resuspending cells in lysis buffer containing (mM): 20
Tris-HCl, 2 EDTA, 150 NaCl, 0.5 % Triton X-100, pH 7.4, and
supplemented with a protease inhibitor cocktail (Boehringer
Mannheim). Cells were sheared through a 26G needle and incubated
on ice for approximately 1 h. The lysate was immediately spun for
10 min at 10 000 g and 4 °C and the supernatant used for subsequent
SDS-PAGE and Western blot analysis. Total protein content was
calculated using the Bradford protein assay (BioRad). Whole cell
lysates (10 µg protein from AtT20 cells and 50 µg from HEK 293
cells) were resolved on 8 % SDS-polyacrylamide gels and transferred
under semi-dry conditions onto polyvinylidene difluoride (PVDF)
membrane. Membranes were blocked using phosphate buffered saline
containing 0.05 % Tween 20 (0.05 %) (PBS-T) and 4 % non-fat dry
milk (Marvel) for 1.5 h at room temperature (or overnight at 4 °C). All
washing stages were carried out using PBS-T. Blots were incubated
for 1 h at room temperature with a 1:2000 dilution of anti-GR (M-20)
rabbit primary antibody (Autogen BioClear UK, Calne, Wiltshire,
UK), and probed with a 1:4000 dilution of donkey anti-rabbit IgG
horseradish peroxidase conjugate (Amersham Life Sciences) under
the same conditions. Visualisation and processing of the blots was by
enhanced chemiluminescence (ECL) essentially as described by the
manufacturer.
Luciferase reporter assay
HEK 293 cells transiently transfected with the MMTV-LTR
luciferase reporter construct were used 24–72 h post-transfection.
Cells were treated with varying concentrations of the synthetic
glucocorticoid agonist dexamethasone or vehicle (DMSO) for 2 h at
37 °C. Cells were quickly washed in phosphate buffered saline, lysed
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by the addition of 0.4 ml lysis buffer mix (25 mM Tris-phosphate, pH
7.8, 2 mM DTT, 1 % Triton X-100 and 10 % glycerol, containing
1.25 mg ml_1 lysozyme and 2.5 mg ml_1 BSA) scraped and briefly
centrifuged at 12 000 g. Duplicate (20 µl) aliquots of the resulting
supernatants were assayed for luciferase activity using Promega
luciferase assay reagent (Promega, Madison, WI, USA) and emitted
light detected with a LKB (Wallac) 1250 luminometer. Light
emission was averaged over 10 s with a 2 s delay after substrate
addition to allow the signal to stabilise. All values were calculated as
a percentage of maximum light production with cells treated with
1000 nM of dexamethasone as 100 % after background (vehicle alone)
subtraction. The apparent KD was calculated according to the
equation:
Y = Ymax/(1 + ([DEX]/KD)
h),
where Y is luciferase activity at a given dexamethasone
concentration [DEX], Ymax is maximal luciferase activity, [DEX] is
concentration of dexamethasone and h is the Hill coefficient.
Patch clamp electrophysiology
All experiments were performed in the inside-out configuration of
the patch clamp technique at room temperature (20–24 °C) using
physiological potassium gradients essentially as described previously
(Clark et al. 1999; Shipston et al. 1999; Tian et al. 2001). The pipette
solution (extracellular) contained (mM): 140 NaCl, 5 KCl, 0.1 CaCl2, 2
MgCl2, 20 glucose, 10 Hepes, pH 7.4. The bath solution (intracellular)
contained (mM): 140 KCl, 5 NaCl, 2 MgCl2, 1 or 5 BAPTA, 30 glucose,
10 Hepes, 1 mM ATP, pH 7.3 with free calcium ([Ca2+]i) buffered to
0.2 µM, unless indicated otherwise. Data acquisition and voltage
protocols were controlled by an Axopatch 200A or -B amplifier and
pCLAMP 6 software (Axon Instruments, Foster City, USA). All
recordings were sampled at 10 kHz and filtered at 2 kHz. Following
patch excision, channel activity was allowed to stabilise for at least
10 min (typically 10–15 min after excision) and stability plot
experiments demonstrated that BK channel activity was stable for
> 1 h under the recording conditions used (data not shown) in the
absence of channel modulators. Application of cAMP or other
reagents to the intracellular face of patches was by gravity-driven
perfusion (10 volumes of the recording bath solution (bath volume,
0.5 ml) at a flow rate of 1–2 ml min_1) or direct application to the
bath. In all experiments, 1 mM cAMP was used to activate
endogenous PKA; similar results were also observed using 0.1 mM
cAMP (not shown). Patches were held at 0 mV and channel activity
was determined during voltage steps to +40 mV. To determine mean
percentage change in channel activity after a treatment, in patches
with low to moderate levels of channel expression, mean NPo (number
of functional channels w open probability of channel) was averaged
from 60 s of recording at +40 mV immediately before and 10 min
after the respective drug treatment. Mean change in activity was
expressed as a percentage of the pre-treatment control ± S.E.M. with
analysis undertaken using pCLAMP 6 and IGOR Pro 3.1
(Wavemetrics, Lake Oswego, OR, USA). In the respective figure
legends and text a positive percentage change in activity reflects
activation whereas a negative percentage change reflects channel
inhibition. 
The single channel slope conductance and half-maximal voltage for
activation (V0.5) for each construct under the recording conditions
detailed above (except that the assays were performed in the absence
of ATP) were as follows: STREX, 126.3 ± 4.1 pS, 26.8 ± 4.2 mV,
n = 4; ZERO, 138.0 ± 5.1 pS, 76.1 ± 5.2 mV, n = 4; STREX-S869A,
125.2 ± 3.2 pS, 38.1 ± 7.3 mV, n = 5; S4STREXA, 124.9 ± 3.7 pS,
32.7 ± 6.5 mV, n = 4. 
Chemicals and materials
ATP magnesium salt, adenosine 5ﬁ-O-(3-thiotriphosphate) (ATPyS)
tetralithium salt, adenosine 3ﬁ,5ﬁ-cyclic monophosphate (cAMP),
dexamethasone, puromycin and 5,6-dichloro-1-b-D-ribofluranosyl-
benzimidazole (DRB) were all purchased from Sigma/Aldrich (Poole,
UK). Nucleotides were stored as buffered 1 M or 0.1 M stock solutions
at _20 °C prior to use. Dexamethasone was stored at _20 °C at 10 mM
in Me2SO. Purified protein phosphatase 2A catalytic subunit was
from Promega. Okadaic acid was from LC Laboratories (Alexis
Laboratories, Nottingham, UK). The specific protein kinase A
inhibitor peptide (PKI5–24) and protein phosphatase 1 inhibitor
(PPI-2) were from Calbiochem-Novabiochem (Nottingham, UK).
Polyvinylidene difluoride membranes and reagents for SDS-
polyacrylamide gel electrophoresis and Western blotting were from
Bio-Rad Laboratories (Hemel Hempstead, UK). All other reagents
were from Sigma or BDH-Merck (Poole, UK). 
Statistical analysis
Data are expressed as means ± S.E.M unless otherwise stated.
Statistical significance was defined at P < 0.05 using a non-para-
metric Kruskal–Wallis or Mann–Whitney U test as appropriate.
RESULTS
HEK 293 cells express functional glucocorticoid
receptors
In whole cell lysates of HEK 293 cells, Western blot
analysis, using a rabbit polyclonal antibody that recognises
both the GRa and GRb isoforms (Hollenberg et al. 1985;
Bamberger et al. 1995), revealed specific immunoreactivity
at a molecular mass consistent with that for the GR
isoforms (~95 kDa, Fig. 1A). No immunoreactivity was
observed in the absence of primary antibody (not shown)
and similar immunoreactive bands were present in whole
cell lysates from mouse anterior pituitary AtT20 D16:16
corticotrophs, a cell line that expresses functional GR at a
high level (Woods et al. 1992).
To examine whether HEK 293 cells contain functional
GRa receptors, the mouse mammary tumour virus long
terminal repeat (MMTV-LTR)–luciferase reporter
plasmid, which responds to activated GR by enhancing
luciferase expression (Leckie et al. 1995), was transiently
transfected into the cells. Indeed, in this system DEX
produced a concentration-dependent stimulation of
luciferase activity with a KD of 4.5 ± 3.6 nM with
maximal activity at 100 nM.
Dexamethasone pre-treatment blocks PKA-mediated
inhibition of STREX BK channels
In inside-out patches from HEK 293 cells expressing
cloned BK channel splice variants, single BK channel
events were characterised by their unitary slope
conductance and sensitivity to voltage and calcium as
previously described (data not shown; Shipston et al.
1999). Pre-treatment of cells with a maximally effective
concentration (0.1–1 µM) of the synthetic glucocorticoid
agonist dexamethasone (Woods et al. 1992; Shipston et al.
1996) had no significant effects on intrinsic BK channel
properties. 
Application of cAMP (0.1–1 mM) to the intracellular face
of isolated inside-out patches from HEK 293 cells
expressing STREX or the site directed mutant STREX-
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S869A in the presence of 1 mM Mg-ATP and 0.2 µM [Ca2+]i
resulted in a significant inhibition of BK channel activity
(expressed as the percentage change of pre-treatment BK
channel activity: for STREX, _57.5 ± 8.7 %, n = 13,
P < 0.01; for STREX-S869A, _58.1 ± 12.6 %, n = 11,
P < 0.01; determined 10 min after cAMP application
compared with pre-treatment BK channel activity,
Fig. 2A and B). As the effect of cAMP was identical in
STREX and STREX-S869A channels, further analysis
was largely carried out on STREX-S869A channels with
results identical to those in STREX channels (not shown).
The cAMP inhibition was dependent upon protein kinase
A associated with the channels as the specific protein
kinase A inhibitor peptide PKI5–24 blocked the inhibitory
effect of cAMP (the change was _2.2 ± 7.8 %, P < 0.01,
compared to _58.1 ± 12.6 % with cAMP alone, Fig. 2B).
In parallel experiments, pre-treatment of HEK 293 cells
with maximally effective concentrations of dexa-
methasone (0.1–1 µM for 2 h) abolished the inhibitory
action of cAMP in excised inside-out patches containing
STREX or STREX-S869A channels compared to the
inhibition observed in patches from control cells (Fig. 2B).
The percentage change in BK channel activity was
0.24 ± 7.7 % in DEX-treated cells (n = 11). 
Dexamethasone action is dependent upon de novo
mRNA and protein synthesis
Early (within 2 h) glucocorticoid action on BK channel
regulation and hormone secretion in corticotrophs is
dependent upon activation of intracellular GR and
induction of new mRNA and protein synthesis (Woods et
al. 1992; Shipston, 1995; Shipston et al. 1996). To address
whether such a genomic mechanism is responsible for the
action of dexamethasone, HEK 293 cells were pre-treated
with inhibitors of mRNA transcription (5,6-dichloro-1-b-
D-ribofluranosylbenzimidazole (DRB), 50 nM, 15 min
before and during DEX treatment) or protein translation
(puromycin, 100 µM (Woods et al. 1992; Tian et al. 1999),
20 min before and during DEX treatment). Treatment of
HEK 293 cells expressing STREX-S869A channels with
either DRB or puromycin prior to and during exposure to
dexamethasone blocked the action of dexamethasone,
i.e. cAMP-mediated inhibition of BK channel activity
returned to near control (non-dexamethasone-treated)
levels (Fig. 2A and B). The cAMP-mediated percentage
inhibition of BK channel activity in DRB and puromycin
pre-treated cells was _39.8 ± 11.4 % (P < 0.01, n = 3)
and _39.7 ± 2.0 % (P < 0.01, n = 4), respectively. These
data suggest that dexamethasone attenuates PKA-
mediated inhibition of BK channel activity via a genomic
mechanism. Dexamethasone had no effect on BK channel
transcript or protein expression levels as determined by
RT-PCR and Western blotting, respectively, over the
time course (2 h) of these studies (not shown).
Glucocorticoid action is mediated via protein
phosphatase activity intimately associated with the
channel complex
Using ATPyS as the phosphate donor in place of ATP in
excised inside-out patches from dexamethasone-treated
STREX-S869A cells restored cAMP-mediated inhibition
of BK channel activity to almost the same extent as that
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Figure 1. HEK 293 cells express functional glucocorticoid receptors
A, whole cell lysates (10 µg protein from AtT20 cells as positive control and 50 µg from HEK 293 cells)
were separated by SDS-PAGE and transferred to PVDF membranes. Blots were probed as described in
methods with an anti-GR (M20) rabbit primary antibody that recognises both GRa and GRb isoforms
with detection by ECL; ~95 kDa immunoreactive bands were detectable in both AtT20 and HEK 293 cell
lysates. B, functional assay of glucocorticoid receptor activation in HEK 293 cells using a MMTV-
luciferase reporter assay. HEK 293 cells were transiently transfected with 1 µg of MMTV-luc plasmid (1)
or pcDNA3 vector alone (0) and treated for 2 h with various concentrations of the synthetic
glucocorticoid receptor agonist dexamethasone or vehicle before assay for luciferase activity as described
in Methods. Data are expressed as a percentage of maximal (with 1 µM dexamethasone) luciferase activity
after vehicle background subtraction. Each data point represents the mean ± S.E.M (n = 4–8).
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Figure 2. Dexamethasone blocks PKA-mediated inhibition of STREX BK channels via a genomic
mechanism
A, representative single channel traces from isolated inside-out patches from vehicle, dexamethasone  and
dexamethasone + DRB pre-treated HEK 293 cells expressing STREX-S869A channels before and 10 min
after application of 1 mM cAMP to the intracellular face of the patch. Patches containing a single STREX
BK channel were exposed to 0.2 µM [Ca2+]i and 1 mM ATP in physiological potassium gradients and
depolarised to +40 mV as described in Methods. B, representative time course of the effect cAMP on BK
channel activity in patches from vehicle-treated (Vehicle, 0) and dexamethasone-treated (DEX, 1) cells.
Activity is expressed as a percentage of the activity at time _10 min before cAMP application and
averaged over 1 min for each data point. The open horizontal bar indicates the period of cAMP
application. C, summary of the effect of cAMP application to the intracellular face of patches from
STREX-S869A-expressing HEK 293 cells pre-treated for 2 h with vehicle (n = 11) or 1 µM dexametha-
sone (n = 11) prior to patch excision. Inhibitors of transcription (DRB, 0.1 mM, n = 4) and translation
(puromycin, 0.1 mM, n = 4) were applied 15 min before and during dexamethasone treatment of intact
HEK 293 cells. The specific PKA inhibitor peptide PKI5–24 (n = 4) was applied to the intracellular face of
inside-out patches 5 min before application of cAMP. All data are expressed as the percentage change of
pre-treatment BK channel activity measured at +40 mV in the presence of 0.2 µM [Ca2+]i and 1 mM ATP
as described in Methods. The bars show means and S.E.M. ** P < 0.01 compared with vehicle-treated cAMP
group.
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observed in control cells (percentage change of BK
channel activity: _33.9 ± 5.2 %, n = 5, Fig. 3B). This
effect required PKA activity as it was abolished by
PKI5–24 (not shown). ATPyS can be used by protein
kinases to phosphorylate target proteins. However, thio-
phosphorylated amino acid residues are largely resistant
to dephosphorylation by protein phosphatases. Thus
these data suggest a closely associated protein
phosphatase is responsible for the attenuation of PKA-
mediated inhibition of BK channel activity in isolated
patches from dexamethasone-treated STREX-S869A
cells. Identical results were obtained using the STREX
channel under the same experimental conditions (n = 3,
data not shown). 
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Figure 3. Glucocorticoid action is mediated via protein phosphatase activity associated with the
patch
A, representative single channel traces from isolated inside-out patches from a vehicle-treated cell with
patch exposed to exogenous PP2A (left) and a dexamethasone pre-treated cell with patch exposed to 10 nM
okadaic acid before (control) and after (cAMP) application of cAMP to the intracellular face of the patch.
Patches containing STREX-S869A BK channels were exposed to 0.2 µM [Ca2+]i and 1 mM ATP in
physiological potassium gradients and depolarised to +40 mV as described in Methods. B, summary of the
effect of manipulating serine/threonine protein phosphatase activity in isolated inside-out patches.
Vehicle: effect of 1 mM cAMP on BK channel activity in the absence (n = 11) and presence (PP2A, n = 4)
of exogenous catalytic subunit of PP2A (1 unit ml_1) applied to the intracellular face of isolated patches
from vehicle-treated HEK 293 cells expressing STREX-S869A channels. DEX: effect of 1 mM cAMP on
STREX-S869A channel activity in the presence of ATP (n = 11) or ATPyS (0.1 mM, n = 5) as phosphate
donor or on co-application with the serine/threonine phosphatase inhibitor, okadaic acid (Ok, 10–100 nM,
n = 5) or the specific protein phosphatase 1 (PP1) inhibitor peptide (PPI-2, 20 nM) in the presence of ATP.
The PKA inhibitor peptide PKI5–24 (0.45 µM) blocked the effects of cAMP in the presence of okadaic acid
(n = 6). All data are expressed as the percentage change of pre-treatment BK channel activity measured
at +40 mV in the presence of 0.2 µM [Ca2+]i and 1 mM ATP as described in Methods. The bars show means
and S.E.M. ** P < 0.01 compared with vehicle-treated cAMP group.
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In the presence of 10–100 nM okadaic acid, a blocker of
serine/threonine phosphatases, cAMP significantly
inhibited BK channel activity in isolated patches from
dexamethasone-treated HEK 293 cells expressing STREX-
S869A channels (Fig. 3A and B). The percentage change
of BK channel activity in the presence of okadaic acid
was _37.3 ± 12.9 % (n = 5), similar to that seen in control
(non-dexamethasone-treated cells). Importantly, the
effect of cAMP was blocked by PKI5–24 (Fig. 3B). The
percentage change of BK channel activity in the presence
of okadaic acid and PKI5–24 was _6.1 ± 12.6 % (P < 0.01,
n = 6). In contrast, application of a specific peptide
inhibitor of protein phosphatase 1 (PP1), PPI-2 (20 nM),
failed to restore cAMP-mediated inhibition of BK
channels in patches from dexamethasone-treated HEK
293 cells expressing STREX-S869A channels (percentage
change of BK channel activity after cAMP application in
the presence of PPI-2 was 3.8 ± 7.8 %, n = 5, Fig. 3B).
The PPI-2 was functionally active in other electro-
physiological and biochemical assays of PP1 action (not
shown). Thus the action of glucocorticoids on BK channel
function does not involve PP1 activity and is likely to be
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Figure 4. The ZERO variant is not regulated by glucocorticoids
A, representative single channel traces from isolated inside-out patches from dexamethasone pre-treated
HEK 293 cells expressing ZERO variant channels before and 10 min after application of 1 mM cAMP to
the intracellular face of the patch. Patches containing ZERO channels were exposed to 0.2 µM [Ca2+]i and
1 mM ATP in physiological potassium gradients and depolarised to +40 mV as described in Methods.
B, representative time course of ZERO channel activity from vehicle-treated cells in the presence
(+cAMP, •) or absence (_cAMP, ª) of cAMP. Activity is expressed as a percentage of the activity at time
_10 min before cAMP application and averaged over 1 min for each data point. Open horizontal bar
indicates the period of cAMP application for the +cAMP patch. C, summary of the effect of cAMP
application to the intracellular face of patches from ZERO-expressing HEK 293 cells pre-treated for 2 h
with vehicle (n = 8) or 1 µM dexamethasone (n = 8) prior to patch excision. The specific PKA inhibitor
peptide PKI5–24 was applied to the intracellular face of inside-out patches 5 min before application of
cAMP in vehicle (n = 4) or dexamethasone-treated (n = 6) cells. All data are expressed as the percentage
change of pre-treatment BK channel activity measured at +40 mV in the presence of 0.2 µM [Ca2+]i and
1 mM ATP as described in Methods. The bars show means and S.E.M. ** P < 0.01 compared with vehicle-
treated cAMP group.
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mediated via PP2A-like phosphatase activity associated
with the channel. 
To test this hypothesis the purified catalytic subunit of
PP2A was applied to the intracellular face of patches
containing STREX-S869A channels from vehicle-treated
HEK 293 cells. In the presence of 1 U ml_1 PP2A, cAMP
failed to inhibit BK channel activity (Fig. 3A and B): the
percentage change of BK channel activity 10 min after
application of cAMP in the presence of PP2A was
15.3 ± 15.0 % (P < 0.01, n = 4).
Overall, these results suggest that the glucocorticoid
blockade of PKA-mediated inhibition of BK channel
activity is mediated via a PP2A-like phosphatase closely
associated with the STREX variant channel complex.
ZERO channels are stimulated by PKA and are not
modulated by dexamethasone
Application of cAMP (1 mM) to the intracellular face of
isolated inside-out patches from vehicle-treated HEK
293 cells expressing ZERO BK channels (identical to
STREX except they lack the STREX insert) results in
significant stimulation of ZERO BK channel activity
(Fig. 4A and B (see also Nara et al. 1998; Tian et al. 2001);
the mean percentage activation was 43.0 ± 10.0 %, n = 8,
P < 0.01). This stimulation is entirely dependent upon
activation of PKA associated with the patch as the
protein kinase A-specific inhibitor peptide, PKI5–24,
prevents channel activation (the mean percentage change
in activity after cAMP in the presence of PKI5–24 was
_9.3 ± 8.2 %, n = 6). 
In direct contrast to the effect of dexamethasone on
PKA-mediated regulation of BK channels containing the
STREX insert, dexamethasone pre-treatment did not
significantly modify PKA-mediated stimulation of
ZERO BK channels. The percentage change of BK
channel activity 10 min after cAMP application to the
intracellular face of patches from dexamethasone-treated
HEK 293 cells expressing ZERO channels was 49.8 ±
13.0 %, n = 8 (Fig. 4B). Importantly, this activation was
dependent upon PKA activation as the specific protein
kinase A inhibitor peptide (PKI5–24, Fig. 4B) blocked
activation by cAMP (mean percentage change in activity
was 3.6 ± 4.8 %, n = 4). 
S4 STREX domain confers glucocorticoid sensitivity to
ZERO channels
To examine whether the lack of glucocorticoid regulation
of ZERO channels is a result of the absence of the STREX
insert per se or a consequence of ZERO channels being
activated by PKA (dependent upon a functional S869;
Nara et al. 1998; Tian et al. 2001) compared to the
inhibition observed with channels containing the STREX
insert, we examined the glucocorticoid regulation of the
site directed mutant channel S4STREXA. This construct is
identical to STREX channels except that the serine
residue (S4STREX) within a PKA consensus site of the
STREX insert (required for PKA-inhibition; Tian et al.
2001) is mutated to alanine. This channel is activated by
PKA as for ZERO and this activation is dependent upon
a functional S869 residue within the C-terminal
consensus PKA site (Fig. 5; see also Tian et al. 2001).
S4STREXA channel activity was stimulated to the same
extent as ZERO channels (by 45.9 ± 8.9 %, P < 0.01,
n = 8) upon cAMP application to the intracellular face of
the channel and this effect was abolished by PKI5–24
(mean percentage change in activity was _0.9 ± 11.9 %,
n = 4, P < 0.01). 
However, in contrast to ZERO channels, dexamethasone
pre-treatment abolished PKA-mediated activation of
S4STREXA channels. The percentage change in BK channel
activity after cAMP application to patches from
dexamethasone-treated S4STREXA was _6.8 ± 8.6 % (n = 8,
P < 0.01, Fig. 5). Importantly, PKA-mediated activation
of S4STREXA channels could be restored in patches from
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Figure 5. S4STREXA is activated by PKA and is
modulated by DEX
Summary of the effect of cAMP application to the
intracellular face of patches from HEK 293 cells
expressing S4STREXA channels pre-treated for 2 h with
vehicle (n = 8) or 1 µM, dexamethasone (n = 8) prior to
patch excision. The specific PKA inhibitor peptide PKI5–24
was applied to the intracellular face of inside-out patches
5 min before application of cAMP in vehicle (n = 4) or
dexamethasone-treated (n = 4) cells. ATPyS, in the
presence (n = 4) or absence (n = 6) of PKI5–24, and okadaic
acid (Ok, 2 nM) (n = 3) were applied as in Fig. 3. All data
are expressed as the percentage change of pre-treatment
BK channel activity measured at +40 mV in the presence
of 0.2 µM [Ca2+]i and 1 mM ATP as described in Methods.
The bars show means and S.E.M. ** P < 0.01 compared
with vehicle-treated cAMP group.
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Figure 6. STREX is required for glucocorticoid regulation of BK channels
A, schematic illustrating that BK channels containing the STREX insert are targets for both protein
kinase A (PKA) and glucocorticoid signalling pathways. PKA closely associated with membrane patches
is activated by cyclic 3ﬁ,5ﬁ-adenosine monophosphate (cAMP). Steroids, such as the synthetic
glucocorticoid dexamethasone, activate intracellular glucocorticoid receptors (GR) to regulate gene
transcription. GR induced de novo synthesis of unidentified (X) proteins that block PKA-dependent
regulation of STREX-containing channels through modification of protein phosphatase 2A-like (PPase)
activity closely associated with the membrane patch in dexamethasone-treated cells. B, schematic
summarising the effect of PKA and glucocorticoids on the different BK channel splice variant constructs
used in this study. The effect of PKA is indicated by activation (up arrow) or inhibition (down arrow) of
channel activity. The ability of dexamethasone to block the PKA-induced regulation of BK channel
activity is indicated. The STREX insert is essential for glucocorticoid-mediated regulation of BK channel
activity irrespective of the functional effect of PKA on channel activity (activation or inhibition) for the
different constructs. Serine residues essential for PKA-mediated activation of channel activity
(conserved S869 in C-terminal tail of channel) and PKA-mediated inhibition (S4 in the STREX insert) are
indicated.
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dexamethasone-treated HEK 293 cells when ATPyS was
used as the phosphate donor (mean percentage PKA
activation of BK channel activity was 60.9 ± 14.9 %,
n = 6, Fig. 5) and this cAMP-dependent stimulation was
blocked by PKI5–24 (mean percentage PKA activation of
BK channel activity was 3.9 ± 5.3 %, n = 4, P < 0.01
Fig. 5). This suggested protein phosphatase activity is
required for the action of glucocorticoid. Indeed,
inhibition of PP2A-like activity with 2 nM okadaic acid,
but not PP1 activity when inhibited by PPI-2 (Fig. 5),
prevented the glucocorticoid block of S4STREXA channel
regulation by PKA (mean percentage PKA activation of
BK channel activity in the presence of okadaic acid was
30.7 ± 3.1 %, n = 3, Fig. 5).
DISCUSSION
We have established in HEK 293 cells a model for the
analysis of the modulation of ion channels by
glucocorticoids. In this system, novel proteins rapidly
induced by dexamethasone differentially modulate the
regulation of BK channels by PKA. The presence of the
59 amino acid STREX insert at splice site 2 of the BK
channel a-subunit is sufficient for modulation by gluco-
corticoid-induced proteins through a serine/threonine
protein phosphatase, irrespective of the direction of the
PKA effect on the channel (Fig. 6). 
Glucocorticoids differentially modulate the activity
of BK channel splice variants 
In order to address whether the pore-forming subunits of
BK channels are the targets for glucocorticoids, the
regulation of cloned BK channel splice variants was
analysed in HEK 293 cells as a heterologous mammalian
expression system. HEK 293 cells do not endogenously
express BK channel subunits and show the pivotal
features of the glucocorticoid response previously
reported in anterior pituitary corticotroph cells and CA1
pyramidal neurones (Joels & de Kloet, 1989; Shipston et
al. 1996). Thus HEK 293 cells are a suitable model for the
analysis of glucocorticoid regulation of BK, and possibly
other, ion channels.
BK channels that express the wild-type STREX insert at
site 2 (STREX and the site directed mutant STREX-
S869A) are potently inhibited by cAMP-dependent
protein kinase (PKA) activity intimately associated with
the channel complex in HEK 293 cells (Shipston et al.
1999; Tian et al. 2001). This inhibition requires a PKA
consensus site in the STREX insert (S4) but is not
dependent upon the conserved PKA site at serine residue
869 of the C-terminus (Tian et al. 2001). Glucocorticoid
pre-treatment blocked the PKA-mediated inhibition of
STREX, or STREX-S869A, BK channels expressed in
HEK 293 cells. Glucocorticoid action was manifest within
2 h of exposure, was dependent upon de novo mRNA and
protein synthesis and was mediated by okadaic acid-
sensitive (PP2A-like) protein phosphatase activity
intimately associated with the channel.
However, glucocorticoid regulation was not evident in
the ZERO BK channel splice variant that does not
contain the STREX insert. ZERO channels are activated
by PKA, dependent upon a functional conserved C-
terminal PKA consensus phosphorylation site serine
residue, S869 (Nara et al. 1998; Tian et al. 2001). The
difference in responsiveness of the STREX and ZERO
variants to glucocorticoids could be a reflection of the
opposite action of PKA on these channels. To address this
issue, we used a STREX site directed mutant (S4STREXA)
that lacks the STREX PKA consensus site but retains a
functional C-terminal site S869. S4STREXA is activated by
PKA and this activation was blocked by glucocorticoids,
which indicates that the STREX domain confers gluco-
corticoid modulation. The exact mode of the STREX-
dependent modulation remains to be clarified.
Evidence for short- and long-term regulation of
cellular excitability through glucocorticoid
modulation of BK channels
Previous studies have shown that endogenously expressed
BK channels from a variety of tissues may be activated or
inhibited by PKA-dependent phosphorylation (Reinhart
et al. 1991, 1995; White et al. 1991) and that the direction
of this regulation is influenced by circulating hormones
such as adrenal corticosteroids (Perez & Toro, 1994;
Shipston et al. 1996; Zhou et al. 2000). The diversity and
plasticity of modulation is, at least in part, a result of the
opposing effects of PKA phosphorylation on distinct BK
channel splice variants. Yet a further level of control is
the ability of proteins rapidly induced by glucocorticoids
to switch the functional outcome of PKA activation
targeted to BK channels. Importantly, STREX subunits
are widely expressed in glucocorticoid-sensitive endocrine
cells and neurones (Tseng-Crank et al. 1994; Ferrer et al.
1996; Xie & McCobb, 1998; Shipston et al. 1999) where
cAMP signalling is pivotal for functional activity. Thus
glucocorticoid modulation of the phosphorylation of BK
channels could provide a short-term switch of cellular
excitability in these systems.
In a longer time domain (> 6 h) the regulation of the
expression of STREX variant subunits, along with other
BK channel splice variants, could also contribute to the
specification of the control of cellular excitability.
Indeed, the expression of STREX channels is regulated
by stress hormones in adrenal medullary chromaffin cells
(Xie & McCobb, 1998) and by depolarisation in GH3
pituitary tumour cells (Xie & Black, 2001), and the
STREX mRNA profile changes during pregnancy in
adult myometrium (Benkusky et al. 2000). Although the
impact of STREX a-subunit expression on hetero-
multimeric BK channel properties has not been explored,
previous evidence suggests that the resultant channel
properties would reflect the functional characteristics of
the STREX subunit (Shen et al. 1994; Lovell & McCobb,
2001). 
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Abstract The molecular and cellular basis of the psy-
chotropic actions of adrenal corticosteroids is poorly
understood. Previously, we reported that modulation of
large conductance Ca2+-activated potassium channel (BK-
channel) function by glucocorticoids can be recapitulated
in human embryonic kidney293 (HEK293) cells (J Physiol
537:57, 2001). In the present paper, we examined the effect
of dexamethasone on the expression of candidate mediator
proteins of glucocorticoid action, dex-ras1 and serum and
glucocorticoid inducible protein kinase 1 (SGK), in
HEK293 cells. Dex-ras1 mRNA was readily detectable
under basal conditions however, no changes of dex-ras1
mRNA expression occurred upon exposure to 100 nM of
dexamethasone for 2 h. In contrast, a 2.5-fold increase of
SGK mRNA was found under similar conditions. Total
levels of cellular SGK protein were unaltered upon expo-
sure to dexamethasone, but a marked increase of SGK in a
Triton-X100 insoluble fraction was observed. BK-channel
a-subunits could not be co-immunoprecipitated with SGK.
In summary, SGK, but not dex-ras1, mRNA is rapidly
induced by glucocorticoid stimulation in HEK293 cells.
However, there appears to be no direct protein-protein
interaction between SGK and BK-channel a-subunits.
Introduction
Adrenal corticosteroids have been implicated in the pat-
hoetiology of mood disorders for a long time cf. [1, 2]. An
important facet of corticosteroid action on the brain that
appears relevant for disorders of mood is the feedback inhi-
bition of the neuroendocrine stress axis [3]. Despite the
established physiological significance of corticosteroid
modulation of neuronal function, precious little is known
about the cellular and molecular actions of corticosteroids in
the brain [4, 5]. The vast majority of neurons and glial cells
are equipped with nuclear receptors for corticosteroids.
However, the steps beyond receptor activation and the bio-
logical outcomes are poorly characterised. With respect to
the neuroendocrine feedback action of corticosteroids,
pyramidal cells in the CA1 region of the hippocampus and
anterior pituitary corticotroph cells have been analysed in
some detail [4, 5]. Overall, these studies provide a conver-
gent picture indicating that corticosteroids influence the
membrane potential by modifying Ca2+-activated K+ cur-
rents. Furthermore, there is broad agreement that rapid
induction of gene transcription and protein synthesis via
Type II glucocorticoid receptors is required for this effect of
corticosteroids. However, the mechanisms beyond Type II
receptor activation remain to be resolved. In the murine
corticotroph tumour cell line AtT20, cAMP-mediated regu-
lation of BK channels is modified by glucocorticoid induced
proteins [6, 7], which is essential for the inhibition of corti-
cotrophin releasing-factor stimulated hormone secretion [6].
The modulation of BK-channel function by glucocorticoids
can be fully recapitulated in HEK293 cells transfected with
the STREX variant a-subunit of BK-channels [8] suggesting
that the complement of glucocorticoid induced genes is
similar in AtT20 and HEK293 cells. A candidate mediator of
glucocorticoid action in AtT20 cells is the Ras related protein
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dex-ras1 [9, 10]. The mRNA for dex-ras1 is rapidly induced
by dexamethasone in AtT20 cells, furthermore overexpres-
sion of dex-ras1 inhibited cAMP induced secretion of a
reporter hormone in this system [11]. In the present study we
examined whether or not dex-ras1 was a glucocorticoid
regulated gene in HEK293 cells and thus a potential candi-
date for the modulation of BK channel function in this
system.
Materials and methods
Cell culture
Wild type HEK293 cells and HEK293 cells stably over-
expressing the STREX variant of the BK-channel a-subunit
[8] were maintained as previously described. Transient
transfections were carried out using Lipofectamine 2000
(Invitrogen, Paisley, U.K.) as per the manufacturer’s
instructions.
Treatment with dexamethasone and luciferase reporter
gene assays
In order to minimize the effect of steroids contained in
serum, the cells were maintained in DMEM supplemented
with insulin, transferrin and selenium, (19 ITS, Sigma, cat
no13146) for 24 h in a humidified incubator containing 5%
CO2 at 37C. Prior to experimental manipulation the cells
were incubated with DMEM supplemented with 25 mM
HEPES pH 7.4 and 0.25% w/v bovine serum albumin
(DMEM–BSA) for 2 h at 37C and then treated with
dexamethasone or vehicle (0.001% DMSO) in DMEM–
BSA at 37C for the time indicated in the respective figure
legends. Reporter gene assays were carried out on wild
type HEK293 cells transiently transfected with a mouse
mammary tumor virus long terminal repeat luciferase
reporter construct (MMTV-Luc) [12] as previously
described [8].
RT-PCR and Northern analysis of mRNA RT-PCR was
carried out as previously described [13]. For Northern
analysis, 20 lg of total RNA prepared by extraction with
Trizol (Invitrogen, Paisley, UK) was electrophoresed under
denaturing conditions and transferred to nylon membranes
(Hybond-N, GE Life Sciences, Aylesbury, UK). The
probes used for hybridization were a 207 bp fragment of
human dex-ras1 (nucleotide 639–846, NCBI accession
number AF172846), a 238 bp (nucleotide 108–346, NCBI
accession number: CAA71138) fragment of human SGK1
and a 170 bp (nucleotides 295–465) fragment of cyclo-
philin A produced by RT-PCR from HEK293 cell mRNA
and labelled with Ready To-Go beads and a 32P-dCTP (GE
Life Sciences, Aylesbury, UK) as per the manufacturer’s
instructions.
The transferred membranes were incubated at 55C with
hybridization buffer for 1.5 h in a sealed plastic box and
then the membranes were incubated with denatured-probes
(incubation of labelled probes at 60C for 10 min) in
hybridization buffer at 55C for 16 h. Autoradiography
was by exposure on a Cyclone storage phosphor screen,
(Canberra-Packard,Pangbourne, U.K.) for 0.5–1 days.
Radioactive bands were outlined and the optical density
(O.D) in each band was determined by the OptiQuant
(Canberra-Packard, Pangbourne, U.K.) image analysis
software.
Analysis of SGK protein levels
Cells in 75 cm2 flasks at 80–90% confluence were washed
3 times with cold phosphate buffered saline (PBS) and
scraped into 0.5 ml of 150 mM NaCl, 50 mM Tris–HCl,
pH 7.4, 1% (v/v) Triton X-100 (Triton lysis buffer) sup-
plemented with 1/100 of protease inhibitor cocktail (P 8340
Sigma, Poole, Dorset, U.K.). The cells were sonicated on
ice with five sonication cycles, each consisting of 10 s
pulses at 10 s intervals with an ultrasonic Cole-Parmer
sonicator (TORBEO, 36800) at setting 3. Subsequently, the
lysate was centrifuged at 1000g for 5 min at 4C to pellet
large cell debri. The resultant supernatant was the total
lysate, which was spun at 20,000g for 30 min at 4C to
obtain the Triton insoluble and soluble fractions, respec-
tively. Aliquots of the lysate and the fractions were
analysed in SDS-PAGE followed by transblotting to PVDF
membranes and ECL based detection of SGK immunore-
active bands using anti-SGK1 rabbit antibodies (Upstate
Biologicals, Dundee, U.K.). Cyclophilin A staining was
performed after membrane stripping (50C for 30 min 2%
w/v SDS, 100 mM mercaptoethanol, 62.5 mM Tris, pH
6.7, followed by 3 washes in PBS/0.3% Tween 20) to
correct for sample loading in total lysates as well as the
Triton soluble fractions. The blots of the insoluble fraction
were initially stained with Coomassie blue and photo-
graphed. Subsequently, the dye was removed and the blots
were reacted for SGK. A prominent Coomassie Blue
stained band was chosen to standardize for gel loading in
these samples. Densitometry was carried out using Opti-
Quant Image analysis software (Packard Bioscience,
Pangbourne, Berkshire, UK).
Immunoprecipitation of BK channels
Total cell lysates adjusted to 2.5 mg protein in 500 ll
were pre-cleared by incubation with 10 ll of 50% (v/v)
610 Neurochem Res (2008) 33:609–613
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washed protein-G-sepharose (Sigma p3296) in 1% Triton
X-100 lysis buffer and agitated for 1 h at 4C, and the
beads were removed by brief centrifugation, Subse-
quently, 5 ll each of antisera raised in sheep against
residues 628–641 and 919–933, respectively, of the
STREX variant of the mouse BK channel a-subunit were
added to the pre-cleared cell lysates and incubated over-
night at 4C under gentle agitation. Subsequently, 16.6 ll
of 50% Protein-G Sepharose were added for 2 h at 4C.
The beads were pelleted at 10,000g for 1 min, and pro-
cessed for SDS-PAGE/immunoblotting [14], with primary
antibodies against the HA-tag (Zymed) to detect the BK
channel a-subunit and anti-SGK antibodies to detect SGK,
respectively.
Results
Exposure to dexamethasone produced a time- and con-
centration-dependent increase of MMTV-Luc activity in
transiently transfected wild type HEK293 cells. The time-
dependence (Fig. 1) appeared biphasic with a significant
increase at 30 min, the degree of which only changed at
90 min and plateaued at 2 h. Concentration-dependence
was examined for the 2 h time-point: the maximal response
to was obtained with 100 nM dexamethasone, EC50 was
around 5 nM (not shown). In subsequent experiments
dexamethasone was used at 100 nM in cells stably
expressing the STREX variant a-subunit of the BK-
channel.
A 5 Kbp mRNA species was readily detectable with the
dex-ras1 anti-sense probe in HEK293 cells under ‘resting’
conditions (Fig. 2). The levels of this transcript were
unaltered by 100 nM dexamethasone at all time-points
examined. In contrast, a clear induction of SGK mRNA
was already apparent at 15 min after the application of
dexamethasone (Fig. 3) and persisted up to 120 min.
Despite the increase of SGK mRNA levels, the concen-
tration of SGK protein was not changed in the total
TritonX-100 lysate prepared from dexamethasone treated
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Fig. 1 Time-course of dexamethasone induction of MMTV-Luc
reporter gene in transiently transfected HEK293 cells. Cells incubated
overnight in DMEM supplemented with insulin, selenium and
transferrin were exposed to DMEM alone (DMEM) or 0.001% v/v
dimethylsulfoxide vehicle (DMSO) for 120 min or to 100 nM
dexamethasone for various time periods. Data are expressed as
percentage of the maximal light intensity at 180 min. means ± SEM
n = 3/group, representative of two separate studies with similar
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HEK293 cells stably expressing the STREX variant a-subunit of the
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cells. However, there appeared to be a substantial dexa-
methasone-induced rise of SGK1 immunoreactive material
in a Triton insoluble fraction of the cells (Fig. 4). In order
to probe the possibility that BK-channels are physically
associated with SGK, immunoprecipitates prepared with
anti-BK sera from vehicle and dexamethasone treated cells
were probed for the presence of SGK. No evidence for co-
immunoprecipitation was found (Fig. 5).
Discussion
The present study is in concordance with previous work
([8] and references therein) showing that glucocorticoid
preferring nuclear receptors (GR), are expressed and are
functionally active in HEK293 cells. Activation of
endogenous GR in HEK293 cells triggers a process
dependent on RNA and protein synthesis and results in a
marked change in the control of STREX type BK-channels
by cAMP-dependent protein kinase. As dex-ras1 (also
known as AGS-1) is a potential modulator of cAMP sig-
nalling [15, 16] and its expression is induced by
dexamethasone in AtT20 cells [9], we analysed cellular
dex-ras1 mRNA levels in HEK293 cells. An mRNA
species of the expected sized was readily detectable by
Northern analysis under ‘‘resting’’ conditions which
involved incubation of the cells in serum free medium
containing insulin, transferrin and selenium. There was no
effect of dexamethasone on the levels of dex-ras1 mRNA
in HEK293 cells, while both the MMTV-Luc data as well
as the analysis of SGK mRNA indicated that the steroid
treatment regime was biologically effective. The regulation
of gene expression by glucocorticoids is complex and it is
entirely conceivable that dex-ras1 is glucocorticoid
inducible in a different cellular context [17]. Furthermore,
the lack of an induction by steroids in HEK293 cells does
not exclude the possible involvement of dex-ras1 in glu-
cocorticoid feedback inhibition, as dex-ras1 mRNA was
already abundantly expressed. Other approaches such as
RNA interference could shed light on this issue.
SGK1 has been implicated in the action of aldosterone
in the urinary tract [18]. The subcellular distribution of
SGK protein in cells is controversial, and plausibly cell-
specific [19]. Most reports concur that the bulk of SGK1 is
found in the particulate fraction of cells indicative of pre-
dominant association to membranes [19–21]. Indeed
association of SGK1 to the plasma membrane [20] as well
as mitochondria [21] has been reported. Furthermore, the
cellular levels of the protein appear to be controlled by
polyubiquinylation and proteosomal degradation [20]. In
our hands, application of proteasome inhibitors failed to
alter the lack of an effect of dexamethasone to total cellular
SGK1 protein concentration (data not shown). However, a
significant increase of SGK protein was found in a Tri-
tonX-100 insoluble fraction the nature of which requires
further study—e.g. using markers for the putative lipid raft
fraction of the plasma membrane [22] or mitochondria
[21]. An immunoprecipitation approach failed to provide
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Fig. 4 Selective increase of SGK immunoreactive protein in a
Triton-X100 insoluble fraction upon exposure of HEK293 cells to
dexamethasone. HEK293 cells stably expressing the STREX variant
BK channel a-subunit were exposed to 0.1% DMSO or 100 nM
dexamethasone for 120 min and Triton soluble (Supernatant) and
insoluble (Pellet) fractions were prepared and analysed for SGK
content using SDS-PAGE. Gel loading was standardised by anti
cyclophilin for the soluble fractions and by selecting a prominent
protein band stained by Coomassie Blue in the Triton insoluble
fraction which contained no detectable levels of cyclophilin A
---------------------------
Vehicle Dex 120MWkDa
150
100
75
50
A
Blot: anti-HA
B
Blot: anti-SGK-1
STREX-HA
stable HEK 293
cell extracts
IP with anti-BK
Fig. 5 Lack of co-immunoprecipitation of SGK with the STREX
variant BK channel a-subunit protein. Homogenates of HEK293 cells
stably expressing the STREX variant BK channel a-subunit and
previously exposed to 0.1% DMSO or 100 nM dexamethasone for
120 min were homogenised and solubilised with 1% Triton-X100.
The lysate was used to carry out an immunoprecipitation reaction
with sheep antibodies against the BK-channel a-subunit. The
immunoprecipitate was analysed for the presence of the HA-tagged
BK channel a-subunit as well as for SGK by Western blotting
612 Neurochem Res (2008) 33:609–613
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evidence of a physical interaction between BK channel a-
subunit protein and SGK. However, work on SGK with
respect to sodium transport in kidney cells indicated a
spatial segregation of sodium transport proteins and SGK
[19]. Thus a direct protein–protein interaction between the
kinase and its target may not be required for SGK-mediated
regulation of ion channels and transporter proteins.
In summary, our data raise the possibility that SGK1 is
involved in the control of BK channels expressed in
HEK293 cells whereas dex-ras1 is not a glucocorticoid
responsive gene in this system.
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Abstract
Characterisation of cyclic nucleotide-hydrolysing phosphodiesterases (PDEs) in recombinant systems has highlighted regulatory properties
indicative of distinct physiological roles for these enzymes. The present study investigated the role of PDEs in the adenosine
3050-monophosphate (cAMP) response to the hypothalamic neuropeptides corticotrophin-releasing factor (CRF) and arginine vasopressin
(AVP) in acutely dispersed rat adenohypophysial cells. Ca2 + -activated PDE (PDE1) and Ca2 + -independent, rolipram-sensitive PDE (PDE4)
accounted for close to 90% of cAMP-hydrolysing activity in the adenohypophysis. Messenger RNA transcripts of PDE1 (isotypes 1A and 1C)
and PDE4 (isotypes B and D3) were detected by RT-PCR. The PDE blockers rolipram and IBMX enhanced cAMP accumulation induced by
CRF or CRF and AVP. Vinpocetine, an inhibitor of low Km PDE1 isotypes, did not alter the response to CRF but enhanced the effect of the
combined CRF/AVP stimulus. Thus, PDE4s terminate the cAMP response tomoderate stimulation, while low-affinity PDE1 becomes important
when the concentrations of CRF and AVP are characteristic of exposure to intensive stress. Crown CopyrightD 2002 Elsevier Science Inc. All
rights reserved.
1. Introduction
Corticotrophin-releasing factor (CRF) [1] is a major
mediator of anxiety and stress in mammals [2]. Arginine
vasopressin (AVP), another physiological regulator of the
neuroendocrine stress response [3], exerts its effects on
anterior pituitary corticotrophs by augmenting the adenosine
3050-monophosphate (cAMP) response to CRF. This effect
may involve the enhancement of cAMP biosynthesis as well
as the inhibition of cAMP hydrolysis [4].
Concepts on the role of cAMP hydrolysis in intracellular
signalling have evolved from viewing cyclic nucleotide-
hydrolysing phosphodiesterases (PDEs) as passive termina-
tors of the cAMP signal to the present level of understanding
where PDEs are established targets of complex intracellular
regulatory pathways [5–7]. At least 11 different gene
families of PDE have been identified in mammals [5–7].
These enzymes have differential tissue and subcellular
distributions and exhibit distinct but functionally concerted
modes of regulation at the levels of mRNA transcription and
posttranslational modification [5–7].
Previous biochemical characterisation of PDEs from the
anterior pituitary gland suggested that the bulk of PDE
activity is Ca2 + /calmodulin (CaM) dependent, i.e. attrib-
utable to PDE1 [8,9]. There are currently three families of
PDE1 enzymes: A, B and C, respectively. These hydrolyse
cAMP as well as guanosine 3050-monophosphate (cGMP)
and have a wide range of Km’s—30 mM for PDE1A and
1 mM for PDE1C isotypes [5,6]. Sensitivity towards Ca2 +
ions is also variable. Moreover, PDE1 enzymes are subject
to isotype-specific regulation by protein phosphorylation
[10,11]. Despite the reported preponderance of PDE1 in
the adenohypophysis, the highly selective PDE4 inhibitor
rolipram is known to activate the hypothalamic–pituitary–
adrenocortical system at the pituitary level [12,13], implic-
ating PDE4 in the control of corticotroph cell function.
PDE4 enzymes are relatively selective for cAMP and are
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regulated by a wide variety of mechanisms including intra-
cellular targeting and protein phosphorylation [14]. Given
the wide range of physiological stimuli [3,15–17] that
regulate the anterior pituitary corticotroph cell, we tested
the hypothesis that multiple PDEs are involved in shaping
the cAMP response to CRF and AVP. The data indicated
that (1) cAMP hydrolysis in the adenohypophysis proceeds
through high-affinity, low-capacity as well as low-affinity,
high-capacity PDEs, (2) PDE1A constitutes the bulk of PDE
activity in the adenohypophysis and (3) PDE1A and PDE4
are key cAMP-metabolising enzymes in rat corticotrophs—
the cAMP response to moderate stimulation is terminated by
PDE4, whereas PDE1A becomes important when high
levels of CRF and AVP characteristic of intensive or chronic
stress are present.
2. Materials and methods
2.1. Reagents
Unless otherwise indicated, all reagents were of the
highest grade available and obtained from Sigma–Aldrich
(Poole, Dorset, UK). Rolipram (Schering, Berlin, F.R.G.)
and vinpocetine (Gedeon Richter, Budapest, Hungary) were
provided by the manufacturers. Human CRF, human GRF
and AVP were from Bachem, UK. [2,8,5-3H]adenosine,
[2-3H]50-AMP and [2,8-3H]30,50-cAMP were from Dupont,
Stevenage, UK or Amersham, Little Chalfont, UK. 1,3-
dimethyl-8-cyclopentyl-xanthine (DMCPX) and 1,3-
dipropyl-8-cyclopentyl-xanthine (DPCPX) were from RBI,
Natick, MA.
2.2. Preparation and incubation of rat anterior
pituitary cells
Male Wistar rats (150–200 g BW) were housed in
individual cages for 24–48 h under controlled lighting and
air conditioning, with free access to tap water and food
pellets. Animals were decapitated between 8:30 and
9:00 AM, taking precautions to avoid stressful stimulation.
The anterior pituitary glands (usually from five animals)
were removed and dispersed cells were prepared by diges-
tion in 1 ml/gland of 0.025% trypsin (TRL-3, Worthington),
10 mg/ml DNAse I and 0.25% BSA (Sigma A-7906) in
Hank’s balanced salt solution without Ca2 + and Mg2 +
(HBSS, GIBCO–Life Technologies, Paisley, UK) supple-
mented with 25-mM HEPES, pH 7.4, 0.15-mM CaCl2 and
0.15-mM MgSO4, for 30 min at 37 C under constant
shaking at 250 cycles/min on an IKAVibrax orbital shaker.
The digested tissue was processed further to obtain dispersed
cells as previously described [18]. The cell suspension was
preincubated for 2–3 h in a sealed tube in HBSS supple-
mented with HEPES, pH 7.4, 2-mM CaCl2, 1-mM MgSO4
and 0.25% BSA by end-over-end rotation in a total volume
of 10 ml, 70 rpm at 37 C in order to allow the cells to adapt
to the in vitro metabolic conditions. After preincubation, the
cells were sedimented by centrifugation, resuspended,
counted in a hematocytometer, diluted and distributed (3–
4 104 cells/50 ml) into conical polypropylene microvials in
96-well format and incubated in a water bath at 37 C. After
20 min, PDE blockers were added, and 5 min later, agonists
were introduced (total volume 200 ml). The incubation was
continued for 8 min after which 200 ml of 0.2-M HCl were
rapidly added. Total cAMP content was measured by RIA
after acetylation [19]. Under these conditions, over 90% of
the immunoreactive cAMP was associated with the cells.
2.3. Assay of PDE activity
Rat anterior pituitary glands were homogenised in Teflon/
glass homogenisers in five volumes of 20-mM Tris–HCl, pH
7.5, 1-mM EDTA, 0.2-mM EGTA, 50-mM sodium fluoride,
10-mM sodium pyrophosphate, 50-mM benzamidine, 0.5-
mg/ml leupeptin, 0.7-mg/ml pepstatin, 4-mg/ml aprotinin, 10-
mg/ml soybean trypsin inhibitor, 2-mM phenylmethylsul-
fonyl fluoride and 1-mM dithiotreitol. The homogenate
was centrifuged at 200 g for 10 min at 4 C. The resultant
supernatant was recentrifuged at 30,000 g for 20 min at 4
C, and the supernatant and the pellet were used as the
cytosolic and the particulate fractions, respectively. Protein
content was measured by the Coomassie blue method with
BSA as standard [20]. PDE activity was measured by minor
modifications of a radiometric assay [21] based on the
coprecipitation of the cAMP hydrolysis product 50-AMP
with BaSO4. The assay buffer contained 100-mM Tris–
HCl, pH 7.5, 5-mM MgSO4 and cell extract (1–10 mg
protein) in a total volume of 150 ml. The reaction was
initiated by the addition of 50-ml substrate to give a final
concentration of 1-mM cAMP and 0.2-mCi/ml [2,8-3H]
cAMP and the tubes were incubated at 30 C for 5–30 min.
The reaction was terminated by the addition of 100 ml of
21.5-mM ZnSO4 followed by 100 ml of 17.5-mMBa(OH)2 to
precipitate the 50-AMP formed. The suspension was filtered
over Whatman GF/C filters on a vacuum manifold and
washed twice with 3 ml of 1-mM NaOH/100-mM NaCl.
Radioactivity retained on the filters was measured by liquid
scintillation counting. Blanks were either with homogenisa-
tion buffer in place of cell extracts or heat-inactivated (90 C,
5 min) cell extracts, which gave similar results. Under these
conditions, cAMP hydrolysis was linear with respect to time
and the amount of protein added, provided substrate deple-
tion was below 30% of total. Total PDE activity is defined as
that measured in the presence of 100-mM Ca2 + and 100-nM
CaM (Sigma P2277), while Ca2 + /CaM-independent activity
was assayed in the presence of 0.5-mM EGTA and 1-mM
calmidazolium. Ca2 + /CaM-dependent (PDE1) activity was
taken as the difference between the two activities. PDE4
activity is defined as Ca2 + /CaM-independent activity inhib-
ited by 10-mM rolipram.
The coprecipitation assay was controlled for the metabol-
ism of 50-AMP to adenosine. Firstly, most of the experiments
K.-L. Ang, F.A. Antoni / Cellular Signalling 14 (2002) 445–452446
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were carried out with cytosolic fractions where 50-nucleoti-
dase activity is low. Secondly, under the conditions of the
filtration assay, 97 ± 0.1% of 3H-AMP (n = 24), 0.6 ± 0.01%
of 3H-cAMP (n = 12) and 1.7 ± 0.01% of 3H-adenosine
(n = 8) were precipitated with BaSO4 in the presence of
up to 3 mM of the respective unlabelled nucleotides (values
are means ± S.E.M. of n separate determinations). Thirdly,
parallel time courses of PDE and 50-nucleotidase activity in
cytosol extracts indicated that less than 0.3% of 3H-AMP
was converted to adenosine by 30 min, while up to 30% of
3H-cAMP was hydrolysed. Finally, the time course of total
PDE activity in the cytosol measured by the coprecipita-
tion assay or with the QAE-Sephadex column elution
method [22] was near identical.
2.4. Chromatographic separation of PDE activities
Whatman DEAE cellulose (DE-52) was used to pack a
9 15-cm column (Pharmacia K9/15 column). The column
was equilibrated with the starting buffer containing 50-mM
sodium acetate, pH 6.5, 0.1-mM EGTA, 5-mM b-mercap-
toethanol, 10-mM sodium fluoride, 1-mM EDTA, 0.5-mg/l
leupeptin, 0.7-mg/l pepstatin and 0.2-mM PMSF. Typically,
2 ml of the cytosolic fraction (approximately 2-mg protein)
was loaded and the column was washed with two-column
volumes of starting buffer. The column was then eluted with
a linear 0.05–1-M sodium acetate gradient. Six-minute
(about 2 ml) fractions were collected and 10 or 20 ml of
each fraction was assayed for PDE activity. All chromato-
graphic steps were carried out at 4 C.
2.5. RT-PCR amplification
Total RNA was prepared from adult male rat or mouse
anterior pituitary glands using TRIzol reagent (GIBCO–
Life Sciences, Paisley, UK) according to the manufactur-
er’s instructions. First-strand cDNA was synthesised from
total RNA using the SUPERSCRIPT preamplification
system (GIBCO). Briefly, 5 mg of total RNA was heated
with 2.5-mM random hexamers to 70 C for 10 min and
quickly chilled on ice. Ten units of SUPERSCRIPT II
reverse transcriptase were added to start first-strand cDNA
synthesis at 42 C for 50 min in a 20-ml reaction volume
containing 1 first-strand buffer, 10-mM DTT and
0.5-mM dNTP mix. The reaction was terminated by
heating at 70 C for 15 min and aliquots of the cDNA
were stored at  40 C. PCR was carried out in a 50-ml
reaction volume containing 1 ml of cDNA, 0.1–0.5-mM
primers, 20-mM Tris–HCl, pH 8.0, 50-mM KCl, 2-mM
MgCl2 and 0.2-mM dNTP mix. After heating the mixture
to 95 C for 5 min, the PCR was initiated by the addition
of 2.5 units Taq DNA polymerase (Life Technologies) at
80 C followed by denaturation at 95 C for 1 min,
annealing at 60 C for 1 min, extension at 72 C for
3 min for 35 cycles and a final 10 min of extension at
72 C. PCR primers were tailed at the 30-end in order to
optimise for adenylation [23] and thus facilitate T/A
ligation. PCR products that corresponded to the expected
size were purified and ligated into pGEM-T or pGEM-T
Easy vectors (Promega) according to the manufacturer’s
instructions and transfected into JM109 cells. Plasmid
DNA was isolated and sequenced in both directions using
Table 1
Detection of cAMP-hydrolysing phosphodiesterase activities in the rat adenohypophysis with 1-mM cAMP as substrate
Cell fraction Ca2 + /CaM activated (PDE1) Rolipram-inhibitable activity (PDE4) Other Ca2 + -independent activity
Homogenate 71 ± 3 19 ± 2 9 ± 0.5
Cytosol 81 ± 2 11 ± 1 8 ± 0.5
Total PDE activity was measured in the presence of 100-mM free Ca2 + , 100-nM CaM, while Ca2 + -independent activity was measured in the presence of
0.5-mM EGTA, and 1-mM calmidazolium, no Ca2 + or CaM was added. Total PDE activity was 537 ± 20-pmol/min/mg protein in the whole homogenate and
555 ± 17-pmol/min/mg protein the soluble fraction. Data are mean ± S.E.M. expressed as percent of the respective total activity. n= 4/group.
Figure 1. DEAE chromatography of rat adenohypophysial cytosol. (A) A
peak of 100-mM Ca2 + /100-nM CaM-stimulated PDE activity at 0.05–
0.1 M as well as a shoulder at 0.1–0.4-M sodium acetate were observed.
(B) Substrate saturation analysis of the PDE activity eluting between 0.05-
and 0.1-M sodium acetate indicated the presence of high and low Km PDE1.
Km values in this particular experiment determined by nonlinear regression
using a two-site binding model (LIGAND) were 0.65 and 63 mM, with Vmax
values of 0.78- and 21-nmol/min/mg protein, respectively. V= velocity,
S = concentration of substrate. Data are individual points from a
representative of three separate experiments.
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the Applied Biosystems Taq DyeDeoxy terminator cycle
kit in a model 373 DNA sequencer.
2.6. Data analysis
Data were evaluated by Student’s t test and one-way
ANOVA followed by Newman–Keuls’ or Dunnett’s two-
tailed test as appropriate. Values of P < 0.05 were considered
statistically significant. Km and Vmax values of substrate
saturation studies were determined by nonlinear regression
analysis [24].
3. Results
3.1. Evidence for multiple cAMP PDEs in
the adenohypophysis
In crude homogenates of rat adenohypophysis, Ca2 + /
CaM-dependent (PDE1) as well as Ca2 + /CaM-independent
PDE activities were detected with 1-mM cAMP as substrate.
Over 90% of the PDE activity was in the soluble fraction, and
the initial characterisation of this activity is shown in Table 1.
It was clear that PDE1 constituted the bulk ( 70%) of
adenohypophysial PDE activity. Importantly, 67 ± 2%
(mean ± S.E.M., n = 3) of the Ca2 + /CaM-independent PDE
activity was inhibited by 10-mM rolipram in the whole
homogenate, i.e. about 19% of total adenohypophysial PDE
activity was attributable to PDE4. Thus, in rat adenohypoph-
ysis, PDE1 and PDE4 type enzymes accounted for approx-
imately 90% of cAMP-hydrolysing activity.
DEAE cellulose chromatography of the cytosol gave a
sharp peak of PDE activity eluting at 0.05–0.1-M sodium
acetate, followed by a broad shoulder (0.1–0.4-M sodium
acetate) which were stimulated 4- and 2.5-fold, respectively,
by 100-mM Ca2 + /100-nM CaM (Fig. 1A). These fractions
are known to contain mainly PDE1 type activity and PDE1
enzymes have substantial cAMP-hydrolysing activity even
Table 2
Analysis of PDE mRNA expression in rat anterior pituitary gland by RT-PCR
Sense Antisense Results
Analysis of PDE1 mRNA expression
pde1af GGGGATGATGAAAAAGA
AGCCTGAAG
pde1r GTTGGCTCCACWATGA
ARTCAATGAAAC
Product obtained with mouse
anterior pituitary, no product
detected with rat tissue.
Sequence of mouse RT-PCR
product matched the conserved
region of mouse PDE1A variants.
pde1bf GCAGTCCACAACTGTCT
CAAGAACCTG
pde1r No RT-PCR product detected in
rat anterior pituitary.
pde1Cf(2) CCTCCTTTATAAGAC
AGGAGTAGCAAAC
pde1cr GTTTCTCTGTCACCCT
GTCTAAAGAACTC
PCR product obtained from rat
tissue sequence matched conserved
region of mouse and rat PDE1Cs.
pde1c2f GTCATGACGGACACCA
GCCACAAGAAG
pde1cr(2) GTTTTCTTTGACTCA
TTTCCGGTGTTGGAG
No PCR product.
pde1c145f GTTTCTGGATGATGT
TTTATCCGTAGTCTCC
pde1c45r GTTTCTGGATGATGT
TTTATCCGTAGTCTCC
RT-PCR product obtained from
mouse tissue which matched
mouse PDE1C4/5 splice variants
[L76946/7]. No product with
rat pituitary.
Analysis of PDE4 mRNA expression
pde4A5f GACCCCGATCCGCATC
CAGCAACG
pde4r MCGRTTMAGCATCCT
YTTGAAC
No PCR product.
pde4Bf GTTTATCACAACAGCCT
GCACGCTGCTGA
pde4br GTTATGGGAGTACCCA
GCCACGTTG
Sequence obtained matched generic
core sequence of rat PDE4Bs.
pde4D3Bf CATTCCTGGATATGT
TTCGATGTGGAC
pde4dr GTTGCCAGACAGCTCC
GCTATTCGG
Sequence obtained matched with
rat PDE4D3 (U09547).
Primer pairs (50! 30) used to detect the presence of mRNAs of PDE1 and PDE4 isozymes/splice variants are tabulated. Where PCR products were obtained,
they were of the expected size. Where relevant, the database accession numbers are shown in brackets.
Fig. 2. Analysis of PDE expression in anterior pituitary tissue by RT-PCR.
Reverse transcriptase reactions and Taq polymerase-based PCR was carried
out on total RNA isolated from rat and mouse anterior pituitary glands.
Primers are summarised in Table 1. The expected products for PDEs 1C, 4B
and 4D3 and PDEs 1A and 1C4/5 from rat and mouse adenohypophysial
RNA, respectively, were purified, subcloned and sequenced.
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in the absence of Ca2 + /CaM [11]. Substrate saturation
analysis of the fractions eluting at 0.05–0.1-M sodium
acetate with cAMP indicated the presence of low as well
as high Km PDE1 activities (Fig. 1B). The mean Km values
from three separate experiments determined by nonlinear
regression analysis using a two-site model were 0.36 ± 0.11
and 53 ± 12 mM with Vmax values of 0.56 ± 0.12 and
20 ± 8 nmol/min/mg, respectively (data are means ± S.E.M,
n = 3), i.e. indicated the presence of low Km, low capacity as
well as high Km and high-capacity PDE1 activities.
RT-PCR analysis of rat anterior pituitary total RNA
showed the expression of PDE1C, PDE4B and PDE4D3
(Table 2 and Fig. 2). The analysis was restricted to three
PDE4 isotypes as parallel studies on AtT20 cells [25]
indicated that these were expressed in corticotroph cells.
Finally, RT-PCR of mouse adenohypophysial RNA revealed
the expression of PDE1A and PDE1C4/5.
3.2. Pharmacological analysis of the role of PDEs in rat
anterior pituitary cells
Corticotrophs constitute maximally 10% of the total cell
population in the rat adenohypophysis. However, the cAMP
response to CRF or CRF and AVP is a selective indicator of
the activation of these cells. Upon exposure to high physio-
logical concentrations of CRF ( 0.3 nM), cAMP levels in
isolated anterior pituitary cells peaked at 2 min and returned
towards basal by 8 min [26], indicating the activation of
cAMP hydrolysis. In the presence of PDE blockers, steady
state was apparent at 8 min. Hence, all measurements
reported here were carried out at the 8-min time point.
Rolipram, an inhibitor highly specific for PDE4, mark-
edly enhanced the CRF-evoked cAMP response with an
apparent EC50 of 1 mM (Fig. 3). Combination of a max-
Fig. 4. Specificity of the action of IBMX as an inhibitor of PDE. Isolated rat
anterior pituitary cells were treated with various combinations of the PDE
blockers rolipram (ROLI, 0.1 mM), IBMX (1 mM) or the adenosine
antagonist DMCPX (1 mM) 5 min before the addition of medium alone or
0.3-nM CRF dissolved in medium. IBMX significantly ( P< .05, one-way
ANOVA followed by Newman–Keuls’ test) increased cAMP production
alone or in the presence of rolipram, while DMCPX had no such effects. In
addition, IBMX enhanced CRF-induced cAMP in the presence of a
maximally effective concentration of rolipram. Data are means ± S.E.M. of
quadruplicates from a representative of two experiments.
Fig. 3. Effect of rolipram on CRF (0.3 nM)- and CRF/AVP (0.3/2 nM)-
induced cAMP responses in dispersed rat anterior pituitary cells. Cells were
pretreated for 5 min with vehicle (0.1% dimethylsulfoxide) and various
concentrations of rolipram for 10 min after which CRF or CRF/AVP was
added and the incubation carried on for 8 min. Data are mean ± S.E.M. (n= 4/
group). The effect of rolipram on CRF- and CRF/AVP-induced cAMP levels
were significant between 1 and 100 mM ( P < .05, one-way ANOVA followed
by Dunnett’s test). Representative of two identical experiments.
Fig. 5. Effect of prototype PDE inhibitors on cAMP levels in dispersed rat
anterior pituitary cells. Isolated rat anterior pituitary cells were treated with
vehicle (0.2% DMSO/0.1% acetone) and various combinations of the PDE
blockers rolipram (0.1 mM), vinpocetine (0.1 mM) and IBMX (1 mM)
5 min before the addition of medium alone (empty columns), 0.3-nM CRF
(hatched column) or 0.3-nM CRF and 2-nM AVP (wavy columns). Data are
means ± S.E.M. of quadruplicates from a representative of two experiments
( P < .05, one-way ANOVA followed by Newman–Keuls’ test). All
inhibitor concentrations, except vinpocetine alone, significantly enhanced
the cAMP response to CRF ( P < .05, one-way ANOVA followed by
Newman–Keuls’ test) and only IMBX or IBMX and rolipram in
combination had a significant ( P< .05, one-way ANOVA followed by
Newman–Keuls’ test) effect on basal cAMP levels.
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imally effective concentration of rolipram with 1-mM
IBMX, an inhibitor of most PDE isotypes, caused signific-
ant further augmentation of the cAMP response when
compared with rolipram alone (Fig. 4). The effect of IBMX
was not due antagonism of adenosine receptors [27] as
known antagonists of these receptors such as DMCPX
(Fig. 4) and 1,3-dipropyl-8-cyclopentyl-xanthine (not
shown) caused no change in the effect of rolipram or
rolipram and IBMX in combination.
Vinpocetine, a potent blocker of low Km PDE1 enzymes
[6], had no significant effect on cAMP responses evoked by
CRF but markedly increased the cAMP response to CRF
and AVP in combination (Fig. 5). Moreover, the effects of
vinpocetine and rolipram on CRF/AVP-induced cAMP
formation were additive (Fig. 5).
Finally, it was examined whether rolipram had any effect
on other pituitary cells. The cAMP response to 1-nM GRF
was significantly enhanced by rolipram (30 mM) (basal:
10 ± 1, basal + rolipram: 10 ± 1.8, GRF 330 ± 30, GRF+ ro-
lipram: 575 ± 43, data are fmol/well, means ± S.E.M., n = 4/
group), a selective activator of adenylyl cyclase in GH-
secreting cells of the adenohypophysis, thus indicating that
type 4 PDEs are not restricted to corticotrophs.
4. Discussion
The studies reported here indicated that the cAMP
response to ACTH secretagogues is dissipated by multiple
species of PDE. Above all, a shift of cAMP hydrolysis from
type 4 PDE to type 1A PDE appears to take place in the
presence of high physiological levels of AVP. Evidence for
the adenohypophysial expression for multiple PDEs that
could correspond to the observed pharmacological profiles
was found by biochemical as well as RT-PCR analysis of
adenohypohysial tissue.
Examination of adenohypophysial cAMP hydrolysis
showed that close to 90% of PDE activity is due to type 1
and 4 PDEs. Furthermore, the presence of high and low Km
Ca2 + -activated PDE1 was evident. At the mRNA level, the
expression low (PDE1C4/5) and high (PDE1A) Km PDE1 as
well as that of two PDE4 isoenzymes (PDE4B, PDE4D3)was
detected. While these latter findings correspond reasonably
well with the pharmacological and biochemical data, some
issues deserve comment. PDE1A mRNA could be only
successfully amplified from mouse adenohypohysial RNA
from which the primers were designed. Examination of a
recent entry of rat PDE1A cDNA sequence (accession no.
AF327838) in the database, which was not available at the
time of these studies, revealed that there are significant
differences between the mouse and rat cDNA sequences in
the region of the primers. By contrast, this was not the case for
PDE1B, where the primers were suitable for amplifying
PDE1B from other tissues (Ang and Antoni, unpublished
data) but gave no PCR product in the adenohypophysis.
Therefore, it seems reasonable to conclude that a PDE1A
type enzyme is the low-affinity, high-capacity PDE in rat and
mouse anterior pituitary gland. This enzyme is reportedly
inhibited by cAMP-dependent phosphorylation [10,11],
which is opposed by Ca2 + -mediated dephosphorylation
through protein phosphatase 2B (calcineurin) and Ca2 + -
mediated activation of catalytic activity through CaM [10].
Thus, PDE1A is an integrator of intracellular cAMP and
Ca2 + signalling.
Previously, Lobban et al. [28] found no evidence for
PDE4 expression in rat pituitary gland. On the basis of the
high pharmacological selectivity of rolipram [6] and the
present RT-PCR analysis, it is justified to conclude that
PDE4 is present in the adenohypophysis and is functionally
important in corticotroph cells. However, the relatively low
abundance of PDE4 in the rat adenohypophysis is unlikely
to reflect a restricted localisation to corticotrophs as roli-
pram enhanced the cAMP response evoked by GRF, which
specifically targets somatotroph cells that represent approx-
imately 30% of the total pituitary cell population. In
summary, the RT-PCR analysis of PDE gene expression in
rat and mouse adenohypophysis demonstrated the presence
of PDE1 and PDE4 isotypes, the characteristics of which
conformed with the biochemical properties of cAMP hydro-
lysis. While this RT-PCR may not be exhaustive, it clearly
underscores the potential for functional plasticity of cAMP
hydrolysis in anterior pituitary cells.
In order to gain insight into the operation of PDEs in
corticotrophs, prototype PDE blockers were applied to
assess the role of PDE1 and PDE4 isotypes in the cAMP
response generated by CRF and AVP. Assuming that pitu-
itary cells in suspension are spherical with a radius of
 15 mm, the average unstimulated level of cAMP in the
cells was between 0.2 and 0.5 mM. Rolipram or vinpocetine
had no appreciable effect on basal cAMP levels, while
IBMX caused a marked increase. The lack of an effect of
rolipram under these conditions is contradictory to previous
reports that it increased ACTH secretion by anterior pitu-
itary tissue in vitro [12,13]. However, the different experi-
mental preparations used in the present (isolated cells) and
the aforementioned (pituitary segments) studies may explain
this discrepancy. Furthermore, as in other systems [29], a
small and selective rise of cAMP in corticotroph cells could
be sufficient to activate protein kinase A and trigger ACTH
release but may not be discernible by measurement of total
cAMP levels in the entire population of pituitary cells. The
effect of IBMX on basal cAMP levels is consistent with the
finding that low Km and IBMX-sensitive PDEs, namely
PDE1C (present study) and PDE type 11 [30], are prom-
inently expressed in the pituitary gland and thus could be
involved in maintaining basal cAMP levels in the majority
of pituitary cells. Interestingly, PDE1C is a major PDE in
AtT20 corticotroph tumour cells [25]. Furthermore, both
AtT20 cells [31,32] and rat anterior pituitary corticotroph
cells [33] generate spontaneous Ca2 + spikes reaching 0.5–
1-mM intracellular free Ca2 + , which is sufficient to activate
PDE1C [34].
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Assuming that  10% of the total population of cells
responds to CRF, peak intracellular cAMP concentrations in
response to 0.3-nM CRF at 2 min [26] may be estimated to
be around 7 mM. This is sufficient to activate PKA, which
would inhibit PDE1C and activate PDE4D3, but is substan-
tially below the Km of PDE1A. Accordingly, rolipram
markedly increased cAMP levels under these conditions,
while the prototype blocker of low Km PDE1 vinpocetine
had no effect. In contrast, in the presence of 2-nM AVP
when CRF-induced cAMP levels were close to 50 mM, both
rolipram and vinpocetine enhanced cAMP levels and their
effects were additive, indicating distinct targets of action.
However, the size of the cAMP response may not be the
only determinant of the effectiveness of vinpocetine. As
shown in Fig. 5, in the presence of CRF and rolipram,
cAMP levels were similar to those seen with CRF and AVP
in combination, yet vinpocetine had no significant effect.
Thus, it appears that the effect of vinpocetine is only
manifest in the presence of AVP. The action of AVP in
corticotroph cells is mediated by protein kinase C [35] and
reportedly involves inhibition of cAMP hydrolysis [4].
Activation of protein kinase C also reduced low-affinity
PDE1 activity in rat kidney [36].
In summary, the data presented indicate remarkable
functional plasticity of cAMP hydrolysis in pituitary corti-
cotroph cells (Fig. 6). Note that the concentrations of CRF
and AVP applied were within the physiological range,
characteristic of intensive surgical stress [37]. Under
unstimulated conditions, slow spontaneous Ca2 + spikes
would delimit cAMP accumulation at the level of the low
Km PDE1C enzyme. Moderate stimulation of the cAMP
system by concentrations of secretagogue expected during
emotional stress [38,39] would tend to shift PDE hydrolysis
to PDE4 isotypes, conceivably PDE4D3, which is activated
by cAMP-dependent protein kinase (reviewed in Ref. [5]),
while the activity of PDE1C would be simultaneously
reduced by cAMP-dependent phosphorylation [25]. Upon
more intensive stimulation, i.e. that seen during physical
stress [38,39], higher levels of AVP would induce more
marked increases of cAMP and intracellular Ca2 + by
enhancing CRF-induced adenylyl cyclase activity through
protein kinase C [4] and inhibition of PDE1A through
protein kinase A and possibly protein kinase C[4] (Fig. 6).
The levels of cAMP ( 50 mM) thus achieved would
require the high capacity of PDE1A to be effectively
controlled. Hence, in the case of intensive agonist stimu-
lation, the regulation of PDE1A would be a pivotal deter-
minant of the ensuing intracellular patterns of cAMP and
free Ca2 + . The three states of the corticotroph cell outlined
above are likely to generate different spatiotemporal patterns
of Ca2 + and cAMP, which could be decoded by effector
systems located in various cellular compartments and serve
to operate the cellular machinery as required by graded
changes in the extracellular stimulus environment.
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Short-Term Plasticity of Cyclic Adenosine
3,5-Monophosphate Signaling in Anterior
Pituitary Corticotrope Cells: The Role of
Adenylyl Cyclase Isotypes
FERENC A. ANTONI, ALEXANDER A. SOSUNOV*, ANDERS HAUNSØ†, JANICE M. PATERSON‡,
AND JAMES SIMPSON
Department of Neuroscience, University of Edinburgh, Edinburgh EH8 9JZ, Scotland, United
Kingdom
Anterior pituitary corticotropes show a wide rep-
ertory of responses to hypothalamic neuropep-
tides and adrenal corticosteroids. The hypothesis
that plasticity of the cAMP signaling system under-
lies this adaptive versatility was investigated. In
dispersed rat anterior pituitary cells, depletion of
intracellular Ca2 stores with thapsigargin com-
bined with ryanodine or caffeine enhanced the cor-
ticotropin releasing-factor (CRF)-evoked cAMP re-
sponse by 4-fold, whereas reduction of Ca2 entry
alone had no effect. CRF-induced cAMP was am-
plified 15-fold by arginine-vasopressin (AVP) or
phorbol-dibutyrate ester. In the presence of inhib-
itors of cyclic nucleotide phosphodiesterases and
phorbol-dibutyrate ester, the depletion of Ca2
stores had no further effect on CRF-induced cAMP
accumulation. Adenohypophysial expression of
mRNAs for the Ca2-inhibited adenylyl cyclases
(ACs) VI and IX, and the protein kinase C-stimu-
lated ACs II and VII was demonstrated. ACIX was
detected in corticotropes by immunocytochemis-
try, whereas ACII and ACVI were not present.
The data show negative feedback regulation of
CRF-induced cAMP levels by Ca2 derived from
ryanodine receptor-operated intracellular stores.
Stimulation of protein kinase C by AVP enhances
Ca2-independent cAMP synthesis, thus changing
the characteristics of intracellular Ca2 feedback.
It is proposed that the modulation of intracellular
Ca2 feedback in corticotropes by AVP is an im-
portant element of physiological control. (Molecular
Endocrinology 17: 692–703, 2003)
FORTY-ONE AMINO ACID residue corticotropin-releasing factor (CRF) and arginine vasopressin
(AVP) are the main hypothalamic mediators of the
stress response (1) that stimulate the secretion of
ACTH by adenohypophysial corticotrope cells. Adre-
nal corticosteroids are mobilized in response to ACTH
and provide a negative feedback signal in the brain
and the anterior pituitary gland to prevent an over-
shoot of the stress response (2, 3). Additional hypo-
thalamic inhibitory factors also contribute to the reg-
ulation of corticotropes (1, 4). Corticotrope cells show
remarkable functional plasticity, e.g. glucocorticoid in-
hibition of pituitary ACTH secretion is diminished in
autoimmune disease models (5, 6), while it is very
pronounced in psychological stress (7).
The currently identified receptors for CRF all acti-
vate adenylyl cyclase (AC) through the stimulatory G
protein Gs (8). In corticotropes, activation of CRF1
receptors enhances cAMP levels, which leads to in-
creased firing of action potentials and oscillations of
intracellular free Ca2 ([Ca2]i) (1, 9). In contrast to
CRF, AVP activates V1 receptors coupled to phos-
pholipase C through Gq in corticotrope cells (10).
When given alone at physiological concentrations (2
nM), AVP has little or no effect on ACTH secretion.
However, it markedly augments ACTH release in-
duced by CRF (11) by amplifying the CRF-evoked
cAMP response (12, 13). These effects are mediated
by protein kinase C (14).
Studies in the AtT20 corticotrope tumor cell line
have shown that CRF-induced cAMP accumulation as
well as membrane depolarization are under feedback
inhibition by [Ca2]i (15, 16). Disruption of the Ca
2
negative feedback in AtT20 cells leads to enhanced
cAMP levels and a marked reduction of glucocorticoid
inhibition of stimulated ACTH release (17). Previous
work in cultured rat anterior pituitary cells (18) sug-
gested that intracellular Ca2 is an obligatory cofactor
for CRF-induced cAMP production. This contradicts
the findings in AtT20 cells (15) and the more general-
ized Ca2-feedback hypothesis of glucocorticoid ac-
tion (17, 19).
Therefore, the aim of the present study was to an-
alyze the effects of Ca2 on cAMP levels in cortico-
Abbreviations: AC, Adenylyl cyclase; AVP, arginine vasopres-
sin; BAPTA-AM, 1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-
tetraacetic acid tetra-(acetoxymethyl)-ester; BCECF-AM, 2,7-
bis-(carboxymethyl)-5(6-carboxyfluorescein acetoxymethyl
ester; [Ca2]i, intracellular free Ca
2; CRF, corticotropin-
releasing factor; FURA2-AM, 1-[2-(5-carboxyoxazole-2-yl)-
6-aminobenzofuran-5-oxy]-2-(2-amino-5methylphenoxy)-
ethane-N,N,NN-tetraacetic acid pentaacetoxymethyl ester;
HBSS, Hanks’ balanced salt solution; IBMX, 3-isobutyl-1-
methylxanthine; PdBu, phorbol-dibutyrate ester; PDE, phos-
phodiesterase; RNase, ribonuclease; RyR, ryanodine receptor.
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trope cells exposed to CRF and AVP. The results
demonstrate Ca2 negative feedback control of CRF-
induced cAMP levels in rat pituitary corticotropes by
[Ca2]i derived from a ryanodine receptor (RyR)-oper-
ated intracellular source. AVP markedly enhanced the
cAMP response to CRF and amplified by 10-fold the
dynamic range of the modulation of cAMP levels by
[Ca2]i. This change was in part due to the enhance-
ment of Ca2-independent cAMP synthesis. Analysis
of AC expression indicated that ACIX and ACVII are
likely to mediate the actions of CRF and AVP in cor-
ticotrope cells. It is proposed that the reduction of
Ca2 feedback inhibition of cAMP synthesis underlies
the ability of AVP to reduce glucocorticoid feedback
inhibition of ACTH release.
RESULTS
Ca2 Feedback Inhibition of CRF-Induced
cAMP Synthesis
The time course of the cAMP response to a high
physiological concentration of CRF (0.3 nM) is shown
in Fig. 1A. Levels of cAMP peaked at 2 min, declined
sharply by 5 min, and returned to baseline at 20 min.
As CRF is highly specific to corticotropes and because
corticotrope cells represent, at best, 10% of the total
number of cells in this preparation, 2- to 3-fold in-
creases of total cAMP may correspond to approxi-
mately 20- to 30-fold increases of intracellular cAMP in
corticotropes.
Depletion of Ca2 pools by means of 2 mM EGTA, 30
M ryanodine, and 2 M thapsigargin before the ap-
plication of CRF increased the basal levels of cAMP in
the cell suspension. The amplitude of the cAMP re-
sponse to CRF was similar to that observed in medium
containing 2 mM Ca2 (Fig. 1B); however, it was sus-
tained: steady state was reached within 5 min and
maintained up to 20 min.
The decline of cAMP levels after 2 min in 2 mM Ca2
medium indicated the involvement of cyclic nucleotide
phosphodiesterases (PDEs), while the steady state seen
in Ca2-depleted cells suggested regulation by Ca2 of
PDE and/or AC. Indeed, the combination of the PDE
inhibitors 3-isobutyl-1-methylxanthine (IBMX) and rolip-
ram markedly enhanced the cAMP response to 0.3 nM
CRF without the involvement of adenosine receptors
(20). In the presence of 1 mM IBMX and 0.1 mM rolipram
(PDE-I), application of 3 M nifedipine or 2 mM CoCl2 or
acute depletion of extracellular Ca2 by resuspension of
the cells in low Ca2 medium failed to alter the cAMP
response to 0.3 nM CRF (not shown). Thus, reduction of
Ca2 entry mechanisms had no apparent effect on the
cAMP response to CRF. Attempts to use intracellular
chelators of Ca2 failed to yield useful data because of
the apparently nonspecific effects of all acetoxy-methyl
esters tested [1-[2-(5-carboxyoxazol-2-yl)-6-amino-
benzofuran-5-oxy]-2-(2-amino-5-methylphenoxy)-
ethane-N,N,NN-tetraacetic acid pentaacetoxymethyl
ester (FURA2/AM), 1, 2-bis-(o-aminophenoxy)-ethane-
N,N,N,N-tetraacetic acid tetra-(acetoxymethyl)-ester
(BAPTA/AM) as well as 2,7-bis-(carboxyethyl)-5(6)-
carboxyfluorescein acetoxymethyl ester (BCECF/AM)]
to enhance cAMP accumulation in this system (data
not shown). Therefore, drugs that deplete or block
intracellular Ca2 stores were used. Application of 10
mM caffeine significantly increased basal cAMP levels,
but failed to enhance the response to 0.3 nM CRF
(Table 1). Thapsigargin at 2 M had no effect; however,
in combination with caffeine it produced a significant
enhancement of basal as well as CRF-induced cAMP
formation (Table 1). Preincubation in low Ca2 me-
dium containing 2 mM EGTA for 30 min augmented
basal and CRF-induced cAMP (Fig. 2A). The applica-
tion of 2 mM EGTA with 10 mM caffeine and 2 M
thapsigargin gave the highest response to CRF
(Fig. 2A).
The time course of the CRF-induced increment of
cAMP in Ca2-depleted cells treated with PDE-I is
shown in Fig. 2B. Note that the rate of cAMP accu-
mulation was close to linear up to 8 min, with a marked
reduction afterward. In medium containing 2 mM Ca2
Fig. 1. Time Course of cAMP Accumulation in Isolated Rat
Anterior Pituitary Cells [Vehicle (Basal) and 0.3 nM CRF-
Treated (CRF) Cells]
A, Incubations in medium containing 2 mM Ca2. B, Incu-
bations in low Ca2 medium containing 30 M ryanodine and
2 M thapsigargin. Data are means  SEM of triplicates, from
a representative of two separate experiments.
Antoni et al. • Plasticity of cAMP Signaling Mol Endocrinol, April 2003, 17(4):692–703 693
               dc_385_12
the response reached steady state as early as 5 min.
At 8 min, the cAMP increment in Ca2-depleted cells
was 4.0  0.22-fold higher (mean  SEM, n  5, each
in quadruplicate) than in 2 mM Ca2. Taken together,
these data indicated that CRF-induced cAMP synthe-
sis was inhibited by Ca2 derived from RyR-operated
Ca2 stores.
Concentration-response curves to CRF in the ab-
sence (Fig. 3A) or the presence of PDE-I (Fig. 3B)
revealed that the Ca2-regulated component of cAMP
synthesis, i.e. the difference between the CRF-
induced increments in Ca2-depleted conditions and
in 2 mM Ca2, approached maximum between 0.3 and
1 nM CRF [Fig. 3, A and B (inset)], which is the upper
limit of the physiological range. Importantly, cellular
cAMP continued to rise in response to concentrations
of CRF up to 100-fold above this level (Fig. 3, A and B).
Activation of Protein Kinase C Reduces the Ca2-
Inhibited Component of cAMP Synthesis
Physiological concentrations of AVP (0.3 and 2 nM)
strongly enhanced the cAMP response to 0.3 nM CRF
(Fig. 4A), whereas there was no detectable change in
cAMP levels in the presence of up to 100 nM AVP alone
(not shown). Pretreatment with the protein kinase in-
hibitor bis-indolyl maleimide I (1 M) blocked approx-
imately 90% of the effect of 2 nM AVP, suggesting its
mediation by protein kinase C (data not shown). Com-
bination of 0.3 nM CRF with 2 nM AVP (CRF/AVP)
augmented the cAMP response to 14.5  2- and
15.9  2.3-fold (mean  SEM; n  3, each carried out
in quadruplicate) of the responses to 0.3 nM CRF in 2
mM Ca2 and 0.3 nM CRF in 2 mM EGTA, 30 M
ryanodine, and 2 M thapsigargin, respectively. Thus,
the effect of AVP was largely independent of Ca2
status and, as a result, the dynamic range of Ca2
control, i.e. the difference in the cAMP response in 2
mM Ca2 vs. ERT-medium, increased almost 10-fold.
The cAMP response to CRF/AVP was not maximal as
application of supraphysiological concentrations of
AVP revealed the ability of the system to produce
greater than 100-fold increases of cAMP (Fig. 4A).
In the presence of PDE-I, AVP produced significant,
concentration-dependent potentiation of the cAMP re-
sponse to 0.3 nM CRF (Fig. 4B). At 2 nM AVP the
amplification was 3.5  0.7-fold (mean  SEM; n  5,
each carried out in quadruplicate) of the control CRF
response, which was substantially less than the 15-
fold increase in the absence of PDE-I. Furthermore,
Ca2-depletion had a significantly smaller effect on
the cAMP response to CRF/AVP in the presence of
PDE inhibitors [Vehicle (4.1  0.7) vs. PDE-I (2.2 
0.4)-fold increase of the response in 2 mM Ca2 me-
dium, mean SEM, n 3 and n 5, respectively, each
Table 1. Effect of Depletion of Intracellular Ca2 Pools on
0.3 nM CRF-Induced cAMP Accumulation in the Presence
of 1 mM IBMX and 0.1 mM Rolipram
Treatment Basal CRF-InducedIncrement
Vehicle 108  12 556  37
Caffeine 220  24a 764  103
Thapsigargin 144  16 652  84.4
Caffeine  Thapsigargin 218  16a 1068  56a
Cells were preincubated for 30 min in medium supplemented
with 0.1% ethanol (vehicle), 10 mM caffeine, or 2 M thapsi-
gargin or the combination of the two drugs. Data are cAMP
(fmol/well), means  SEM, n  4, representative of two ex-
periments.
a P 0.05 when compared with the respective vehicle group.
One-way ANOVA, followed by Dunnett’s test.
Fig. 2. Analysis of the Effects of Ca2 on cAMP Synthesis
Induced by CRF in Isolated Rat Anterior Pituitary Cells
A, Depletion of intracellular Ca2 pools leads to enhanced
synthesis of cAMP in the presence of PDE blockers (1 mM
IBMX, 0.1 mM rolipram). Cells were preincubated in 2 mM
Ca2 (Ca2), or various combinations of 2 mM EGTA (E), 2 M
thapsigargin (T), and 10 mM caffeine (C). Data are means 
SEM of quadruplicates from a representative of four experi-
ments. Note marked increases in basal (hatched columns)
cAMP levels; however, these were not proportional to the
enhancement of the response to CRF: two-way ANOVA gave
a significant interaction (P  0.05) between the effects of
Ca2 depletion and CRF. The increments of cAMP (empty
portion of columns) were analyzed by one-way ANOVA and
Newman-Keuls test. *, P  0.05 when compared with the
increment of cAMP in 2 mM Ca2 group; , P  0.05 when
compared with the increment of the EGTA group. B, Time
course of 0.3 nM CRF-stimulated cAMP accumulation in the
presence of blockers of PDE in control cells (2 mM Ca2) and
in Ca2-depleted cells in 2 mM EGTA, 10 mM caffeine, and 2
M thapsigargin (ECT). Increments above basal cAMP levels
are shown; the basal level of cAMP in 2 mM Ca2 was 0.11 
0.014 pmol/well. Data are means  SEM of quadruplicates
from a representative of two experiments.
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in quadruplicate, P  0.05 compared by Student’s t
test]. At a high, supraphysiological AVP concentration
(50 nM), no enhancement of the cAMP response was
observed upon Ca2 depletion (Fig. 4B). Similarly, in-
creasing concentrations of the protein kinase C acti-
vator PdBu (phorbol-dibutyrate ester) progressively di-
minished the Ca2 modulation of CRF-induced cAMP
production (Fig. 4C).
In sum, both AVP-induced protein kinase C activa-
tion and the depletion of Ca2 pools enhanced the
cAMP response to CRF in the presence as well as the
absence of PDE-I. In the absence of PDE-I there was
clear synergy between the effects of AVP and Ca2
depletion, whereas in the presence of PDE-I the ef-
fects were additive and much smaller in amplitude. In
the presence of PDE-I, intensive stimulation of the
protein kinase C pathway eventually enhanced the
cAMP response to levels at which the effects of Ca2
depletion were not discernible.
Specificity of Ca2 Inhibition of Stimulus-
Induced cAMP
Introduction of Ca/EGTA into the medium suppressed
the CRF-induced increment of cAMP levels to that
seen in cells incubated with 2 mM Ca2 throughout in
the presence (Fig. 5A) as well as in the absence of
PDE-I (not shown). This was also the case for cells
stimulated with CRF/AVP (Fig. 5A); moreover, inclu-
sion of 1 M of the Ca2 ionophore ionomycin which
supports Ca2-dependent ACTH secretion in this sys-
tem (21) failed to augment the inhibitory effect of 2 mM
extracellular Ca2 on CRF- or CRF/AVP-induced
cAMP responses (data not shown).
Specificity of the action of Ca2 was analyzed in
cells incubated in 0.2 mM EGTA, 10 mM caffeine, and
2 M thapsigargin to avoid displacement of significant
amounts of Ca2 by Co2 and Ba2 which have much
higher affinities for EGTA. In the presence of PDE-I the
inhibitory effect of Ca2 was mimicked by Co2 but
not by Ba2 (Fig. 5B).
AC Isotype Expression and Localization in
Rat Adenohypophysis
The data presented so far indicated the involvement of
Ca2-inhibited and protein kinase C-stimulated ACs in
the response to CRF and AVP. RT-PCR with primers
that amplify ACV and ACVI yielded the expected
1095-bp product, which was cleaved by restriction
enzymes in a pattern that indicated the presence of
ACVI but not of ACV in rat adenohypophysis (Fig. 6).
The expression of ACVII was also observed with RT-
PCR (Fig. 6; GenBank accession no. AF542508).
In situ hybridization revealed diffuse positive label-
ing for ACII (Fig. 7), as well as ACIX (Fig. 7), in the
adenohypophysis. Ribonuclease (RNase) protection
assays showed a strong signal for both ACII and ACIX
(Fig. 7). Immunohistochemical staining showed that
ACIX was widely expressed in the adenohypophysis
and was found in all ACTH-immunopositive cells (Fig.
8). In contrast, ACII (Fig. 8), as well as ACVI, were
completely segregated from ACTH. No discernible
positive signal could be obtained with the antibody
against ACVII in pituitary or brain tissue (data not
shown).
DISCUSSION
These data show that in rat anterior pituitary cortico-
tropes the CRF-induced cAMP response is under
feedback inhibition by intracellular free Ca2 primarily
derived from intracellular stores sensitive to ryanodine
and caffeine. AVP, the physiologically relevant cohor-
mone of CRF, modulates Ca2 feedback by shifting
Fig. 3. Enhancement of the CRF-Induced cAMP Response
by Ca2 Depletion in Isolated Rat Anterior Pituitary Cells
A, Cells in medium containing 2 mM Ca2 or low Ca2
medium with 30 M ryanodine and 2 M thapsigargin (ERT);
the inset shows the difference between the CRF-induced
increments of cAMP in the ERT and 2 mM Ca2 groups for
each concentration of CRF. B, Cells treated with 1 mM IBMX
and 0.1 mM rolipram, incubated in medium containing 2 mM
Ca2 or low Ca2 medium with 10 mM caffeine and 2 M
thapsigargin (ECT); means SEM of quadruplicates represen-
tative of two experiments. The inset is as in panel A.
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cAMP synthesis toward a Ca2-independent pathway,
thereby markedly enhancing the cAMP response.
Nature of the Ca2 Feedback Signal
CRF triggers an increase of [Ca2]i through cAMP in
corticotropes (1, 9). Hence, the inhibition of cAMP
accumulation by [Ca2]i constitutes a negative feed-
back effect. In contrast, previous work carried out in
cultured rat anterior pituitary cells suggested that
Ca2 is a necessary cofactor for CRF-induced cAMP
synthesis (18). However, this conclusion was derived
from cells extensively treated with the ionophore
A23187, which may lead to mitochondrial Ca2 leak-
age and thus impairment of oxidative metabolism (e.g.
see Ref. 22).
Acute reduction of extracellular Ca2 entry pro-
duced no change in CRF-induced cAMP responses,
while treatment with 2 mM EGTA, caffeine, and thap-
sigargin had marked effects. Previously, Abou-Samra
et al. (18) reported that intracellular Ca2 stores con-
tributed to the secretagogue action of CRF, but at the
time these pools were not identified. An inositol-1,3,5-
triphosphate receptor-operated intracellular Ca2
store is functional in pituitary corticotropes (reviewed
in Refs. 1 and 10). A RyR-operated store has not been
previously reported, although caffeine is a well es-
tablished stimulus for ACTH release (23). Moreover,
mRNAs for RyR type 2 and type 3 are abundant in rat
adenohypophysis (24). In smooth muscle cells, the
RyR system is known to play a prominent role in the
regulation of Ca2-activated membrane proteins such
as ion channels (25), while the control of RyR stores in
nonmuscle cells is not well characterized. All RyR iso-
types are capable of Ca2-induced Ca2 release. Fur-
thermore, the type 2 receptor is sensitized to Ca2 by
cAMP-dependent phosphorylation (reviewed in Ref.
26). The present data suggest that the stimulation of
protein kinase A by CRF may be sufficient to activate
the RyR-operated store, e.g. by amplification of spon-
taneous Ca2 sparks (25). Another possibility, that of
activation of RyR through dihydropyridine-sensitive
channels (26), seems unlikely as nifedipine had no
significant effect on cAMP production evoked by CRF.
The Ca2 control of CRF-induced cAMP appeared
redundant: upon the depletion of intracellular Ca2
stores, CRF- as well as CRF/AVP-induced cAMP was
effectively suppressed by Ca2 added to the extracel-
lular fluid. The mode of entry of Ca2 that controls
cAMP synthesis was not addressed in detail, as this
was beyond the power of resolution of the experimen-
tal system. Previous work suggests that voltage-
regulated (15, 27, 28) as well as capacitative Ca2
entry (29, 30), i.e. that evoked by the depletion of
intracellular Ca2 stores, may control cAMP synthesis
in a variety of systems.
The action of Ca2 to inhibit cAMP synthesis ap-
peared specific. Co2, which is known to be taken up
by cells via capacitative Ca2 entry mechanisms (31),
and to mimic some of the biological actions of Ca2
(32, 33) suppressed CRF-induced cAMP synthesis. In
contrast, Ba2 was ineffective, which is consistent
with the general view that Ba2 does not readily re-
place Ca2 as an effector in biological systems, in-
cluding the inhibition of ACs (34).
In sum, the primary source of Ca2 for the regulation
of cAMP levels appears to be a RyR-operated intra-
cellular Ca2 pool. If this pool is depleted, Ca2 entry
mechanisms may also provide a negative feedback
signal to secretagogue-induced cAMP synthesis.
Targets of Ca2 Feedback in Cells Exposed to
Physiological Concentrations of CRF
The effects of Ca2 on CRF-induced cAMP accumu-
lation were prominent in the presence of PDE block-
Fig. 4. Interaction of Protein Kinase C Activation and Ca2 Depletion on cAMP Accumulation Evoked by 0.3 nM CRF
A, Cells in medium containing 2 mM Ca2 or low Ca2 medium with 30 M ryanodine and 2 M thapsigargin (ERT). The basal
level of cAMP in 2 mM Ca2 was 0.04  0.006 pmol/well. B and C, Cells treated with 1 mM IBMX and 0.1 mM rolipram, incubated
in medium containing 2 mM Ca2 or low Ca2 medium with 10 mM caffeine and 2 M thapsigargin (ECT). Data are means  SEM
of quadruplicates representative of three separate experiments. The basal level of cAMP in 2 mM Ca2 was 0.10  0.02 in panel
B and 0.12  0.02 pmol/well in panel C.
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ers, indicating that Ca2 inhibits CRF-activated AC in
corticotrope cells. Currently, there are no examples of
Ca2 inhibition of CRF-Gs-AC coupling, whereas inhi-
bition of ACs by Ca2 is well established (29, 35). Here
we have demonstrated the expression of mRNAs for
the Ca2-inhibited ACs, ACVI and ACIX in the rat
anterior pituitary gland, also reported in sheep (36).
Furthermore, immunocytochemical analysis indicated
the presence of ACIX but not ACVI in corticotropes.
Others (37) have reported that the activity of AC in rat
anterior pituitary membranes is strongly inhibited by
Fig. 5. Introduction of Ca2 into the Extracellular Fluid
Suppresses cAMP Responses to CRF or CRF and AVP in
Combination
Experiments carried out in the presence of PDE block-
ers, 0.1 mM rolipram and 1 mM IBMX. A, Increments of
cAMP above respective basals; data are means SEM from
quadruplicates representative of four experiments. *, P 
0.05 when compared with 0 Ca2 group, but not different
from response of cells incubated in 2 mM Ca2 throughout
(dashed line, CRF 0.3 nM/AVP 2 nM; dotted line, CRF 0.3
nM); one-way ANOVA, Newman-Keuls test. B, Specificity
of the inhibitory effect of Ca2 on CRF-induced cAMP
synthesis. Cells incubated in 2 mM Ca2 throughout, or
depleted of Ca2 with 0.2 EGTA, 10 mM caffeine, 2 M
thapsigargin (ECT) before the addition of 0.3 nM CRF in
medium containing Ca2, Co2, and Ba2 to reach 2 mM
final concentration. Data are means  SEM from quadru-
plicates representative of two experiments. *, P  0.05
when compared with the increment of cAMP above the
respective basal in the 2 mM Ca2 group, one-way ANOVA
followed by Dunnett’s test.
Fig. 6. Analysis of AC mRNA Expression in Rat Adenohy-
pophysis by RT-PCR
A, RT-PCRs with common primers for ACV and ACVI and
restriction digests of the PCR products were carried out as
described by Premont et al. (55). Agarose gel chromatogram
of PCR/restriction digest products from rat adenohypophysis
(lanes 1, 3, 5, and 7) and brain (lanes 2, 4, 6, and 8). PCR
products were digested with XhoI (lanes 1 and 2), SacI (lanes
5 and 6), or both enzymes (lanes 3 and 4). Undigested PCR
products are shown in lanes 7 and 8. The positions of stan-
dards (bp) are shown in the extreme left and right lanes (m).
Upper arrow indicates 1095-bp product derived from ACV
mRNA digested by SacI to yield fragments of 220 bp and 875
bp (middle arrow); 1095-bp ACVI product remains undi-
gested. Digestion with XhoI yields fragments of 300 bp and
795 bp (lower arrow) from the ACVI-derived PCR product but
does not cut that derived from ACV. B, Agarose gel chro-
matogram of the PCR product for ACVII using unique se-
quence-specific primers; the amplified segment was sub-
cloned, sequenced, and verified as ACVII.
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submicromolar Ca2. Both ACVI (29) and ACIX (38) are
inhibited by 0.1–1 M Ca2 and [Ca2]i levels in CRF-
stimulated corticotropes are within this range (39, 40).
A further possible mode of Ca2 negative feedback
action on cAMP is the stimulation of cAMP hydrolysis.
Approximately 70% of the total PDE activity in the
adenohypophysis is Ca2/calmodulin activated (20,
41) and consists of both low Km (1.5 M) and high Km
(50 M) species. Based on studies with various in-
hibitors of PDE (20), it would appear that high Km,
Ca2-activated PDE is active only during stimulation
by CRF and AVP. Work in GH3 pituitary tumor cells
indicates that low Km Ca
2-activated PDEs (PDE1C)
may be important for basal cAMP levels (42). These
enzymes are expressed in the rat adenohypophysis
(20); however, there is no compelling evidence for a
major involvement of Ca2-activated PDEs in the re-
sponse to physiological levels of CRF.
Taken together, the main target of Ca2 feedback
inhibition upon activation by physiological concentra-
tions of CRF appears to be ACIX (Fig. 9A).
Modulation of Ca2 Feedback Inhibition of cAMP
Synthesis by AVP
AVP augmented CRF-induced cAMP accumulation in
the presence of PDE blockers and had no detectable
effects on basal cAMP in the presence or absence of
PDE blockers. This confirms previous reports (12, 14)
showing that, in corticotrope cells, AC is a coincidence
detector for the simultaneous activation of Gs and
protein kinase C by CRF and AVP, respectively. In-
deed, mRNA for both ACII and ACVII, ACs that are
stimulated by protein kinase C in the context of acti-
vation by Gs, is expressed in rat adenohypophysis
(Refs. 36 and 43 and present study). The potentiation
of the cAMP response by AVP and PdBu was promi-
nent in Ca2-depleted cells, suggesting the involve-
ment of a Ca2-independent and phorbol ester-acti-
vated form of protein kinase C, such as  or , which
are prominently expressed in rat adenohypophysis
(44, 45). Human erythroid progenitor cells, which ex-
press predominantly ACVII, show a similar potentia-
tion of cAMP synthesis by Ca2-independent, phorbol
ester-activated protein kinase C (46). As ACII protein
was not found in corticotrope cells, it is reasonable to
suggest that ACVII is the AC activated by the combi-
nation of physiological concentrations CRF and AVP,
and by supraphysiological (1 nM) concentrations of
CRF.
The reduction of the effect of AVP on CRF-induced
cAMP formation in the presence of PDE blockers ob-
served in the present study is consistent with the
inhibition of high Km PDE activity by AVP observed
previously (12). The cAMP concentration in cortico-
Fig. 7. Expression of ACII and ACIX mRNAs in Rat Adenohypophysis
In situ hybridization with 35S-labeled antisense (A) and sense (B) riboprobes for ACII indicating specific mRNA labeling in the
anterior lobe. C, RNase protection assay with 32P-labeled ACII probe (330 bp). Lanes 1 and 2, skeletal muscle; lanes 3 and 4,
adenohypophysis; lanes 5 and 6, hypothalamus. D, In situ hybridization with 35F-labeled antisense and (E) sense riboprobes for
ACIX indicating specific mRNA labeling in the anterior lobe. F, RNase protection assay with 32P-labeled AC9 probe (356 bp) and
a 220-bp -actin probe in both lanes. Each probe produced a single protected radiolabeled band.
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trope cells exposed to high physiological levels of
CRF/AVP was approximately 100–200 M, which is in
the range of high Km, high-capacity, Ca
2-activated
PDEs (47). Indeed, this type of PDE constitutes close
to 70% of cAMP-hydrolyzing activity in the adenohy-
pophysis (41) and is likely to be PDE1A or a closely
related enzyme (20). In the presence of PDE blockers,
Ca2 control of cAMP was blocked by PdBu activation
of protein kinase C or supraphysiological AVP concen-
trations. In the absence of PDE inhibitors, Ca2 de-
pletion still markedly enhanced the cAMP response at
all AVP concentrations tested. Hence, the data indi-
cate that the predominant mode of operation of Ca2
feedback is switched by AVP from the inhibition of
ACIX to the activation of high Km PDE (Fig. 9, A and B).
Intriguingly, AVP also appears to suppress the activity
of the same PDE, leading to a functionally concerted
and highly effective augmentation of intracellular
cAMP levels. Whether or not there are intracellular
gradients of cAMP (48, 49) in corticotropes, and what
the physiological target(s) of 100 M cAMP may be,
remains to be investigated.
Implications for Physiological Control
The present data conform to a model incorporating
Ca2-inhibited ACIX, protein kinase C-activated
ACVII, and high-Km, high-capacity PDE (Fig. 9, A and
B). The Ca2-inhibited component of the CRF-in-
duced cAMP response appeared to saturate between
0.3 nM and 1 nM CRF. Thus, it is reasonable to hypoth-
esize that at physiological concentrations (i.e. 0.3
nM) of CRF, ACIX is predominant and ACVII is only
weakly activated (Fig. 9A). Under these conditions,
PDE4 is important for cAMP hydrolysis and no evi-
dence for the involvement of high-Km, Ca
2-activated
PDE was apparent (20). Activation of protein kinase C
stimulates ACVII; thus, in the presence of AVP, ACVII
would emerge as the dominant AC (Fig. 9B). A further
mechanism that would facilitate the switch to Ca2-
independent cAMP synthesis through ACVII is that
activation of protein kinase C inhibits the activation of
ACIX by Gs-coupled receptors (50).
The concentrations of CRF (0.3 nM) and AVP (0.3–
2 nM) used in the present study approximate the
physiological levels in the hypophysial portal blood
of animals subjected to various forms of stress (re-
viewed in Refs. 1 and 51). The intracellular cAMP
response is a major determinant of the efficiency of
glucocorticoid inhibition at the pituitary gland (52),
which is the main site of action of the synthetic
glucocorticoid dexamethasone (53) and is also sig-
nificant for physiological control by endogenous
corticosteroids. The present study shows that func-
tionally concerted actions of AVP through protein
kinase C produce a rapid switch in the cAMP bio-
synthetic pathway. An escape of cAMP biosynthesis
from Ca2-negative feedback inhibition ensues,
which is made possible by the molecular diversity of
cAMP signaling proteins expressed in corticotrope
Fig. 8. Localization of AC Expression In Corticotrope Cells
by Indirect Immunofluorescence
Affinity-purified antibodies against ACII, V/VI, and IX were
reacted with free-floating sections of rat adenohypohysis.
The reaction for ACs was detected with secondary antibodies
conjugated to Alexa 488 dye, ACTH was visualized with Alexa
546 conjugates. The bar represents 20 m. Note widespread
expression of ACIX and its colocalization with ACTH. No
colocalization with ACTH was apparent for ACII or ACV/VI.
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Fig. 9. Schematic Summary of the Effects of AVP and Ca2 on CRF-Induced cAMP Responses in Adenohypophysial Cortico-
trope Cells
A, CRF signaling at physiological concentrations of the neurohormone. Note that the main mode of Ca2 feedback (in thick line)
is the inhibition of AC. Whether this is a direct action of Ca2 on the enzyme or is mediated by other factors remains to be
investigated. B, Switch of Ca2 feedback by AVP. Note functionally coordinated effects of AVP to activate ACVII and to suppress
the Ca2-inhibited AC as well as the Ca2-activated PDE. As a result, the rate of cAMP synthesis is increased, and the main
avenue of Ca2 feedback is through Ca2-activated PDE (PDE1A). CRF1R, CRF1 type receptor; AVP1R,V1 receptor; PLC,
Phopholipase C’3b; P*ACVII, phosphorylated adenylyl cyclase VII; IP3, inositol 1,3,5 trisphosphate; ACIX, adenylyl cyclase IX;
PDE1, type 1, Ca2/calmodulin-activated cyclic nucleotide phosphodiesterase; PDE4, type 4, cAMP-specific cyclic nucleotide
phosphodiesterase; IP3R, IP3 receptor; Kinase A, cAMP-dependent protein kinase; Kinase C, Ca
2-independent, phorbol-ester
activated protein kinase C; CiCr, Ca2-induced Ca2 release from intracellular stores.
700 Mol Endocrinol, April 2003, 17(4):692–703 Antoni et al. • Plasticity of cAMP Signaling
               dc_385_12
cells. The main physiological consequence is the
resistance of ACTH release to glucocorticoid feed-
back inhibition (52).
MATERIALS AND METHODS
Reagents
Unless stated otherwise, all reagents were of the highest
analytical grade available. Rat/hCRF and AVP were from
Bachem (Saffron Walden, UK); bis-indolyl maleimide I, PdBu,
thapsigargin, and ryanodine (technical grade 96%) were
supplied by LC Laboratories, Alexis Corp., Nottingham, UK);
IBMX and caffeine were from Sigma-Aldrich Corp. (Poole,
Dorset, UK); and rolipram was provided courtesy of Schering
AG (Berlin, Germany). BAPTA/AM, BCECF/AM, and
FURA2/AM were from Calbiochem-Novabiochem (Notting-
ham, UK).
Rat Anterior Pituitary Cells
Isolated cells were prepared by tryptic digestion from the
anterior pituitary glands of male Wistar rats (150–200 g body
weight) and preconditioned for 2–3 h in Hanks’ balanced salt
solution (HBSS) without Mg2 and Ca2 (HBSS, Life Tech-
nologies, Inc., Paisley, UK) supplemented with HEPES (pH
7.4), 2 mM CaCl2, and 1 mM MgSO4 0.25% BSA as previously
described (20). Subsequently the cells were sedimented by
centrifugation, resuspended, counted in a hematocytometer,
and diluted 10-fold or greater with low Ca2 medium [HBSS
with 2 mM EGTA, 1 mM MgSO4, 25 mM HEPES (pH 7.4),
0.25% wt/vol BSA] or the same medium containing 4 mM
CaCl2 as required by the experiment. Aliquots (50 l) of the
cell suspension (0.6–1  106 cells/ml) were distributed into
conical polypropylene RIA microvials (Sarstedt, Leicester,
UK) in 96-well format and incubated in a water bath at 37 C.
Ca2 Depletion Protocols and the Measurement of
cAMP in Intact Cells
Depletors/blockers of intracellular Ca2 stores or acetoxy-
methyl-esters (BAPTA-AM, FURA2-AM, and BCECF-AM)
were added in 50 l at the start of preincubation, as indicated
in the text and figure legends. The drugs used to modify
intracellular Ca2 handling were caffeine, an activator of RyR,
ryanodine, a blocker of RyRs, and thapsigargin, an inhibitor of
intracellular Ca2-ATPases that refill RyR and inositol-1,3,5-
triphosphate receptor-operated Ca2 stores. The two latter
drugs were dissolved in ethanol; hence, vehicle controls were
used as appropriate (0.1–0.3% vol/vol ethanol). Caffeine, be-
cause it has PDE inhibitor activity, was applied only in the
presence of blockers of cyclic nucleotide PDEs. Overall,
when combined with 2 mM EGTA and 2 M thapsigargin in the
presence of PDE blockers, caffeine or ryanodine produced
similar changes of cAMP levels.
Aliquoted cells were preincubated in 100 l of medium for
30 min. Unless indicated otherwise, blockers of PDE (1 mM
IBMX and 0.1 mM rolipram) were introduced after 20 min of
preincubation in a volume of 10 l. The only exception to this
pattern was when the effects of acutely applied modified low
Ca2 medium containing 0.2 instead of 2 mM EGTA were
assessed, in which case the cells received PDE blockers
immediately upon resuspension in the incubation medium.
After 30 min of preincubation, agonists dissolved in 2 mM
or low Ca2 medium were added in 50 l volume. The pH of
this solution was 7.65 to minimize the change of pH upon
mixing with 2 mM EGTA; a pH shift from 7.40–7.29 occurred
upon achieving a free Ca2 concentration of 2 mM. This
protocol was modified when the effects of Ba2 and Co2
were compared with those of Ca2, as these divalent cations
potently displace Ca2 from EGTA. Hence, cells were incu-
bated for 20 min under Ca2-depleting conditions and sub-
sequently pelleted by centrifugation at 200  g for 5 min.
Resuspension and all other additions were in modified low
Ca2 medium with 30 M ryanodine and 2 M thapsigargin.
Ca2 and other divalent cations were added assuming that
0.2 mM EGTA was present.
Incubation with agonists continued for 8 min unless indi-
cated otherwise. An equal volume (160 l) of 0.2 M HCl was
added to terminate the reaction. Total cAMP levels were
measured by RIA upon freeze-thawing and acetylation (15).
More than 90% of the cAMP content was associated with the
cells under these conditions, both in the presence and the
absence of PDE blockers.
RNAse Protection Assay
Total tissue RNA was prepared using Trizol reagent (Life
Technologies, Inc., Paisley, UK) according to the manufac-
turer’s instructions. The general solution hybridization
method and reagents were as provided in kit form by Ambion,
Inc. (Austin, TX). ACIX mRNA was detected using a probe
transcribed from rat ACIX cDNA (Paterson, J. M., unpub-
lished) corresponding to nucleotides 1107–1450 of the
mouse ACIX cDNA (GenBank accession no. Z50190) and
subcloned into pcDNA3. The riboprobe for ACII was tran-
scribed from cDNA corresponding to nucleotides 1755–2106
of the rat ACII cDNA (GenBank M80550, courtesy of Dr. R. R.
Reed, John Hopkins University, Baltimore, MD), which was
subcloned into pcDNA3 (Invitrogen, San Diego, CA) by stan-
dard procedures (54). 32P-labeled sense and antisense ribo-
probes were synthesized using the requisite RNA poly-
merases. 32P-labeled -actin (220 bp) cRNA probe was also
prepared and used as control for sample loading according
to the manufacturer’s instructions.
In Situ Hybridization
Plasmids described above for RNase protection assay were
transcribed with the requisite RNA polymerases to generate
35S-UTP-labeled sense and antisense strand riboprobes ac-
cording to standard procedures (54). The radiolabeled ribo-
probes were used for in situ hybridization histochemistry on
15-m sections of rat pituitary gland as previously described
(38). The sections were autoradiographed on Kodak x-ray
film (Eastman Kodak Co., Rochester, NY) for 5–18 d at
	70 C.
RT-PCR
Total RNA was prepared from brains and pituitary glands of
male Wistar rats and reverse transcribed as previously re-
ported (15). The PCR reaction and restriction enzyme analy-
sis of the products for ACV and ACVI were as described by
Premont et al. (55). Primers for rat ACVII were: forward,
GAAGAAGTTCAAGAAGGAGC; and reverse, AATCACTC-
CAGCAATCACAGGC. PCR was carried out as previously
reported (15) and the product was subcloned into pGEM-T
and sequenced in an automated DNA sequencer (Microsynth
A.G., Balgach, Switzerland).
Immunocytochemistry
Male Wistar rats (200–300 g body weight) were perfused
transcardially with 4% freshly depolymerized paraformalde-
hyde in 0.1 M sodium phosphate, pH 7.4. The pituitary gland
was removed from the skull and postfixed overnight at 4 C.
Subsequently the tissue was placed in 15% and then 30%
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sucrose in PBS for cryoprotection. Transverse, 60- to 90-m-
thick sections were cut on a cryostat, collected, and pro-
cessed for immunocytochemistry as free floating sections
(56). Primary antisera were as follows: chicken antibodies
directed against the C terminus of ACIX (38) were purified
from egg-yolk extracts on antigen peptide coupled to Sepha-
rose 4B by differential desorption (57) and used at 1:200 to
1:500 dilution. Affinity-purified rabbit antibodies against rat
ACII (lots J105 and L227, used at 1:300), human ACVII (lot
K070 used up to 1:50), and rat ACV/VI (lot I 110, 1:400) and
their respective antigen peptides were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). C-terminally di-
rected mouse anti-ACTH monoclonal antibody (clone CBL56)
was purchased from Cymbus Biotech (Chandlers Fords,
Hants, UK) and used at 1:1000. Affinity-purified secondary
antibodies raised against rabbit or mouse IgG in goat, and
coupled to Alexa 488 and 598 fluorescent dyes, respectively,
were from Molecular Probes, Inc. (Eugene, OR) and used at
1:300-fold dilution. Sections were mounted on glass slides
coated with polylysine (Merck & Co., Inc.), covered with Per-
mafluor (Beckman Coulter, Inc., High Wycombe, Bucking-
hamshire, UK) and viewed in a E600FM Eclipse microscope
(Nikon, Melville, NY) equipped with a Radiance 2000 confocal
headstage (Bio-Rad Laboratories, Inc., Hercules, CA) at 10
and 40 (oil immersion) magnifications. Image acquisition
was adjusted by the Lasersharp software (Bio-Rad Labora-
tories, Inc.), so that no cross-talk between the green and red
detection channels was apparent. The specificity of each of
the primary sera was verified by preabsorption with the re-
spective peptide antigens at 5 M for commercial antibodies
and 10 M for chick anti-ACIX for 16 h at 4 C before appli-
cation to the sections; secondary antibody specificities were
also verified in reactions where one or both of the primary
antibodies were omitted.
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GUANOSINE 3':5'CYCLIC MONOPHOSPHATE AND ACTIVATORS OF GUANYLATE CYCLASE 
INHIBIT SECRETAGOGUE-INDUCED CORTICOTROPIN RELEASE BY RAT 
ANTERIOR PITUITARYCELGS 
Ferenc A. Antoni and Govindan Dayanithi 
Department of Human Anatomy, University of Oxford, 
Oxford, OX1 3QX, England 
Received November 29, 1988 
The secretion of corticotropin by perfused rat anterior pituitary cell 
columns was studied. Forty-one residue corticotropin releasing factor, vaso- 
pressin and high extracellular KC1 all stimulated the secretion of cf6ticotro- 
. The hormo 
ZZZopressin (IO- ?P 
response to corticotropin-releasing factor (IO' 
mol/l) 
mol/l 1, 
as well as KC1 (48 mmol/l) was reduced by membrane 
permesnt 
Y analog (1 o- 
ogs of cGMP, such as 8-BrcGMP and dibutyryl-cGMP. The 8-BrcGMP 
mol/l) inhibited corticotropin release in res nse to corticotre 
pin-releasing factor by 302, that t $" 
50% Atriopeptin,-2 (10 and 10-4v~~~XQs~",~~ttl~e~~~w~~~ ~~~~~ 
membrane-bound guany 9 ate cyclase in the antkior pituitary gland, decreased 
the release of corticotropin induced by vssopressin to about 30 $ of control. 
Similarly, activators of solu'$Le gusnylate cyclsse, such es glyceryltrinitrate 
and sodium nitroprusside (IO- 
cotropin release by 6C$. 
mol/l) inhibited vasopressin-stimulated corti- 
In conclusion, the data show that purported activators of particulate and 
soluble guanylate cyclase, as well as derivatives of cGMP itself are strong 
inhibitors of secretagogue-induced corticotropin release by corticotroph cells 
of the anterior pituitary gland. B 1989 Academic Press, Inc. 
The secretion of ACTH by the anterior pituitary gland is regulated by 
hypothalamic neurons that release their neurohormones into hypophysial portal 
blood. Forty-one residue corticotropin releasing factor and vasopressin are 
physiologically relevant mediators of the hypothalamic control of ACTH release 
[l-3]. Furthermore, a cohort of other hypothalamic neuropeptides have a 
direct stimulatory effect on adenohypophysiel corticotroph cells [l-3]. In 
contrast, the only known functionally significant inhibitors of ACTH release 
are adrenocortical steroid hormones with glucocorticoid activity [3,4]. 
Abbreviations used: 41-residue corticotropin- releasing factor (CRF-41), 
guanosine3':5'cyclic monophospha 
monophosphate (8-BrcGMP) and 2 
(cGMP), 8-bromoguanosine3':5'-cyclic 
cyclicmonophosphate (di-BucGMP). 
,2'-0-Dibutyrylgusnosine3':5'- 
0006-291X/89 $1.50 
Copyright 0 1989 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 824 
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Several laboratories have investigated the effects of atriopeptin on ACTH 
secretion. The findings of these studies are highly controversial, minor 
stimulation [5] or inhibition [6] and no change [7-IO], all have been repor- 
ted. Atriopeptin activates membrane-bound guanylate cyclsse in a number of 
tissues, including the adenohypophysis [7,10], moreover, some of its effects 
on cellular activity are mimicked by membrane permeant cGMP derivatives [cf. 
11 1. In the present study we examined whether such cGMP derivatives, atric- 
peptin and nitroso activators of soluble guanylate cyclase can influence the 
secretion of ACTH. 
MATERIAL9 AND ME?THODS 
If not otherwise indicated all chemicals were of the highest anslytical 
standard available. The 
(Peninsula, St Helens, U.K. , T 
ptides used in this study were as follows: CRF-41 
8-arginine-vasopressin and rat atriopeptin 
(Bachem, Saffron Walden, U.K.) Another batch of atriopeptinl-28, the d&g 
snalogs 8-BrcGMP and di-BucGMP, as well as sodium nitroprusslde were from 
%g;dc:;;le, Dorset U.K. Glyceryltrinitrate was obtained as lmg/ml solution 
, San01 Schwarz Pharmaceuticals). 
Dispersed anterior pituitary cells were prepared from the anterior pitui- 
tary glands of 8-10 randomly cycling female Wistar albino rats (body weight 
250-350 g, supplier Harlan Olac, Bicester, U.K., by digestion with trypsin 
1 
Code TRL, Worthington Biologicds) following previously published procedures 
12-j. The cells (1 ml) were resuspended in Dulbecco's MEM (GIBCO), buffered 
with HEPES at pH 7.4, containing bovine serum albumin (Miles) Ig/l and mixed 
with 1 ml of preswollen Sephsdex G-10 (Pharmacia) in the same medium. Ali- 
quots of the gel-cell slurry were then transferred to the cell columns [IS], 
the chamber volume was adjusted to 0.6 mland perifusion was started with a 
multichannel peristaltic pump at a rate of lml/ 5min. Fractions of the ef- 
fluent were collected every 5 min on ice. The transit-time from the medium 
reservoir to the fraction collector was 1.5 min. After an equilibration period 
of 2h, various treatments were applied every hour for 5 min. Fiftyplali- 
quots of the effluent were assayed for immunoreactive ACTH content using 
antiserum No. 6 (courtesy of G.B. Mskara, Budapest, Hungary) as previously 
described [ 141. The essay standard ACTH 
AG., Basel, Switzerland. The sensitivi -zy 
-39 was kindly provided by CIBA-Geigy 
of the assay is 0.5 fmol/tube ACTH, 
and no interference by 8-BrcGMP is apparent. 
Upon a 5 min exposure to secretsgogues the concentration of ACTH in the 
column effluent increased in three consecutive 5 min fractions. Net ACTH 
release is therefore defined as (X+Y+Z)/3(B), where X is the fraction collec- 
ted during the presence of stimulus ( 1.5 min transit-time effluent discard- 
ed), Y and Z are the next consecutive 5 min fractions, and B is the basal 
value immediately before the application of a stimulus. 
The experiments were performed in a balanced complete block design. 
Because of the significant variation in the output of ACTH between experiments 
and the low number of observations per treatment (usually 4-8) data were 
sndysed by non-parametric statistics with correction for repeated measures. 
In particular, Wilcoxon's matched pairs, signed ranks test, and L&de's two- 
way snalysis of variance with subsequent multiple comparisons were used as 
described in ref 15. For the ease of comparison data from a pool of columns 
are expressed after division with the amount of ACTH released in response to 
the control AVP, CHF or KC1 stimulus applied in the respective column. 
RESULTS 
Basal ACTH release was usually around the limit of detection of the 
radioimmunoasssy (10 fmol/ 5 min). Five minute exposure to increasing concen- 
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150 
50 
0 -II ’ 
, I 
10‘10 10-g 10-e 
Conc.Imol/ll 
F1GUR.H 1. The effect of CRF-41, vasopressin and KC1 on ACTH release by per- 
fused rat anterior pituitary cell columns. The secretsgogues were applied fc§ 
5 min. Net ACTH release is expressed as the percentile of the response to 10 
mol/l CR%41 (net ACTH release per 15 min = 37OtZ3 fmol, mean+ S.E.M.) which 
was run in sill columns. n=4/group. Basal release is usually aTout 10% of the 
loo9 mol/l CRF-41 stimulated response. 
trations of CRF-41 end vasopressin stimulated ACTH release in a dose-dependent 
manner, CKF-41 being the more potent secretegogue (FIG 1); 48 mmol/l KC1 was 
slso effective (FIG 1). Administration of 8-BrcGMP 10 min before and during 
the 5 min application of CRF-41 (lo-" mol/l) reduced the ACTH response to 
this stimulus in a dose-dependent manner (FIG 2). Vasopressin-induced ACTS 
release was diminished by 8-BrcGMP as well as di-BucGMP (FIG 2 & 3). The 8- 
BrcGMP analog (10-4m01/1) also supressed ACTH release induced by the combina- 
tion of CRF-41 (5 x IO-" mol/l)a.nd vasopressin (5 x 1O-1o mol/l>, which is 
the physiological cocktail of these stimulators found in pituitary portal 
blood, to 25+_11$ (mean 5S.E.M. n=6, PcO.05) of the control stimulus. The 
ACTH response to 48 mmol/l KC1 was reduced to 55 +_ 6 $ (mean +_S.E.M., n=8, 
P<O.Ol) of the control stimulus by 8-BrcGMP at loo5 mol/l. No consistent 
effect of cGMP analogs on basal ACTH release could be discerned. 
Atriopeptin, administered in the same temporal pattern es the cGMP ane+ 
logs, markedly inhibited the ACTH response to vasopressin (FIG 3 and Table I). 
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fects of membrane permeant analogs of cGMP on ACTH release 
mol/l CRF-41 (left pan-q, net ACTH to control stimulus = 
275233 fmol/l5 min, mean+ S.E.M.) and IO mol/l axginine-vasopressin (right 
net ACTH to con501 stimulus = 212+ 14 fmol/l5 min {di-BUcGMP 
z;%nent} and 120+13 fmol/l5 min {&BrcGMP>xperiment}) 
the bars represent t?ie S.E.M., n=4 in all groups. Symbols : 
di-BucGMP, * P<O.@, when compared with the control 
The nitroso compounds glyceroltrinitrate and sodium nitroprusside were also 
effective inhibitors of vasopressin-stimulated ACTH release (Table I). 
DISCUSSION 
The data presented here suggest that a rise of intracellular cGMP levels 
strongly suppresses ACTH release induced by three secretagogues that utilize 
distinct transmembrane signaling mechanisms [1,16]. 
The concentrations of CR%41 and vasopressin used are in the range of the 
concentrations of these peptides in the hypophysial portal blood of anaesthe- 
tized rats [cf.2,17] or conscious rams exposed to stressful stimuli [18]. It 
seems therefore reasonable to suggest that elevation of intracellular cGMP 
levels mey inhibit ACTH release under physiological conditions. 
The mechanism of cGMP action was not addressed in the present study. 
However, it is known that a common requirement for the ACTH stimulating action 
of CRF-41, vasopressin and KC1 is en increase of cytoplasmic free Ca 2+ [cf.l], 
and it is now well established that cGMP reduces the stimulus induced rise in 
intracellular free Ca2+ levels [I 9-211. This mechanism could also explain its 
inhibitory effects on secretagogue-stimulated ACTH release. 
Current evidence indicates that most tissues contain two distinct types 
of guanylate cyclaSe, a particulate enzyme in the plasma membrane and a solub- 
le cytosolic species [II]. Atriopeptin is one of the few agents known to 
stimulate particulate guanylate cyclase [cf.ll], and also increases cGMP 
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too 
a 
EXP.266 
166 216 
- EXP.266 
100 - 
2 4 6 
Tlms lhl 
wmol/l. Vasopressin 
The effects of di-BucGMP and atriopeptin on ACTH release stimulated 
. Data from two individual exDeriment,s are shown. 
which are included !in the summaries presented in FIG 2. &Black boxes indicate 
the application of vasopressin (5 min), boxes with numbers show the 
application of di-BucGMP the number is the 
concentration in mol/l, striped boxes indicate 10 -~"~~~,lo~Ii~i~~~~ 
The numbers on the top of secretory peaks show the net amount of ACTH released 
over 15 min in the respective peaks, the dashed line indicates the limit of 
detection of the radioimmunoassqy. 
levels in anterior pituitary cell cultures [7,10J. However, despite the 
increase in cGMP levels no prominent effect on CRF-41 stimulated ACTH release 
was detected, as measured in static incubations lasting 3 h [6,7,9,10]. In 
the present study we have used acutely dispersed cells in a perifusion system, 
and applied stimuli of short duration to demonstrate a strong inhibitory 
action of atriopeptin on secretsgogue induced ACTH release. These differen- 
ces in methodology mqy well explain the failure of previous workers to reveal 
the inhibitory effect of the peptide. 
Atriopeptin is found in hypothalamic neurons that project to the external 
layer of the median eminence [cf. 22 end references therein]. Thus, the pr+ 
sent data raise the possibility that atriopeptin may function as a hypothala- 
mic corticotropin-release inhibiting factor. Alternatively, since atriopeptin 
is a circulating hormone [23] it may antagonize fluid and salt retention 
caused by the excess production of adrenocortical mineralocorticoids brought 
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Table I. Eefeds of activators of m -- 
bya minuteexposuretovasopresein (1 3 
cyclase on ACM release induced 
mol/l). !Che columns were treated 
with the guanylate cyclase activators 10 min before and 5 min during the 
application of vasopressin. Data are means + S.E.M., expressed as percentage 
of the control stimulus (vasopressin alone) i’i the respective column. Experi- 
ments were performed in a balanced complete block design, n is the number 
observations per group, * means P<O.@ using Wilcoxon’s matched pairs, signed 
ranks test or Quade’s 2-wsy analysis of variance as applicable 
Compound net ACM release [$I n 
Gly eroltrinitrate 
5 lo- mol/l 475 * 6 
SodJumnitroprusside 
IO mol/l 
10e5 mol/l 
42+5 * 
5510 * t 
At$opeptin (Bachem) 
10 mol/l 
1 o-%lo l/l 
4 
4 - 
about by increased release of ACTH. However, further studies with more phy- 
siological concentrations of the peptide are required to establish the 
validity of these hypotheses. 
Glyceryltrinitrate and sodium nitroprusside, activators of soluble gua- 
nylate cyclsse in several types of tissue [cf.ll] also decreased ACTH release 
induced by vesopressin. It appears therefore, that activation of both types 
ofguanylate cyclase suppresses ACTH release, and in subsequent studies it 
should be possible to examine the regulation of the soluble enzyme in anterior 
pituitary corticotroph cells. 
In summary, the present data show that a rise in intracellular levels of 
cGMP strongly inhibits the secretagogue-induced release of ACTH. Further work 
is warranted to identify bioactive compounds that regulate cGMP metabolism in 
anterior pituitary corticotrophs. 
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ABSTRACT
The current concept of the regulation of adenohypo-
physial corticotrophin secretion assigns a stimulatory
role to neuropeptides of hypothalamic origin and an
inhibitory function to adrenocortical glucocorticoid
hormones. It has been shown that in isolated perifused
rat anterior pituitary cells atriopeptins (1\p=n-\28) and(5\p=n-\28), but not (5\p=n-\25), potently suppress corticotro-
phin secretion elicited by 41-residue corticotrophin\x=req-\
releasing factor and arginine vasopressin. The action of
atriopeptins is associated with a marked increase in
the cellular content of cyclic GMP. Moreover, 8-Br\x=req-\
cyclic GMP, a cell membrane permeant analogue of
cyclic GMP, also inhibited secretagogue-stimulated
corticotrophin release. It is suggested that atrio-
peptins of hypothalamic and perhaps of cardiac origin
may be functionally significant corticotrophin-release
inhibiting factors.
Journal ofEndocrinology (1990) 125, 39\p=n-\44
INTRODUCTION
Forty-one residue corticotrophin-releasing factor(CRF-41) and arginine vasopressin (AVP) are the
principal hypothalamic stimuli of anterior pituitary
adrenocorticotrophin (ACTH) secretion (Antoni,
1986; Rivier & Plotsky, 1986). These neurohormones
are co-secreted into hypophysial portal blood by
hypophysiotrophic neurones (Antoni, 1986; Whitnall,
1988) and synergistically stimulate ACTH release(Gillies, Linton & Lowry, 1982).
Previously, we have shown in vitro that cyclic GMP(cGMP) derivatives that permeate the cell membrane
inhibit the release of ACTH (Antoni & Dayanithi,
1989a) elicited by the combined stimulus of 005 nmol
CRF-41/1 and 0-5 nmol AVP/1 (CRF-41/AVP), which
is the physiological ACTH-releasing cocktail in the
hypophysial portal blood of rats (Plotsky, 1987; Fink,
Robinson & Tannahill, 1988) and sheep (Caraty,
Grino, Locatelli & Oliver, 1988; Engler, Pham,
Fullerton et al. 1989) subjected to stressful stimuli.
In the search for physiologically relevant sub¬
stances that may regulate the production of cGMP in
adenohypophysial corticotroph cells we examined
whether atriopeptins, which are well-known acti¬
vators of particulate guanylyl cyclase in various
tissues (Waldman & Murad, 1987; Goetz, 1988), can
influence the secretion of ACTH.
MATERIALS AND METHODS
Isolated anterior pituitary cells were prepared from the
adenohypophyses of female Wistar rats (250-350 g
body weight) by digestion with trypsin (Dayanithi &
Antoni, 1989). The cells were mixed with preswollen
Sephadex G-10 (Pharmacia, Milton Keynes, Bucks,
U.K.) and loaded into columns which were perfused
at a rate of 0-3 ml/min with Dulbecco's Minimal
Essential Medium (GIBCO, Paisley, Strathclyde,
U.K.) containing 2-5 g bovine serum albumin/1, 105 U
penicillin/1, 1 g streptomycin/1 and 2-5 mg amphoteri-
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ein B/l (Gillies et al. 1982; Dayanithi & Antoni, 1989).
Fractions of the column effluent were collected every
2-5 min and ACTH content was determined by
radioimmunoassay (Dayanithi & Antoni, 1989).
Unless stated otherwise, the columns were primed
before the experimental treatments as follows. At 1 h
after the start of the perifusion CRF-41 (1 nmol/1;
Bachern, Saffron Waiden, Essex, U.K.) was applied to
the cell columns for 5 min, followed by 0-5 nmol CRF-
41/1 and 0-5 nmol AVP/1 (Ferring, Malmö, Sweden)
for 5 min at 1-5 h and 2-5 min at 2 h after the start of
perifusion. This priming procedure (treatment A) was
necessary to ensure that the response of ACTH to
CRF-41 /AVP was uniform during the course of the
experiment. Another priming protocol, treatment B,
involved applying CRF-41/AVP for 5 min at 0-5,1 and
1
-5 h and for 2-5 min at 2 h after the start of the peri¬
fusion. This protocol also produced virtually uniform
net responses of ACTH to a repeated challenge with
CRF-41 /AVP.
Following priming, experimental treatments were
applied in a randomized block design. The cells were
exposed to rat atriopeptins (all from CRB, Cambridge,
Cambs, U.K.) for 10 min before and 2-5 min during
stimulation with CRF-41/AVP. In the experiments
shown in Fig. 2 atriopeptin or 8-Br-cGMP were given as
a continuous infusion starting 10 min before the second
stimulation with CRF-41/AVP and terminating after
the fourth stimulation period.
Net ACTH release was calculated (Dayanithi &
Antoni, 1989) and, because of the variation in the net
ACTH release between experiments, data were stan¬
dardized within each column by expressing net ACTH
release as a percentage of the net hormonal response
to the control CRF-41/AVP stimulus. Statistical
analysis was by Quade's two-way non-parametric
analysis of variance for repeated measures (Conover,
1980).
For the measurement of cGMP the cells (without
Sephadex G-10) were preincubated for 2 h in the
medium used for perifusion experiments, then collected
by centrifugation and resuspended in medium contain¬
ing mol iso-butyl-methyl xanthine (5  10~4 mol/1) at106 cells/ml. Aliquots (0-5 ml) of the cell suspension
were incubated with various concentrations of atrio¬
peptins at 37 °C for 20 min after which the tubes were
placed on ice, and the cells pelleted at lOOg. The
supernatant was aspirated and 0-25 ml 6% (w/v) tri-
chloroacetic acid added to the pellet which was soni¬
cated. After centrifugation, the supernatant was
collected and extracted with 0-5 ml of a mixture of tri-
N-octyl-amine and 1,1,2-tri-chloro-tri-fluoro-ethane(2-2:7-8, v/v; Aldrich Chemical Co., Gillingham,
Dorset, U.K.) to remove the tri-chloroacetic acid(Martin, Morgan, Smith & White, 1986). The cGMP
content of the aequous upper phase was determined
by radioimmunoassay after acetylation (Harper &
Brooker, 1975), the cross-reaction with acetylated
cAMP was less than 0-1 %.
RESULTS
Figure 1 characterizes the CRF-41/AVP stimulus in
relation to baseline secretion.
600
400
X
H 200
<
AVP CRF-41 AVP +
CRF-41
figure 1. Effects of arginine vasopressin (AVP; 0-5 nmol/1)
and 41-residue corticotrophin-releasing factor (CRF-41;
005 nmol/1) or their combination on the release of ACTH
by perifused isolated rat anterior pituitary cells. Values are
means ± s.e.m. (n = 4/group), the shaded bar is the basal
hormone release inclusive ofs.e.m. *P< 001 compared with
CRF-41 or AVP alone (Quade's test).
Atriopeptin(l-28) markedly suppressed ACTH
secretion evoked by CRF-41/AVP (Fig. 2). A cell
membrane permeant analogue ofcGMP, 8-Br-cGMP,
also inhibited the hormonal response to CRF-41/
AVP (Fig. 2). The effect of atriopeptin(l-28) on
secretagogue-evoked ACTH release was concen¬
tration dependent (Fig. 3a), the maximal effect being
an approximately 70% reduction of hormone release
at 100 nmol inhibitor/1. Atriopeptin(l-28) increased
the cGMP content of anterior pituitary cells (Fig. 3b).
Atriopeptin(5-28), the predominant molecular
species found in the hypothalamus (Nakao, Morii,
Itoh et al. 1986), also inhibited ACTH release and
increased the accumulation of cGMP (Fig. 3).
Importantly, atriopeptin(5-25), an analogue which
had only a minor effect on cellular cGMP content,
was a weak inhibitor of secretagogue-stimulated
ACTH secretion (Fig. 3). Overall, atriopeptins had no
consistent effects on the basal secretion of ACTH,
which was generally in the range of the limit of detec¬
tion of the ACTH assay (0-5 fmol/tube). The relatively
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figure 2. Effect ofatriopeptin(l-28; D) (0-5 nmol/1) and 8-Br-
guanosine 3',5' monophosphate (8-Br-cGMP; A) (10 pmol/l) on the
release ofACTH evoked by the combined stimulus of 41 -residue
corticotrophin-releasing factor (005 nmol/1) and arginine vasopressin(005 nmol/1) (solid boxes) in perifused isolated rat anterior pituitary
cells. The hatched bar indicates the application of the inhibitor com¬
pounds. Values are means ± s.e.m. (n = 4/group). *P<0-05,
**P<001 compared with control (·) group (Quade's test).
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figure 3. Effects of atriopeptins(l-28;  ), (5-28; D) and (5-25; A) on (a) ACTH release evoked by
the combined stimulus of41-residue corticotrophin-releasing factor (005 nmol/1) and arginine vaso-
pressin (005 nmol/1) in perifused isolated rat anterior pituitary cells and (b) cyclic GMP (cGMP)
content of the cells in static incubation for 20 min. Values are means ± s.e.m. (a)  = 4/group (b)
 
= 3/group. *P < 005 compared with control value (Quade's test).
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figure 4. Effect of priming protocol on isolated perifused rat anterior pituitary cells. Cells became
refractory to inhibition by (a) atriopeptin(l-28) or (b) atriopeptin(5-28); the control stimulus is the
combination of41-residue corticotrophin-releasing factor (0-05 nmol/1) and arginine vasopressin(005 nmol/1) (CRF-41 /AVP). Values are means ± s.e.m. (« = 4/group). Treatment A ( O ) involved
applying 0-5 nmol CRF-41 /l for 5 min at 1 h after the start of perifusion followed by CRF-41 /AVP for
5 min at 1 -5 h and 2-5 min at 2 h. For treatment  ( ) CRF-41/AVP was given for 5 min every 30 min
up to 1 -5 h and for 2-5 min at 2 h before experimental treatments were started. For further details on
priming consult Materials and Methods.
poor precision of these measurements may, therefore,
have masked an inhibitory action of atriopeptins on
basal ACTH release.
Finally, it was found that atriopeptin(l-28) as well
as atriopeptin(5-28) were relatively ineffective in cells
primed according to treatment B, as compared with
their efficacy in cells primed according to treatment A(Fig. 4).
DISCUSSION
The results presented here indicate that atriopeptins
inhibit ACTH secretion evoked by CRF-41/AVP
through the atriopeptin receptor domain of the
membrane-bound guanylyl cyclase protein (Leitman,
Andersen, Kuno et al. 1986; Scarborough, Schenk,
McEnroe et al. 1986; Chinkers, Garbers, Chang et al.
1989).
Several groups have previously examined the effects
of atriopeptins on pituitary hormone secretion and
the increase of cGMP production has been reported(Heisler, Simard, Assayag et al. 1986; Shibasaki,
Naruse, Yamauchio et al. 1986; Abou-Samra, Catt &
Aguilera, 1987; Hashimoto, Hattori, Suemaru et al.
1987; King & Baertschi, 1989). However, the release
of ACTH was either unaltered by atriopeptins(Heisler et al. 1986; Abou-Samra et al. 1987;
Hashimoto et al. 1987) or a minor inhibitory effect
occurred which could not be correlated with the acti¬
vation of guanylyl cyclase (Shibasaki et al. 1986; King
& Baertschi, 1989), indicating that the action of atrio-
peptin is not through atriopeptin receptors coupled
with guanylyl cyclase. Finally, two other previous
studies have reported that atriopeptin actually stimu¬
lates ACTH release (Horváth, Erti & Schally, 1986;
Koch & Lutz-Bucher, 1989).
In contrast, in the present study atriopeptins were
found to be potent inhibitors of ACTH release, their
action is related to the increase of cellular cGMP con¬
tent, and is also mimicked by a membrane permeant
analogue of cGMP (Antoni & Dayanithi, 1989a) thus
bearing the hallmarks of an atriopeptin-A (previously
B-atriopeptin) receptor effect (Leitman et al. 1986;
Scarborough et al. 1986; Chang, Lowe, Lewis et al.
1989).
The probable explanation of this discrepancy lies in
the nature of the in-vitro models used. All of the pre¬
vious studies were carried out on primary cultures of
pituitary cells in static incubation, whereas we have used
acutely isolated perifused cells. Precedents for marked
alterations in the function properties of corticotroph
cells in primary culture when compared with freshly
dispersed cells are known (Antoni, 1986; Boyle,
Yamamoto, Chen et al. 1988), the reason for the lack
of responsiveness to atriopeptin, however, is not clear
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at present. It appears that cell surface receptors for the
peptide are present in cultured pituitary cells, since the
increase of cGMP production upon exposure to atrio¬
peptin has been consistently demonstrated (Heisler
et al. 1986; Abou-Samra et al. 1987), although the
possibility of a selective loss of atriopeptin receptors in
corticotrophs cannot be excluded at present. It seems
more plausible, however, that the target(s) of cGMP
action, e.g. protein kinase G, or an ion channel, may
be modified during culturing.
With respect to these possibilities, it has been shown
that at least two types of potassium ion channels are
required for the ACTH-release inhibiting action of
atriopeptin (Antoni & Dayanithi, 19896). The plasti¬
city of ion channels in various types of cell are well
documented, and conditions of cell culture may pro¬
duce an ion channel profile which is quite different
from that found in vivo (Lewis & Cahalan, 1988; Gilly
& Brisman, 1989). A decrease in the cellular concen¬
tration of cGMP-dependent protein kinase has been
demonstrated in cultured vascular smooth muscle
cells and appears to be the cause of the poor respon¬
siveness of these cells to atriopeptins (Cornwell &
Lincoln, 1989). Finally, evidence has been presented
that the type of atriopeptin receptor expressed by
vascular smooth muscle cells is altered during cultur¬
ing (Uchida, Mizuno, Shimonaka et al. 1989). Further
work is clearly required to elucidate the precise nature
of the changes in the properties of corticotrophs
during cell culture which lead to the poor response
to atriopeptin. It is, however, tempting to speculate
that, in our experiments, treatment of the cells with
secretagogue pulses soon after trypsinization may
have accelerated the development of these changes.
From the point of view of physiological function,
the results presented here indicate that atriopeptins of
cardiac (cf. Goetz, 1988) as well as hypothalamic(Nakao et al. 1986) origin may effectively inhibit the
pituitary secretion of ACTH.
The concentration of atriopeptins in the systemic
circulation is normally below 0-1 nmol/1 (cf. Goetz,
1988). It appears, therefore, that atriopeptins released
from the heart may only influence ACTH secretion
when the release of atriopeptin is enhanced, as in the
case of increased intravascular fluid volume (cf.
Goetz, 1988). Given the ability of ACTH to stimulate
the production of mineralocorticoid hormones such a
mechanism may contribute to the suppressive effect
of atriopeptins on adrenocortical function, and thus
promote the reduction of extracellular fluid volume.
Functional evidence for a hypothalamic inhibitor
of ACTH secretion that acts in a tonic manner has
been presented (Engler, Pham, Fullerton et al. 1988).
Atriopeptin-containing terminal axons that originate
in the hypothalamic para- and periventricular nuclei
have been observed in the immediate vicinity of pri-
mary portal capillaries in the external lamina of
the median eminence (Kawata, Nakao, Morii et al.
1985; Skofitsch, Jacobowitz, Eskay & Zamir, 1986;
Standaert, Needleman & Saper, 1986; Palkovits, Eskay
& Antoni, 1987), indicating that atriopeptin is released
into the hypophysial portal circulation. We have
shown here that atriopeptin(5-28), the major form of
atriopeptin in the hypothalamus, is a potent inhibitor
of CRF-41/AVP-stimulated ACTH secretion. We
suggest, therefore, that atriopeptin is a hypothalamic
corticotrophin-release inhibiting hormone.
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ABSTRACT. The aim of this study was to resolve previous
controversies regarding the effect of atriopeptin on the secretion
of ACTH in vivo. Male Wistar rats were used throughout. The
animals were subjected to lesioning of the hypothalamic para-
ventricular nucleus (PVN) or sham operation and implanted
with indwelling jugular cannulae 5 days later for blood sampling
and drug infusion. Two days after the insertion of the cannulae
the animals were treated with saline or 103-126 amino acid
residue atriopeptin iv: a bolus injection was given (200 or 40
pmol/rat) followed by an infusion (40 or 8 pmol/min) which was
maintained for the entire duration of the experiment (70 min).
Ten minutes after the bolus of atriopeptin the animals received
iv a combination of 1 pmol 41-residue CRF and 10 pmol arginine
vasopressin (CRF/AVP) to stimulate ACTH secretion. Serial
blood samples (0.1 ml) were obtained at —10 min and immedi-
ately before the injection of CRF/AVP and at 5, 10, 20, 30, and
60 min afterwards. Plasma ACTH concentration was measured
by RIA.
In sham-operated rats CRF/AVP caused a 4-fold increase in
plasma ACTH which peaked at 5 min and returned to baseline
by 60 min. In sham-operated rats the higher dose of atriopeptin
(200 pmol bolus, 40 pmol/min infusion) did not alter the effect
of the stimulus between 5 and 30 min, and augmented plasma
ACTH at 60 min. The smaller dose of atriopeptin reduced
plasma ACTH at 10 and 20 min by 54% and 48%, respectively,
and also decreased by 48% the net amount of ACTH released
over 30 min in response to CRF/AVP. When given alone, the
higher dose of atriopeptin caused a persistent (60 min) 10-13%
reduction of mean arterial blood pressure, while the lower dose
decreased blood pressure by about 9% for less than 10 min. In
parallel, the higher dose of atriopeptin increased plasma ACTH
concentration while the lower dose produced no change.
In PVN-lesioned rats the CRF/AVP induced ACTH response
was similar to that seen in sham-operated controls. Only the
higher dose of atriopeptin was tested, and this markedly reduced
CRF/AVP stimulated ACTH secretion at 5-60 min after CRF/
AVP. Given alone, atriopeptin had no marked effect on plasma
ACTH in PVN-lesioned rats, while its hypotensive action was
similar to that in sham-operated animals.
It is concluded that: 1) Atriopeptin inhibits stimulated ACTH
secretion in rats; 2) High systemic doses of atriopeptin that
cause persistent hypotension release endogenous ACTH-releas-
ing factors of paraventricular nucleus origin, and this may mask
an inhibitory action of the peptide at the pituitary level; 3)
Atriopeptin may function as a hypothalamic corticotropin re-
lease-inhibiting factor. (Endocrinology 127: 3003-3008,1990)
THE secretion of ACTH by the anterior pituitarygland is stimulated by the hypothalamic neurohor-
mones CRF and arginine-vasopressin (AVP), and inhib-
ited by adrenocortical glucocorticoid hormones (1-4).
There is also a considerable body of evidence for the
existence of an as yet unidentified hypothalamic corti-
cotropin-release inhibiting factor (CIF) (5-7).
Recent studies have revealed a novel, cGMP-mediated
mechanism of inhibiting ACTH release by isolated rat
anterior pituitary cells in vitro (8, 9). Atriopeptin, an
activator of particulate guanylyl cyclase is a potent stim-
ulus of cGMP production in anterior pituitary cells (10-
Received April 16,1990.
Address correspondence and requests for reprints to: F. A. Antoni,
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12) and inhibits ACTH release evoked by CRF and AVP
at subnanomolar concentrations (12-15). Since atriopep-
tin is found in the hypothalamo-hypophysial tract (16-
19) and is released into hypophysial portal blood (20) it
is a candidate for the role of the purported corticotropin
release-inhibiting substance. However, in vivo studies of
the action of atriopeptin on pituitary-adrenocortical
function generally do not support this notion (21-25),
although some workers have reported a reduction of
stimulated ACTH (26) or corticosterone (27) secretion
in rats.
In the present study we have sought to resolve this
issue by examining the effect of atriopeptin on plasma
ACTH levels in rats injected with CRF and AVP. A
possible source of the discrepancies in previous studies
appeared to be the hypotensive action of atriopeptin
which may stimulate the secretion of endogenous ACTH
3003
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releasing peptides (28, 29). Therefore, some of the exper-
iments were carried out in animals in which the main
source of hypophysiotropic CRF, the hypothalamic par-
aventricular nucleus had been destroyed.
Materials and Methods
Animals
Male Wistar rats (190-220 g BW, supplied by Harlan-Olac
(Bicester, Oxon, UK) or LATI (Godollo, Hungary) were housed
under standard lighting (0700-1900 h) in a temperature-con-
troled (23 C) room. Pelleted rat chow and tap water were
available ad libitum. The animals were anesthetized with pen-
tobarbital (40 mg/kg ip) and subjected to surgical lesioning or
sham lesioning of the hypothalamic paraventricular nucleus
(PVN), which is the main site of production of hypophysi-
otropic CRF (30). The procedures for the lesioning of the PVN
and the histological verification of the lesions have been pre-
viously described in detail (31). Briefly, animals were anesthe-
tized with pentobarbital and placed in a stereotaxic frame. A
specially designed microknife was lowered to the base of the
skull through a burrhole behind the Bregma suture, rotated
360° and withdrawn. For sham lesions the knife was lowered 5
mm below the surface of the brain and withdrawn. The site of
the lesion was verified in each animal by microscopic exami-
nation of serial 50 urn frontal sections of the frozen hypothal-
amus that were prepared on a sliding microtome and stained
with cresyl violet. Rostrally, the lesion usually damaged or
destroyed the anterior commissural nucleus while posteriorly
it extended into the dorsomedial nucleus. Laterally it did not
reach beyond the fornix. Results from animals with a complete
lesion of the PVN are reported.
Experimental treatments for monitoring plasma ACTH
Five days after hypothalamic surgery, the rats were again
anesthetized with pentobarbital and two cannulae were intro-
duced through a cut in the right jugular vein: a Silastic cannula
(od: 0.047 in; id: 0.025 in; Dow Corning, Midland, MI) for blood
sampling and a PP10 polypropylene cannula (Portex, Hythe,
Kent, UK) for parallel drug infusion. The cannulae were se-
cured in the vein, externalized sc at the back of the skull, and
fixed to the bone with an anchoring screw and dental cement.
Subsequently the animals were caged singly, and two days later
extension tubings were attached between 0900 and 1030 h to
the cannulae for blood sampling and continuous drug infusion.
The animals were left undisturbed for 4 h, then 0.1 ml blood
was withdrawn for measuring initial plasma ACTH concentra-
tion, and iv treatment with atriopeptin (residues 103-126 sup-
plied by Cambridge Research Biochemicals, Cambridge, UK)
was started. The treatment consisted of a bolus injection (200
or 40 pmol/rat in 0.1 ml saline) through the blood sampling
cannula while a constant infusion of 40 or 8 pmol/min in a vol
of 0.005 ml/min saline was started through the infusion can-
nula. Ten minutes later blood was sampled again and a mixture
of 1 pmol CRF/10 pmol AVP (CRF/AVP, both peptides from
Bachem, Saffron Walden, UK) in 0.2 ml saline was injected.
Further blood samples (0.1 ml) were withdrawn 5, 10, 20, 30,
and 60 min after the injection of CRF/AVP. Blood was collected
into chilled tubes containing Na2EDTA and centrifuged. The
plasma was collected and stored at —20 C. The concentration
of ACTH in plasma was measured by direct RIA as described
previously (32). In order to exclude the possibility that the
changes in plasma ACTH are due to changes in the volume of
distribution and/or the metabolism of ACTH we have deter-
mined the half-life of radioiodinated ACTH in conscious can-
nulated rats. The animals were implanted with jugular cannulae
and treated with CRF/AVP and saline or the larger dosage
regimen of ANF as above. Radioiodinated ACTH (cca 0.5 /*Ci)
(32) was coinjected with CRF/AVP, blood samples (0.1 ml)
were taken 1, 3, 5, 10, 20, 30, and 60 min after the injection of
the radiolabel. The radioactivity in plasma was counted in a
LKB Clini7-counter at 70% efficiency. The rate of disappear-
ance of the radiolabel from plasma was identical in saline and
atriopeptin treated rats, the apparent half-life was 2.6 min.
Measurement of mean arterial blood pressure (MABP)
In separate experiments MABP was monitored through an
arterial catheter (PP30), implanted into the left carotid artery
under pentobarbital anesthesia 1 day before the experiment,
using a Statham pressure transducer and a Hellige recorder.
The rats also received jugular cannulae as above. On the day
of the experiment at least 2 h were allowed for the stabilization
of MABP, then blood sampling and treatment with atriopeptin
was started as described above except that atriopeptin or saline
treatment was initiated at time 0 instead of —10 min. An
additional set of rats treated with the high ANF dosage regimen
and a bolus of CRF/AVP was also monitored for MABP.
Data analysis
Data were evaluated by the Kruskal-Wallis test followed by
multiple comparisons as described by Conover (33) or by Mann-
Whitney U test, as appropriate.
Results
Paradox effects of atriopeptin in sham-operated rats
In sham-operated rats iv injection of (CRF/AVP) pro-
duced a steep rise of plasma ACTH concentration which
peaked at 5 min after injection and declined to baseline
by 60 min. Treatment with atriopeptin that consisted of
an iv bolus of 200 pmol 10 min before CRF/AVP and an
infusion of 40 pmol/min for the entire duration of the
experiment, had no effect on the peak ACTH response
and prolonged the duration of the increase above basal
secretion (Fig. 1). Lowering the dose of atriopeptin to 40
pmol bolus and 8 pmol/min infusion caused a significant
reduction of plasma ACTH concentration at 10 and 20
min after CRF/AVP. Moreover, the average net ACTH
response (area under the curve) over 30 min was about
50% less than that in controls (Fig. 1, inset).
When atriopeptin was given alone the higher dose of
the peptide significantly increased plasma ACTH levels,
whereas the lower dose had no effect (Table 1). Plasma
ACTH levels tended to rise in all groups with time,
               dc_385_12
ANF INHIBITS ACTH IN VIVO 3005
a.
|
re
v>
J2
a.
60
40
20
-20 20
time [min]
40 60
FIG. 1. The effect of atriopeptin on plasma ACTH in conscious sham-
lesioned male rats injected at time zero with 1 pmol CRF and 10 pmol
AVP (CRF/AVP) iv. Atriopeptin was given iv as a bolus injection
(arrow) followed by a continuous infusion at a rate of 0.005 ml/min
(striped bar). Control animals received saline. Data are means ± SEM.
*, P < 0.05 when compared with saline treated controls at the same
time point by Kruskall-Wallis test. Inset, Plasma ACTH expressed as
the average increase over baseline during a period of 30 min after the
injection of CRF/AVP. Data are means ± SEM. *, P < 0.05 by Kruskall-
Wallis test.
possibly because of the mild hypovolemia caused by
repeated blood sampling. MABP was persistently sup-
pressed by the higher dosage regimen of atriopeptin,
while the lower dose produced only a transient reduction
(Fig. 2a). Injection of CRF/AVP 10 min after the start
of the infusion of the higher dose of ANF caused a
marked increase in MABP (control: 115.2 ± 4.5; 10 min
after atriopeptin: 97 ± 4.1; peak at 0.83 ± 0.04 min after
CRF/AVP: 117.2 ± 4.6; data in mmHg, mean ± SEM n
= 5) which returned to the low, atriopeptin treated values
by 3.8 ± 0.3 min after the injection of CRF/AVP and
remained suppressed during the infusion of atriopeptin.
Marked inhibition of ACTH secretion by atriopeptin in
PVN-lesioned rats
The data presented above raised the possibility that
atriopeptin may facilitate the release of endogenous CRF
and AVP possibly through its hypotensive action and
thus an inhibitory effect at the pituitary level would be
obscured. Therefore, a series of experiments were per-
formed in PVN-lesioned animals in which over 90% of
the CRF is depleted from the median eminence (34-36)
as well as from the pituitary portal circulation (37).
In PVN-lesioned rats the plasma ACTH response to
CRF/AVP was similar to that of intact rats in all respects
(Fig. 3). Only the higher dose of atriopeptin (200 pmol
bolus, 40 pmol/min infusion) was applied which de-
creased the ACTH response between 5 and 60 min, but
had no effect on the initial hormone levels (Fig. 3). On
its own, the same dosage regimen of atriopeptin had no
substantial effect on plasma ACTH (Table 1), but mark-
edly reduced mean arterial pressure during the entire
period of observation (Fig. 2b).
Discussion
The experiments presented here show that atriopeptin
is an inhibitor of stimulated ACTH release in vivo.
Clinical studies have reported either no effect of atrio-
peptin on plasma cortisol (24) or found a marked inhi-
bition (23, 25), without a change in ACTH (23). These
studies did not examine the effect of atriopeptin on
stimulated ACTH secretion, furthermore, a direct action
of the peptide on adrenocortical cells could not be ex-
cluded.
A previous study in the rat reported no effect of
atriopeptin on ACTH release induced by CRF or AVP
(22), however, atriopeptin was only given as a bolus in
this study and was probably eliminated from the circu-
lation by the time the secretagogue stimuli were applied
(38-40). The same workers have reported that atriopep-
tin administered in the same manner inhibits ACTH
secretion evoked by hemorrhage (26). Another group of
investigators (27) found that atriopeptin given intracer-
ebroventricularly suppressed the increase of plasma cor-
ticosterone concentration elicited by intrathecal angio-
tensin II. In the sheep atriopeptin enhanced hemorrhage
induced ACTH and cortisol secretion (21). The dose of
TABLE 1. Effect of atriopeptin on plasma ACTH in conscious, cannulated sham-operated, or PVN-lesioned rats
Sham-op
Saline
ANF40/8
ANF200/40
PVN-L
Saline
ANF200/40
-10
4.5 ± 1.2
5.3 ± 1.9
3.0 ± 0.5
4.5 ± 1.7
2.8 ± 1.1
6.9
8.6
9
6.8
4.1
0
±2.5
± 1.8
±3.8
±1.3
± 2
5
7.5 ± 2.1
10.0 ± 2.5
12.4 ± 3.3
7.3 ± 1.1
4.7 ± 1.4
Time (min)
10
11.8 ± 3.0
9.4 ± 3.5
12.6 ± 3.6
6.3 ± 1.4
4.5 ± 1.4
20
6.7 ± 1.6
10.9 ±3.1
12.6 ± 5.4
9 ± 1.9
6.6 ± 1.8
30
17 ±
14.5 ±
14.1 ±
9.66 ±
6.7 ±
4.6
3.4
4.6
2.9
2.0
60
20.6 ± 3.4
32.2 ± 6.1
69.9 ± 17.2°
9.24 ± 1
4.3 ± 1.1°
5
6
4
5
5
Atriopeptin or saline was given at -10 min iv as a 0.1 ml bolus injection (200 or 40 pmol/rat) followed by a continuous infusion at a rate of
0.005 ml/min (40 or 8 pmol/min-rat). Saline (0.2 ml) was also injected iv at time zero. Data are means (pM) ± SEM.
" P < 0.05 us. saline-treated controls using Kruskall-Wallis test or U test.
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FIG. 2. MABP in (a) sham-operated rats and (b) paraventricular nu-
cleus-lesioned rats. Atriopeptin was given as iv bolus (0.1 ml) at time
zero followed by an infusion (striped bar) in a volume of 0.005 ml/min,
controls received saline. Means, the standard errors were all less than
4% of their respective means.
atriopeptin used caused persistent hypotension (15%
decrease in MABP) and stimulated ACTH as well as
cortisol release (21). The site of action of atriopeptin was
not clarified in any of these studies.
Our present data in rats confirm that if the adminis-
tration of atriopeptin causes persistent hypotension, no
inhibition of CRF/AVP evoked ACTH release occurs, in
fact, an enhancement of the response is found at a later
time point. However, a lower dose of atriopeptin, which
caused only a transient drop of blood pressure markedly
blunted the ACTH response to CRF/AVP. In addition,
ACTH secretion was enhanced by the higher, strongly
hypotensive dose of atriopeptin given alone, but not by
the lower dose of the peptide which was only mildly
60
1 40
|
(0
E 20
.2
Q.
• saline n= 9
• ANF 200/40 n= 9
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FIG. 3. The effect of atriopeptin on plasma ACTH in conscious para-
ventricular nucleus-lesioned male rats injected at time zero with 1 pmol
CRF and 10 pmol AVP (CRF/AVP) iv. Atriopeptin was given iv as a
bolus injection (arrow) followed by a continuous infusion at a rate of
0.005 ml/min (striped bar). Control animals received saline. Data are
means ± SEM. *, P < 0.05 when compared with saline-treated controls
at the same time point by U test. Inset, Plasma ACTH expressed as
the average increase over baseline during a period of 30 min after the
injection of CRF/AVP. Data are means ± SEM. *, P < 0.05 by U test.
hypotensive and inhibited CRF/AVP induced ACTH
release. The enhancement of ACTH secretion by atrio-
peptin was manifested only about 1 h after the treatment
with the peptide was initiated. This is possibly due to
the complex interaction between factors favoring an
increase (hypotension, mild hypovolemia, mild stress due
to cannulation, approach of the circadian peak in hypo-
thalamo-pituitary-adrenocortical activity), or inhibition
(exogenous atriopeptin, endogenous glucocorticoids) of
ACTH secretion. Note that while the intensity of the
stimuli favoring an increase is likely to increase as the
experiment progresses with time, the inhibitory factors
are constant.
A plausible explanation of these findings is that at
high concentrations the cardiovascular effects of atrio-
peptin facilitate the release of hypothalamic ACTH-
releasing hormones into the hypophysial portal system
thereby enhancing the secretagogue drive to adenohy-
pophysial corticotrophs. This may fully mask the inhib-
itory effect of the peptide on ACTH release at the pitui-
tary level.
With respect to this hypothesis, it is well established
that hypotension due to vasodilatation evokes a reflex
release of hypophysiotropic CRF and AVP from the
parvicellular hypothalamo-hypophysial pathway (29), as
well as that of AVP by magnocellular neurones (28).
Both of these mechanisms are thought to contribute to
the increase of ACTH release in response to hypotension
caused by vasodilatation (28, 29). Other factors, such as
hypovolemia and changes in blood pH caused by pro-
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longed exposure to high peripheral levels of atriopeptin
may also contribute to enhance CRF and AVP release
(28, 29).
The experiments with PVN-lesioned rats support the
hypothesis that atriopeptin elicits ACTH secretion by
mobilizing hypothalamic ACTH secretagogues.
Lesioning of the paraventricular nucleus eliminates
over 90% of the hypophysiotropic CRF and AVP pro-
ducing parvicellular neurons (2). The size of the plasma
ACTH response to CRF/AVP in PVN-lesioned rats was
comparable to that seen in sham-lesioned rats. In con-
trast, atriopeptin at a dose which actually enhanced
CRF/AVP-stimulated ACTH release in sham-operated
rats, was strongly inhibitory in PVN-lesioned animals.
Moreover, the infusion of atriopeptin on its own did not
increase plasma ACTH in PVN-lesioned rats despite a
marked decrease of MABP which was similar to that
seen in sham-operated rats.
These data conform with the hypothesis that the
ACTH stimulating action of atriopeptin requires neuro-
hormones derived from the PVN. Thus, the results pre-
sented here indicate that atriopeptin inhibits secreta-
gogue stimulated ACTH secretion at the pituitary level,
but this effect may be masked if the dose of the peptide
is sufficient to provoke CRF and AVP secretion.
The concentration of atriopeptin in plasma was not
measured in our studies, but based on the roughly 30 sec
half-life of the peptide in the circulation of the rat (38-
40), we estimate that the levels attained at the time of
the CRF/AVP injection are between 0.1 and 1 nmol/
liter. Such concentrations have been measured in the
hypophysial portal blood of anesthetized, surgically
stressed rats (20), and also suppress CRF/AVP stimu-
lated ACTH secretion by rat anterior pituitary cells in
vitro (12-15).
In summary, our findings show that atriopeptin is a
potent inhibitor of stimulus evoked ACTH secretion in
vivo indicating that it may function as a hypothalamic
CIF.
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Atriopeptin: An Endogenous Corticotropin-Release Inhibiting Hormone. 
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Activation of the hypothalamic-pihdtary-adrenocortical axis is a major component of the body’s response to stress. Current theories on the 
pathophysiology of disorders associated with hyperfunction of the axis, such as depression and Gushing’s disease, are based on the concept that 
anterior pituitary adrenocorticotropin CACTI-I) secretion is stimulated by hypothalamic corticotropin-releasing hormones and inhibited by adrenal 
corticosteroids. Hypothalamic inhibitory control of pituitary ACTH secretion has been also postulated, but has not gained general acceptance 
because of the lack of definitive evidence for a corticotropin-release inhibiting hormone. It is shown here that in conscious rats stress-induced 
secretion of ACTH and corticosterone is markedly enhanced by the immunoneutralisation of atriopeptin. Therefore, we propose that atriopeptin is 
a physiologically relevant corticotropin-release inhibiting hormone. 
Evidence suggesting an inhibitory component of the 
hypothalamic control of ACTH secretion dates back to 
the early sixties cf. Ref. 1. A considerable body of data 
now indicates that the mediator of this inhibition may 
be atriopeptin (atria1 natriuretic peptide, ANP) produced 
in the hypothalamo-hypophyseal pathway to the 
external zone of the median eminence cf. Ref. 2. 
Although earlier studies have suggested that ANP has 
no significant action on pituitary hormone release [3,4) 
more recent systematic analysis has shown that at 
physiologically relevant subnanomolar concentrations 
ANP inhibits stimulated ACTH secretion in vitro (5-91 as 
well as in viva [lo] by a direct action on the anterior 
pituitary gland. In anterior pituitary cells ANP 
suppresses ACTH release by activating particulate 
guanylyl cyclase, a mechanism distinct from the nuclear 
receptor-mediated effects of glucocorticoid hormones, 
the classical inhibitors of ACTH release cf. Refs. 6 & 11. 
Finally, ANP is released into the hypophyseal portal 
circulation by hypothalamic neurons [12]. 
The outstanding pivotal question is whether or not 
endogenous ANP is involved in the control of ACTH 
secretion? Since no effective antagonist of ANP action is 
available at present we have addressed this problem by 
injecting immunoneutralising antisera against ANP 
into conscious chronically cannulated rats subjected to 
stress. 
Materials and Methods 
Animals All procedures with animals were in accordance with the 
Cruelty to Animals Act 1986 (U.K.). Male Wistar-derived rats 
(Animal House, Western General Hospital, Edinburgh, 200-250 g BW) 
were anesthetized with halothane and equipped with an 
intraarterial catheter in the right external carotid artery. The 
cannula was exteriorized by suturing to the skin of the neck and 
flushed daily with 0.3 ml of 5000 IU/ml heparin. Animals were 
housed in individual cages in a controlled environment (lights on 
05.00-19.00 h). At least 48h after the implantation of the cannula an 
extension tubing was attached for the collection of blood samples. 
Two h afterwards blood samples (0.25 ml; volume replaced with 
saline) were obtained in the following order: 10 min and immediately 
before the stress stimulus. Anti-ANP antisera or pre-immune rabbit 
serum (0.2 ml/rat) were injected through the carotid cannula at 2min 
before stress. Stress consisted of brief immobilisation and the 
intraperitoneal injection of 0.2 ml of 0.9% NaCl. Further blood 
samples were obtained 5, 10 , 20, 30, and 60 min afterwards. All 
experiments were performed between 09.00 and 13.00 h. ACl’H in 
Received in Iowa City: ,mvoshr 24, ,991 
plasma was determined by direct radioimmunoassay using antiserum 
8514 as described previously, with minor modifications to ensure that 
the anti-ANP rabbit serum in the samples did not interfere with the 
measurement of ACI’H[lOl. Plasma corticosterone was also measured 
by radioimmunoassay [131. 
Sern Antisera against ANP were raised in New Zealand white 
rabbits using various synthetic rat ANP analogues (Peninsula Labs, St. 
Helen’s, Merse side, U.K.) conjugated to mammalian purified protein 
derivative or & vme thyroglobulin with glutaraldehyde. The titer 
and specificity of the antisera were characterized in 
radioimmunoassay using 1251-ANP(99-126) as tracer. The sera were 
also screened for immunoneutralising activity in vitro at l/100 and 
l/300 dilutions by examining the effects of antiserum on the ANP- 
induced accumulation of cyclic guanosine3’:Smonophosphate (cGMP) 
in suspensions of rat anterior pituitary cells as previously described 
[6]. Four different antisera (Pink, Orange, RD and RIJ) all directed 
against the C-terminus of ANP, blocked the effects of ANP on 
pituitary cGMP accumulation in t&o and were selected for in oioo 
studies. Specificity studies with these sera at 1/4O&fold dilution 
showed negligible cross reaction (c 1 %) with human brain natriuretic 
peptide, somatostatin and vasopressin. None of the antisera 
recognized ANP (99-109) and all reacted avidly with ANP (111-126). 
Each antiserum was injected into three rats and the data are reported 
as a single anti-ANP serum-treated group. 
Results 
A submaximal stress stimulus (intraperitoneal 
injection of saline into previously handled rats) was 
used in order to reveal any facilitation of the ACTH 
response by anti-ANP serum. Intraperitoneal injection 
of saline increased plasma ACTH at least 2-fold above 
basal in 5 out of 9 control rats receiving pre-immune 
rabbit serum and in 8 out of 12 rats treated with 
antiserum against ANP, (p > 0.1 by 2x2 contingency table 
and chi-square test) indicating that the threshold of the 
stress response was not changed by the injection of anti- 
ANP serum. In the rats that showed an increase of 
plasma ACTH upon stress the size of the hormonal 
response at 5 and 10 min after stress was significantly 
enhanced by the administration of anti-ANP serum (Fig 
la). Overall, the amount of ACTH secreted after stress 
was three times greater in the group treated with anti- 
ANP serum (Fig la, inset). By 60 min plasma ACTH 
returned to baseline levels in both groups. The plasma 
corticosterone response in these animals was also 
significantly enhanced at 5, 10 and 20 min when 
compared with controls (Fig lb). 
Administration of ANP antiserum to unstressed rats 
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Figure 1. a.) Effect of pre-immune rabbit serum (I’RS) and anti-ANP 
sera (anti-ANP) on stress-induced ACTH secretion in conscious 
cannulated male rats. Sera (0.2 ml) were given intraarterially at -2 
min (arrow). Data are geometric means bars show SEM; * ~~0.05, 
Student’s t-test performed after log-transformation of the data which 
was necessary to achieve homogeneity of variances. Inset: Data from 
the same experimental series shown as area under the curve between 0 
and 60 min. Data are geometrical means bars show SEM; ** p<O.Ol, 
compared with pre-immune serum group, Student’s t-test after log 
transformation of data. b.) Plasma corticosterone in the same groups 
of animals as in a. Data are geometric means bars show SEM; * ~~0.05, 
Student’s t-test performed after log-transformation of the data. Data 
are geometrical means bars show SEM. 
caused no marked changes in plasma ACTH or 
corticosterone showing that a stress stimulus is required 
to reveal the effect of endogenous ANP (Data not 
shown). 
Discussion 
These data demonstrate that endogenous ANP plays 
an important role in determining the size of the pitu- 
itary-adrenocortical response to stress. With respect to 
the origin of ANP involved in the regulation of ACTH 
secretion two sources deserve consideration: the heart cf. 
Refs. 14 & 15 and the hypothalamo-hypophyseal 
system[l6-181. Atriopeptin in the peripheral circulation 
Vol130. No 3 
originates largely from the heart, but ANP levels in 
peripheral blood are normally very low (0.001-0.01 nM) 
and generally do not change in response to acute 
stressful stimuli cf. Ref. 19. Atriopeptin is released from 
the hypothalamo-hypophyseal pathway into hypophy- 
seal portal blood attaining concentrations (0.1-l nM) that 
are relevant for ANP mediated inhibition of pituitary 
ACTH secretion in vitro [5,6] as well as in vivo [lo]. 
Moreover, the release of ANP by hypothalamic cultures 
is enhanced by glucocorticoids suggesting that 
adrenocortical feedback inhibition of the hypothalamic- 
pituitary-adrenocortical axis may involve an action of 
steroids on the hypothalamic ANP system [20]. 
In summary, the present data show that endogenous 
ANP is a physiologically relevant inhibitory factor in the 
control of pituitary ACTH secretion during stress. The 
site of action of endogenous ANP, whether at the 
pituitary gland or in the hypothalamus, is not resolved 
by the present study. However, on the basis of previous 
evidence it seems reasonable to suggest that this ANP 
originates from the hypothalamo-hypophyseal tract to 
the external zone of the median eminence [12,16-181, acts 
directly at the pituitary level to suppress ACTH secretion 
[6,8,10,21] and thus constitutes a hypothalamic 
corticotropin-release inhibiting pathway. 
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